0001628280-23-010093.txt : 20230331 0001628280-23-010093.hdr.sgml : 20230331 20230331143228 ACCESSION NUMBER: 0001628280-23-010093 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20230228 FILED AS OF DATE: 20230331 DATE AS OF CHANGE: 20230331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANGIODYNAMICS INC CENTRAL INDEX KEY: 0001275187 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 113146460 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-50761 FILM NUMBER: 23786679 BUSINESS ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 BUSINESS PHONE: 5187981215 MAIL ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 10-Q 1 ango-20230228.htm 10-Q ango-20230228
false2023Q30001275187--05-31trueP2Yhttp://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent00012751872022-06-012023-02-280001275187us-gaap:CommonStockMember2022-06-012023-02-280001275187ango:PreferredStockPurchaseRightsMember2022-06-012023-02-2800012751872023-03-30xbrli:shares00012751872022-12-012023-02-28iso4217:USD00012751872021-12-012022-02-2800012751872021-06-012022-02-280001275187us-gaap:RetainedEarningsMember2022-12-012023-02-28iso4217:USDxbrli:shares00012751872023-02-2800012751872022-05-3100012751872021-05-3100012751872022-02-280001275187us-gaap:CommonStockMember2022-05-310001275187us-gaap:AdditionalPaidInCapitalMember2022-05-310001275187us-gaap:RetainedEarningsMember2022-05-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-05-310001275187us-gaap:TreasuryStockCommonMember2022-05-310001275187us-gaap:RetainedEarningsMember2022-06-012022-08-3100012751872022-06-012022-08-310001275187us-gaap:CommonStockMember2022-06-012022-08-310001275187us-gaap:AdditionalPaidInCapitalMember2022-06-012022-08-310001275187us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-012022-08-310001275187us-gaap:AdditionalPaidInCapitalMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-012022-08-310001275187us-gaap:RestrictedStockUnitsRSUMember2022-06-012022-08-310001275187us-gaap:CommonStockMemberus-gaap:PerformanceSharesMember2022-06-012022-08-310001275187us-gaap:AdditionalPaidInCapitalMemberus-gaap:PerformanceSharesMember2022-06-012022-08-310001275187us-gaap:PerformanceSharesMember2022-06-012022-08-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-012022-08-310001275187us-gaap:CommonStockMember2022-08-310001275187us-gaap:AdditionalPaidInCapitalMember2022-08-310001275187us-gaap:RetainedEarningsMember2022-08-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-08-310001275187us-gaap:TreasuryStockCommonMember2022-08-3100012751872022-08-3100012751872022-09-012022-11-300001275187us-gaap:CommonStockMember2022-09-012022-11-300001275187us-gaap:AdditionalPaidInCapitalMember2022-09-012022-11-300001275187us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2022-09-012022-11-300001275187us-gaap:AdditionalPaidInCapitalMemberus-gaap:RestrictedStockUnitsRSUMember2022-09-012022-11-300001275187us-gaap:RestrictedStockUnitsRSUMember2022-09-012022-11-300001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-012022-11-300001275187us-gaap:CommonStockMember2022-11-300001275187us-gaap:AdditionalPaidInCapitalMember2022-11-300001275187us-gaap:RetainedEarningsMember2022-11-300001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-11-300001275187us-gaap:TreasuryStockCommonMember2022-11-3000012751872022-11-300001275187us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2022-12-012023-02-280001275187us-gaap:AdditionalPaidInCapitalMemberus-gaap:RestrictedStockUnitsRSUMember2022-12-012023-02-280001275187us-gaap:RestrictedStockUnitsRSUMember2022-12-012023-02-280001275187us-gaap:CommonStockMember2022-12-012023-02-280001275187us-gaap:AdditionalPaidInCapitalMember2022-12-012023-02-280001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-012023-02-280001275187us-gaap:CommonStockMember2023-02-280001275187us-gaap:AdditionalPaidInCapitalMember2023-02-280001275187us-gaap:RetainedEarningsMember2023-02-280001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-02-280001275187us-gaap:TreasuryStockCommonMember2023-02-280001275187us-gaap:CommonStockMember2021-05-310001275187us-gaap:AdditionalPaidInCapitalMember2021-05-310001275187us-gaap:RetainedEarningsMember2021-05-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-05-310001275187us-gaap:TreasuryStockCommonMember2021-05-310001275187us-gaap:RetainedEarningsMember2021-06-012021-08-3100012751872021-06-012021-08-310001275187us-gaap:CommonStockMember2021-06-012021-08-310001275187us-gaap:AdditionalPaidInCapitalMember2021-06-012021-08-310001275187us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2021-06-012021-08-310001275187us-gaap:AdditionalPaidInCapitalMemberus-gaap:RestrictedStockUnitsRSUMember2021-06-012021-08-310001275187us-gaap:RestrictedStockUnitsRSUMember2021-06-012021-08-310001275187us-gaap:CommonStockMemberus-gaap:PerformanceSharesMember2021-06-012021-08-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-012021-08-310001275187us-gaap:CommonStockMember2021-08-310001275187us-gaap:AdditionalPaidInCapitalMember2021-08-310001275187us-gaap:RetainedEarningsMember2021-08-310001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-08-310001275187us-gaap:TreasuryStockCommonMember2021-08-3100012751872021-08-310001275187us-gaap:RetainedEarningsMember2021-09-012021-11-3000012751872021-09-012021-11-300001275187us-gaap:CommonStockMember2021-09-012021-11-300001275187us-gaap:AdditionalPaidInCapitalMember2021-09-012021-11-300001275187us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2021-09-012021-11-300001275187us-gaap:AdditionalPaidInCapitalMemberus-gaap:RestrictedStockUnitsRSUMember2021-09-012021-11-300001275187us-gaap:RestrictedStockUnitsRSUMember2021-09-012021-11-300001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-012021-11-300001275187us-gaap:CommonStockMember2021-11-300001275187us-gaap:AdditionalPaidInCapitalMember2021-11-300001275187us-gaap:RetainedEarningsMember2021-11-300001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-11-300001275187us-gaap:TreasuryStockCommonMember2021-11-3000012751872021-11-300001275187us-gaap:RetainedEarningsMember2021-12-012022-02-280001275187us-gaap:CommonStockMember2021-12-012022-02-280001275187us-gaap:AdditionalPaidInCapitalMember2021-12-012022-02-280001275187us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2021-12-012022-02-280001275187us-gaap:AdditionalPaidInCapitalMemberus-gaap:RestrictedStockUnitsRSUMember2021-12-012022-02-280001275187us-gaap:RestrictedStockUnitsRSUMember2021-12-012022-02-280001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-012022-02-280001275187us-gaap:CommonStockMember2022-02-280001275187us-gaap:AdditionalPaidInCapitalMember2022-02-280001275187us-gaap:RetainedEarningsMember2022-02-280001275187us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-02-280001275187us-gaap:TreasuryStockCommonMember2022-02-280001275187ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember2021-07-272021-07-270001275187ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember2021-07-270001275187ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMemberus-gaap:TechnologyBasedIntangibleAssetsMember2021-07-272021-07-270001275187ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember2019-12-172019-12-170001275187country:USango:MedTechMember2022-12-012023-02-280001275187us-gaap:NonUsMemberango:MedTechMember2022-12-012023-02-280001275187ango:MedTechMember2022-12-012023-02-280001275187country:USango:MedTechMember2021-12-012022-02-280001275187us-gaap:NonUsMemberango:MedTechMember2021-12-012022-02-280001275187ango:MedTechMember2021-12-012022-02-280001275187country:USango:MedDeviceMember2022-12-012023-02-280001275187us-gaap:NonUsMemberango:MedDeviceMember2022-12-012023-02-280001275187ango:MedDeviceMember2022-12-012023-02-280001275187country:USango:MedDeviceMember2021-12-012022-02-280001275187us-gaap:NonUsMemberango:MedDeviceMember2021-12-012022-02-280001275187ango:MedDeviceMember2021-12-012022-02-280001275187country:US2022-12-012023-02-280001275187us-gaap:NonUsMember2022-12-012023-02-280001275187country:US2021-12-012022-02-280001275187us-gaap:NonUsMember2021-12-012022-02-280001275187country:USango:MedTechMember2022-06-012023-02-280001275187us-gaap:NonUsMemberango:MedTechMember2022-06-012023-02-280001275187ango:MedTechMember2022-06-012023-02-280001275187country:USango:MedTechMember2021-06-012022-02-280001275187us-gaap:NonUsMemberango:MedTechMember2021-06-012022-02-280001275187ango:MedTechMember2021-06-012022-02-280001275187country:USango:MedDeviceMember2022-06-012023-02-280001275187us-gaap:NonUsMemberango:MedDeviceMember2022-06-012023-02-280001275187ango:MedDeviceMember2022-06-012023-02-280001275187country:USango:MedDeviceMember2021-06-012022-02-280001275187us-gaap:NonUsMemberango:MedDeviceMember2021-06-012022-02-280001275187ango:MedDeviceMember2021-06-012022-02-280001275187country:US2022-06-012023-02-280001275187us-gaap:NonUsMember2022-06-012023-02-280001275187country:US2021-06-012022-02-280001275187us-gaap:NonUsMember2021-06-012022-02-280001275187srt:MinimumMember2022-06-012023-02-280001275187srt:MaximumMember2022-06-012023-02-28xbrli:pure00012751872022-06-012022-11-30ango:unitango:segment0001275187ango:MedTechMember2022-06-010001275187ango:MedDeviceMember2022-06-0100012751872022-06-010001275187ango:MedTechMember2022-06-022022-08-310001275187ango:MedDeviceMember2022-06-022022-08-3100012751872022-06-022022-08-310001275187ango:MedTechMember2022-08-310001275187ango:MedDeviceMember2022-08-310001275187ango:MedTechMember2022-09-012022-11-300001275187ango:MedDeviceMember2022-09-012022-11-300001275187ango:MedTechMember2022-11-300001275187ango:MedDeviceMember2022-11-300001275187ango:MedTechMember2022-12-012023-02-280001275187ango:MedDeviceMember2022-12-012023-02-280001275187ango:MedTechMember2023-02-280001275187ango:MedDeviceMember2023-02-2800012751872020-12-312020-12-310001275187ango:ProductTechnologiesMember2023-02-280001275187us-gaap:CustomerRelationshipsMember2023-02-280001275187us-gaap:TrademarksMember2023-02-280001275187us-gaap:LicenseAgreementTermsMember2023-02-280001275187ango:ProductTechnologiesMember2022-05-310001275187us-gaap:CustomerRelationshipsMember2022-05-310001275187us-gaap:TrademarksMember2022-05-310001275187us-gaap:LicenseAgreementTermsMember2022-05-310001275187us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-08-300001275187us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-08-300001275187us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-06-030001275187us-gaap:LineOfCreditMember2022-08-302022-08-300001275187us-gaap:LineOfCreditMember2019-06-032019-06-030001275187us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:LineOfCreditMember2022-08-302022-08-300001275187srt:MinimumMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMember2022-06-012023-02-280001275187us-gaap:BaseRateMemberus-gaap:LineOfCreditMember2022-06-012023-02-280001275187srt:MaximumMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMember2022-06-012023-02-280001275187us-gaap:LineOfCreditMember2022-06-012023-02-280001275187us-gaap:SecuredDebtMembersrt:MinimumMemberus-gaap:LineOfCreditMember2022-06-012023-02-280001275187us-gaap:SecuredDebtMembersrt:MaximumMemberus-gaap:LineOfCreditMember2022-06-012023-02-28ango:covenant0001275187us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-02-280001275187us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2023-02-280001275187us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-06-012023-02-280001275187ango:A2020StockAndIncentiveAwardPlanMember2022-11-032022-11-030001275187ango:A2020StockAndIncentiveAwardPlanMember2023-02-280001275187ango:EmployeeStockPurchasePlanMember2022-11-032022-11-030001275187ango:EmployeeStockPurchasePlanMember2023-02-280001275187us-gaap:NonUsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-12-012023-02-280001275187us-gaap:NonUsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-12-012022-02-280001275187us-gaap:NonUsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-06-012023-02-280001275187us-gaap:NonUsMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-06-012022-02-280001275187country:USus-gaap:NetAssetsGeographicAreaMemberus-gaap:GeographicConcentrationRiskMember2022-06-012023-02-280001275187us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-02-280001275187us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-02-280001275187us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-02-280001275187us-gaap:FairValueMeasurementsRecurringMember2023-02-280001275187us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-05-310001275187us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-05-310001275187us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-05-310001275187us-gaap:FairValueMeasurementsRecurringMember2022-05-310001275187us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberango:RevenueBasedPaymentMemberus-gaap:FairValueInputsLevel3Member2023-02-280001275187us-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberango:RevenueBasedPaymentMemberus-gaap:FairValueInputsLevel3Member2023-02-280001275187us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMemberango:MeasurementInputProbabilityofPaymentMemberango:RevenueBasedPaymentMemberus-gaap:FairValueInputsLevel3Member2023-02-280001275187srt:MaximumMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberango:MeasurementInputProbabilityofPaymentMemberango:RevenueBasedPaymentMemberus-gaap:FairValueInputsLevel3Member2023-02-280001275187us-gaap:CostOfSalesMember2022-12-012023-02-280001275187us-gaap:CostOfSalesMember2021-12-012022-02-280001275187us-gaap:CostOfSalesMember2022-06-012023-02-280001275187us-gaap:CostOfSalesMember2021-06-012022-02-280001275187us-gaap:ResearchAndDevelopmentExpenseMember2022-12-012023-02-280001275187us-gaap:ResearchAndDevelopmentExpenseMember2021-12-012022-02-280001275187us-gaap:ResearchAndDevelopmentExpenseMember2022-06-012023-02-280001275187us-gaap:ResearchAndDevelopmentExpenseMember2021-06-012022-02-280001275187us-gaap:SellingAndMarketingExpenseMember2022-12-012023-02-280001275187us-gaap:SellingAndMarketingExpenseMember2021-12-012022-02-280001275187us-gaap:SellingAndMarketingExpenseMember2022-06-012023-02-280001275187us-gaap:SellingAndMarketingExpenseMember2021-06-012022-02-280001275187us-gaap:GeneralAndAdministrativeExpenseMember2022-12-012023-02-280001275187us-gaap:GeneralAndAdministrativeExpenseMember2021-12-012022-02-280001275187us-gaap:GeneralAndAdministrativeExpenseMember2022-06-012023-02-280001275187us-gaap:GeneralAndAdministrativeExpenseMember2021-06-012022-02-280001275187ango:CrBardIncMember2012-01-112012-01-11ango:patent0001275187ango:TheDelawareActionMember2015-03-102015-03-100001275187ango:LegalCostsMember2022-12-012023-02-280001275187ango:LegalCostsMember2021-12-012022-02-280001275187ango:LegalCostsMember2022-06-012023-02-280001275187ango:LegalCostsMember2021-06-012022-02-280001275187ango:MergersandAcquisitionsMember2022-12-012023-02-280001275187ango:MergersandAcquisitionsMember2021-12-012022-02-280001275187ango:MergersandAcquisitionsMember2022-06-012023-02-280001275187ango:MergersandAcquisitionsMember2021-06-012022-02-280001275187ango:ManufacturingRelocationMember2022-12-012023-02-280001275187ango:ManufacturingRelocationMember2021-12-012022-02-280001275187ango:ManufacturingRelocationMember2022-06-012023-02-280001275187ango:ManufacturingRelocationMember2021-06-012022-02-280001275187ango:IsraeliInnovationAuthorityPrepaymentMember2022-12-012023-02-280001275187ango:IsraeliInnovationAuthorityPrepaymentMember2021-12-012022-02-280001275187ango:IsraeliInnovationAuthorityPrepaymentMember2022-06-012023-02-280001275187ango:IsraeliInnovationAuthorityPrepaymentMember2021-06-012022-02-280001275187us-gaap:OtherExpenseMember2022-12-012023-02-280001275187us-gaap:OtherExpenseMember2021-12-012022-02-280001275187us-gaap:OtherExpenseMember2022-06-012023-02-280001275187us-gaap:OtherExpenseMember2021-06-012022-02-280001275187us-gaap:AccumulatedTranslationAdjustmentMember2022-11-300001275187us-gaap:AccumulatedTranslationAdjustmentMember2022-12-012023-02-280001275187us-gaap:AccumulatedTranslationAdjustmentMember2023-02-280001275187us-gaap:AccumulatedTranslationAdjustmentMember2022-05-310001275187us-gaap:AccumulatedTranslationAdjustmentMember2022-06-012023-02-28
    
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended February 28, 2023
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                  to                 
Commission file number 0-50761
AngioDynamics, Inc.
(Exact name of registrant as specified in its charter)
ango-20230228_g1.gif
 
Delaware11-3146460
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)

14 Plaza Drive, Latham, New York 12110
(Address of principal executive offices and zip code)
(518) 795-1400
Registrant’s telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common Stock, par value $.01ANGONASDAQ Global Select Market
Preferred Stock Purchase RightsNASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act:
None
(Title of Class)

 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  ☐    No  ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ☒  Accelerated filer ☐
Non-accelerated filer ☐Smaller reporting company ☐
Emerging growth company☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
Indicate the number of shares outstanding of each of the Registrant’s classes of common stock, as of the latest practicable date.
Class Outstanding as of March 30, 2023
Common Stock, par value $.01 39,236,422


AngioDynamics, Inc. and Subsidiaries
TABLE OF CONTENTS
 
Page
Item 1.
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.

2
PART 1. FINANCIAL INFORMATION
Item 1. Financial Statements.

AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands of dollars, except per share data)

 
Three Months Ended
Nine Months Ended
Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Net sales$80,712 $73,970 $247,678 $229,221 
Cost of sales (exclusive of intangible amortization)40,208 35,387 119,791 109,944 
Gross profit40,504 38,583 127,887 119,277 
Operating expenses:
Research and development6,852 7,280 22,023 22,873 
Sales and marketing25,406 20,416 77,956 68,468 
General and administrative8,839 8,727 29,775 27,348 
Amortization of intangibles4,739 4,895 14,384 14,605 
Change in fair value of contingent consideration227 201 2,084 1,005 
Acquisition, restructuring and other items, net3,369 2,359 12,009 7,052 
Total operating expenses49,432 43,878 158,231 141,351 
Operating loss(8,928)(5,295)(30,344)(22,074)
Other expense:
Interest expense, net(736)(173)(1,801)(503)
Other expense, net— (289)(427)(651)
Total other expense, net(736)(462)(2,228)(1,154)
Loss before income tax benefit(9,664)(5,757)(32,572)(23,228)
Income tax benefit(179)(799)(1,597)(2,947)
Net loss$(9,485)$(4,958)$(30,975)$(20,281)
Loss per share
Basic$(0.24)$(0.13)$(0.79)$(0.52)
Diluted$(0.24)$(0.13)$(0.79)$(0.52)
Weighted average shares outstanding
Basic39,509 39,092 39,436 38,959 
Diluted39,509 39,092 39,436 38,959 
The accompanying notes are an integral part of these consolidated financial statements.
3
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(unaudited)
(in thousands of dollars)
 
Three Months Ended
Nine Months Ended
Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Net loss$(9,485)$(4,958)$(30,975)$(20,281)
Other comprehensive income (loss), before tax:
Foreign currency translation (3,562)(1,036)(5,207)373 
Other comprehensive income (loss), before tax(3,562)(1,036)(5,207)373 
Income tax expense related to items of other comprehensive income (loss)— — — — 
Other comprehensive income (loss), net of tax(3,562)(1,036)(5,207)373 
Total comprehensive loss, net of tax$(13,047)$(5,994)$(36,182)$(19,908)
The accompanying notes are an integral part of these consolidated financial statements.

4
AngioDynamics, Inc. and Subsidiaries

CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands of dollars, except share data)
Feb 28, 2023May 31, 2022
Assets
Current assets
Cash and cash equivalents$30,111 $28,825 
Accounts receivable, net of allowances of $2,030 and $1,939 respectively
50,892 52,304 
Inventories63,532 51,392 
Prepaid expenses and other8,039 10,824 
Total current assets152,574 143,345 
Property, plant and equipment, net45,559 45,005 
Intangible assets, net134,011 152,380 
Goodwill199,976 201,058 
Other assets10,729 10,963 
Total assets$542,849 $552,751 
Liabilities and stockholders' equity
Current liabilities
Accounts payable$35,600 $28,047 
Accrued liabilities21,775 34,842 
Current portion of contingent consideration9,877 8,783 
Other current liabilities2,380 2,652 
Total current liabilities69,632 74,324 
Long-term debt49,807 25,000 
Deferred income taxes13,490 16,037 
Contingent consideration, net of current portion9,182 8,165 
Other long-term liabilities3,083 4,736 
Total liabilities145,194 128,262 
Commitments and contingencies (Note 14)
Stockholders' equity
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding
— — 
Common stock, par value $0.01 per share, 75,000,000 shares authorized; 39,976,422 and 39,541,173 shares issued and 39,606,422 and 39,171,173 shares outstanding at February 28, 2023 and May 31, 2022, respectively
382 380 
Additional paid-in capital596,225 586,879 
Accumulated deficit (189,388)(158,413)
Treasury stock, 370,000 shares at February 28, 2023 and May 31, 2022, respectively
(5,714)(5,714)
Accumulated other comprehensive income(3,850)1,357 
Total Stockholders’ Equity397,655 424,489 
Total Liabilities and Stockholders' Equity$542,849 $552,751 
The accompanying notes are an integral part of these consolidated financial statements.
5
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands of dollars)
Nine Months Ended
Feb 28, 2023Feb 28, 2022
Cash flows from operating activities:
Net loss$(30,975)$(20,281)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization23,316 21,682 
Non-cash lease expense1,883 1,822 
Stock based compensation8,177 7,789 
Change in fair value of contingent consideration2,084 1,005 
Deferred income taxes(1,752)(3,121)
Change in accounts receivable allowances560 (66)
Fixed and intangible asset impairments and disposals144 245 
Other(317)(27)
Changes in operating assets and liabilities:
Accounts receivable759 (6,441)
Inventories(12,254)588 
Prepaid expenses and other(392)(7,147)
Accounts payable, accrued and other liabilities(7,109)(11,802)
Net cash used in operating activities(15,876)(15,754)
Cash flows from investing activities:
Additions to property, plant and equipment(2,756)(3,258)
Additions to placement and evaluation units(4,922)(8,676)
Cash paid for acquisitions(540)(3,600)
Net cash used in investing activities(8,218)(15,534)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt70,000 5,000 
Repayment of long-term debt(45,000)— 
Deferred financing costs on long-term debt(751)— 
Proceeds from exercise of stock options and employee stock purchase plan1,171 2,354 
Net cash provided by financing activities25,420 7,354 
Effect of exchange rate changes on cash and cash equivalents(40)(337)
Increase (decrease) in cash and cash equivalents1,286 (24,271)
Cash and cash equivalents at beginning of period28,825 48,161 
Cash and cash equivalents at end of period$30,111 $23,890 
Supplemental disclosure of non-cash investing and financing activities:
Accrual for capital expenditures incurred during the period$140 $(5)
The accompanying notes are an integral part of these consolidated financial statements.
6
AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited)
(in thousands of dollars, except share data)

  
Common StockAdditional
paid in
capital		Accumulated deficit Accumulated
other
comprehensive
income (loss)		Treasury Stock
SharesAmountSharesAmountTotal
Balance at May 31, 202239,541,173 $380 $586,879 $(158,413)$1,357 (370,000)$(5,714)$424,489 
Net loss(13,004)(13,004)
Exercise of stock options6,617 (29)(29)
Issuance/Cancellation of restricted stock units213,241 (648)(648)
Issuance/Cancellation of performance share units29,826 (312)(312)
Purchases of common stock under ESPP56,894 1 1,070 1,071 
Stock-based compensation3,024 3,024 
Other comprehensive loss, net of tax(550)(550)
Balance at August 31, 202239,847,751 $381 $589,984 $(171,417)$807 (370,000)$(5,714)$414,041 
Net loss(8,486)(8,486)
Exercise of stock options15,000 184 184 
Issuance/Cancellation of restricted stock units11,393 (36)(36)
Stock-based compensation3,350 3,350 
Other comprehensive loss, net of tax(1,095)(1,095)
Balance at November 30, 202239,874,144 $381 $593,482 $(179,903)$(288)(370,000)$(5,714)$407,958 
Net loss(9,485)(9,485)
Issuance/Cancellation of restricted stock units9,394 (36)(36)
Purchases of common stock under ESPP92,884 1 976 977 
Stock-based compensation1,803 1,803 
Other comprehensive loss, net of tax(3,562)(3,562)
Balance at February 28, 202339,976,422 $382 $596,225 $(189,388)$(3,850)(370,000)$(5,714)$397,655 


7
Common StockAdditional
paid in
capital		Accumulated deficit Accumulated
other
comprehensive
income		Treasury Stock
SharesAmountSharesAmountTotal
Balance at May 31, 202138,920,951 $377 $573,507 $(131,866)$3,153 (370,000)$(5,714)$439,457 
Net loss(6,972)(6,972)
Exercise of stock options80,635 1 1,279 1,280 
Issuance/Cancellation of restricted stock units279,495 (1,734)(1,734)
Issuance/Cancellation of performance share units59,371 — 
Purchases of common stock under ESPP49,789 1 899 900 
Stock-based compensation2,429 2,429 
Other comprehensive income, net of tax590 590 
Balance at August 31, 202139,390,241 $379 $576,380 $(138,838)$3,743 (370,000)$(5,714)$435,950 
Net loss(8,351)(8,351)
Exercise of stock options56,064 1,022 1,022 
Issuance/Cancellation of restricted stock units8,695 (83)(83)
Purchases of common stock under ESPP19333 
Stock-based compensation3,008 3,008 
Other comprehensive income, net of tax819 819 
Balance at November 30, 202139,455,193 $379 $580,330 $(147,189)$4,562 (370,000)$(5,714)$432,368 
Net loss(4,958)(4,958)
Exercise of stock options5,000 77 77 
Issuance/Cancellation of restricted stock units11,304 (84)(84)
Purchases of common stock under ESPP48,604 1 972 973 
Stock-based compensation2,352 2,352 
Other comprehensive loss, net of tax(1,036)(1,036)
Balance at February 28, 202239,520,101 $380 $583,647 $(152,147)$3,526 (370,000)$(5,714)$429,692 

The accompanying notes are an integral part of these consolidated financial statements.
8
AngioDynamics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. CONSOLIDATED FINANCIAL STATEMENTS
The Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Loss for the three and nine months ended February 28, 2023 and 2022, the Consolidated Balance Sheet as of February 28, 2023, the Consolidated Statements of Cash Flows for the nine months ended February 28, 2023 and 2022, and the Consolidated Statements of Stockholders’ Equity for the nine months ended February 28, 2023 and 2022 have been prepared by the Company and are unaudited. The Consolidated Balance Sheet as of May 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended February 28, 2023 (and for all periods presented) have been made.
The unaudited interim consolidated financial statements for the three and nine months ended February 28, 2023 and 2022 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries (collectively, the "Company", "we", "our" or "us"). All intercompany balances and transactions have been eliminated.
2. ACQUISITIONS
Camaro Support Catheter Asset Acquisition
On July 27, 2021, the Company acquired the Camaro support catheter (rebranded as Syntrax) from QX Medical, LLC for an aggregate purchase price of $4.0 million, which included an upfront payment of $3.6 million and $0.4 million in purchase price holdbacks, along with $1.0 million of potential future contingent consideration related to revenue milestones. This acquisition supports the Auryon product family and the Company's strategic plan. The Company accounted for this acquisition as an asset purchase. The Company recorded the amount paid at closing as inventory and fixed assets of $0.1 million and an intangible asset product technology of $3.9 million. The intangible asset will be amortized over 15 years. The contingent consideration is comprised of revenue milestones and will be accounted for when the contingency is resolved or becomes probable and reasonably estimable.
3. REVENUE FROM CONTRACTS WITH CUSTOMERS
Revenue Recognition
Under ASC 606, Revenue from Contracts with Customers, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company has one primary revenue stream which is the sales of its products.
Disaggregation of Revenue
As the Company has previously announced, the Company is focused on its ongoing transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company that delivers unique and innovative health care solutions. The Company believes that this transformation will enable the Company to shift the portfolio from the mature, lower-growth markets where we have competed in the past by investing in technology and products that provide access to larger and faster growing markets. As such, we believe the growth in the near to mid-term will be driven by our Med Tech segment.
The following table summarizes net sales by Med Tech, Med Device and by geography:
9
Three Months Ended February 28, 2023Three Months Ended February 28, 2022
(in thousands)United StatesInternationalTotalUnited StatesInternationalTotal
Net sales
Med Tech $20,381 $2,493 $22,874 $17,782 $1,830 $19,612 
Med Device47,239 10,599 57,838 44,663 9,695 54,358 
Total$67,620 $13,092 $80,712 $62,445 $11,525 $73,970 
Nine Months Ended February 28, 2023
Nine Months Ended February 28, 2022
(in thousands)United StatesInternationalTotalUnited StatesInternationalTotal
Net sales
Med Tech $61,373 $8,820 $70,193 $49,249 $6,857 $56,106 
Med Device146,901 30,584 177,485 143,010 30,105 173,115 
Total$208,274 $39,404 $247,678 $192,259 $36,962 $229,221 
Net Product Revenue
The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's products are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distributors and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.
Contracts and Performance Obligations
The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.
Transaction Price and Allocation to Performance Obligations
Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer, net of any variable consideration as described below.
If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.
Revenue Recognition
Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the shipping terms of a contract.
In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.
The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.
The Company enters into agreements to place placement and evaluation units (“units”) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer’s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units. In these arrangements, revenue recognized for the sale of the disposables is not allocated
10
between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value.
Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
Variable Consideration
Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset.
Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes. The Company is also required to pay administrative fees to group purchasing organizations.
Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the nine months ended February 28, 2023, such product returns were not material.
Contract Balances with Customers
A receivable is generally recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.
The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:
(in thousands)Feb 28, 2023
May 31, 2022
Receivables$50,892 $52,304 
Contract assets$— $— 
Contract liabilities$571 $526 
During the nine months ended February 28, 2023, the Company had additions to contract liabilities of $0.6 million. This was offset by $0.6 million in revenue that was recognized during the nine months ended February 28, 2023.
Costs to Obtain or Fulfill a Customer Contract
Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.
The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping and handling are recorded in net sales.


11
4. INVENTORIES
Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:
(in thousands)Feb 28, 2023May 31, 2022
Raw materials$34,471 $28,251 
Work in process7,924 7,186 
Finished goods21,137 15,955 
Inventories$63,532 $51,392 
The Company periodically reviews inventory for both obsolescence and loss of value. The Company makes assumptions about the future demand for and market value of the inventory. Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow-moving inventory. The total inventory reserve at February 28, 2023 and May 31, 2022 was $3.1 million and $3.7 million, respectively.

5. GOODWILL AND INTANGIBLE ASSETS
Goodwill
Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination.
The Company has historically performed its annual goodwill assessment during the third quarter of each fiscal year. During the fourth quarter of fiscal year 2022, the Company changed its annual impairment assessment date from December 31 to April 30 to more closely align the impairment assessment date with the Company's long term planning and forecasting process.
The Company's annual testing for impairment of goodwill was completed as of April 30, 2022. Prior to the first quarter of fiscal year 2023, the Company managed its operations as one reporting unit. At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as two operating segments and two reporting units, namely Med Tech and Med Device (see Note 11 "Segment and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Quarterly Report on Form 10-Q). As a result of this change, goodwill was required to be allocated to each reporting unit and an interim goodwill impairment assessment was performed at the Company and reporting unit levels. To determine the fair value of the individual reporting units and the entire company as of June 1, 2022, the Company utilized the income approach. The income approach is based on the projected cash flows discounted to their present value using discount rates, that in the Company's judgment, consider the timing and risk of the forecasted cash flows using internally developed forecasts and assumptions. Under the income approach, the discount rate used is the average estimated value of a market participant’s cost of capital and debt, derived using customary market metrics. Other significant assumptions include revenue growth rates, profitability projections, and terminal value growth rates. The market approach was also considered; however, the income approach was chosen as the Company determined it is a better representation of both the Med Tech and Med Device reporting units' projected long-term performance. The fair value of each reporting unit and the Company as a whole was assessed to determine if there was any impairment. The Company compared each reporting unit's fair value to the adjusted carrying value to conclude that there was no impairment for either reporting unit or the Company as a whole. The adjusted carrying value of each reporting unit was used to calculate the Company's book value to compare to its market capitalization at the assessment date. Based on the results of this evaluation, there were no adjustments to goodwill for either reporting unit or the Company as a whole as of August 31, 2022.






12
Goodwill for each reporting unit is allocated as follows:
Nine months ended Feb 28, 2023
(in thousands)Med Tech Med Device Total
Balance, June 1, 2022$160,529 $40,529 $201,058 
Foreign currency translation adjustments (20)— (20)
Balance, August 31, 2022$160,509 $40,529 $201,038 
Foreign currency translation adjustments(283)— (283)
Balance, November 30, 2022$160,226 $40,529 $200,755 
Foreign currency translation adjustments$(779)$— $(779)
Balance, February 28, 2023
$159,447 $40,529 $199,976 
There were no adjustments to goodwill for the nine months ended February 28, 2023 other than foreign currency translation adjustments.
Even though the Company determined that there was no goodwill impairment at February 28, 2023, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that one of the reporting units or a significant portion of either of the reporting units will be sold or disposed of, would require an interim assessment for the reporting units prior to the next required annual assessment as of April 30, 2023.
Definite Lived Intangible Assets
Intangible assets other than goodwill are amortized over their estimated useful lives on a straight-line basis. Useful lives range from two to eighteen years. The Company periodically reviews, and adjusts, if necessary, the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.
Intangible assets consisted of the following:
Feb 28, 2023
(in thousands)Gross carrying valueAccumulated amortizationNet carrying value
Product technologies$233,752 $(122,017)$111,735 
Customer relationships60,096 (40,995)19,101 
Trademarks9,950 (7,396)2,554 
Licenses5,377 (4,756)621 
$309,175 $(175,164)$134,011 
May 31, 2022
(in thousands)Gross carrying valueAccumulated amortizationNet carrying value
Product technologies$239,467 $(112,141)$127,326 
Customer relationships60,115 (38,003)22,112 
Trademarks9,950 (7,185)2,765 
Licenses4,837 (4,660)177 
$314,369 $(161,989)$152,380 
Amortization expense for the three months ended February 28, 2023 and 2022 was $4.7 million and $4.9 million, respectively. Amortization expense for the nine months ended February 28, 2023 and 2022 was $14.4 million and $14.6 million, respectively.
13
Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows:
(in thousands)
Remainder of 2023$5,918 
202416,406 
202516,388 
202616,207 
202716,036 
2028 and thereafter63,056 
$134,011 

6. ACCRUED LIABILITIES
Accrued liabilities consisted of the following:
(in thousands)Feb 28, 2023May 31, 2022
Payroll and related expenses$9,355 $20,232 
Royalties2,202 2,986 
Outside services3,171 3,731 
Research and development1,368 1,279 
Sales and franchise taxes328 750 
Rebates359 511 
Other4,992 5,353 
$21,775 $34,842 
7. LONG-TERM DEBT
On August 30, 2022, the Company repaid all amounts outstanding under its then existing credit agreement and entered into a new Credit Agreement (the "Credit Agreement") with its lenders, JPMorgan Chase Bank, N.A., as Administrative Agent, sole bookrunner, and sole lead arranger, and Bank of America, N.A. and KeyBank National Association, as Syndication Agents.
The Credit Agreement provides for a $75.0 million secured revolving credit facility (the "Revolving Facility") and a $30.0 million delayed draw term loan (the "Delayed Draw Term Loan"), and also includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million.  Each exercise of such expansion feature must be drawn in $5.0 million increments. The proceeds of the Revolving Facility may be used for general corporate purposes, including permitted acquisitions. The proceeds of the Delayed Draw Term Loan may be used for general corporate purposes, including primarily to finance the manufacturing costs of the Auryon laser capital equipment.
The Credit Agreement has a five-year maturity. Interest on the Revolving Facility and Delayed Draw Term Loan will be based, at the Company's option, on a rate equal to (i) the Secured Overnight Financing Rate ("SOFR") plus 0.10% (subject to a floor of 0%), or (ii) if the Company elects to treat a borrowing as an ABR Borrowing, an alternate base rate based on SOFR, plus, in each case, an applicable margin of 1.25%, 1.50% or 1.75%, depending on the leverage ratio. If any amounts are not paid when due, such overdue amounts will bear interest at an amount generally equal to 2.0% plus the existing loan rate. The Credit Agreement also carries a commitment fee in the case of the Revolving Facility, and a ticking fee, in the case of the Delayed Draw Term Loans of 0.20% to 0.25% per annum on the unused portion.
The Company's obligations under the Credit Agreement are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of the Company and the Guarantors under the Credit Agreement are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors.
The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows: 
•Maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than 3.00 to 1.00 (during certain periods following material acquisitions the ratio shall be increased to 3.50 to 1.00).
14
•Fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures* to consolidated interest expense* paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00.
* The definitions of consolidated total indebtedness, consolidated EBITDA, consolidated capital expenditures and consolidated interest expense are specifically defined in the Credit Agreement included as an exhibit to Form 8-K filed on August 31, 2022.
As of February 28, 2023, there was $25.0 million outstanding on the Revolving Facility and $25.0 million outstanding on the Delayed Draw Term Loan and the interest rate at February 28, 2023 applicable to each was 6.15%. As of February 28, 2023 and May 31, 2022, the carrying value of long-term debt approximated its fair market value.
(in thousands)Feb 28, 2023
Revolving Facility$25,000 
Delayed Draw Term Loan25,000 
Less: unamortized debt issuance costs(193)
      Total long-term debt$49,807 

Principal payments of approximately 3.57% on the Delayed Draw Term Loan will amortize in equal quarterly installments over a five year period beginning on the earlier of a full draw or the expiry of the draw period (March 1, 2024).

8. INCOME TAXES
The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur.  The estimated annual effective tax rate prior to discrete items was 5.2% as of the third quarter of fiscal year 2023, as compared to 12.7% for the same period in fiscal year 2022. In fiscal year 2023, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share-based compensation).
The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity.
Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of February 28, 2023. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.

9. SHARE-BASED COMPENSATION
On October 13, 2020, the Company's shareholders approved the 2020 Stock and Incentive Award Plan (the “2020 Plan”). The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance share units, performance shares and other incentive awards to the Company's employees, directors and other service providers. On November 3, 2022 the Company's shareholders approved an amendment to the 2020 Plan to increase the reserve of shares of common stock available for future grants by 1,950,000 shares. As of February 28, 2023, there was a maximum of 2.9 million shares of common stock available for future grant under the 2020 Plan.
Prior to the adoption of the 2020 Plan, equity awards were issued under the 2004 Stock and Incentive Award Plan (the “2004 Plan”). The adoption of the 2020 Plan did not impact the administration of equity awards issued under the 2004 Plan but following the adoption of the 2020 Plan, equity award grants are no longer made under the 2004 Plan.
The Company also has an employee stock purchase plan. On November 3, 2022 the Company's shareholders approved an amendment to the employee stock purchase plan to increase the reserve of shares of common stock available for future grants by 1,000,000 shares. As of February 28, 2023, there was a maximum of 3.2 million shares of common stock available for future grant under the employee stock purchase plan.
15
For the three months ended February 28, 2023 and 2022, share-based compensation expense was $1.8 million and $2.4 million, respectively. For the nine months ended February 28, 2023 and 2022, share-based compensation expense was $8.2 million and $7.8 million, respectively.
During the nine months ended February 28, 2023 and 2022, the Company granted stock options and restricted stock units under the 2020 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company’s common stock on the date of grant and then amortized on a straight-line basis over the requisite service period of the award.
During the nine months ended February 28, 2023 and 2022, the Company granted performance share units under the 2020 Plan to certain employees. The awards may be earned by achieving performance levels over the requisite service period. The performance criteria are based on achieving certain performance targets and the total shareholder return (“TSR”) of the Company’s common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards is based on a Monte Carlo simulation model.
As of February 28, 2023, there was $17.6 million of unrecognized compensation expense related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately three years. The Company has sufficient shares to satisfy expected share-based payment arrangements.
10. EARNINGS PER SHARE
Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.
The following table reconciles basic to diluted weighted-average shares outstanding:
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Basic39,509 39,092 39,436 38,959 
Effect of dilutive securities— — — — 
Diluted39,509 39,092 39,436 38,959 
Securities excluded as their inclusion would be anti-dilutive3,706 3,457 3,706 3,457 

11. SEGMENT AND GEOGRAPHIC INFORMATION
Segment information
The Company regularly reviews its segments and the approach used by the chief operating decision maker, the President and Chief Executive Officer ("CEO"), and management to evaluate performance and allocate resources. Prior to the first quarter of fiscal year 2023, the Company considered the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis. Commencing with the first quarter of fiscal year 2023, the Company began to manage its operations through two segments, Med Tech and Med Device to align with the transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company. The CEO evaluates these two segments based on net sales and gross margin to, among other items, allocate resources and assess performance. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates all other elements of profitability, investment and cash flow metrics on a consolidated global basis due to shared infrastructure and resources.
The Company manages its assets on a total company basis, not by operating segment; therefore, the CEO does not review any asset information by operating segment and, accordingly, asset information is not reported or evaluated by operating segment. Total assets were $542.8 million as of February 28, 2023.
The table below summarizes net sales and gross margin by Med Tech and Med Device including prior periods during which the Company considered the business to be a single operating segment, in order to conform to the current period presentation:
16
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Med Tech Net Sales$22,874 $19,612 $70,193 $56,106 
Gross profit 14,774 12,965 44,816 37,060 
Gross margin 64.6 %66.1 %63.8 %66.1 %
Med Device Net Sales$57,838 $54,358 177,485 $173,115 
Gross profit 25,730 25,618 83,071 $82,217 
Gross margin 44.5 %47.1 %46.8 %47.5 %
Total Net Sales$80,712 $73,970 $247,678 $229,221 
Gross profit40,504 38,583 127,887 119,277 
Gross margin50.2 %52.2 %51.6 %52.0 %
Geographic information
The table below summarizes net sales by geographic area based on external customer location:
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Net Sales
United States$67,620 $62,445 $208,274 $192,259 
International13,092 11,525 39,404 36,962 
Total$80,712 $73,970 $247,678 $229,221 
For the three months ended February 28, 2023 and 2022, international sales as a percentage of total net sales were 16.2% and 15.6%, respectively. For the nine months ended February 28, 2023 and 2022, international sales as a percentage of total net sales were 15.9% and 16.1%, respectively. Sales to any one country outside the U.S., as determined by shipment destination, did not comprise a material portion of net sales in any of the last three fiscal years. In addition, no one customer represents more than 10% of consolidated net sales and 85% of long-lived assets are located within the United States.

12. FAIR VALUE
On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•Level 3 - Inputs to the valuation methodology are significant unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to their immediate or short-term maturities. The recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities.
17
The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis:
Fair Value Measurements using inputs considered as:
Fair Value at Feb 28, 2023
(in thousands)Level 1Level 2Level 3
Financial Liabilities
Contingent consideration for acquisition earn outs$— $— $19,059 $19,059 
Total Financial Liabilities$— $— $19,059 $19,059 
Fair Value Measurements using inputs considered as:
Fair Value at May 31, 2022
(in thousands)Level 1Level 2Level 3
Financial Liabilities
Contingent consideration for acquisition earn outs$— $— $16,948 $16,948 
Total Financial Liabilities$— $— $16,948 $16,948 
There were no transfers between Level 1, 2 and 3 for the three and nine months ended February 28, 2023 and 2022.
The table below presents the changes in fair value components of Level 3 instruments:
Three Months Ended Feb 28, 2023
(in thousands)Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, November 30, 2022$18,832 
Change in present value of contingent consideration (1)
227 
Balance, February 28, 2023
$19,059 
Nine Months Ended Feb 28, 2023
(in thousands)Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, May 31, 2022$16,948 
Change in present value of contingent consideration (1)
2,084 
Currency gain from remeasurement27 
Balance, February 28, 2023
$19,059 
(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.
Contingent Liability for Acquisition Earn Outs
Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations.
The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements, which is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net
18
sales are based on internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future.
The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 28, 2023:
(in thousands)Fair ValueValuation TechniqueUnobservable InputRange
Revenue based payments$19,059 Discounted cash flowDiscount rate5%
Probability of payment
90% - 100%
Projected fiscal year of payment2023 - 2025
At February 28, 2023, the amount of undiscounted future contingent consideration that the Company expects to pay as a result of all completed acquisitions is approximately $20.0 million. The milestones, including revenue projections and technical milestones associated with the contingent consideration, must be reached in future periods ranging from fiscal years 2023 to 2029 in order for the associated consideration to be paid.

13. LEASES
The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&D, manufacturing and warehousing.
Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.
The following table presents supplemental balance sheet information related to leases:
(in thousands)Balance Sheet LocationFeb 28, 2023May 31, 2022
Assets
Operating lease ROU assetOther assets$5,143 $6,974 
Liabilities
Current operating lease liabilitiesOther current liabilities2,299 2,560 
Non-current operating lease liabilitiesOther long-term liabilities3,049 4,703 
Total lease liabilities$5,348 $7,263 
The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate:
Feb 28, 2023
Weighted average remaining term (in years)2.72
Weighted average discount rate3.8 %
19
The maturities of the lease liabilities for each of the following fiscal years is:
(in thousands)Feb 28, 2023
Remainder of 2023$699 
20242,191 
20251,428 
20261,130 
2027 and thereafter171 
Total lease payments$5,619 
Less: Imputed Interest271 
Total lease obligations$5,348 
Less: Current portion of lease obligations2,299 
Long-term lease obligations$3,049 
During the three months ended February 28, 2023 and 2022, the Company recognized $0.7 million and $0.7 million of operating lease expense, respectively, which includes immaterial short-term leases. During the nine months ended February 28, 2023 and 2022, the Company recognized $2.0 million and $2.1 million of operating leases expense, respectively, which includes immaterial short-term leases. The expenses on the Consolidated Statement of Operations were classified as follows:
Three Months Ended
Nine Months Ended
(in thousands)
Feb 28, 2023
Feb 28, 2022
Feb 28, 2023
Feb 28, 2022
Cost of sales$221 $218 $661 $656 
Research and development54 52 158 201 
Sales and marketing42 40 122 119 
General and administrative379 374 1,103 1,138 
$696 $684 $2,044 $2,114 
The following table presents supplemental cash flow and other information related to leases for the nine months ended:
(in thousands)Feb 28, 2023Feb 28, 2022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$2,079 $2,041 
ROU assets obtained in exchange for lease liabilities
Operating leases$— $33 

14. COMMITMENTS AND CONTINGENCIES

The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation.

C.R. Bard, Inc. v. AngioDynamics, Inc.

On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 7,785,302 ("302"), 7,959,615 (“615”) and 7,947,022 ("022")). The case was stayed pending reexamination in the US Patent and Trademark Office ("USPTO"). Following the reexamination proceedings, and the parties’ related appeals to the Federal Circuit which resulted in further proceedings at the USPTO, certain claims of the 615 patent were held invalid, while the remaining claims of the 615 patent and the other two patents were upheld over the prior art references considered in the reexamination proceedings. Thereafter, the case was transferred from the District of Utah to the United States District Court for the District of Delaware (“District of Delaware”). On July 22, 2021, in another case against a different defendant, the District of Utah invalidated multiple claims of the ‘302, ‘022, and ‘615 Patents under 35 USC §101, including claims asserted against the Company. On December 27, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal from the Utah Decision. On February 17, 2023, the Federal Circuit Reversed-in-Part, Vacated-in-Part, and Remanded the Utah
20
Decision. The other defendant subsequently filed a Petition for Rehearing with the Federal Circuit on March 20, 2023, and a mandate has not yet issued. The District of Delaware lifted the stay on February 28, 2023 and held a status conference on March 23, 2023. A scheduling order has not yet been entered, but a jury trial is currently scheduled for April 29, 2024. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

On March 10, 2015, Bard and Bard Peripheral Vascular filed suit in the District of Delaware claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 8,475,417, 8,545,460, 8,805,478). The case proceeded through trial which began on March 4, 2019. At the close of Bard’s case, the Court granted the Company's oral motion for judgment as a matter of law as well as its motions for summary judgment on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed. On May 10, 2019, the Company filed a motion for attorney fees and non-taxable expenses under 35 USC Sec. 285. Bard appealed the judgment to the Federal Circuit and on November 10, 2020, the Federal Circuit reversed the judgment in part with respect to Section 101 (subject matter eligibility), and vacated and remanded the trial court’s invalidity and non-infringement judgments. Following remand from the Federal Circuit, a jury trial commenced in the District of Delaware beginning November 14, 2022. On November 22, 2022, a jury entered a verdict finding that certain of the Company’s implantable port products infringe certain claims of U.S. patents held by Bard. The issue of damages was bifurcated by the Court during trial, was not determined by the jury and will be subject to a separate proceeding. The Company strongly disagrees with the claims and the verdict. The issues presented to the jury do not comprise all of the issues to be determined in the case. Equitable issues remain to be decided by the judge, and damages remain to be decided by a jury. The Company believes it has meritorious defenses and positions with respect to the matters remaining to be decided and the jury decision, and intends to vigorously pursue all available remedies and defenses, including post-trial motions and appeals. The parties have filed post-trial briefs, and the Court heard argument on March 13, 2023. A decision is forthcoming. The Company maintains its belief that Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

On March 8, 2021, Bard filed suit in the District of Delaware asserting certain of the Company’s port products (including certain related infusion sets) infringe U.S. Patent Nos. 8,025,639, 9,603,992 and 9,603,993. On December 27, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal of the Utah decision invalidating multiple claims of the ‘302, ‘022, and ‘615 patents under 35 USC §101. Following the Federal Circuit’s decision on appeal, the District of Delaware lifted the stay on February 28, 2023, and held a scheduling conference on March 23, 2023. A scheduling order has not yet been entered, but a jury trial is currently scheduled for June 9, 2025. The Company maintains its belief that Bard's claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

AngioDynamics, Inc. v. C.R. Bard, Inc.

On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”). In this action, the Company alleged that Bard had illegally tied the sales of its tip location systems to the sales of its PICCs in violation of federal antitrust laws and this practice had an anti-competitive effect in the US market for PICCs. The Company sought both monetary damages and injunctive relief. On October 6, 2022, a jury verdict was rendered finding Bard did not restrain competition in violation of federal antitrust laws.

15. ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET
Acquisition, Restructuring and Other Items
21
Acquisition, restructuring and other items, net, consisted of:
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Legal (1)
$2,614 $1,681 $6,899 $5,837 
Mergers and acquisitions (2)
— — — 59 
Manufacturing relocation (3)
324 396 1,062 455 
Israeli Innovation Authority prepayment (4)
— — 3,544 — 
Other431 282 504 701 
Total$3,369 $2,359 $12,009 $7,052 
(1) Legal expenses related to litigation that is outside the normal course of business.
(2) Legal and due diligence expenses related to mergers and acquisitions.
(3) Expenses to relocate certain manufacturing lines from Queensbury, NY to Costa Rica.
(4) In the first quarter of fiscal year 2023, a $3.5 million payment was made to the Israeli Innovation Authority to fully satisfy the obligation related to grant funds that were provided to Eximo for development of the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020.

16. ACCUMULATED OTHER COMPREHENSIVE INCOME
Changes in each component of accumulated other comprehensive income, net of tax, are as follows:
Three Months Ended Feb 28, 2023
(in thousands)Foreign currency translation income
Balance at November 30, 2022$(288)
Other comprehensive loss, net of tax(3,562)
Net other comprehensive loss$(3,562)
Balance at February 28, 2023
$(3,850)
Nine Months Ended Feb 28, 2023
(in thousands)Foreign currency translation income
Balance at May 31, 2022$1,357 
Other comprehensive loss, net of tax(5,207)
Net other comprehensive loss$(5,207)
Balance at February 28, 2023
$(3,850)

17. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
Recently Issued Accounting Pronouncements - Adopted
StandardDescriptionEffective DateEffect on the Consolidated Financial Statements
ASU 2021-10,  Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance
This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. June 1, 2022The Company adopted the new standard in the first quarter of fiscal year 2023 and it did not have an impact on the Company's consolidated financial statements.
22
Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted
StandardDescriptionEffective DateEffect on the Consolidated Financial Statements
ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers

This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer.
June 1, 2023The Company plans to adopt the new standard in the first quarter of fiscal year 2024 and does not expect there to be a material impact to the consolidated financial statements.

23
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q. The following discussion should be read in conjunction with the Company's 2022 Annual Report on Form 10-K, and the consolidated financial statements and notes thereto included elsewhere in the Form 10-Q.
Disclosure Regarding Forward-Looking Statements
This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the Securities and Exchange Commission (the "SEC").
Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this report. AngioDynamics disclaims any obligation to update the forward-looking statements. 
Disclosure Regarding Trademarks
This report includes trademarks, tradenames and service marks that are our property or the property of other third parties. Solely for convenience, such trademarks and tradenames sometimes appear without any “™” or “®” symbol. However, failure to include such symbols is not intended to suggest, in any way, that we will not assert our rights or the rights of any applicable licensor, to these trademarks and tradenames. For a complete listing of all our trademarks, tradenames and service marks please visit www.angiodynamics.com/IP. Information on our website or connected to our website is not incorporated by reference into this Quarterly Report on Form 10-Q.
Executive Overview
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Many of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or long-term use.
24
Our business operations cross a variety of markets. Our financial performance is impacted by changing market dynamics, which have included an emergence of value-based purchasing by healthcare providers, consolidation of healthcare providers, the increased role of the consumer in health care decision-making and an aging population, among others. In addition, our growth is impacted by changes within our sector, such as the merging of competitors to gain scale and influence; changes in the regulatory environment for medical devices; and fluctuations in the global economy.
Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions of our product offerings are created through internal and external product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in research and development activities and selective business development opportunities to provide growth opportunities.
We sell our products in the United States primarily through a direct sales force, and outside the U.S. through a combination of direct sales and distributor relationships. Our end users include interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses. We expect our businesses to grow in both sales and profitability by expanding geographically, penetrating new markets, introducing new products and increasing our presence internationally.
The COVID-19 global pandemic has impacted our business and may continue to pose future risks with the emergence of new variants. Even with the public health actions that have been taken to reduce the spread of the virus, the market continues to experience disruptions with respect to consumer demand, hospital operating procedures and workflow, trends that may continue. The Company's ability to manufacture products, the reliability of our supply chain, labor shortages, backlog and inflation (including the cost and availability of raw materials, direct labor and shipping) have impacted our business, trends that may continue. Accordingly, management continues to evaluate the Company’s liquidity position, communicate with and monitor the actions of our customers and suppliers, and review our near-term financial performance.
On August 30, 2022, the Company repaid all amounts outstanding under its then existing credit agreement and entered into a new Credit Agreement. The new Credit Agreement provides for a $75.0 million Revolving Facility and a $30.0 million Delayed Draw Term Loan. As of February 28, 2023, $25.0 million was drawn on the Revolving Facility and $25.0 million was drawn on the Delayed Draw Term Loan. See Note 7 "Long-Term Debt" set forth in the Notes to the consolidated financial statements.
Commencing with the first quarter of fiscal year 2023, the Company began to manage its operations through two segments, Med Tech and Med Device to align with the transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company.
In evaluating the operating performance of our business, management focuses on company-wide and segment revenue and gross margin and company-wide operating income, earnings per share and cash flow from operations. A summary of these key financial metrics for the three and nine months ended February 28, 2023 compared to the three and nine months ended February 28, 2022 are as follows:
Three months ended February 28, 2023:
•Revenue increased by 9.1% to $80.7 million.
•Med Tech growth of 16.6% and Med Device growth of 6.4%.
•Gross profit decreased 200 bps to 50.2%.
•Med Tech gross profit decreased 150 bps to 64.6% and Med Device gross profit decreased 260 bps to 44.5%.
•Net loss increased by $4.5 million to $9.5 million.
•Loss per share increased by $0.11 to a loss of $0.24.
Nine months ended February 28, 2023:
•Revenue increased by 8.1% to $247.7 million.
•Med Tech growth of 25.1% and Med Device growth of 2.5%.
•Gross profit decreased 40 bps to 51.6%.
•Med Tech gross profit decreased 230 bps to 63.8% and Med Device gross profit decreased 70 bps to 46.8%.
•Net loss increased by $10.7 million to $31.0 million.
•Loss per share increased by $0.27 to a loss of $0.79.
Our Med Tech revenue, comprised of Auryon, the thrombus management platform and NanoKnife, grew 16.6% in the third quarter of fiscal year 2023. The growth in Auryon, AlphaVac and NanoKnife disposables was partially offset by
25
continued softness in AngioVac. Our Med Device revenue grew 6.4% in the third quarter of fiscal year 2023 driven by growth in Core, Dialysis, Ports and Microwave products.
Results of Operations
For the three months ended February 28, 2023, the Company reported a net loss of $9.5 million, or a loss of $0.24 per diluted share, on net sales of $80.7 million, compared with a net loss of $5.0 million, or a loss of $0.13 per diluted share, on net sales of $74.0 million during the same quarter of the prior year. For the nine months ended February 28, 2023, the Company reported a net loss of $31.0 million, or a loss of $0.79 per diluted share, on net sales of $247.7 million, compared with a net loss of $20.3 million, or a loss of $0.52 per diluted share, on net sales of $229.2 million during the same quarter of the prior year.
Net Sales
Net sales - Net sales are derived from the sale of products and related freight charges, less discounts, rebates and returns.
Three Months Ended
Nine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022% ChangeFeb 28, 2023Feb 28, 2022% Change
Net Sales
Med Tech$22,874 $19,612 16.6%$70,193 $56,106 25.1%
Med Device57,838 54,358 6.4%177,485 173,115 2.5%
Total$80,712 $73,970 9.1%$247,678 $229,221 8.1%
Three Months Ended
Nine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022% ChangeFeb 28, 2023Feb 28, 2022% Change
Net Sales
       United States$67,620 $62,445 8.3%$208,274 $192,259 8.3%
       International13,092 11,525 13.6%39,404 36,962 6.6%
           Total$80,712 $73,970 9.1%$247,678 $229,221 8.1%
For the three months ended February 28, 2023, net sales increased $6.7 million to $80.7 million compared to the same period in the prior year. For the nine months ended February 28, 2023, net sales increased $18.5 million to $247.7 million compared to the same period in the prior year. At February 28, 2023, the Company had a backlog of $5.4 million, an increase of $0.4 million from November 30, 2022.
The Med Tech segment net sales increased $3.3 million and $14.1 million for the three and nine months ended February 28, 2023 compared to the same periods in the prior year, respectively. The change in sales for both periods was primarily driven by:
•Increased Auryon sales of $3.1 million and $9.9 million compared to the same periods in the prior year, respectively;
•Growth in the thrombus management platform of $2.3 million for the nine months ended February 28, 2023 compared to the same period in the prior year, while the thrombus management platform decreased $0.1 million for the three months ended February 28, 2023 compared to the same period in the prior year. Growth in the mechanical thrombectomy platform was driven by AlphaVac sales of $2.0 million and $5.4 million compared to the same periods in the prior year, respectively, offset by softness in AngioVac sales of of 15.7% and 8.2% compared to the same periods in the prior year, respectively; and
•Increased NanoKnife sales of $0.2 million and $1.9 million compared to the same periods in the prior year, respectively, which was primarily driven by increased probe sales domestically and internationally.
The Med Device segment net sales increased $3.5 million and $4.4 million for the three and nine months ended February 28, 2023 compared to the same periods in the prior year, respectively. The change in sales for both periods was primarily driven by:
•The backlog of $5.4 million at February 28, 2023, which primarily impacted sales of Core and Vascular Access products; and
•Increased sales of Core, Ports and Dialysis, despite the impact of the backlog, along with increased Microwave and other Oncology sales for the three months ended February 28, 2023 compared to the same period in the prior year of $2.1 million, $1.4 million, $1.1 million, $0.7 million and $0.5 million, respectively. These increases were partially offset by decreased Venous, PICCs and Midlines sales for the three months ended February 28, 2023 compared to the same period in the prior year of $1.4 million, $0.6 million and $0.4 million, respectively; and
26
•Increased sales of Core, Dialysis and Ports, despite the impact of the backlog, along with increased Microwave sales for the nine months ended February 28, 2023 compared to the same period in the prior year of $4.9 million, $3.9 million, $1.4 million and $1.3 million, respectively. These increases were partially offset by decreased Venous, PICCs, Midlines and other Oncology and Vascular Access sales for the nine months ended February 28, 2023 compared to the same period in the prior year of $3.1 million, $1.9 million, $0.8 million and $1.3 million, respectively.

Gross Profit
Three Months Ended
Nine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022% ChangeFeb 28, 2023Feb 28, 2022$ Change
Med Tech $14,774 $12,965 14.0 %$44,816 $37,060 20.9 %
Gross profit % of sales64.6 %66.1 %63.8 %66.1 %
Med Device$25,730 $25,618 0.4 %$83,071 $82,217 1.0 %
Gross profit % of sales44.5 %47.1 %46.8 %47.5 %
Total $40,504 $38,583 5.0 %$127,887 $119,277 7.2 %
Gross profit % of sales50.2 %52.2 %51.6 %52.0 %
Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.
Total Company gross profit increased by $1.9 million and $8.6 million for the three months and nine months ended February 28, 2023 compared to the same periods in the prior year. The change for both periods was primarily driven by:
•Sales volume, which positively impacted gross profit by $3.7 million and $10.6 million, respectively;
•Production volume, mix and other incentives which positively impacted gross profit by $1.8 million and $11.1 million, respectively;
•Pricing, which negatively impacted gross profit by $0.5 million and $3.8 million, respectively;
•Inflationary costs on raw materials, labor shortages and freight costs, which negatively impacted gross profit by $1.7 million and $6.9 million, respectively;
•Depreciation on placement units of $0.5 million and $1.7 million, respectively; and
•A benefit of $0.8 million that was recorded as a result of the employee retention credit that the Company filed for under the provision of the CARES Act in the third quarter of the prior year.

The Med Tech segment gross profit increased by $1.8 million and $7.8 million for the three and nine months ended February 28, 2023 compared to the same periods in the prior year. The change for both periods was primarily driven by:    
•Sales volume, which positively impacted gross profit by $2.6 million and $11.2 million, respectively;
•Production volume, overhead, manufacturing and other incentives which positively impacted gross profit by $0.5 million and $2.7 million, respectively;
•Pricing pressures and mix, which negatively impacted gross profit by $0.9 million and $4.7 million, respectively;
•Inflationary costs on raw materials, labor shortages and freight costs, which negatively impacted gross profit by $0.1 million and $0.5 million, respectively; and
•Depreciation on placement units of $0.4 million and $1.0 million, respectively.

The Med Device segment gross profit increased by $0.1 million and $0.9 million for the three and nine months ended February 28, 2023 compared to the same periods in the prior year. The change for both periods was primarily driven by:
    
•Sales volume, which positively impacted gross profit by $1.5 million and $1.6 million, respectively;
•Production volume, manufacturing and other incentives which positively impacted gross profit by $0.4 million and $6.8 million, respectively;
•Pricing pressures and mix, which negatively impacted gross profit by $0.1 million and $0.8 million, respectively;
•Inflationary costs on raw materials, labor shortages and freight costs, which negatively impacted gross profit by $1.6 and $6.4 million, respectively; and
•Depreciation on placement units of $0.1 million and $0.3 million, respectively.


27
Operating Expenses, and Other Income (expense)
Three Months Ended
Nine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022% ChangeFeb 28, 2023Feb 28, 2022% Change
Research and development$6,852 $7,280 (5.9)%$22,023 $22,873 (3.7)%
% of sales8.5 %9.8 %8.9 %10.0 %
Selling and marketing$25,406 $20,416 24.4 %$77,956 $68,468 13.9 %
% of sales31.5 %27.6 %31.5 %29.9 %
General and administrative$8,839 $8,727 1.3 %$29,775 $27,348 8.9 %
% of sales11.0 %11.8 %12.0 %11.9 %
Research and development expense - Research and development (“R&D”) expense includes internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.
R&D expense decreased $0.4 million and $0.9 million for the three and nine months ended February 28, 2023 compared to the same periods in the prior year, respectively. The change for both periods was primarily driven by:
•The timing of certain projects and clinical spend associated with the ongoing clinical trials, which decreased R&D expense by $0.7 million and $1.3 million, respectively;
•Compensation and benefits expenses, which decreased $0.1 million for the three months ended February 28, 2023; and
•A benefit of $0.5 million that was recorded as a result of the employee retention credit that the Company filed for under the provision of the CARES Act in the third quarter of the prior year.

Sales and marketing expense - Sales and marketing (“S&M”) expense consists primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.
S&M expense increased $5.0 million and $9.5 million for the three and nine months ended February 28, 2023 compared to the same periods in the prior year, respectively. The change for both periods was primarily driven by:
•Additional headcount from the build-out of the Auryon and mechanical thrombectomy sales and marketing teams, which increased compensation and benefits expense by $0.9 million and $3.4 million, respectively; and
•Travel, meeting, tradeshow and other selling expenses, which increased $1.3 million and $3.9 million, respectively;
•Other fixed expenses (utilities, insurance, depreciation, etc.), which decreased $0.2 million and $0.5 million, respectively; and
•A benefit of $2.8 million that was recorded as a result of the employee retention credit that the Company file for under the provision of the CARES Act in the third quarter of the prior year.

General and administrative expense - General and administrative (“G&A”) expense includes executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.
G&A expense increased $0.1 million and $2.4 million for the three and nine months ended February 28, 2023 compared to the same periods in the prior year, respectively. The change for both periods was primarily driven by:
•Compensation and benefits expenses, which increased $0.3 million for the nine months ended February 28, 2023 and decreased $0.2 million for the three months ended February 28, 2023; and
•Other outside consultant spend for legal and IT which increased $0.3 million and $2.0 million, respectively.
28
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022$ ChangeFeb 28, 2023Feb 28, 2022$ Change
Amortization of intangibles$4,739 $4,895 $(156)$14,384 $14,605 $(221)
Change in fair value of contingent consideration$227 $201 $26 $2,084 $1,005 $1,079 
Acquisition, restructuring and other items, net$3,369 $2,359 $1,010 $12,009 $7,052 $4,957 
Other expense, net$(736)$(462)$(274)$(2,228)$(1,154)$(1,074)
Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.
•Amortization expense remained consistent with the prior year.
Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.
•The change in the fair value for the nine months ended February 28, 2023 is related to the Eximo contingent consideration and the increased probability of achieving the revenue milestones.
Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.
Acquisition, restructuring and other items, net, increased by $1.0 million and $5.0 million for the three and nine months ended February 28, 2023, compared to the same periods in the prior year, respectively. The change for both periods was primarily driven by:
•Legal expense, related to litigation that is outside of the normal course of business, which increased $0.9 million and $1.1 million, respectively;
•Manufacturing relocation expense related to the move of certain manufacturing lines to Costa Rica, which decreased $0.1 million for the three months ended February 28, 2023 and increased $0.6 million for the nine months ended February 28, 2023;
•Other expenses (mainly severance associated with organizational changes), which increased $0.1 million for the three months ended February 28, 2023 and decreased $0.2 million for the nine months ended February 28, 2023; and
•The payment to the Israeli Innovation Authority of $3.5 million related to grant funds that were provided to Eximo to develop the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020. These grant funds were fully repaid in the first quarter of fiscal year 2023 to satisfy the obligation which was otherwise being paid as a royalty based on a percentage of sales.

Other expense, net - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.
•The change in other expense of $0.3 million and $1.1 million for the three and nine months ended February 28, 2023, respectively, compared to the same periods in the prior year, is primarily due to increased interest expense of $0.6 million and $1.3 million, respectively and unrealized foreign currency fluctuations of $0.3 million and $0.2 million, respectively.
29
Income Tax Benefit
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Income tax benefit$(0.2)$(0.8)$(1.6)$(2.9)
Effective tax rate including discrete items1.9 %13.9 %4.9 %12.7 %
Our effective tax rate including discrete items for the three months ended February 28, 2023 and 2022 was 1.9% and 13.9%, respectively. Our effective tax rate including discrete items for the nine months ended February 28, 2023 and 2022 was 4.9% and 12.7%, respectively. In fiscal year 2023, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share-based compensation).
Liquidity and Capital Resources
We regularly review our liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 global pandemic. We believe that our current cash on hand and availability under our Credit Agreement provides sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. We are closely monitoring receivables and payables.
Our cash and cash equivalents totaled $30.1 million as of February 28, 2023, compared with $28.8 million as of May 31, 2022. As of February 28, 2023 and May 31, 2022, total debt outstanding related to the Credit Agreement was $50.0 million ($25.0 million on the Revolving Facility and $25.0 million on the Delayed Draw Term Loan) and $25.0 million, respectively. The fair value of contingent consideration liability as of February 28, 2023 and May 31, 2022, was $19.1 million and $16.9 million, respectively.
The table below summarizes our cash flows:
Nine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022
Cash provided by (used in):
Operating activities$(15,876)$(15,754)
Investing activities(8,218)(15,534)
Financing activities25,420 7,354 
Effect of exchange rate changes on cash and cash equivalents(40)(337)
Net change in cash and cash equivalents$1,286 $(24,271)
During the quarters ended February 28, 2023 and 2022, cash flows consisted of the following:
Cash used in operating activities
Nine months ended February 28, 2023 and 2022:
•Net loss of $31.0 million and $20.3 million, respectively, plus the non-cash items, primarily driven by depreciation and amortization and stock based compensation, along with the changes in working capital below, contributed to cash used in operations of $15.9 million and $15.8 million, respectively, for these periods.
•For the period ended February 28, 2023, working capital was unfavorably impacted by decreased accounts payable, accrued liabilities and other liabilities of $7.1 million, along with increased inventory and prepaid expenses of $12.3 million and $0.4 million, respectively, partially offset by decreased accounts receivable of $0.8 million.
•For the period ended February 28, 2022, working capital was unfavorably impacted by decreased accounts payable, accrued liabilities and other liabilities of $11.8 million, along with increased receivables and prepaid expenses of $6.4 million and $7.1 million, respectively.
Cash used in investing activities
Nine months ended February 28, 2023 and 2022:
•$2.8 million and $3.3 million, respectively, of cash was used for fixed asset additions;
•$4.9 million and $8.7 million, respectively, of cash was used for Auryon placement and evaluation unit additions;
•$0.5 million of cash was used for the acquisition of an exclusive license in the first quarter of fiscal year 2023; and
•$3.6 million of cash was used for the QX Medical asset acquisition in the first quarter of fiscal year 2022.
30
Cash provided by financing activities
Nine months ended February 28, 2023 and 2022:
•$70.0 million in proceeds on long-term debt less the repayment of $45.0 million associated with the new Credit Agreement in the first quarter of fiscal year 2023. The $25.0 million draw on the Delayed Draw Term Loan associated with the new Credit Agreement is to fund the historical and planned fiscal year 2023 purchases of Auryon placement and evaluation units. See Note 7 "Long-Term Debt" set forth in the Notes to the consolidated financial statements;
•$0.8 million of deferred financing costs associated with the new Credit Agreement;
•$5.0 million draw on the Revolving Facility in the first quarter of fiscal year 2022 for the QX Medical asset acquisition; and
•$1.2 million and $2.4 million, respectively, of proceeds from stock option and ESPP activity.
On August 30, 2022, the Company repaid all amounts outstanding under its then existing credit agreement and entered into a new Credit Agreement. The new Credit Agreement provides for a $75.0 million Revolving Facility and a $30.0 million Delayed Draw Term Loan, and also includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million.  The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. One financial covenant requires us to maintain a fixed charge coverage ratio of not less than 1.25 to 1.00. The other financial covenant requires us to maintain a total leverage ratio of not greater than 3.00 to 1.00. The total leverage ratio is based upon our trailing twelve months total adjusted EBITDA (as defined in the Credit Agreement). The amount that we can borrow under our Credit Agreement is directly based on our leverage ratio. The interest rate at February 28, 2023 applicable to each was 6.15%. The Company was in compliance with the Credit Agreement covenants as of February 28, 2023.
In the first quarter of fiscal year 2023 and in connection with the new Credit Agreement, the Company drew $25.0 million on the Revolving Facility. The Company also drew $25.0 million on the Delayed Draw Term Loan to fund the historical and planned fiscal year 2023 purchases of Auryon placement and evaluation units for total long-term debt outstanding of $50.0 million. In the first quarter of fiscal year 2022, the Company made a $5.0 million draw on the Revolving Facility in conjunction with the QX Medical asset acquisition. We believe that our current cash balance, together with cash generated from operations and access to our Revolving Facility, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make acquisitions of other businesses or technologies in the future for cash, we may require external financing.
New Accounting Pronouncements
Information regarding new accounting pronouncements is included in Note 17 to our consolidated financial statements in this Quarterly Report on Form 10-Q.
31
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Foreign Currency Exchange Rate Risk
We are exposed to market risk from changes in currency exchange rates, as well as interest rate fluctuations on our Credit Agreement and investments that could impact our results of operations and financial position.
We transact sales in currencies other than the U.S. Dollar, particularly the Euro, British Pound and Canadian Dollar. For the nine months ended February 28, 2023, approximately 5% of our sales were denominated in foreign currencies. We do not have expenses denominated in foreign currencies at the level of our sales and as a result, our profitability is exposed to currency fluctuations. When the U.S. Dollar strengthens, our sales and gross profit will be negatively impacted. In addition, we have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period, with the offset to changes presented as a component of Other (Expenses) Income. Significant non-functional balances include accounts receivable due from a sub-section of our international customers.
Interest Rate Risk
The Credit Agreement provides for a $75.0 million Revolving Facility and a $30.0 million Delayed Draw Term Loan. Interest on the Revolving Facility and Delayed Draw Term Loan will be based, at the Company's option, on a rate equal to (i) the SOFR plus 0.10% (subject to a floor of 0%), or (ii) if the Company elects to treat a borrowing as an ABR Borrowing, an alternate base rate based on SOFR, plus, in each case an applicable margin of 1.25%, 1.50% or 1.75%, depending on the leverage ratio. If any amount is not paid when due, the interest rate may be increased by 2.0%. As of February 28, 2023, there was $25.0 million outstanding on the Delayed Draw Term Loan and $25.0 million outstanding on the Revolving Facility and the interest rate at February 28, 2023 was 6.15%.
Concentration of Credit Risk
Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, our Credit Facility and trade accounts receivable.
The Company maintains cash and cash equivalents at various institutions and performs periodic evaluations of the relative credit standings of these financial institutions to ensure their credit worthiness. In addition, the Credit Agreement is structured across three above investment grade banks. The Company has the ability to draw amongst the three banks which limits the concentration of credit risk of one institution.
Concentration of credit risk with respect to trade accounts receivable is limited due to the large number of customers that purchase products from the Company. No single customer represents more than 10% of total sales. The Company monitors the creditworthiness of its customers. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers. Although the Company does not currently foresee a significant credit risk associated with the outstanding accounts receivable, repayment is dependent upon the financial stability of our customers.
32
Item 4. Controls and Procedures.
Evaluation of disclosure controls and procedures
As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting for the fiscal quarter ended February 28, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

33
AngioDynamics, Inc. and Subsidiaries
PART II: OTHER INFORMATION
Item 1. Legal Proceedings.
See Note 14 "Commitments and Contingencies" set forth in the notes to our consolidated financial statements included in Part I, Item I of this Quarterly Report on Form 10-Q.
Item 1A. Risk Factors.
In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2022 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
The following table provides information with respect to the shares of the Company’s common stock repurchased during the three months ended February 28, 2023:
Issuer Purchases of Equity Securities
Total
Number of
Shares
Purchased (1)		Average
Price Paid
per Share		Total
Number of
Shares
Purchased
as Part of
Publicly
Announced
Programs (2)		Maximum
Approximate
Dollar Value
of Shares
that May Yet
Be
Purchased
Under Plans
or Programs (2)
December 1, 2022 - December 31, 2022— $12.76 — $— 
January 1, 2023 -January 31, 2023— $13.64 — $— 
February 1, 2023 - February 28, 20232,725 $12.97 — $— 
Total2,725 $12.97 — — 
(1)These shares were purchased from employees to satisfy tax withholding requirements on the vesting of restricted shares/units from equity-based awards.
(2)These amounts are not applicable as the Company currently does not have a share repurchase program in effect.
Item 3. Defaults on Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
Item 5. Other Information.
None.
34
Item 6
EXHIBIT INDEXIncorporated by Reference
No.DescriptionFormExhibit Filing Date
31.1
31.2
32.1
32.2
101.INSThe instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document
101.SCHXBRL Schema Document
101.CALXBRL Calculation Linkbase Documents
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.LABXBRL Labels Linkbase Documents
101.PREXBRL Presentation Linkbase Documents

35
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
ANGIODYNAMICS, INC.
(Registrant)
Date:March 31, 2023
/ S /    JAMES C. CLEMMER      
James C. Clemmer, President,
Chief Executive Officer
(Principal Executive Officer)
Date:March 31, 2023/ S /    STEPHEN A. TROWBRIDGE 
Stephen A. Trowbridge, Executive Vice President,
Chief Financial Officer
(Principal Financial and Accounting Officer)

36
 EX-31.1 2 a02282023-exx311.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATION

I, James C. Clemmer, certify that:
1.I have reviewed this quarterly report on Form 10-Q of AngioDynamics, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 31, 2023

/ S / JAMES C. CLEMMER
James C. Clemmer, President,
Chief Executive Officer

 EX-31.2 3 a02282023-exx312.htm EX-31.2 Document

Exhibit 31.2

CERTIFICATION

I, Stephen A. Trowbridge, certify that:
1.I have reviewed this quarterly report on Form 10-Q of AngioDynamics, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 31, 2023

/ S / STEPHEN A. TROWBRIDGE
Stephen A. Trowbridge, Executive Vice President,
Chief Financial Officer


 EX-32.1 4 a02282023-exx321.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO TITLE 18,
UNITED STATES CODE, SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, James C. Clemmer, President, Chief Executive Officer and Director of ANGIODYNAMICS, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge:

1.
the quarterly report on Form 10-Q of the Company for the fiscal quarter ended February 28, 2023 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 31, 2023

/ S / JAMES C. CLEMMER
James C. Clemmer, President,
Chief Executive Officer


 EX-32.2 5 a02282023-exx322.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO TITLE 18,
UNITED STATES CODE, SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen A. Trowbridge, Executive Vice President and Chief Financial Officer of ANGIODYNAMICS, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge:

1.
the quarterly report on Form 10-Q of the Company for the fiscal quarter ended February 28, 2023 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 31, 2023

/ S / STEPHEN A. TROWBRIDGE
Stephen A. Trowbridge, Executive Vice President,
Chief Financial Officer


EX-101.SCH 6 ango-20230228.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Consolidated Financial Statements link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Revenue from Contracts with Customers link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Segment and Geographic Information link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Acquisition, Restructuring and Other Items, Net link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Recently Issued Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Recently Issued Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Revenue from Contracts with Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Segment and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Acquisition, Restructuring and Other Items, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Revenue from Contracts with Customers - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Revenue from Contracts with Customers - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Revenue from Contracts with Customers - Contract Balances with Customers (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Goodwill and Intangible Assets - Change in Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Goodwill and Intangible Assets - Expected Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Long-Term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Long-Term Debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Share-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Segment and Geographic Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Segment and Geographic Information - Summary of Net Sales by Product Category (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Segment and Geographic Information - Summary of Net Sales by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Fair Value - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Leases - Liability Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Leases - Liability Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Leases - Supplemental Statement of Operations Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Leases - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Acquisition, Restructuring and Other Items, Net (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ango-20230228_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 ango-20230228_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 ango-20230228_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Asset Acquisition [Axis] Asset Acquisition [Axis] Commitments and Contingencies Legal Matters and Contingencies [Text Block] Work in process Inventory, Work in Process, Gross Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Operating lease ROU asset Operating Lease, Right-of-Use Asset Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Payroll and related expenses Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Range [Domain] Statistical Measurement [Domain] Mergers and acquisitions Mergers and Acquisitions [Member] Mergers and Acquisitions [Member] Sales and franchise taxes Sales and Excise Tax Payable, Current Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code C.R. Bard, Inc. Cr Bard Inc [Member] C.R. Bard, Inc. [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Contract Balances with Customers Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Weighted average remaining term (in years) Operating Lease, Weighted Average Remaining Lease Term Manufacturing relocation Manufacturing Relocation [Member] Manufacturing Relocation Number of patents allegedly infringed upon Loss Contingency, Patents Allegedly Infringed, Number Other assets Other Assets, Noncurrent Other comprehensive income (loss), before tax Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Principal payment percentage Debt Instrument, Redemption Price, Percentage Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Floor interest rate Debt Instrument, Floor Interest Rate Debt Instrument, Floor Interest Rate Amortization of intangibles Amortization of Intangible Assets Accrual for capital expenditures incurred during the period Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Research and development Accrued Research And Development, Current Accrued Research And Development, Current Fixed and intangible asset impairments and disposals Impairment of Long-Lived Assets to be Disposed of Acquisition, restructuring and other items, net Acquisition Restructuring and Other Items Net Acquisition Restructuring And Other Items Net. Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Securities excluded as their inclusion would be anti-dilutive (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Research and development Research and Development Expense [Member] Preferred Stock Purchase Rights Preferred Stock Purchase Rights [Member] Preferred Stock Purchase Rights [Member] Business Combination and Asset Acquisition [Abstract] Commitment fee (percentage) Line of Credit Facility, Commitment Fee Percentage Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Proceeds from exercise of stock options and employee stock purchase plan Proceeds (Outlays), Issuance Of Shares, Share-based Payment Arrangement, Including Option Exercised Proceeds (Outlays), Issuance Of Shares, Share-based Payment Arrangement, Including Option Exercised Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Equity Award [Domain] Award Type [Domain] Local Phone Number Local Phone Number Credit Facility [Domain] Credit Facility [Domain] Assets Assets [Abstract] Concentration risk percentage Concentration Risk, Percentage Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Intangible asset acquired Finite-lived Intangible Assets Acquired Accumulated deficit Retained Earnings [Member] Prepaid expenses and other Increase (Decrease) in Prepaid Expense and Other Assets Weighted average shares outstanding Weighted Average Number Of Shares Outstanding, Basic And Diluted [Abstract] Weighted Average Number Of Shares Outstanding, Basic And Diluted Payment for acquisition Payments for Previous Acquisition Change in present value of contingent consideration Change in Fair Value of Contingent Consideration The expense charged against earnings in the period resulting from remeasurement to fair value of contingent earn out liabilities related to acquisitions. Contingent consideration, liability, measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Gross margin Gross Margin, Percentage Gross Margin, Percentage Delayed Draw Term Loan Secured Debt [Member] Accounts receivable Increase (Decrease) in Accounts Receivable ROU assets obtained in exchange for lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Number of operating segments Number of Operating Segments Current portion of contingent consideration Business Combination, Contingent Consideration, Liability, Current Loss per share, basic (USD per share) Earnings Per Share, Basic Non-cash lease expense Operating Lease, Expense Non-cash lease expense Non-Cash Lease Expense Non-Cash Lease Expense 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Revenue from Contracts with Customers Revenue from Contract with Customer [Text Block] Document Information [Line Items] Document Information [Line Items] No Trading Symbol Flag No Trading Symbol Flag Revenue based payments Revenue Based Payment [Member] Revenue Based Payment [Member] Financial liabilities, beginning balance Financial liabilities, ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Reporting Unit [Domain] Reporting Unit [Domain] Raw materials Inventory, Raw Materials, Gross Geographic Concentration Risk Geographic Concentration Risk [Member] Operating cash flows from operating leases Operating Lease, Payments Amount of shares issuable through two stock-based compensation plans (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Other Other Noncash Income (Expense) Change in accounts receivable allowances Accounts Receivable, Credit Loss Expense (Reversal) Summary of Net Sales by Geographic Area Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Long-term debt, gross Long-term Debt, Gross Goodwill [Roll Forward] Goodwill [Roll Forward] Summary of Net Sales by Product Category Schedule of Net Revenue by Product Group [Table Text Block] Schedule of net revenue by product group. Reporting Unit [Axis] Reporting Unit [Axis] Plan Name [Axis] Plan Name [Axis] Outstanding draw term loan Total long-term debt Long-term Debt Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] 2028 and thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Three Lessee, Operating Lease, Liability, To Be Paid, After Year Three Goodwill impairment Goodwill, Impairment Loss Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Number of petitions filed for reexamination of patents Number Of Patents Asserted For Reexamination Number of patents asserted for reexamination. Base Rate Base Rate [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total Liabilities and Stockholders' Equity Liabilities and Equity Other Other Accrued Liabilities, Current Purchase price holdbacks Contract with Customer, Liability, Current Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Liabilities and stockholders' equity Liabilities and Equity [Abstract] Earnings Per Share Earnings Per Share [Text Block] Operating expenses: Operating Expenses [Abstract] Entity Interactive Data Current Entity Interactive Data Current 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] Consolidated Financial Statements Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Gross profit Gross profit Gross Profit 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Borrowings outstanding Long-term Line of Credit Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Currency gain from remeasurement Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Currency Gain (Loss) From Remeasurement Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Currency Gain (Loss) From Remeasurement Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Total Financial Liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Less: unamortized debt issuance costs Debt Issuance Costs, Net Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Probability of payment Measurement Input, Probability of Payment [Member] Measurement Input, Probability of Payment [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Address, State or Province Entity Address, State or Province Current liabilities Liabilities, Current [Abstract] General and administrative General and Administrative Expense Cash paid for acquisitions Payments to Acquire Businesses, Net of Cash Acquired Foreign currency translation income Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Beginning Balance (in shares) Ending Balance (in shares) Shares, Outstanding Credit Facility Line of Credit [Member] Share-Based Compensation Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Number of patents upheld over prior art references Number Of Patents Upheld Over Prior Art References Number Of Patents Upheld Over Prior Art References Inventories Inventory Disclosure [Text Block] Accounting Policies [Abstract] Accounting Policies [Abstract] Outside services Accrued Professional Fees, Current Total lease liabilities Operating Lease, Liability Document Transition Report Document Transition Report Common stock, par value $0.01 per share, 75,000,000 shares authorized; 39,976,422 and 39,541,173 shares issued and 39,606,422 and 39,171,173 shares outstanding at February 28, 2023 and May 31, 2022, respectively Common Stock, Value, Issued Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total other expense, net Nonoperating Income (Expense) Recognition period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Treasury Stock Treasury Stock, Common [Member] Performance share units Performance Shares [Member] Commitments and contingencies (Note 14) Commitments and Contingencies Leases Lessee, Operating Leases [Text Block] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Accounts receivable, allowances Accounts Receivable, Allowance for Credit Loss, Current Remainder of 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Acquisitions Business Combination Disclosure [Text Block] Deferred financing costs on long-term debt Payments of Debt Issuance Costs Employee Stock Purchase Plan Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan Legal Legal Costs [Member] Legal Costs [Member] Maximum total leverage ratio Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio Cover page. Cover [Abstract] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Goodwill [Line Items] Goodwill [Line Items] Days after purchase after which pre-approval is required for product return Contract With Customer, Right Of Return, Product Return Period After Purchase Date Requiring Pre-Approval Contract With Customer, Right Of Return, Product Return Period After Purchase Date Requiring Pre-Approval Class of Stock [Axis] Class of Stock [Axis] Less: Imputed Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Potential amount of undiscounted future contingent consideration Undiscounted Contingent Consideration Disclosure Undiscounted Contingent Consideration Disclosure Prepaid expenses and other Prepaid Expense and Other Assets, Current Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Net sales Revenue from Contract with Customer, Excluding Assessed Tax Document Information [Table] Document Information [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Equity [Abstract] Equity [Abstract] Document Quarterly Report Document Quarterly Report Measurement Input Type [Domain] Measurement Input Type [Domain] Common Stock Common Stock [Member] Variable Rate [Axis] Variable Rate [Axis] Other expense: Other Nonoperating Income (Expense) [Abstract] Other comprehensive loss, net of tax OCI, before Reclassifications, Net of Tax, Attributable to Parent Segment and Geographic Information Segment Reporting Disclosure [Text Block] Operating loss Operating Income (Loss) Current operating lease liabilities Operating Lease, Liability, Current 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Treasury stock, shares (in shares) Beginning Balance, Treasury (in shares) Ending Balance, Treasury (in shares) Treasury Stock, Common, Shares Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Stock based compensation Share-based Payment Arrangement, Noncash Expense Variable Rate [Domain] Variable Rate [Domain] Acquisition, Restructuring and Other Items, Net Restructuring and Related Activities Disclosure [Text Block] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Additional paid in capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Technology-Based Intangible Assets Technology-Based Intangible Assets [Member] Income tax expense related to items of other comprehensive income (loss) Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] QX Medical, LLC Camaro Support Catheter Asset Acquisition QX Medical, LLC Camaro Support Catheter Asset Acquisition [Member] QX Medical, LLC Camaro Support Catheter Asset Acquisition Operating lease, liability, current, statement of financial position, extensible list Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Product technologies Product Technologies [Member] Product technologies. Other expense, net Other Nonoperating Income (Expense) Additions to property, plant and equipment Payments to Acquire Property, Plant, and Equipment Other current liabilities Other Liabilities, Current Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Interest rate at period end (percentage) Line of Credit Facility, Interest Rate at Period End Maximum Maximum [Member] Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Award Type [Axis] Award Type [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Lease Liability Schedule Lessee, Operating Lease, Liability, Maturity [Table Text Block] Measurement Input Type [Axis] Measurement Input Type [Axis] Total Stockholders’ Equity Beginning Balance Ending Balance Stockholders' Equity Attributable to Parent Common stock, shares issued (in shares) Common Stock, Shares, Issued Approved increase of common stock reserve (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease) Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued City Area Code City Area Code Accounts payable, accrued and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Entity Address, City or Town Entity Address, City or Town Payment term Revenue, Performance Obligation, Payment Term Revenue, Performance Obligation, Payment Term Minimum remaining period prior to product expiration Contract With Customer, Right Of Return, Minimum Remaining Product Life Prior To Return Contract With Customer, Right Of Return, Minimum Remaining Product Life Prior To Return Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] 2020 Stock And Incentive Award Plan 2020 Stock And Incentive Award Plan [Member] 2020 Stock And Incentive Award Plan Accumulated Other Comprehensive Income Comprehensive Income (Loss) Note [Text Block] Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Term loan Debt Instrument, Face Amount Interest expense, net Interest Expense Accumulated deficit Retained Earnings (Accumulated Deficit) Litigation Case [Domain] Litigation Case [Domain] Restricted stock units Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Purchase of common stock under ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Entity Filer Category Entity Filer Category Business Acquisition [Line Items] Business Acquisition [Line Items] Net Assets, Geographic Area Net Assets, Geographic Area [Member] Discounted cash flow Valuation Technique, Discounted Cash Flow [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Registrant Name Entity Registrant Name Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Fair Value Measurements Using Significant Unobservable Inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Recently Issued Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax benefit Income Tax Expense (Benefit) Accounts receivable, net of allowances of $2,030 and $1,939 respectively Receivables Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Proceeds from borrowings on long-term debt Proceeds from Issuance of Long-term Debt Equity Components [Axis] Equity Components [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Tax Identification Number Entity Tax Identification Number Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Other comprehensive income (loss), before tax: Other Comprehensive Income (Loss), before Tax [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Sales and marketing Selling and Marketing Expense [Member] Total lease payments Lessee, Operating Lease, Liability, to be Paid Concentration Risk Type [Domain] Concentration Risk Type [Domain] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Inventories Inventories Inventory, Net Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Contingent consideration, net of current portion Business Combination, Contingent Consideration, Liability, Noncurrent Product and Service [Axis] Product and Service [Axis] Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding Schedule of Weighted Average Number of Shares [Table Text Block] Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Equity Component [Domain] Equity Component [Domain] Issuance/Cancellation of performance share units and restricted stock units, net (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Sales and marketing Selling and Marketing Expense 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Intangible Assets Schedule of Intangible Assets [Table Text Block] Schedule of intangible assets. Statement [Line Items] Statement [Line Items] Litigation Case [Axis] Litigation Case [Axis] Issuance/Cancellation of performance share units and restricted stock units Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Debt Disclosure [Abstract] Debt Disclosure [Abstract] Loss before income tax benefit Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Number of covenants Line Of Credit Facility, Number Of Covenants Line Of Credit Facility, Number Of Covenants Segment Reporting [Abstract] Segment Reporting [Abstract] Estimated useful life of intangible assets other than goodwill Finite-Lived Intangible Asset, Useful Life Other Other Expense [Member] Long-term debt Loans Payable, Noncurrent Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Maximum total leverage ratio subsequent to material acquisitions Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio, Subsequent To Material Acquisitions Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio, Subsequent To Material Acquisitions Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Med Device Med Device [Member] Med Device Title of 12(b) Security Title of 12(b) Security Total assets Assets Assets Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Geographical [Domain] Geographical [Domain] Document Type Document Type Product and Service [Domain] Product and Service [Domain] Research and development Research and Development Expense Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Contingent consideration for acquisition earn outs Contingent consideration, liabilities Business Combination, Contingent Consideration, Liability Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving Credit Facility Revolving Credit Facility [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Supplemental Cash Flow Information Lease, Cost [Table Text Block] Loss per share Earnings Per Share, Basic [Abstract] Geographical [Axis] Geographical [Axis] Basic weighted average shares outstanding (in shares) Basic (shares) Weighted Average Number of Shares Outstanding, Basic Loss per share, diluted (USD per share) Earnings Per Share, Diluted Effect of dilutive securities (shares) Weighted Average Number Diluted Shares Outstanding Adjustment International Non-US [Member] 2028 and thereafter Finite-Lived Intangible Asset, Expected Amortization, After Year Four Finite-Lived Intangible Asset, Expected Amortization, After Year Four Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Total comprehensive loss, net of tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Contract liabilities Contract with Customer, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Treasury stock, 370,000 shares at February 28, 2023 and May 31, 2022, respectively Treasury Stock, Value Inventory and fixed assets Asset Acquisition, Inventory And Fixed Assets Asset Acquisition, Inventory And Fixed Assets Fair Value Fair Value Disclosures [Text Block] Accounts payable Accounts Payable, Current Concentration Risk Type [Axis] Concentration Risk Type [Axis] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Fair Value of Assets and Liabilities Measured on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Accumulated other comprehensive income AOCI Attributable to Parent [Member] Remainder of 2023 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Inventories Increase (Decrease) in Inventories Royalties Accrued Royalties, Current Contract assets Contract with Customer, Asset, after Allowance for Credit Loss Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Cost of sales (exclusive of intangible amortization) Cost of Goods and Services Sold Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Document Period End Date Document Period End Date Number of reporting units Number of Reporting Units Entity Central Index Key Entity Central Index Key Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Income Statement Location [Domain] Income Statement Location [Domain] Debt instrument term (years) Debt Instrument, Term Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Supplemental disclosure of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Customer relationships Customer Relationships [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Property, plant and equipment, net Property, Plant and Equipment, Net Total operating expenses Operating Expenses Minimum fixed charge coverage ratio Debt Instrument, Covenant Terms, Minimum Fixed Charge Coverage Ratio Debt Instrument, Covenant Terms, Minimum Fixed Charge Coverage Ratio Other long-term liabilities Other Liabilities, Noncurrent Schedule of Principal Obligations Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Repayment of long-term debt Repayments of Long-term Debt Trading Symbol Trading Symbol Earnings Per Share [Abstract] Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Trademarks Trademarks [Member] Finished goods Inventory, Finished Goods, Gross Aggregate purchase price Asset Acquisition, Consideration Transferred Operating lease, liability, noncurrent, statement of financial position, extensible list Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Additions to placement and evaluation units Payments to Acquire Equipment on Lease Asset Acquisition [Domain] Asset Acquisition [Domain] Financial Liabilities Liabilities, Fair Value Disclosure [Abstract] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Charges against income for share-based payment arrangements Share-based Payment Arrangement, Expense Entity Current Reporting Status Entity Current Reporting Status Deferred income taxes Deferred Income Taxes and Other Liabilities, Noncurrent Inventory valuation reserves Inventory Valuation Reserves Payables and Accruals [Abstract] Payables and Accruals [Abstract] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents United States UNITED STATES Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Discount rate Measurement Input, Discount Rate [Member] Current assets Assets, Current [Abstract] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Gross carrying value, finite intangible items Finite-Lived Intangible Assets, Gross Leases [Abstract] Leases [Abstract] Intangible asset amortization period Finite-Lived Intangible Assets, Remaining Amortization Period Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Debt default interest rate increase (percentage) Debt Instrument, Debt Default, Interest Rate Increase Debt Instrument, Debt Default, Interest Rate Increase Entity Address, Postal Zip Code Entity Address, Postal Zip Code Rebates Customer Refund Liability, Current Revenue from Contracts with Customers Revenue from Contract with Customer [Policy Text Block] Exercise of stock option (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Diluted weighted average shares outstanding (in shares) Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax Recurring Fair Value, Recurring [Member] Med Tech Med Tech [Member] Med Tech Income Taxes Income Tax Disclosure [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Basis spread on variable rate (percentage) Debt Instrument, Basis Spread on Variable Rate Licenses License Agreement Terms [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Credit Facility [Axis] Credit Facility [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Entity Address, Address Line One Entity Address, Address Line One Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Purchases of common stock under ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] General and administrative General and Administrative Expense [Member] Entity Shell Company Entity Shell Company Total current liabilities Liabilities, Current Class of Stock [Domain] Class of Stock [Domain] Israeli Innovation Authority Prepayment Israeli Innovation Authority Prepayment [Member] Israeli Innovation Authority Prepayment Line of credit Line of Credit Facility, Maximum Borrowing Capacity Foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Restocking charge (as percent) Contract With Customer, Right Of Return, Restocking Charge Contract With Customer, Right Of Return, Restocking Charge Loss Contingencies [Table] Loss Contingencies [Table] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Line of credit accordion feature Line Of Credit Facility, Maximum Borrowing Capacity, Accordion Feature Line Of Credit Facility, Maximum Borrowing Capacity, Accordion Feature Estimated federal statutory income tax rate Effective Income Tax Rate Reconciliation Before Discreet Items, Percent Effective Income Tax Rate Reconciliation Before Discreet Items, Percent Statement [Table] Statement [Table] Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Revenue recognized Customer With Customer, Liability, Revenue Recognized, Including Current Period Customer With Customer, Liability, Revenue Recognized, Including Current Period Unrecognized compensation expenses related to share-based payment arrangements Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Range [Axis] Statistical Measurement [Axis] Net carrying value, finite intangible items Finite-Lived Intangible Assets, Net Goodwill Beginning balance Ending balance Goodwill Operating lease, right-of-use asset, statement of financial position, extensible list Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Cost of sales Cost of Sales [Member] Potential future contingent consideration Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Change in fair value of contingent consideration Change In Fair Value Of Contingent Consideration One Change In Fair Value Of Contingent Consideration Goodwill for Each Reporting Unit Schedule of Goodwill [Table Text Block] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] The Delaware Action The Delaware Action [Member] The Delaware Action Additions to contract liabilities Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination Long-Term Debt Long-term Debt [Text Block] Gain on contingent consideration for IPR&D Write-off Deferred Income Tax Expense (Benefit) EX-101.PRE 10 ango-20230228_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 ango-20230228_g1.gif begin 644 ango-20230228_g1.gif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�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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page - shares
 9 Months Ended
Feb. 28, 2023
Mar. 30, 2023
Document Information [Line Items]    
Amendment Flag false  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001275187  
Current Fiscal Year End Date --05-31  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Feb. 28, 2023  
Document Transition Report false  
Entity File Number 0-50761  
Entity Registrant Name AngioDynamics, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 11-3146460  
Entity Address, Address Line One 14 Plaza Drive  
Entity Address, City or Town Latham  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 12110  
City Area Code 518  
Local Phone Number 795-1400  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   39,236,422
Entity Filer Category Large Accelerated Filer  
Common Stock    
Document Information [Line Items]    
Title of 12(b) Security Common Stock, par value $.01  
Trading Symbol ANGO  
Security Exchange Name NASDAQ  
Preferred Stock Purchase Rights    
Document Information [Line Items]    
No Trading Symbol Flag true  
Title of 12(b) Security Preferred Stock Purchase Rights  
Security Exchange Name NASDAQ  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Feb. 28, 2023
Feb. 28, 2022
Feb. 28, 2023
Feb. 28, 2022
Income Statement [Abstract]        
Net sales $ 80,712 $ 73,970 $ 247,678 $ 229,221
Cost of sales (exclusive of intangible amortization) 40,208 35,387 119,791 109,944
Gross profit 40,504 38,583 127,887 119,277
Operating expenses:        
Research and development 6,852 7,280 22,023 22,873
Sales and marketing 25,406 20,416 77,956 68,468
General and administrative 8,839 8,727 29,775 27,348
Amortization of intangibles 4,739 4,895 14,384 14,605
Change in fair value of contingent consideration 227 201 2,084 1,005
Acquisition, restructuring and other items, net 3,369 2,359 12,009 7,052
Total operating expenses 49,432 43,878 158,231 141,351
Operating loss (8,928) (5,295) (30,344) (22,074)
Other expense:        
Interest expense, net (736) (173) (1,801) (503)
Other expense, net 0 (289) (427) (651)
Total other expense, net (736) (462) (2,228) (1,154)
Loss before income tax benefit (9,664) (5,757) (32,572) (23,228)
Income tax benefit (179) (799) (1,597) (2,947)
Net loss $ (9,485) $ (4,958) $ (30,975) $ (20,281)
Loss per share        
Loss per share, basic (USD per share) $ (0.24) $ (0.13) $ (0.79) $ (0.52)
Loss per share, diluted (USD per share) $ (0.24) $ (0.13) $ (0.79) $ (0.52)
Weighted average shares outstanding        
Basic weighted average shares outstanding (in shares) 39,509 39,092 39,436 38,959
Diluted weighted average shares outstanding (in shares) 39,509 39,092 39,436 38,959
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Feb. 28, 2023
Feb. 28, 2022
Feb. 28, 2023
Feb. 28, 2022
Statement of Comprehensive Income [Abstract]        
Net loss $ (9,485) $ (4,958) $ (30,975) $ (20,281)
Other comprehensive income (loss), before tax:        
Foreign currency translation (3,562) (1,036) (5,207) 373
Other comprehensive income (loss), before tax (3,562) (1,036) (5,207) 373
Income tax expense related to items of other comprehensive income (loss) 0 0 0 0
Other comprehensive income (loss), net of tax (3,562) (1,036) (5,207) 373
Total comprehensive loss, net of tax $ (13,047) $ (5,994) $ (36,182) $ (19,908)
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Feb. 28, 2023
May 31, 2022
Current assets    
Cash and cash equivalents $ 30,111 $ 28,825
Accounts receivable, net of allowances of $2,030 and $1,939 respectively 50,892 52,304
Inventories 63,532 51,392
Prepaid expenses and other 8,039 10,824
Total current assets 152,574 143,345
Property, plant and equipment, net 45,559 45,005
Intangible assets, net 134,011 152,380
Goodwill 199,976 201,058
Other assets 10,729 10,963
Total assets 542,849 552,751
Current liabilities    
Accounts payable 35,600 28,047
Accrued liabilities 21,775 34,842
Current portion of contingent consideration 9,877 8,783
Other current liabilities 2,380 2,652
Total current liabilities 69,632 74,324
Long-term debt 49,807 25,000
Deferred income taxes 13,490 16,037
Contingent consideration, net of current portion 9,182 8,165
Other long-term liabilities 3,083 4,736
Total liabilities 145,194 128,262
Commitments and contingencies (Note 14)
Stockholders' equity    
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, par value $0.01 per share, 75,000,000 shares authorized; 39,976,422 and 39,541,173 shares issued and 39,606,422 and 39,171,173 shares outstanding at February 28, 2023 and May 31, 2022, respectively 382 380
Additional paid-in capital 596,225 586,879
Accumulated deficit (189,388) (158,413)
Treasury stock, 370,000 shares at February 28, 2023 and May 31, 2022, respectively (5,714) (5,714)
Accumulated other comprehensive income (3,850) 1,357
Total Stockholders’ Equity 397,655 424,489
Total Liabilities and Stockholders' Equity $ 542,849 $ 552,751
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Feb. 28, 2023
May 31, 2022
Statement of Financial Position [Abstract]    
Accounts receivable, allowances $ 2,030 $ 1,939
Preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 75,000,000 75,000,000
Common stock, shares issued (in shares) 39,976,422 39,541,173
Common stock, shares outstanding (in shares) 39,606,422 39,171,173
Treasury stock, shares (in shares) 370,000 370,000
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Feb. 28, 2023
Feb. 28, 2022
Cash flows from operating activities:    
Net loss $ (30,975) $ (20,281)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 23,316 21,682
Non-cash lease expense 1,883 1,822
Stock based compensation 8,177 7,789
Change in fair value of contingent consideration 2,084 1,005
Gain on contingent consideration for IPR&D Write-off (1,752) (3,121)
Change in accounts receivable allowances 560 (66)
Fixed and intangible asset impairments and disposals 144 245
Other (317) (27)
Changes in operating assets and liabilities:    
Accounts receivable 759 (6,441)
Inventories (12,254) 588
Prepaid expenses and other (392) (7,147)
Accounts payable, accrued and other liabilities (7,109) (11,802)
Net cash used in operating activities (15,876) (15,754)
Cash flows from investing activities:    
Additions to property, plant and equipment (2,756) (3,258)
Additions to placement and evaluation units (4,922) (8,676)
Cash paid for acquisitions (540) (3,600)
Net cash used in investing activities (8,218) (15,534)
Cash flows from financing activities:    
Proceeds from borrowings on long-term debt 70,000 5,000
Repayment of long-term debt (45,000) 0
Deferred financing costs on long-term debt (751) 0
Proceeds from exercise of stock options and employee stock purchase plan 1,171 2,354
Net cash provided by financing activities 25,420 7,354
Effect of exchange rate changes on cash and cash equivalents (40) (337)
Increase (decrease) in cash and cash equivalents 1,286 (24,271)
Cash and cash equivalents at beginning of period 28,825 48,161
Cash and cash equivalents at end of period 30,111 23,890
Supplemental disclosure of non-cash investing and financing activities:    
Accrual for capital expenditures incurred during the period $ 140 $ (5)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Restricted stock units
Performance share units
Common Stock
Common Stock
Restricted stock units
Common Stock
Performance share units
Additional paid in capital
Additional paid in capital
Restricted stock units
Additional paid in capital
Performance share units
Accumulated deficit
Accumulated other comprehensive income
Treasury Stock
Beginning Balance (in shares) at May. 31, 2021       38,920,951,000                
Beginning Balance at May. 31, 2021 $ 439,457     $ 377     $ 573,507     $ (131,866) $ 3,153 $ (5,714)
Beginning Balance, Treasury (in shares) at May. 31, 2021                       (370,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (6,972)                 (6,972)    
Exercise of stock option (in shares)       80,635,000                
Exercise of stock options 1,280     $ 1     1,279          
Issuance/Cancellation of performance share units and restricted stock units, net (in shares)         279,495,000 59,371,000            
Issuance/Cancellation of performance share units and restricted stock units   $ (1,734)           $ (1,734)        
Purchase of common stock under ESPP (in shares)       49,789,000                
Purchases of common stock under ESPP 900     $ 1     899          
Stock-based compensation 2,429           2,429          
Other comprehensive loss, net of tax 590                   590  
Ending Balance (in shares) at Aug. 31, 2021       39,390,241,000                
Ending Balance at Aug. 31, 2021 435,950     $ 379     576,380     (138,838) 3,743 $ (5,714)
Ending Balance, Treasury (in shares) at Aug. 31, 2021                       (370,000,000)
Beginning Balance (in shares) at May. 31, 2021       38,920,951,000                
Beginning Balance at May. 31, 2021 439,457     $ 377     573,507     (131,866) 3,153 $ (5,714)
Beginning Balance, Treasury (in shares) at May. 31, 2021                       (370,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (20,281)                      
Ending Balance (in shares) at Feb. 28, 2022       39,520,101,000                
Ending Balance at Feb. 28, 2022 429,692     $ 380     583,647     (152,147) 3,526 $ (5,714)
Ending Balance, Treasury (in shares) at Feb. 28, 2022                       (370,000,000)
Beginning Balance (in shares) at Aug. 31, 2021       39,390,241,000                
Beginning Balance at Aug. 31, 2021 435,950     $ 379     576,380     (138,838) 3,743 $ (5,714)
Beginning Balance, Treasury (in shares) at Aug. 31, 2021                       (370,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (8,351)                 (8,351)    
Exercise of stock option (in shares)       56,064,000                
Exercise of stock options 1,022           1,022          
Issuance/Cancellation of performance share units and restricted stock units, net (in shares)         8,695,000              
Issuance/Cancellation of performance share units and restricted stock units   (83)           (83)        
Purchase of common stock under ESPP (in shares)       193,000                
Purchases of common stock under ESPP 3           3          
Stock-based compensation 3,008           3,008          
Other comprehensive loss, net of tax 819                   819  
Ending Balance (in shares) at Nov. 30, 2021       39,455,193,000                
Ending Balance at Nov. 30, 2021 432,368     $ 379     580,330     (147,189) 4,562 $ (5,714)
Ending Balance, Treasury (in shares) at Nov. 30, 2021                       (370,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (4,958)                 (4,958)    
Exercise of stock option (in shares)       5,000,000                
Exercise of stock options 77         77          
Issuance/Cancellation of performance share units and restricted stock units, net (in shares)         11,304,000              
Issuance/Cancellation of performance share units and restricted stock units   (84)           (84)        
Purchase of common stock under ESPP (in shares)       48,604,000                
Purchases of common stock under ESPP 973     $ 1     972          
Stock-based compensation 2,352           2,352          
Other comprehensive loss, net of tax (1,036)                   (1,036)  
Ending Balance (in shares) at Feb. 28, 2022       39,520,101,000                
Ending Balance at Feb. 28, 2022 429,692     $ 380     583,647     (152,147) 3,526 $ (5,714)
Ending Balance, Treasury (in shares) at Feb. 28, 2022                       (370,000,000)
Beginning Balance (in shares) at May. 31, 2022       39,541,173                
Beginning Balance at May. 31, 2022 $ 424,489     $ 380     586,879     (158,413) 1,357 $ (5,714)
Beginning Balance, Treasury (in shares) at May. 31, 2022 (370,000)                     (370,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss $ (13,004)                 (13,004)    
Exercise of stock option (in shares)       6,617                
Exercise of stock options (29)           (29)          
Issuance/Cancellation of performance share units and restricted stock units, net (in shares)         213,241 29,826            
Issuance/Cancellation of performance share units and restricted stock units   (648) $ (312)         (648) $ (312)      
Purchase of common stock under ESPP (in shares)       56,894                
Purchases of common stock under ESPP 1,071     $ 1     1,070          
Stock-based compensation 3,024           3,024          
Other comprehensive loss, net of tax (550)                   (550)  
Ending Balance (in shares) at Aug. 31, 2022       39,847,751                
Ending Balance at Aug. 31, 2022 414,041     $ 381     589,984     (171,417) 807 $ (5,714)
Ending Balance, Treasury (in shares) at Aug. 31, 2022                       370,000
Beginning Balance (in shares) at May. 31, 2022       39,541,173                
Beginning Balance at May. 31, 2022 $ 424,489     $ 380     586,879     (158,413) 1,357 $ (5,714)
Beginning Balance, Treasury (in shares) at May. 31, 2022 (370,000)                     (370,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss $ (30,975)                      
Ending Balance (in shares) at Feb. 28, 2023       39,976,422                
Ending Balance at Feb. 28, 2023 $ 397,655     $ 382     596,225     (189,388) (3,850) $ (5,714)
Ending Balance, Treasury (in shares) at Feb. 28, 2023 (370,000)                     (370,000)
Beginning Balance (in shares) at Aug. 31, 2022       39,847,751                
Beginning Balance at Aug. 31, 2022 $ 414,041     $ 381     589,984     (171,417) 807 $ (5,714)
Beginning Balance, Treasury (in shares) at Aug. 31, 2022                       370,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (8,486)                      
Exercise of stock option (in shares)       15,000                
Exercise of stock options 184           184          
Issuance/Cancellation of performance share units and restricted stock units, net (in shares)         11,393              
Issuance/Cancellation of performance share units and restricted stock units   (36)           (36)        
Stock-based compensation 3,350           3,350          
Other comprehensive loss, net of tax (1,095)                   (1,095)  
Ending Balance (in shares) at Nov. 30, 2022       39,874,144                
Ending Balance at Nov. 30, 2022 407,958     $ 381     593,482     (179,903) (288) $ (5,714)
Ending Balance, Treasury (in shares) at Nov. 30, 2022                       (370,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (9,485)                 (9,485)    
Issuance/Cancellation of performance share units and restricted stock units, net (in shares)         9,394              
Issuance/Cancellation of performance share units and restricted stock units   $ (36)           $ (36)        
Purchase of common stock under ESPP (in shares)       92,884                
Purchases of common stock under ESPP 977     $ 1     976          
Stock-based compensation 1,803           1,803          
Other comprehensive loss, net of tax (3,562)                   (3,562)  
Ending Balance (in shares) at Feb. 28, 2023       39,976,422                
Ending Balance at Feb. 28, 2023 $ 397,655     $ 382     $ 596,225     $ (189,388) $ (3,850) $ (5,714)
Ending Balance, Treasury (in shares) at Feb. 28, 2023 (370,000)                     (370,000)
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Financial Statements
 9 Months Ended
Feb. 28, 2023
Accounting Policies [Abstract]  
Consolidated Financial Statements CONSOLIDATED FINANCIAL STATEMENTS
The Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Loss for the three and nine months ended February 28, 2023 and 2022, the Consolidated Balance Sheet as of February 28, 2023, the Consolidated Statements of Cash Flows for the nine months ended February 28, 2023 and 2022, and the Consolidated Statements of Stockholders’ Equity for the nine months ended February 28, 2023 and 2022 have been prepared by the Company and are unaudited. The Consolidated Balance Sheet as of May 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended February 28, 2023 (and for all periods presented) have been made.
The unaudited interim consolidated financial statements for the three and nine months ended February 28, 2023 and 2022 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries (collectively, the "Company", "we", "our" or "us"). All intercompany balances and transactions have been eliminated.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions
 9 Months Ended
Feb. 28, 2023
Business Combination and Asset Acquisition [Abstract]  
Acquisitions ACQUISITIONSCamaro Support Catheter Asset AcquisitionOn July 27, 2021, the Company acquired the Camaro support catheter (rebranded as Syntrax) from QX Medical, LLC for an aggregate purchase price of $4.0 million, which included an upfront payment of $3.6 million and $0.4 million in purchase price holdbacks, along with $1.0 million of potential future contingent consideration related to revenue milestones. This acquisition supports the Auryon product family and the Company's strategic plan. The Company accounted for this acquisition as an asset purchase. The Company recorded the amount paid at closing as inventory and fixed assets of $0.1 million and an intangible asset product technology of $3.9 million. The intangible asset will be amortized over 15 years. The contingent consideration is comprised of revenue milestones and will be accounted for when the contingency is resolved or becomes probable and reasonably estimable.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue from Contracts with Customers
 9 Months Ended
Feb. 28, 2023
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers REVENUE FROM CONTRACTS WITH CUSTOMERS
Revenue Recognition
Under ASC 606, Revenue from Contracts with Customers, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company has one primary revenue stream which is the sales of its products.
Disaggregation of Revenue
As the Company has previously announced, the Company is focused on its ongoing transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company that delivers unique and innovative health care solutions. The Company believes that this transformation will enable the Company to shift the portfolio from the mature, lower-growth markets where we have competed in the past by investing in technology and products that provide access to larger and faster growing markets. As such, we believe the growth in the near to mid-term will be driven by our Med Tech segment.
The following table summarizes net sales by Med Tech, Med Device and by geography:
Three Months Ended February 28, 2023Three Months Ended February 28, 2022
(in thousands)United StatesInternationalTotalUnited StatesInternationalTotal
Net sales
Med Tech $20,381 $2,493 $22,874 $17,782 $1,830 $19,612 
Med Device47,239 10,599 57,838 44,663 9,695 54,358 
Total$67,620 $13,092 $80,712 $62,445 $11,525 $73,970 
Nine Months Ended February 28, 2023
Nine Months Ended February 28, 2022
(in thousands)United StatesInternationalTotalUnited StatesInternationalTotal
Net sales
Med Tech $61,373 $8,820 $70,193 $49,249 $6,857 $56,106 
Med Device146,901 30,584 177,485 143,010 30,105 173,115 
Total$208,274 $39,404 $247,678 $192,259 $36,962 $229,221 
Net Product Revenue
The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's products are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distributors and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.
Contracts and Performance Obligations
The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.
Transaction Price and Allocation to Performance Obligations
Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer, net of any variable consideration as described below.
If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.
Revenue Recognition
Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the shipping terms of a contract.
In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.
The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.
The Company enters into agreements to place placement and evaluation units (“units”) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer’s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units. In these arrangements, revenue recognized for the sale of the disposables is not allocated
between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value.
Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
Variable Consideration
Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset.
Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes. The Company is also required to pay administrative fees to group purchasing organizations.
Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the nine months ended February 28, 2023, such product returns were not material.
Contract Balances with Customers
A receivable is generally recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.
The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:
(in thousands)Feb 28, 2023
May 31, 2022
Receivables$50,892 $52,304 
Contract assets$— $— 
Contract liabilities$571 $526 
During the nine months ended February 28, 2023, the Company had additions to contract liabilities of $0.6 million. This was offset by $0.6 million in revenue that was recognized during the nine months ended February 28, 2023.
Costs to Obtain or Fulfill a Customer Contract
Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.
The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping and handling are recorded in net sales.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories
 9 Months Ended
Feb. 28, 2023
Inventory Disclosure [Abstract]  
Inventories INVENTORIESInventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:
(in thousands)Feb 28, 2023May 31, 2022
Raw materials$34,471 $28,251 
Work in process7,924 7,186 
Finished goods21,137 15,955 
Inventories$63,532 $51,392 
The Company periodically reviews inventory for both obsolescence and loss of value. The Company makes assumptions about the future demand for and market value of the inventory. Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow-moving inventory. The total inventory reserve at February 28, 2023 and May 31, 2022 was $3.1 million and $3.7 million, respectively.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Intangible Assets
 9 Months Ended
Feb. 28, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets GOODWILL AND INTANGIBLE ASSETS
Goodwill
Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination.
The Company has historically performed its annual goodwill assessment during the third quarter of each fiscal year. During the fourth quarter of fiscal year 2022, the Company changed its annual impairment assessment date from December 31 to April 30 to more closely align the impairment assessment date with the Company's long term planning and forecasting process.
The Company's annual testing for impairment of goodwill was completed as of April 30, 2022. Prior to the first quarter of fiscal year 2023, the Company managed its operations as one reporting unit. At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as two operating segments and two reporting units, namely Med Tech and Med Device (see Note 11 "Segment and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Quarterly Report on Form 10-Q). As a result of this change, goodwill was required to be allocated to each reporting unit and an interim goodwill impairment assessment was performed at the Company and reporting unit levels. To determine the fair value of the individual reporting units and the entire company as of June 1, 2022, the Company utilized the income approach. The income approach is based on the projected cash flows discounted to their present value using discount rates, that in the Company's judgment, consider the timing and risk of the forecasted cash flows using internally developed forecasts and assumptions. Under the income approach, the discount rate used is the average estimated value of a market participant’s cost of capital and debt, derived using customary market metrics. Other significant assumptions include revenue growth rates, profitability projections, and terminal value growth rates. The market approach was also considered; however, the income approach was chosen as the Company determined it is a better representation of both the Med Tech and Med Device reporting units' projected long-term performance. The fair value of each reporting unit and the Company as a whole was assessed to determine if there was any impairment. The Company compared each reporting unit's fair value to the adjusted carrying value to conclude that there was no impairment for either reporting unit or the Company as a whole. The adjusted carrying value of each reporting unit was used to calculate the Company's book value to compare to its market capitalization at the assessment date. Based on the results of this evaluation, there were no adjustments to goodwill for either reporting unit or the Company as a whole as of August 31, 2022.
Goodwill for each reporting unit is allocated as follows:
Nine months ended Feb 28, 2023
(in thousands)Med Tech Med Device Total
Balance, June 1, 2022$160,529 $40,529 $201,058 
Foreign currency translation adjustments (20)— (20)
Balance, August 31, 2022$160,509 $40,529 $201,038 
Foreign currency translation adjustments(283)— (283)
Balance, November 30, 2022$160,226 $40,529 $200,755 
Foreign currency translation adjustments$(779)$— $(779)
Balance, February 28, 2023
$159,447 $40,529 $199,976 
There were no adjustments to goodwill for the nine months ended February 28, 2023 other than foreign currency translation adjustments.
Even though the Company determined that there was no goodwill impairment at February 28, 2023, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that one of the reporting units or a significant portion of either of the reporting units will be sold or disposed of, would require an interim assessment for the reporting units prior to the next required annual assessment as of April 30, 2023.
Definite Lived Intangible Assets
Intangible assets other than goodwill are amortized over their estimated useful lives on a straight-line basis. Useful lives range from two to eighteen years. The Company periodically reviews, and adjusts, if necessary, the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.
Intangible assets consisted of the following:
Feb 28, 2023
(in thousands)Gross carrying valueAccumulated amortizationNet carrying value
Product technologies$233,752 $(122,017)$111,735 
Customer relationships60,096 (40,995)19,101 
Trademarks9,950 (7,396)2,554 
Licenses5,377 (4,756)621 
$309,175 $(175,164)$134,011 
May 31, 2022
(in thousands)Gross carrying valueAccumulated amortizationNet carrying value
Product technologies$239,467 $(112,141)$127,326 
Customer relationships60,115 (38,003)22,112 
Trademarks9,950 (7,185)2,765 
Licenses4,837 (4,660)177 
$314,369 $(161,989)$152,380 
Amortization expense for the three months ended February 28, 2023 and 2022 was $4.7 million and $4.9 million, respectively. Amortization expense for the nine months ended February 28, 2023 and 2022 was $14.4 million and $14.6 million, respectively.
Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows:
(in thousands)
Remainder of 2023$5,918 
202416,406 
202516,388 
202616,207 
202716,036 
2028 and thereafter63,056 
$134,011 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Liabilities
 9 Months Ended
Feb. 28, 2023
Payables and Accruals [Abstract]  
Accrued Liabilities ACCRUED LIABILITIESAccrued liabilities consisted of the following:
(in thousands)Feb 28, 2023May 31, 2022
Payroll and related expenses$9,355 $20,232 
Royalties2,202 2,986 
Outside services3,171 3,731 
Research and development1,368 1,279 
Sales and franchise taxes328 750 
Rebates359 511 
Other4,992 5,353 
$21,775 $34,842 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt
 9 Months Ended
Feb. 28, 2023
Debt Disclosure [Abstract]  
Long-Term Debt LONG-TERM DEBT
On August 30, 2022, the Company repaid all amounts outstanding under its then existing credit agreement and entered into a new Credit Agreement (the "Credit Agreement") with its lenders, JPMorgan Chase Bank, N.A., as Administrative Agent, sole bookrunner, and sole lead arranger, and Bank of America, N.A. and KeyBank National Association, as Syndication Agents.
The Credit Agreement provides for a $75.0 million secured revolving credit facility (the "Revolving Facility") and a $30.0 million delayed draw term loan (the "Delayed Draw Term Loan"), and also includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million.  Each exercise of such expansion feature must be drawn in $5.0 million increments. The proceeds of the Revolving Facility may be used for general corporate purposes, including permitted acquisitions. The proceeds of the Delayed Draw Term Loan may be used for general corporate purposes, including primarily to finance the manufacturing costs of the Auryon laser capital equipment.
The Credit Agreement has a five-year maturity. Interest on the Revolving Facility and Delayed Draw Term Loan will be based, at the Company's option, on a rate equal to (i) the Secured Overnight Financing Rate ("SOFR") plus 0.10% (subject to a floor of 0%), or (ii) if the Company elects to treat a borrowing as an ABR Borrowing, an alternate base rate based on SOFR, plus, in each case, an applicable margin of 1.25%, 1.50% or 1.75%, depending on the leverage ratio. If any amounts are not paid when due, such overdue amounts will bear interest at an amount generally equal to 2.0% plus the existing loan rate. The Credit Agreement also carries a commitment fee in the case of the Revolving Facility, and a ticking fee, in the case of the Delayed Draw Term Loans of 0.20% to 0.25% per annum on the unused portion.
The Company's obligations under the Credit Agreement are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of the Company and the Guarantors under the Credit Agreement are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors.
The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows: 
•Maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than 3.00 to 1.00 (during certain periods following material acquisitions the ratio shall be increased to 3.50 to 1.00).
•Fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures* to consolidated interest expense* paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00.
* The definitions of consolidated total indebtedness, consolidated EBITDA, consolidated capital expenditures and consolidated interest expense are specifically defined in the Credit Agreement included as an exhibit to Form 8-K filed on August 31, 2022.
As of February 28, 2023, there was $25.0 million outstanding on the Revolving Facility and $25.0 million outstanding on the Delayed Draw Term Loan and the interest rate at February 28, 2023 applicable to each was 6.15%. As of February 28, 2023 and May 31, 2022, the carrying value of long-term debt approximated its fair market value.
(in thousands)Feb 28, 2023
Revolving Facility$25,000 
Delayed Draw Term Loan25,000 
Less: unamortized debt issuance costs(193)
      Total long-term debt$49,807 

Principal payments of approximately 3.57% on the Delayed Draw Term Loan will amortize in equal quarterly installments over a five year period beginning on the earlier of a full draw or the expiry of the draw period (March 1, 2024).
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
 9 Months Ended
Feb. 28, 2023
Income Tax Disclosure [Abstract]  
Income Taxes INCOME TAXES
The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur.  The estimated annual effective tax rate prior to discrete items was 5.2% as of the third quarter of fiscal year 2023, as compared to 12.7% for the same period in fiscal year 2022. In fiscal year 2023, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share-based compensation).
The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity.
Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of February 28, 2023. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation
 9 Months Ended
Feb. 28, 2023
Share-based Payment Arrangement [Abstract]  
Share-Based Compensation SHARE-BASED COMPENSATION
On October 13, 2020, the Company's shareholders approved the 2020 Stock and Incentive Award Plan (the “2020 Plan”). The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance share units, performance shares and other incentive awards to the Company's employees, directors and other service providers. On November 3, 2022 the Company's shareholders approved an amendment to the 2020 Plan to increase the reserve of shares of common stock available for future grants by 1,950,000 shares. As of February 28, 2023, there was a maximum of 2.9 million shares of common stock available for future grant under the 2020 Plan.
Prior to the adoption of the 2020 Plan, equity awards were issued under the 2004 Stock and Incentive Award Plan (the “2004 Plan”). The adoption of the 2020 Plan did not impact the administration of equity awards issued under the 2004 Plan but following the adoption of the 2020 Plan, equity award grants are no longer made under the 2004 Plan.
The Company also has an employee stock purchase plan. On November 3, 2022 the Company's shareholders approved an amendment to the employee stock purchase plan to increase the reserve of shares of common stock available for future grants by 1,000,000 shares. As of February 28, 2023, there was a maximum of 3.2 million shares of common stock available for future grant under the employee stock purchase plan.
For the three months ended February 28, 2023 and 2022, share-based compensation expense was $1.8 million and $2.4 million, respectively. For the nine months ended February 28, 2023 and 2022, share-based compensation expense was $8.2 million and $7.8 million, respectively.
During the nine months ended February 28, 2023 and 2022, the Company granted stock options and restricted stock units under the 2020 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company’s common stock on the date of grant and then amortized on a straight-line basis over the requisite service period of the award.
During the nine months ended February 28, 2023 and 2022, the Company granted performance share units under the 2020 Plan to certain employees. The awards may be earned by achieving performance levels over the requisite service period. The performance criteria are based on achieving certain performance targets and the total shareholder return (“TSR”) of the Company’s common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards is based on a Monte Carlo simulation model.
As of February 28, 2023, there was $17.6 million of unrecognized compensation expense related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately three years. The Company has sufficient shares to satisfy expected share-based payment arrangements.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share
 9 Months Ended
Feb. 28, 2023
Earnings Per Share [Abstract]  
Earnings Per Share EARNINGS PER SHARE
Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.
The following table reconciles basic to diluted weighted-average shares outstanding:
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Basic39,509 39,092 39,436 38,959 
Effect of dilutive securities— — — — 
Diluted39,509 39,092 39,436 38,959 
Securities excluded as their inclusion would be anti-dilutive3,706 3,457 3,706 3,457 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Segment and Geographic Information
 9 Months Ended
Feb. 28, 2023
Segment Reporting [Abstract]  
Segment and Geographic Information SEGMENT AND GEOGRAPHIC INFORMATION
Segment information
The Company regularly reviews its segments and the approach used by the chief operating decision maker, the President and Chief Executive Officer ("CEO"), and management to evaluate performance and allocate resources. Prior to the first quarter of fiscal year 2023, the Company considered the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis. Commencing with the first quarter of fiscal year 2023, the Company began to manage its operations through two segments, Med Tech and Med Device to align with the transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company. The CEO evaluates these two segments based on net sales and gross margin to, among other items, allocate resources and assess performance. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates all other elements of profitability, investment and cash flow metrics on a consolidated global basis due to shared infrastructure and resources.
The Company manages its assets on a total company basis, not by operating segment; therefore, the CEO does not review any asset information by operating segment and, accordingly, asset information is not reported or evaluated by operating segment. Total assets were $542.8 million as of February 28, 2023.
The table below summarizes net sales and gross margin by Med Tech and Med Device including prior periods during which the Company considered the business to be a single operating segment, in order to conform to the current period presentation:
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Med Tech Net Sales$22,874 $19,612 $70,193 $56,106 
Gross profit 14,774 12,965 44,816 37,060 
Gross margin 64.6 %66.1 %63.8 %66.1 %
Med Device Net Sales$57,838 $54,358 177,485 $173,115 
Gross profit 25,730 25,618 83,071 $82,217 
Gross margin 44.5 %47.1 %46.8 %47.5 %
Total Net Sales$80,712 $73,970 $247,678 $229,221 
Gross profit40,504 38,583 127,887 119,277 
Gross margin50.2 %52.2 %51.6 %52.0 %
Geographic information
The table below summarizes net sales by geographic area based on external customer location:
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Net Sales
United States$67,620 $62,445 $208,274 $192,259 
International13,092 11,525 39,404 36,962 
Total$80,712 $73,970 $247,678 $229,221 
For the three months ended February 28, 2023 and 2022, international sales as a percentage of total net sales were 16.2% and 15.6%, respectively. For the nine months ended February 28, 2023 and 2022, international sales as a percentage of total net sales were 15.9% and 16.1%, respectively. Sales to any one country outside the U.S., as determined by shipment destination, did not comprise a material portion of net sales in any of the last three fiscal years. In addition, no one customer represents more than 10% of consolidated net sales and 85% of long-lived assets are located within the United States.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value
 9 Months Ended
Feb. 28, 2023
Fair Value Disclosures [Abstract]  
Fair Value FAIR VALUE
On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•Level 3 - Inputs to the valuation methodology are significant unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to their immediate or short-term maturities. The recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities.
The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis:
Fair Value Measurements using inputs considered as:
Fair Value at Feb 28, 2023
(in thousands)Level 1Level 2Level 3
Financial Liabilities
Contingent consideration for acquisition earn outs$— $— $19,059 $19,059 
Total Financial Liabilities$— $— $19,059 $19,059 
Fair Value Measurements using inputs considered as:
Fair Value at May 31, 2022
(in thousands)Level 1Level 2Level 3
Financial Liabilities
Contingent consideration for acquisition earn outs$— $— $16,948 $16,948 
Total Financial Liabilities$— $— $16,948 $16,948 
There were no transfers between Level 1, 2 and 3 for the three and nine months ended February 28, 2023 and 2022.
The table below presents the changes in fair value components of Level 3 instruments:
Three Months Ended Feb 28, 2023
(in thousands)Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, November 30, 2022$18,832 
Change in present value of contingent consideration (1)
227 
Balance, February 28, 2023
$19,059 
Nine Months Ended Feb 28, 2023
(in thousands)Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, May 31, 2022$16,948 
Change in present value of contingent consideration (1)
2,084 
Currency gain from remeasurement27 
Balance, February 28, 2023
$19,059 
(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.
Contingent Liability for Acquisition Earn Outs
Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations.
The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements, which is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net
sales are based on internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future.
The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 28, 2023:
(in thousands)Fair ValueValuation TechniqueUnobservable InputRange
Revenue based payments$19,059 Discounted cash flowDiscount rate5%
Probability of payment
90% - 100%
Projected fiscal year of payment2023 - 2025
At February 28, 2023, the amount of undiscounted future contingent consideration that the Company expects to pay as a result of all completed acquisitions is approximately $20.0 million. The milestones, including revenue projections and technical milestones associated with the contingent consideration, must be reached in future periods ranging from fiscal years 2023 to 2029 in order for the associated consideration to be paid.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
 9 Months Ended
Feb. 28, 2023
Leases [Abstract]  
Leases LEASES
The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&D, manufacturing and warehousing.
Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.
The following table presents supplemental balance sheet information related to leases:
(in thousands)Balance Sheet LocationFeb 28, 2023May 31, 2022
Assets
Operating lease ROU assetOther assets$5,143 $6,974 
Liabilities
Current operating lease liabilitiesOther current liabilities2,299 2,560 
Non-current operating lease liabilitiesOther long-term liabilities3,049 4,703 
Total lease liabilities$5,348 $7,263 
The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate:
Feb 28, 2023
Weighted average remaining term (in years)2.72
Weighted average discount rate3.8 %
The maturities of the lease liabilities for each of the following fiscal years is:
(in thousands)Feb 28, 2023
Remainder of 2023$699 
20242,191 
20251,428 
20261,130 
2027 and thereafter171 
Total lease payments$5,619 
Less: Imputed Interest271 
Total lease obligations$5,348 
Less: Current portion of lease obligations2,299 
Long-term lease obligations$3,049 
During the three months ended February 28, 2023 and 2022, the Company recognized $0.7 million and $0.7 million of operating lease expense, respectively, which includes immaterial short-term leases. During the nine months ended February 28, 2023 and 2022, the Company recognized $2.0 million and $2.1 million of operating leases expense, respectively, which includes immaterial short-term leases. The expenses on the Consolidated Statement of Operations were classified as follows:
Three Months Ended
Nine Months Ended
(in thousands)
Feb 28, 2023
Feb 28, 2022
Feb 28, 2023
Feb 28, 2022
Cost of sales$221 $218 $661 $656 
Research and development54 52 158 201 
Sales and marketing42 40 122 119 
General and administrative379 374 1,103 1,138 
$696 $684 $2,044 $2,114 
The following table presents supplemental cash flow and other information related to leases for the nine months ended:
(in thousands)Feb 28, 2023Feb 28, 2022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$2,079 $2,041 
ROU assets obtained in exchange for lease liabilities
Operating leases$— $33 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
 9 Months Ended
Feb. 28, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies COMMITMENTS AND CONTINGENCIES
The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation.

C.R. Bard, Inc. v. AngioDynamics, Inc.

On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 7,785,302 ("302"), 7,959,615 (“615”) and 7,947,022 ("022")). The case was stayed pending reexamination in the US Patent and Trademark Office ("USPTO"). Following the reexamination proceedings, and the parties’ related appeals to the Federal Circuit which resulted in further proceedings at the USPTO, certain claims of the 615 patent were held invalid, while the remaining claims of the 615 patent and the other two patents were upheld over the prior art references considered in the reexamination proceedings. Thereafter, the case was transferred from the District of Utah to the United States District Court for the District of Delaware (“District of Delaware”). On July 22, 2021, in another case against a different defendant, the District of Utah invalidated multiple claims of the ‘302, ‘022, and ‘615 Patents under 35 USC §101, including claims asserted against the Company. On December 27, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal from the Utah Decision. On February 17, 2023, the Federal Circuit Reversed-in-Part, Vacated-in-Part, and Remanded the Utah
Decision. The other defendant subsequently filed a Petition for Rehearing with the Federal Circuit on March 20, 2023, and a mandate has not yet issued. The District of Delaware lifted the stay on February 28, 2023 and held a status conference on March 23, 2023. A scheduling order has not yet been entered, but a jury trial is currently scheduled for April 29, 2024. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

On March 10, 2015, Bard and Bard Peripheral Vascular filed suit in the District of Delaware claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 8,475,417, 8,545,460, 8,805,478). The case proceeded through trial which began on March 4, 2019. At the close of Bard’s case, the Court granted the Company's oral motion for judgment as a matter of law as well as its motions for summary judgment on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed. On May 10, 2019, the Company filed a motion for attorney fees and non-taxable expenses under 35 USC Sec. 285. Bard appealed the judgment to the Federal Circuit and on November 10, 2020, the Federal Circuit reversed the judgment in part with respect to Section 101 (subject matter eligibility), and vacated and remanded the trial court’s invalidity and non-infringement judgments. Following remand from the Federal Circuit, a jury trial commenced in the District of Delaware beginning November 14, 2022. On November 22, 2022, a jury entered a verdict finding that certain of the Company’s implantable port products infringe certain claims of U.S. patents held by Bard. The issue of damages was bifurcated by the Court during trial, was not determined by the jury and will be subject to a separate proceeding. The Company strongly disagrees with the claims and the verdict. The issues presented to the jury do not comprise all of the issues to be determined in the case. Equitable issues remain to be decided by the judge, and damages remain to be decided by a jury. The Company believes it has meritorious defenses and positions with respect to the matters remaining to be decided and the jury decision, and intends to vigorously pursue all available remedies and defenses, including post-trial motions and appeals. The parties have filed post-trial briefs, and the Court heard argument on March 13, 2023. A decision is forthcoming. The Company maintains its belief that Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

On March 8, 2021, Bard filed suit in the District of Delaware asserting certain of the Company’s port products (including certain related infusion sets) infringe U.S. Patent Nos. 8,025,639, 9,603,992 and 9,603,993. On December 27, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal of the Utah decision invalidating multiple claims of the ‘302, ‘022, and ‘615 patents under 35 USC §101. Following the Federal Circuit’s decision on appeal, the District of Delaware lifted the stay on February 28, 2023, and held a scheduling conference on March 23, 2023. A scheduling order has not yet been entered, but a jury trial is currently scheduled for June 9, 2025. The Company maintains its belief that Bard's claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

AngioDynamics, Inc. v. C.R. Bard, Inc.

On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”). In this action, the Company alleged that Bard had illegally tied the sales of its tip location systems to the sales of its PICCs in violation of federal antitrust laws and this practice had an anti-competitive effect in the US market for PICCs. The Company sought both monetary damages and injunctive relief. On October 6, 2022, a jury verdict was rendered finding Bard did not restrain competition in violation of federal antitrust laws.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisition, Restructuring and Other Items, Net
 9 Months Ended
Feb. 28, 2023
Restructuring and Related Activities [Abstract]  
Acquisition, Restructuring and Other Items, Net ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NETAcquisition, Restructuring and Other Items
Acquisition, restructuring and other items, net, consisted of:
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Legal (1)
$2,614 $1,681 $6,899 $5,837 
Mergers and acquisitions (2)
— — — 59 
Manufacturing relocation (3)
324 396 1,062 455 
Israeli Innovation Authority prepayment (4)
— — 3,544 — 
Other431 282 504 701 
Total$3,369 $2,359 $12,009 $7,052 
(1) Legal expenses related to litigation that is outside the normal course of business.
(2) Legal and due diligence expenses related to mergers and acquisitions.
(3) Expenses to relocate certain manufacturing lines from Queensbury, NY to Costa Rica.
(4) In the first quarter of fiscal year 2023, a $3.5 million payment was made to the Israeli Innovation Authority to fully satisfy the obligation related to grant funds that were provided to Eximo for development of the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Accumulated Other Comprehensive Income
 9 Months Ended
Feb. 28, 2023
Equity [Abstract]  
Accumulated Other Comprehensive Income ACCUMULATED OTHER COMPREHENSIVE INCOME
Changes in each component of accumulated other comprehensive income, net of tax, are as follows:
Three Months Ended Feb 28, 2023
(in thousands)Foreign currency translation income
Balance at November 30, 2022$(288)
Other comprehensive loss, net of tax(3,562)
Net other comprehensive loss$(3,562)
Balance at February 28, 2023
$(3,850)
Nine Months Ended Feb 28, 2023
(in thousands)Foreign currency translation income
Balance at May 31, 2022$1,357 
Other comprehensive loss, net of tax(5,207)
Net other comprehensive loss$(5,207)
Balance at February 28, 2023
$(3,850)
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Recently Issued Accounting Pronouncements
 9 Months Ended
Feb. 28, 2023
Accounting Changes and Error Corrections [Abstract]  
Recently Issued Accounting Pronouncements RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
Recently Issued Accounting Pronouncements - Adopted
StandardDescriptionEffective DateEffect on the Consolidated Financial Statements
ASU 2021-10,  Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance
This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. June 1, 2022The Company adopted the new standard in the first quarter of fiscal year 2023 and it did not have an impact on the Company's consolidated financial statements.
Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted
StandardDescriptionEffective DateEffect on the Consolidated Financial Statements
ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers

This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer.
June 1, 2023The Company plans to adopt the new standard in the first quarter of fiscal year 2024 and does not expect there to be a material impact to the consolidated financial statements.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Recently Issued Accounting Pronouncements (Policies)
 9 Months Ended
Feb. 28, 2023
Accounting Changes and Error Corrections [Abstract]  
Revenue from Contracts with Customers Revenue RecognitionUnder ASC 606, Revenue from Contracts with Customers, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
Revenue Recognition
Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the shipping terms of a contract.
In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.
The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.
The Company enters into agreements to place placement and evaluation units (“units”) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer’s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units. In these arrangements, revenue recognized for the sale of the disposables is not allocated
between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value.
Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
Variable Consideration
Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset.
Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes. The Company is also required to pay administrative fees to group purchasing organizations.
Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls.
Contract Balances with Customers
A receivable is generally recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.
Costs to Obtain or Fulfill a Customer Contract
Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.
The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping and handling are recorded in net sales.
Recently Issued Accounting Pronouncements RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
Recently Issued Accounting Pronouncements - Adopted
StandardDescriptionEffective DateEffect on the Consolidated Financial Statements
ASU 2021-10,  Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance
This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. June 1, 2022The Company adopted the new standard in the first quarter of fiscal year 2023 and it did not have an impact on the Company's consolidated financial statements.
Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted
StandardDescriptionEffective DateEffect on the Consolidated Financial Statements
ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers

This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer.
June 1, 2023The Company plans to adopt the new standard in the first quarter of fiscal year 2024 and does not expect there to be a material impact to the consolidated financial statements.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue from Contracts with Customers (Tables)
 9 Months Ended
Feb. 28, 2023
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue The following table summarizes net sales by Med Tech, Med Device and by geography:
Three Months Ended February 28, 2023Three Months Ended February 28, 2022
(in thousands)United StatesInternationalTotalUnited StatesInternationalTotal
Net sales
Med Tech $20,381 $2,493 $22,874 $17,782 $1,830 $19,612 
Med Device47,239 10,599 57,838 44,663 9,695 54,358 
Total$67,620 $13,092 $80,712 $62,445 $11,525 $73,970 
Nine Months Ended February 28, 2023
Nine Months Ended February 28, 2022
(in thousands)United StatesInternationalTotalUnited StatesInternationalTotal
Net sales
Med Tech $61,373 $8,820 $70,193 $49,249 $6,857 $56,106 
Med Device146,901 30,584 177,485 143,010 30,105 173,115 
Total$208,274 $39,404 $247,678 $192,259 $36,962 $229,221 
Contract Balances with Customers
The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:
(in thousands)Feb 28, 2023
May 31, 2022
Receivables$50,892 $52,304 
Contract assets$— $— 
Contract liabilities$571 $526 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories (Tables)
 9 Months Ended
Feb. 28, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventories Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:
(in thousands)Feb 28, 2023May 31, 2022
Raw materials$34,471 $28,251 
Work in process7,924 7,186 
Finished goods21,137 15,955 
Inventories$63,532 $51,392 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Intangible Assets (Tables)
 9 Months Ended
Feb. 28, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
Intangible assets consisted of the following:
Feb 28, 2023
(in thousands)Gross carrying valueAccumulated amortizationNet carrying value
Product technologies$233,752 $(122,017)$111,735 
Customer relationships60,096 (40,995)19,101 
Trademarks9,950 (7,396)2,554 
Licenses5,377 (4,756)621 
$309,175 $(175,164)$134,011 
May 31, 2022
(in thousands)Gross carrying valueAccumulated amortizationNet carrying value
Product technologies$239,467 $(112,141)$127,326 
Customer relationships60,115 (38,003)22,112 
Trademarks9,950 (7,185)2,765 
Licenses4,837 (4,660)177 
$314,369 $(161,989)$152,380 
Schedule of Future Amortization Expense Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows:
(in thousands)
Remainder of 2023$5,918 
202416,406 
202516,388 
202616,207 
202716,036 
2028 and thereafter63,056 
$134,011 
Goodwill for Each Reporting Unit
Goodwill for each reporting unit is allocated as follows:
Nine months ended Feb 28, 2023
(in thousands)Med Tech Med Device Total
Balance, June 1, 2022$160,529 $40,529 $201,058 
Foreign currency translation adjustments (20)— (20)
Balance, August 31, 2022$160,509 $40,529 $201,038 
Foreign currency translation adjustments(283)— (283)
Balance, November 30, 2022$160,226 $40,529 $200,755 
Foreign currency translation adjustments$(779)$— $(779)
Balance, February 28, 2023
$159,447 $40,529 $199,976 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Liabilities (Tables)
 9 Months Ended
Feb. 28, 2023
Payables and Accruals [Abstract]  
Accrued Liabilities Accrued liabilities consisted of the following:
(in thousands)Feb 28, 2023May 31, 2022
Payroll and related expenses$9,355 $20,232 
Royalties2,202 2,986 
Outside services3,171 3,731 
Research and development1,368 1,279 
Sales and franchise taxes328 750 
Rebates359 511 
Other4,992 5,353 
$21,775 $34,842 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt (Tables)
 9 Months Ended
Feb. 28, 2023
Debt Disclosure [Abstract]  
Schedule of Principal Obligations
(in thousands)Feb 28, 2023
Revolving Facility$25,000 
Delayed Draw Term Loan25,000 
Less: unamortized debt issuance costs(193)
      Total long-term debt$49,807 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share (Tables)
 9 Months Ended
Feb. 28, 2023
Earnings Per Share [Abstract]  
Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding The following table reconciles basic to diluted weighted-average shares outstanding:
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Basic39,509 39,092 39,436 38,959 
Effect of dilutive securities— — — — 
Diluted39,509 39,092 39,436 38,959 
Securities excluded as their inclusion would be anti-dilutive3,706 3,457 3,706 3,457 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Segment and Geographic Information (Tables)
 9 Months Ended
Feb. 28, 2023
Segment Reporting [Abstract]  
Summary of Net Sales by Product Category The table below summarizes net sales and gross margin by Med Tech and Med Device including prior periods during which the Company considered the business to be a single operating segment, in order to conform to the current period presentation:
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Med Tech Net Sales$22,874 $19,612 $70,193 $56,106 
Gross profit 14,774 12,965 44,816 37,060 
Gross margin 64.6 %66.1 %63.8 %66.1 %
Med Device Net Sales$57,838 $54,358 177,485 $173,115 
Gross profit 25,730 25,618 83,071 $82,217 
Gross margin 44.5 %47.1 %46.8 %47.5 %
Total Net Sales$80,712 $73,970 $247,678 $229,221 
Gross profit40,504 38,583 127,887 119,277 
Gross margin50.2 %52.2 %51.6 %52.0 %
Summary of Net Sales by Geographic Area The table below summarizes net sales by geographic area based on external customer location:
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Net Sales
United States$67,620 $62,445 $208,274 $192,259 
International13,092 11,525 39,404 36,962 
Total$80,712 $73,970 $247,678 $229,221 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value (Tables)
 9 Months Ended
Feb. 28, 2023
Fair Value Disclosures [Abstract]  
Fair Value of Assets and Liabilities Measured on a Recurring Basis The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis:
Fair Value Measurements using inputs considered as:
Fair Value at Feb 28, 2023
(in thousands)Level 1Level 2Level 3
Financial Liabilities
Contingent consideration for acquisition earn outs$— $— $19,059 $19,059 
Total Financial Liabilities$— $— $19,059 $19,059 
Fair Value Measurements using inputs considered as:
Fair Value at May 31, 2022
(in thousands)Level 1Level 2Level 3
Financial Liabilities
Contingent consideration for acquisition earn outs$— $— $16,948 $16,948 
Total Financial Liabilities$— $— $16,948 $16,948 
Fair Value Measurements Using Significant Unobservable Inputs
The table below presents the changes in fair value components of Level 3 instruments:
Three Months Ended Feb 28, 2023
(in thousands)Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, November 30, 2022$18,832 
Change in present value of contingent consideration (1)
227 
Balance, February 28, 2023
$19,059 
Nine Months Ended Feb 28, 2023
(in thousands)Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, May 31, 2022$16,948 
Change in present value of contingent consideration (1)
2,084 
Currency gain from remeasurement27 
Balance, February 28, 2023
$19,059 
(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.
Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability
The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 28, 2023:
(in thousands)Fair ValueValuation TechniqueUnobservable InputRange
Revenue based payments$19,059 Discounted cash flowDiscount rate5%
Probability of payment
90% - 100%
Projected fiscal year of payment2023 - 2025
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Tables)
 9 Months Ended
Feb. 28, 2023
Leases [Abstract]  
Supplemental Balance Sheet Information The following table presents supplemental balance sheet information related to leases:
(in thousands)Balance Sheet LocationFeb 28, 2023May 31, 2022
Assets
Operating lease ROU assetOther assets$5,143 $6,974 
Liabilities
Current operating lease liabilitiesOther current liabilities2,299 2,560 
Non-current operating lease liabilitiesOther long-term liabilities3,049 4,703 
Total lease liabilities$5,348 $7,263 
The following table presents the weighted average remaining lease term and discount rate:
Feb 28, 2023
Weighted average remaining term (in years)2.72
Weighted average discount rate3.8 %
Lease Liability Schedule The maturities of the lease liabilities for each of the following fiscal years is:
(in thousands)Feb 28, 2023
Remainder of 2023$699 
20242,191 
20251,428 
20261,130 
2027 and thereafter171 
Total lease payments$5,619 
Less: Imputed Interest271 
Total lease obligations$5,348 
Less: Current portion of lease obligations2,299 
Long-term lease obligations$3,049 
Supplemental Cash Flow Information The expenses on the Consolidated Statement of Operations were classified as follows:
Three Months Ended
Nine Months Ended
(in thousands)
Feb 28, 2023
Feb 28, 2022
Feb 28, 2023
Feb 28, 2022
Cost of sales$221 $218 $661 $656 
Research and development54 52 158 201 
Sales and marketing42 40 122 119 
General and administrative379 374 1,103 1,138 
$696 $684 $2,044 $2,114 
The following table presents supplemental cash flow and other information related to leases for the nine months ended:
(in thousands)Feb 28, 2023Feb 28, 2022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$2,079 $2,041 
ROU assets obtained in exchange for lease liabilities
Operating leases$— $33 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisition, Restructuring and Other Items, Net (Tables)
 9 Months Ended
Feb. 28, 2023
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs
Acquisition, restructuring and other items, net, consisted of:
Three Months EndedNine Months Ended
(in thousands)Feb 28, 2023Feb 28, 2022Feb 28, 2023Feb 28, 2022
Legal (1)
$2,614 $1,681 $6,899 $5,837 
Mergers and acquisitions (2)
— — — 59 
Manufacturing relocation (3)
324 396 1,062 455 
Israeli Innovation Authority prepayment (4)
— — 3,544 — 
Other431 282 504 701 
Total$3,369 $2,359 $12,009 $7,052 
(1) Legal expenses related to litigation that is outside the normal course of business.
(2) Legal and due diligence expenses related to mergers and acquisitions.
(3) Expenses to relocate certain manufacturing lines from Queensbury, NY to Costa Rica.
(4) In the first quarter of fiscal year 2023, a $3.5 million payment was made to the Israeli Innovation Authority to fully satisfy the obligation related to grant funds that were provided to Eximo for development of the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020.
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Accumulated Other Comprehensive Income (Tables)
 9 Months Ended
Feb. 28, 2023
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
Changes in each component of accumulated other comprehensive income, net of tax, are as follows:
Three Months Ended Feb 28, 2023
(in thousands)Foreign currency translation income
Balance at November 30, 2022$(288)
Other comprehensive loss, net of tax(3,562)
Net other comprehensive loss$(3,562)
Balance at February 28, 2023
$(3,850)
Nine Months Ended Feb 28, 2023
(in thousands)Foreign currency translation income
Balance at May 31, 2022$1,357 
Other comprehensive loss, net of tax(5,207)
Net other comprehensive loss$(5,207)
Balance at February 28, 2023
$(3,850)
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions (Details) - USD ($)
$ in Thousands
Jul. 27, 2021
Dec. 17, 2019
Feb. 28, 2023
May 31, 2022
Business Acquisition [Line Items]        
Contract liabilities     $ 571 $ 526
QX Medical, LLC Camaro Support Catheter Asset Acquisition        
Business Acquisition [Line Items]        
Aggregate purchase price $ 4,000      
Contract liabilities 3,600      
Purchase price holdbacks 400      
Potential future contingent consideration 1,000      
Inventory and fixed assets 100      
Intangible asset amortization period   15 years    
Technology-Based Intangible Assets | QX Medical, LLC Camaro Support Catheter Asset Acquisition        
Business Acquisition [Line Items]        
Intangible asset acquired $ 3,900      
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Feb. 28, 2023
Feb. 28, 2022
Feb. 28, 2023
Feb. 28, 2022
Disaggregation of Revenue [Line Items]        
Net sales $ 80,712 $ 73,970 $ 247,678 $ 229,221
United States        
Disaggregation of Revenue [Line Items]        
Net sales 67,620 62,445 208,274 192,259
International        
Disaggregation of Revenue [Line Items]        
Net sales 13,092 11,525 39,404 36,962
Med Tech        
Disaggregation of Revenue [Line Items]        
Net sales 22,874 19,612 70,193 56,106
Med Tech | United States        
Disaggregation of Revenue [Line Items]        
Net sales 20,381 17,782 61,373 49,249
Med Tech | International        
Disaggregation of Revenue [Line Items]        
Net sales 2,493 1,830 8,820 6,857
Med Device        
Disaggregation of Revenue [Line Items]        
Net sales 57,838 54,358 177,485 173,115
Med Device | United States        
Disaggregation of Revenue [Line Items]        
Net sales 47,239 44,663 146,901 143,010
Med Device | International        
Disaggregation of Revenue [Line Items]        
Net sales $ 10,599 $ 9,695 $ 30,584 $ 30,105
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue from Contracts with Customers - Narrative (Details)
$ in Millions
 9 Months Ended
Feb. 28, 2023
USD ($)
Disaggregation of Revenue [Line Items]  
Days after purchase after which pre-approval is required for product return 30 days
Restocking charge (as percent) 20.00%
Minimum remaining period prior to product expiration 12 months
Additions to contract liabilities $ 0.6
Revenue recognized $ 0.6
Minimum  
Disaggregation of Revenue [Line Items]  
Payment term 30 days
Maximum  
Disaggregation of Revenue [Line Items]  
Payment term 90 days
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue from Contracts with Customers - Contract Balances with Customers (Details) - USD ($)
$ in Thousands
Feb. 28, 2023
May 31, 2022
Revenue from Contract with Customer [Abstract]    
Receivables $ 50,892 $ 52,304
Contract assets 0 0
Contract liabilities $ 571 $ 526
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories - Schedule of Inventories (Details) - USD ($)
$ in Thousands
Feb. 28, 2023
May 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 34,471 $ 28,251
Work in process 7,924 7,186
Finished goods 21,137 15,955
Inventories $ 63,532 $ 51,392
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories - Narrative (Details) - USD ($)
$ in Millions
Feb. 28, 2023
May 31, 2022
Inventory Disclosure [Abstract]    
Inventory valuation reserves $ 3.1 $ 3.7
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Intangible Assets - Narrative (Details)
 3 Months Ended 6 Months Ended 9 Months Ended
Dec. 31, 2020
USD ($)
Feb. 28, 2023
USD ($)
segment
unit
Feb. 28, 2022
USD ($)
Nov. 30, 2022
unit
Feb. 28, 2023
USD ($)
segment
Feb. 28, 2022
USD ($)
Finite-Lived Intangible Assets [Line Items]            
Number of reporting units | unit   2   1    
Number of operating segments | segment   2     2  
Goodwill impairment $ 0          
Amortization of intangibles   $ 4,739,000 $ 4,895,000   $ 14,384,000 $ 14,605,000
Minimum            
Finite-Lived Intangible Assets [Line Items]            
Estimated useful life of intangible assets other than goodwill         2 years  
Maximum            
Finite-Lived Intangible Assets [Line Items]            
Estimated useful life of intangible assets other than goodwill         18 years  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Intangible Assets - Change in Goodwill (Details) - USD ($)
$ in Thousands
 3 Months Ended
Feb. 28, 2023
Nov. 30, 2022
Aug. 31, 2022
Goodwill [Roll Forward]      
Beginning balance $ 200,755 $ 201,038 $ 201,058
Foreign currency translation adjustments (779) (283) (20)
Ending balance 199,976 200,755 201,038
Med Tech      
Goodwill [Roll Forward]      
Beginning balance 160,226 160,509 160,529
Foreign currency translation adjustments (779) (283) (20)
Ending balance 159,447 160,226 160,509
Med Device      
Goodwill [Roll Forward]      
Beginning balance 40,529 40,529 40,529
Foreign currency translation adjustments 0 0 0
Ending balance $ 40,529 $ 40,529 $ 40,529
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)
$ in Thousands
Feb. 28, 2023
May 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Gross carrying value, finite intangible items $ 309,175 $ 314,369
Accumulated amortization (175,164) (161,989)
Net carrying value, finite intangible items 134,011 152,380
Product technologies    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying value, finite intangible items 233,752 239,467
Accumulated amortization (122,017) (112,141)
Net carrying value, finite intangible items 111,735 127,326
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying value, finite intangible items 60,096 60,115
Accumulated amortization (40,995) (38,003)
Net carrying value, finite intangible items 19,101 22,112
Trademarks    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying value, finite intangible items 9,950 9,950
Accumulated amortization (7,396) (7,185)
Net carrying value, finite intangible items 2,554 2,765
Licenses    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying value, finite intangible items 5,377 4,837
Accumulated amortization (4,756) (4,660)
Net carrying value, finite intangible items $ 621 $ 177
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Intangible Assets - Expected Future Amortization Expense (Details) - USD ($)
$ in Thousands
Feb. 28, 2023
May 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
Remainder of 2023 $ 5,918  
2024 16,406  
2025 16,388  
2026 16,207  
2027 16,036  
2028 and thereafter 63,056  
Net carrying value, finite intangible items $ 134,011 $ 152,380
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Liabilities (Details) - USD ($)
$ in Thousands
Feb. 28, 2023
May 31, 2022
Payables and Accruals [Abstract]    
Payroll and related expenses $ 9,355 $ 20,232
Royalties 2,202 2,986
Outside services 3,171 3,731
Research and development 1,368 1,279
Sales and franchise taxes 328 750
Rebates 359 511
Other 4,992 5,353
Total accrued liabilities $ 21,775 $ 34,842
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt - Narrative (Details)
$ in Thousands
 9 Months Ended
Aug. 30, 2022
USD ($)
Jun. 03, 2019
USD ($)
Feb. 28, 2023
USD ($)
covenant
Feb. 28, 2022
USD ($)
Debt Instrument [Line Items]        
Proceeds from borrowings on long-term debt     $ 70,000 $ 5,000
Outstanding draw term loan     $ 49,807  
Credit Facility        
Debt Instrument [Line Items]        
Proceeds from borrowings on long-term debt $ 5,000      
Debt instrument term (years)   5 years    
Debt default interest rate increase (percentage)     2.00%  
Number of covenants | covenant     2  
Maximum total leverage ratio     3.00  
Maximum total leverage ratio subsequent to material acquisitions     3.50  
Minimum fixed charge coverage ratio     1.25  
Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate        
Debt Instrument [Line Items]        
Basis spread on variable rate (percentage) 0.10%      
Floor interest rate 0.00%      
Credit Facility | Base Rate        
Debt Instrument [Line Items]        
Basis spread on variable rate (percentage)     1.50%  
Credit Facility | Minimum | Base Rate        
Debt Instrument [Line Items]        
Basis spread on variable rate (percentage)     1.25%  
Credit Facility | Maximum | Base Rate        
Debt Instrument [Line Items]        
Basis spread on variable rate (percentage)     1.75%  
Credit Facility | Revolving Credit Facility        
Debt Instrument [Line Items]        
Line of credit $ 75,000      
Line of credit accordion feature   $ 75,000    
Borrowings outstanding     $ 25,000  
Interest rate at period end (percentage)     6.15%  
Credit Facility | Delayed Draw Term Loan        
Debt Instrument [Line Items]        
Term loan $ 30,000      
Debt instrument term (years)     5 years  
Outstanding draw term loan     $ 25,000  
Principal payment percentage     3.57%  
Credit Facility | Delayed Draw Term Loan | Minimum        
Debt Instrument [Line Items]        
Commitment fee (percentage)     0.20%  
Credit Facility | Delayed Draw Term Loan | Maximum        
Debt Instrument [Line Items]        
Commitment fee (percentage)     0.25%  
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Debt - Schedule of Debt (Details)
$ in Thousands
Feb. 28, 2023
USD ($)
Debt Instrument [Line Items]  
Less: unamortized debt issuance costs $ (193)
Total long-term debt 49,807
Credit Facility | Revolving Credit Facility  
Debt Instrument [Line Items]  
Long-term debt, gross 25,000
Credit Facility | Delayed Draw Term Loan  
Debt Instrument [Line Items]  
Long-term debt, gross 25,000
Total long-term debt $ 25,000
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details)
 3 Months Ended
Feb. 28, 2023
Feb. 28, 2022
Income Tax Disclosure [Abstract]    
Estimated federal statutory income tax rate 5.20% 12.70%
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Nov. 03, 2022
Feb. 28, 2023
Feb. 28, 2022
Feb. 28, 2023
Feb. 28, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Charges against income for share-based payment arrangements   $ 1.8 $ 2.4 $ 8.2 $ 7.8
Unrecognized compensation expenses related to share-based payment arrangements   $ 17.6   $ 17.6  
Recognition period       3 years  
2020 Stock And Incentive Award Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Approved increase of common stock reserve (shares) 1,950,000        
Amount of shares issuable through two stock-based compensation plans (shares)   2,900,000   2,900,000  
Employee Stock Purchase Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Approved increase of common stock reserve (shares) 1,000,000        
Amount of shares issuable through two stock-based compensation plans (shares)   3,200,000   3,200,000  
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share (Details) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Feb. 28, 2023
Feb. 28, 2022
Feb. 28, 2023
Feb. 28, 2022
Earnings Per Share [Abstract]        
Basic (shares) 39,509 39,092 39,436 38,959
Effect of dilutive securities (shares) 0 0 0 0
Diluted (shares) 39,509 39,092 39,436 38,959
Securities excluded as their inclusion would be anti-dilutive (shares) 3,706 3,457 3,706 3,457
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Segment and Geographic Information - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Feb. 28, 2023
USD ($)
segment
Feb. 28, 2022
Feb. 28, 2023
USD ($)
segment
Feb. 28, 2022
May 31, 2022
USD ($)
Segment Reporting Information [Line Items]          
Number of operating segments | segment 2   2    
Assets | $ $ 542,849   $ 542,849   $ 552,751
International | Revenue from Contract with Customer Benchmark | Geographic Concentration Risk          
Segment Reporting Information [Line Items]          
Concentration risk percentage 16.20% 15.60% 15.90% 16.10%  
United States | Net Assets, Geographic Area | Geographic Concentration Risk          
Segment Reporting Information [Line Items]          
Concentration risk percentage     85.00%    
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Segment and Geographic Information - Summary of Net Sales by Product Category (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Feb. 28, 2023
Feb. 28, 2022
Feb. 28, 2023
Feb. 28, 2022
Segment Reporting Information [Line Items]        
Net sales $ 80,712 $ 73,970 $ 247,678 $ 229,221
Gross profit $ 40,504 $ 38,583 $ 127,887 $ 119,277
Gross margin 50.20% 52.20% 51.60% 52.00%
Med Tech        
Segment Reporting Information [Line Items]        
Net sales $ 22,874 $ 19,612 $ 70,193 $ 56,106
Gross profit $ 14,774 $ 12,965 $ 44,816 $ 37,060
Gross margin 64.60% 66.10% 63.80% 66.10%
Med Device        
Segment Reporting Information [Line Items]        
Net sales $ 57,838 $ 54,358 $ 177,485 $ 173,115
Gross profit $ 25,730 $ 25,618 $ 83,071 $ 82,217
Gross margin 44.50% 47.10% 46.80% 47.50%
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Segment and Geographic Information - Summary of Net Sales by Geographic Area (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Feb. 28, 2023
Feb. 28, 2022
Feb. 28, 2023
Feb. 28, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]        
Net sales $ 80,712 $ 73,970 $ 247,678 $ 229,221
United States        
Revenues from External Customers and Long-Lived Assets [Line Items]        
Net sales 67,620 62,445 208,274 192,259
International        
Revenues from External Customers and Long-Lived Assets [Line Items]        
Net sales $ 13,092 $ 11,525 $ 39,404 $ 36,962
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details) - Recurring - USD ($)
$ in Thousands
Feb. 28, 2023
May 31, 2022
Financial Liabilities    
Contingent consideration for acquisition earn outs $ 19,059 $ 16,948
Total Financial Liabilities 19,059 16,948
Level 1    
Financial Liabilities    
Contingent consideration for acquisition earn outs 0 0
Total Financial Liabilities 0 0
Level 2    
Financial Liabilities    
Contingent consideration for acquisition earn outs 0 0
Total Financial Liabilities 0 0
Level 3    
Financial Liabilities    
Contingent consideration for acquisition earn outs 19,059 16,948
Total Financial Liabilities $ 19,059 $ 16,948
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Feb. 28, 2023
Feb. 28, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Financial liabilities, beginning balance $ 18,832 $ 16,948
Change in present value of contingent consideration 227 2,084
Currency gain from remeasurement   27
Financial liabilities, ending balance $ 19,059 $ 19,059
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Details) - Recurring
$ in Thousands
Feb. 28, 2023
USD ($)
May 31, 2022
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liabilities $ 19,059 $ 16,948
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liabilities 19,059 $ 16,948
Revenue based payments | Level 3 | Discounted cash flow    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liabilities $ 19,059  
Discount rate | Revenue based payments | Level 3 | Discounted cash flow    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liability, measurement input 5  
Probability of payment | Revenue based payments | Level 3 | Discounted cash flow | Minimum    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liability, measurement input 0.90  
Probability of payment | Revenue based payments | Level 3 | Discounted cash flow | Maximum    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liability, measurement input 1  
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value - Additional Information (Details)
$ in Millions
Feb. 28, 2023
USD ($)
Fair Value Disclosures [Abstract]  
Potential amount of undiscounted future contingent consideration $ 20.0
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Thousands
Feb. 28, 2023
May 31, 2022
Leases [Abstract]    
Operating lease ROU asset $ 5,143 $ 6,974
Current operating lease liabilities 2,299 2,560
Non-current operating lease liabilities 3,049 4,703
Total lease liabilities $ 5,348 $ 7,263
Operating lease, right-of-use asset, statement of financial position, extensible list Other assets Other assets
Operating lease, liability, current, statement of financial position, extensible list Other current liabilities Other current liabilities
Operating lease, liability, noncurrent, statement of financial position, extensible list Other long-term liabilities Other long-term liabilities
Weighted average remaining term (in years) 2 years 8 months 19 days  
Weighted average discount rate 3.80%  
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Liability Maturity Schedule (Details) - USD ($)
$ in Thousands
Feb. 28, 2023
May 31, 2022
Leases [Abstract]    
Remainder of 2023 $ 699  
2024 2,191  
2025 1,428  
2026 1,130  
2028 and thereafter 171  
Total lease payments 5,619  
Less: Imputed Interest 271  
Total lease liabilities 5,348 $ 7,263
Current operating lease liabilities 2,299 2,560
Non-current operating lease liabilities $ 3,049 $ 4,703
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Supplemental Statement of Operations Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Feb. 28, 2023
Feb. 28, 2022
Feb. 28, 2023
Feb. 28, 2022
Lessee, Lease, Description [Line Items]        
Non-cash lease expense $ 696 $ 684 $ 2,044 $ 2,114
Cost of sales        
Lessee, Lease, Description [Line Items]        
Non-cash lease expense 221 218 661 656
Research and development        
Lessee, Lease, Description [Line Items]        
Non-cash lease expense 54 52 158 201
Sales and marketing        
Lessee, Lease, Description [Line Items]        
Non-cash lease expense 42 40 122 119
General and administrative        
Lessee, Lease, Description [Line Items]        
Non-cash lease expense $ 379 $ 374 $ 1,103 $ 1,138
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 9 Months Ended
Feb. 28, 2023
Feb. 28, 2022
Leases [Abstract]    
Operating cash flows from operating leases $ 2,079 $ 2,041
ROU assets obtained in exchange for lease liabilities $ 0 $ 33
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Details) - patent
Mar. 10, 2015
Jan. 11, 2012
The Delaware Action    
Loss Contingencies [Line Items]    
Number of patents allegedly infringed upon 3  
C.R. Bard, Inc.    
Loss Contingencies [Line Items]    
Number of petitions filed for reexamination of patents   3
Number of patents upheld over prior art references   2
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisition, Restructuring and Other Items, Net (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Feb. 28, 2023
Nov. 30, 2022
Feb. 28, 2022
Feb. 28, 2023
Feb. 28, 2022
Restructuring Cost and Reserve [Line Items]          
Acquisition, restructuring and other items, net $ 3,369   $ 2,359 $ 12,009 $ 7,052
Payment for acquisition   $ 3,500      
Legal          
Restructuring Cost and Reserve [Line Items]          
Acquisition, restructuring and other items, net 2,614   1,681 6,899 5,837
Mergers and acquisitions          
Restructuring Cost and Reserve [Line Items]          
Acquisition, restructuring and other items, net 0   0 0 59
Manufacturing relocation          
Restructuring Cost and Reserve [Line Items]          
Acquisition, restructuring and other items, net 324   396 1,062 455
Israeli Innovation Authority Prepayment          
Restructuring Cost and Reserve [Line Items]          
Acquisition, restructuring and other items, net 0   0 3,544 0
Other          
Restructuring Cost and Reserve [Line Items]          
Acquisition, restructuring and other items, net $ 431   $ 282 $ 504 $ 701
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.23.1
Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Feb. 28, 2023
Feb. 28, 2022
Feb. 28, 2023
Feb. 28, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning Balance $ 407,958 $ 432,368 $ 424,489 $ 439,457
Other comprehensive income (loss), net of tax (3,562) (1,036) (5,207) 373
Ending Balance 397,655 $ 429,692 397,655 $ 429,692
Foreign currency translation income        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning Balance (288)   1,357  
Other comprehensive loss, net of tax (3,562)   (5,207)  
Other comprehensive income (loss), net of tax (3,562)   (5,207)  
Ending Balance $ (3,850)   $ (3,850)  
XML 78 ango-20230228_htm.xml IDEA: XBRL DOCUMENT 0001275187 2022-06-01 2023-02-28 0001275187 us-gaap:CommonStockMember 2022-06-01 2023-02-28 0001275187 ango:PreferredStockPurchaseRightsMember 2022-06-01 2023-02-28 0001275187 2023-03-30 0001275187 2022-12-01 2023-02-28 0001275187 2021-12-01 2022-02-28 0001275187 2021-06-01 2022-02-28 0001275187 us-gaap:RetainedEarningsMember 2022-12-01 2023-02-28 0001275187 2023-02-28 0001275187 2022-05-31 0001275187 2021-05-31 0001275187 2022-02-28 0001275187 us-gaap:CommonStockMember 2022-05-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001275187 us-gaap:RetainedEarningsMember 2022-05-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-05-31 0001275187 us-gaap:TreasuryStockCommonMember 2022-05-31 0001275187 us-gaap:RetainedEarningsMember 2022-06-01 2022-08-31 0001275187 2022-06-01 2022-08-31 0001275187 us-gaap:CommonStockMember 2022-06-01 2022-08-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2022-06-01 2022-08-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-06-01 2022-08-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AdditionalPaidInCapitalMember 2022-06-01 2022-08-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember 2022-06-01 2022-08-31 0001275187 us-gaap:PerformanceSharesMember us-gaap:CommonStockMember 2022-06-01 2022-08-31 0001275187 us-gaap:PerformanceSharesMember us-gaap:AdditionalPaidInCapitalMember 2022-06-01 2022-08-31 0001275187 us-gaap:PerformanceSharesMember 2022-06-01 2022-08-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-01 2022-08-31 0001275187 us-gaap:CommonStockMember 2022-08-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2022-08-31 0001275187 us-gaap:RetainedEarningsMember 2022-08-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-08-31 0001275187 us-gaap:TreasuryStockCommonMember 2022-08-31 0001275187 2022-08-31 0001275187 2022-09-01 2022-11-30 0001275187 us-gaap:CommonStockMember 2022-09-01 2022-11-30 0001275187 us-gaap:AdditionalPaidInCapitalMember 2022-09-01 2022-11-30 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-09-01 2022-11-30 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AdditionalPaidInCapitalMember 2022-09-01 2022-11-30 0001275187 us-gaap:RestrictedStockUnitsRSUMember 2022-09-01 2022-11-30 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-01 2022-11-30 0001275187 us-gaap:CommonStockMember 2022-11-30 0001275187 us-gaap:AdditionalPaidInCapitalMember 2022-11-30 0001275187 us-gaap:RetainedEarningsMember 2022-11-30 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-11-30 0001275187 us-gaap:TreasuryStockCommonMember 2022-11-30 0001275187 2022-11-30 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-12-01 2023-02-28 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AdditionalPaidInCapitalMember 2022-12-01 2023-02-28 0001275187 us-gaap:RestrictedStockUnitsRSUMember 2022-12-01 2023-02-28 0001275187 us-gaap:CommonStockMember 2022-12-01 2023-02-28 0001275187 us-gaap:AdditionalPaidInCapitalMember 2022-12-01 2023-02-28 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-01 2023-02-28 0001275187 us-gaap:CommonStockMember 2023-02-28 0001275187 us-gaap:AdditionalPaidInCapitalMember 2023-02-28 0001275187 us-gaap:RetainedEarningsMember 2023-02-28 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-02-28 0001275187 us-gaap:TreasuryStockCommonMember 2023-02-28 0001275187 us-gaap:CommonStockMember 2021-05-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001275187 us-gaap:RetainedEarningsMember 2021-05-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-05-31 0001275187 us-gaap:TreasuryStockCommonMember 2021-05-31 0001275187 us-gaap:RetainedEarningsMember 2021-06-01 2021-08-31 0001275187 2021-06-01 2021-08-31 0001275187 us-gaap:CommonStockMember 2021-06-01 2021-08-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2021-08-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2021-06-01 2021-08-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2021-08-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember 2021-06-01 2021-08-31 0001275187 us-gaap:PerformanceSharesMember us-gaap:CommonStockMember 2021-06-01 2021-08-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-01 2021-08-31 0001275187 us-gaap:CommonStockMember 2021-08-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001275187 us-gaap:RetainedEarningsMember 2021-08-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-08-31 0001275187 us-gaap:TreasuryStockCommonMember 2021-08-31 0001275187 2021-08-31 0001275187 us-gaap:RetainedEarningsMember 2021-09-01 2021-11-30 0001275187 2021-09-01 2021-11-30 0001275187 us-gaap:CommonStockMember 2021-09-01 2021-11-30 0001275187 us-gaap:AdditionalPaidInCapitalMember 2021-09-01 2021-11-30 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2021-09-01 2021-11-30 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AdditionalPaidInCapitalMember 2021-09-01 2021-11-30 0001275187 us-gaap:RestrictedStockUnitsRSUMember 2021-09-01 2021-11-30 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-01 2021-11-30 0001275187 us-gaap:CommonStockMember 2021-11-30 0001275187 us-gaap:AdditionalPaidInCapitalMember 2021-11-30 0001275187 us-gaap:RetainedEarningsMember 2021-11-30 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-11-30 0001275187 us-gaap:TreasuryStockCommonMember 2021-11-30 0001275187 2021-11-30 0001275187 us-gaap:RetainedEarningsMember 2021-12-01 2022-02-28 0001275187 us-gaap:CommonStockMember 2021-12-01 2022-02-28 0001275187 us-gaap:AdditionalPaidInCapitalMember 2021-12-01 2022-02-28 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2021-12-01 2022-02-28 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AdditionalPaidInCapitalMember 2021-12-01 2022-02-28 0001275187 us-gaap:RestrictedStockUnitsRSUMember 2021-12-01 2022-02-28 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-01 2022-02-28 0001275187 us-gaap:CommonStockMember 2022-02-28 0001275187 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001275187 us-gaap:RetainedEarningsMember 2022-02-28 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-02-28 0001275187 us-gaap:TreasuryStockCommonMember 2022-02-28 0001275187 ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember 2021-07-27 2021-07-27 0001275187 ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember 2021-07-27 0001275187 ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2021-07-27 2021-07-27 0001275187 ango:QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember 2019-12-17 2019-12-17 0001275187 ango:MedTechMember country:US 2022-12-01 2023-02-28 0001275187 ango:MedTechMember us-gaap:NonUsMember 2022-12-01 2023-02-28 0001275187 ango:MedTechMember 2022-12-01 2023-02-28 0001275187 ango:MedTechMember country:US 2021-12-01 2022-02-28 0001275187 ango:MedTechMember us-gaap:NonUsMember 2021-12-01 2022-02-28 0001275187 ango:MedTechMember 2021-12-01 2022-02-28 0001275187 ango:MedDeviceMember country:US 2022-12-01 2023-02-28 0001275187 ango:MedDeviceMember us-gaap:NonUsMember 2022-12-01 2023-02-28 0001275187 ango:MedDeviceMember 2022-12-01 2023-02-28 0001275187 ango:MedDeviceMember country:US 2021-12-01 2022-02-28 0001275187 ango:MedDeviceMember us-gaap:NonUsMember 2021-12-01 2022-02-28 0001275187 ango:MedDeviceMember 2021-12-01 2022-02-28 0001275187 country:US 2022-12-01 2023-02-28 0001275187 us-gaap:NonUsMember 2022-12-01 2023-02-28 0001275187 country:US 2021-12-01 2022-02-28 0001275187 us-gaap:NonUsMember 2021-12-01 2022-02-28 0001275187 ango:MedTechMember country:US 2022-06-01 2023-02-28 0001275187 ango:MedTechMember us-gaap:NonUsMember 2022-06-01 2023-02-28 0001275187 ango:MedTechMember 2022-06-01 2023-02-28 0001275187 ango:MedTechMember country:US 2021-06-01 2022-02-28 0001275187 ango:MedTechMember us-gaap:NonUsMember 2021-06-01 2022-02-28 0001275187 ango:MedTechMember 2021-06-01 2022-02-28 0001275187 ango:MedDeviceMember country:US 2022-06-01 2023-02-28 0001275187 ango:MedDeviceMember us-gaap:NonUsMember 2022-06-01 2023-02-28 0001275187 ango:MedDeviceMember 2022-06-01 2023-02-28 0001275187 ango:MedDeviceMember country:US 2021-06-01 2022-02-28 0001275187 ango:MedDeviceMember us-gaap:NonUsMember 2021-06-01 2022-02-28 0001275187 ango:MedDeviceMember 2021-06-01 2022-02-28 0001275187 country:US 2022-06-01 2023-02-28 0001275187 us-gaap:NonUsMember 2022-06-01 2023-02-28 0001275187 country:US 2021-06-01 2022-02-28 0001275187 us-gaap:NonUsMember 2021-06-01 2022-02-28 0001275187 srt:MinimumMember 2022-06-01 2023-02-28 0001275187 srt:MaximumMember 2022-06-01 2023-02-28 0001275187 2022-06-01 2022-11-30 0001275187 ango:MedTechMember 2022-06-01 0001275187 ango:MedDeviceMember 2022-06-01 0001275187 2022-06-01 0001275187 ango:MedTechMember 2022-06-02 2022-08-31 0001275187 ango:MedDeviceMember 2022-06-02 2022-08-31 0001275187 2022-06-02 2022-08-31 0001275187 ango:MedTechMember 2022-08-31 0001275187 ango:MedDeviceMember 2022-08-31 0001275187 ango:MedTechMember 2022-09-01 2022-11-30 0001275187 ango:MedDeviceMember 2022-09-01 2022-11-30 0001275187 ango:MedTechMember 2022-11-30 0001275187 ango:MedDeviceMember 2022-11-30 0001275187 ango:MedTechMember 2022-12-01 2023-02-28 0001275187 ango:MedDeviceMember 2022-12-01 2023-02-28 0001275187 ango:MedTechMember 2023-02-28 0001275187 ango:MedDeviceMember 2023-02-28 0001275187 2020-12-31 2020-12-31 0001275187 ango:ProductTechnologiesMember 2023-02-28 0001275187 us-gaap:CustomerRelationshipsMember 2023-02-28 0001275187 us-gaap:TrademarksMember 2023-02-28 0001275187 us-gaap:LicenseAgreementTermsMember 2023-02-28 0001275187 ango:ProductTechnologiesMember 2022-05-31 0001275187 us-gaap:CustomerRelationshipsMember 2022-05-31 0001275187 us-gaap:TrademarksMember 2022-05-31 0001275187 us-gaap:LicenseAgreementTermsMember 2022-05-31 0001275187 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-08-30 0001275187 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2022-08-30 0001275187 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-06-03 0001275187 us-gaap:LineOfCreditMember 2022-08-30 2022-08-30 0001275187 us-gaap:LineOfCreditMember 2019-06-03 2019-06-03 0001275187 us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-08-30 2022-08-30 0001275187 srt:MinimumMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-06-01 2023-02-28 0001275187 us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-06-01 2023-02-28 0001275187 srt:MaximumMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-06-01 2023-02-28 0001275187 us-gaap:LineOfCreditMember 2022-06-01 2023-02-28 0001275187 srt:MinimumMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2022-06-01 2023-02-28 0001275187 srt:MaximumMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2022-06-01 2023-02-28 0001275187 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-02-28 0001275187 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2023-02-28 0001275187 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2022-06-01 2023-02-28 0001275187 ango:A2020StockAndIncentiveAwardPlanMember 2022-11-03 2022-11-03 0001275187 ango:A2020StockAndIncentiveAwardPlanMember 2023-02-28 0001275187 ango:EmployeeStockPurchasePlanMember 2022-11-03 2022-11-03 0001275187 ango:EmployeeStockPurchasePlanMember 2023-02-28 0001275187 us-gaap:NonUsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-12-01 2023-02-28 0001275187 us-gaap:NonUsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-12-01 2022-02-28 0001275187 us-gaap:NonUsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-06-01 2023-02-28 0001275187 us-gaap:NonUsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-06-01 2022-02-28 0001275187 country:US us-gaap:NetAssetsGeographicAreaMember us-gaap:GeographicConcentrationRiskMember 2022-06-01 2023-02-28 0001275187 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-02-28 0001275187 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-02-28 0001275187 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-02-28 0001275187 us-gaap:FairValueMeasurementsRecurringMember 2023-02-28 0001275187 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-05-31 0001275187 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-05-31 0001275187 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-05-31 0001275187 us-gaap:FairValueMeasurementsRecurringMember 2022-05-31 0001275187 ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-02-28 0001275187 ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-02-28 0001275187 srt:MinimumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ango:MeasurementInputProbabilityofPaymentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-02-28 0001275187 srt:MaximumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ango:MeasurementInputProbabilityofPaymentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-02-28 0001275187 us-gaap:CostOfSalesMember 2022-12-01 2023-02-28 0001275187 us-gaap:CostOfSalesMember 2021-12-01 2022-02-28 0001275187 us-gaap:CostOfSalesMember 2022-06-01 2023-02-28 0001275187 us-gaap:CostOfSalesMember 2021-06-01 2022-02-28 0001275187 us-gaap:ResearchAndDevelopmentExpenseMember 2022-12-01 2023-02-28 0001275187 us-gaap:ResearchAndDevelopmentExpenseMember 2021-12-01 2022-02-28 0001275187 us-gaap:ResearchAndDevelopmentExpenseMember 2022-06-01 2023-02-28 0001275187 us-gaap:ResearchAndDevelopmentExpenseMember 2021-06-01 2022-02-28 0001275187 us-gaap:SellingAndMarketingExpenseMember 2022-12-01 2023-02-28 0001275187 us-gaap:SellingAndMarketingExpenseMember 2021-12-01 2022-02-28 0001275187 us-gaap:SellingAndMarketingExpenseMember 2022-06-01 2023-02-28 0001275187 us-gaap:SellingAndMarketingExpenseMember 2021-06-01 2022-02-28 0001275187 us-gaap:GeneralAndAdministrativeExpenseMember 2022-12-01 2023-02-28 0001275187 us-gaap:GeneralAndAdministrativeExpenseMember 2021-12-01 2022-02-28 0001275187 us-gaap:GeneralAndAdministrativeExpenseMember 2022-06-01 2023-02-28 0001275187 us-gaap:GeneralAndAdministrativeExpenseMember 2021-06-01 2022-02-28 0001275187 ango:CrBardIncMember 2012-01-11 2012-01-11 0001275187 ango:TheDelawareActionMember 2015-03-10 2015-03-10 0001275187 ango:LegalCostsMember 2022-12-01 2023-02-28 0001275187 ango:LegalCostsMember 2021-12-01 2022-02-28 0001275187 ango:LegalCostsMember 2022-06-01 2023-02-28 0001275187 ango:LegalCostsMember 2021-06-01 2022-02-28 0001275187 ango:MergersandAcquisitionsMember 2022-12-01 2023-02-28 0001275187 ango:MergersandAcquisitionsMember 2021-12-01 2022-02-28 0001275187 ango:MergersandAcquisitionsMember 2022-06-01 2023-02-28 0001275187 ango:MergersandAcquisitionsMember 2021-06-01 2022-02-28 0001275187 ango:ManufacturingRelocationMember 2022-12-01 2023-02-28 0001275187 ango:ManufacturingRelocationMember 2021-12-01 2022-02-28 0001275187 ango:ManufacturingRelocationMember 2022-06-01 2023-02-28 0001275187 ango:ManufacturingRelocationMember 2021-06-01 2022-02-28 0001275187 ango:IsraeliInnovationAuthorityPrepaymentMember 2022-12-01 2023-02-28 0001275187 ango:IsraeliInnovationAuthorityPrepaymentMember 2021-12-01 2022-02-28 0001275187 ango:IsraeliInnovationAuthorityPrepaymentMember 2022-06-01 2023-02-28 0001275187 ango:IsraeliInnovationAuthorityPrepaymentMember 2021-06-01 2022-02-28 0001275187 us-gaap:OtherExpenseMember 2022-12-01 2023-02-28 0001275187 us-gaap:OtherExpenseMember 2021-12-01 2022-02-28 0001275187 us-gaap:OtherExpenseMember 2022-06-01 2023-02-28 0001275187 us-gaap:OtherExpenseMember 2021-06-01 2022-02-28 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2022-11-30 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-01 2023-02-28 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2023-02-28 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2022-05-31 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-01 2023-02-28 shares iso4217:USD iso4217:USD shares pure ango:unit ango:segment ango:covenant ango:patent false 2023 Q3 0001275187 --05-31 true P2Y http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent 10-Q true 2023-02-28 false 0-50761 AngioDynamics, Inc. DE 11-3146460 14 Plaza Drive Latham NY 12110 518 795-1400 Common Stock, par value $.01 ANGO NASDAQ Preferred Stock Purchase Rights NASDAQ Yes Yes Large Accelerated Filer false false false 39236422 80712000 73970000 247678000 229221000 40208000 35387000 119791000 109944000 40504000 38583000 127887000 119277000 6852000 7280000 22023000 22873000 25406000 20416000 77956000 68468000 8839000 8727000 29775000 27348000 4739000 4895000 14384000 14605000 227000 201000 2084000 1005000 3369000 2359000 12009000 7052000 49432000 43878000 158231000 141351000 -8928000 -5295000 -30344000 -22074000 736000 173000 1801000 503000 0 -289000 -427000 -651000 -736000 -462000 -2228000 -1154000 -9664000 -5757000 -32572000 -23228000 -179000 -799000 -1597000 -2947000 -9485000 -4958000 -30975000 -20281000 -0.24 -0.13 -0.79 -0.52 -0.24 -0.13 -0.79 -0.52 39509000 39092000 39436000 38959000 39509000 39092000 39436000 38959000 -9485000 -4958000 -30975000 -20281000 -3562000 -1036000 -5207000 373000 -3562000 -1036000 -5207000 373000 0 0 0 0 -3562000 -1036000 -5207000 373000 -13047000 -5994000 -36182000 -19908000 30111000 28825000 2030000 1939000 50892000 52304000 63532000 51392000 8039000 10824000 152574000 143345000 45559000 45005000 134011000 152380000 199976000 201058000 10729000 10963000 542849000 552751000 35600000 28047000 21775000 34842000 9877000 8783000 2380000 2652000 69632000 74324000 49807000 25000000 13490000 16037000 9182000 8165000 3083000 4736000 145194000 128262000 0.01 0.01 5000000 5000000 0 0 0 0 0 0 0.01 0.01 75000000 75000000 39976422 39541173 39606422 39171173 382000 380000 596225000 586879000 -189388000 -158413000 370000 370000 5714000 5714000 -3850000 1357000 397655000 424489000 542849000 552751000 -30975000 -20281000 23316000 21682000 1883000 1822000 8177000 7789000 2084000 1005000 -1752000 -3121000 560000 -66000 144000 245000 317000 27000 -759000 6441000 12254000 -588000 392000 7147000 -7109000 -11802000 -15876000 -15754000 2756000 3258000 4922000 8676000 540000 3600000 -8218000 -15534000 70000000 5000000 45000000 0 751000 0 1171000 2354000 25420000 7354000 -40000 -337000 1286000 -24271000 28825000 48161000 30111000 23890000 140000 -5000 39541173 380000 586879000 -158413000 1357000 370000 -5714000 424489000 -13004000 -13004000 6617 -29000 -29000 213241 -648000 -648000 29826 -312000 -312000 56894 1000 1070000 1071000 3024000 3024000 -550000 -550000 39847751 381000 589984000 -171417000 807000 -370000 -5714000 414041000 -8486000 -8486000 15000 184000 184000 11393 -36000 -36000 3350000 3350000 -1095000 -1095000 39874144 381000 593482000 -179903000 -288000 370000 -5714000 407958000 -9485000 -9485000 9394 -36000 -36000 92884 1000 976000 977000 1803000 1803000 -3562000 -3562000 39976422 382000 596225000 -189388000 -3850000 370000 -5714000 397655000 38920951000 377000 573507000 -131866000 3153000 370000000 -5714000 439457000 -6972000 -6972000 80635000 1000 1279000 1280000 279495000 -1734000 -1734000 59371000 49789000 1000 899000 900000 2429000 2429000 590000 590000 39390241000 379000 576380000 -138838000 3743000 370000000 -5714000 435950000 -8351000 -8351000 56064000 1022000 1022000 8695000 -83000 -83000 193000 3000 3000 3008000 3008000 819000 819000 39455193000 379000 580330000 -147189000 4562000 370000000 -5714000 432368000 -4958000 -4958000 5000000 77000 77000 11304000 -84000 -84000 48604000 1000 972000 973000 2352000 2352000 -1036000 -1036000 39520101000 380000 583647000 -152147000 3526000 370000000 -5714000 429692000 CONSOLIDATED FINANCIAL STATEMENTS<div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Loss for the three and nine months ended February 28, 2023 and 2022, the Consolidated Balance Sheet as of February 28, 2023, the Consolidated Statements of Cash Flows for the nine months ended February 28, 2023 and 2022, and the Consolidated Statements of Stockholders’ Equity for the nine months ended February 28, 2023 and 2022 have been prepared by the Company and are unaudited. The Consolidated Balance Sheet as of May 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended February 28, 2023 (and for all periods presented) have been made.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim consolidated financial statements for the three and nine months ended February 28, 2023 and 2022 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries (collectively, the "Company", "we", "our" or "us"). All intercompany balances and transactions have been eliminated.</span></div> ACQUISITIONSCamaro Support Catheter Asset AcquisitionOn July 27, 2021, the Company acquired the Camaro support catheter (rebranded as Syntrax) from QX Medical, LLC for an aggregate purchase price of $4.0 million, which included an upfront payment of $3.6 million and $0.4 million in purchase price holdbacks, along with $1.0 million of potential future contingent consideration related to revenue milestones. This acquisition supports the Auryon product family and the Company's strategic plan. The Company accounted for this acquisition as an asset purchase. The Company recorded the amount paid at closing as inventory and fixed assets of $0.1 million and an intangible asset product technology of $3.9 million. The intangible asset will be amortized over 15 years. The contingent consideration is comprised of revenue milestones and will be accounted for when the contingency is resolved or becomes probable and reasonably estimable. 4000000 3600000 400000 1000000 100000 3900000 P15Y REVENUE FROM CONTRACTS WITH CUSTOMERS<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one primary revenue stream which is the sales of its products.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company has previously announced, the Company is focused on its ongoing transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company that delivers unique and innovative health care solutions. The Company believes that this transformation will enable the Company to shift the portfolio from the mature, lower-growth markets where we have competed in the past by investing in technology and products that provide access to larger and faster growing markets. As such, we believe the growth in the near to mid-term will be driven by our Med Tech segment.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net sales by Med Tech, Med Device and by geography:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended February 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,874 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,620 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,092 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,712 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,445 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,525 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,970 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended February 28, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended February 28, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,274 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,404 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,678 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,259 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,962 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,221 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's products are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distributors and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts and Performance Obligations</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Price and Allocation to Performance Obligations</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer, net of any variable consideration as described below.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the shipping terms of a contract.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements to place placement and evaluation units (“units”) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer’s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units. In these arrangements, revenue recognized for the sale of the disposables is not allocated </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes. The Company is also required to pay administrative fees to group purchasing organizations.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the nine months ended February 28, 2023, such product returns were not material. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances with Customers</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A receivable is generally recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,304 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended February 28, 2023, the Company had additions to contract liabilities of $0.6 million. This was offset by $0.6 million in revenue that was recognized during the nine months ended February 28, 2023. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs to Obtain or Fulfill a Customer Contract </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.</span></div>The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping and handling are recorded in net sales. Revenue Recognition<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span>, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the shipping terms of a contract.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements to place placement and evaluation units (“units”) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer’s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units. In these arrangements, revenue recognized for the sale of the disposables is not allocated </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Consideration</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes. The Company is also required to pay administrative fees to group purchasing organizations.</span></div>Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances with Customers</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A receivable is generally recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs to Obtain or Fulfill a Customer Contract </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.</span></div>The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping and handling are recorded in net sales. The following table summarizes net sales by Med Tech, Med Device and by geography:<div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended February 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,874 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,620 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,092 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,712 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,445 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,525 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,970 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended February 28, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended February 28, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,274 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,404 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,678 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,259 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,962 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,221 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 20381000 2493000 22874000 17782000 1830000 19612000 47239000 10599000 57838000 44663000 9695000 54358000 67620000 13092000 80712000 62445000 11525000 73970000 61373000 8820000 70193000 49249000 6857000 56106000 146901000 30584000 177485000 143010000 30105000 173115000 208274000 39404000 247678000 192259000 36962000 229221000 P30D P90D P30D 0.20 P12M <div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,304 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 50892000 52304000 0 0 571000 526000 600000 600000 INVENTORIES<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,251 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,532 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,392 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The Company periodically reviews inventory for both obsolescence and loss of value. The Company makes assumptions about the future demand for and market value of the inventory. Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow-moving inventory. The total inventory reserve at February 28, 2023 and May 31, 2022 was $3.1 million and $3.7 million, respectively. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,251 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,532 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,392 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 34471000 28251000 7924000 7186000 21137000 15955000 63532000 51392000 3100000 3700000 GOODWILL AND INTANGIBLE ASSETS<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically performed its annual goodwill assessment during the third quarter of each fiscal year. During the fourth quarter of fiscal year 2022, the Company changed its annual impairment assessment date from December 31 to April 30 to more closely align the impairment assessment date with the Company's long term planning and forecasting process.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's annual testing for impairment of goodwill was completed as of April 30, 2022. Prior to the first quarter of fiscal year 2023, the Company managed its operations as one reporting unit. At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as two operating segments and two reporting units, namely Med Tech and Med Device (see Note 11 "Segment and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Quarterly Report on Form 10-Q). As a result of this change, goodwill was required to be allocated to each reporting unit and an interim goodwill impairment assessment was performed at the Company and reporting unit levels. To determine the fair value of the individual reporting units and the entire company as of June 1, 2022, the Company utilized the income approach. The income approach is based on the projected cash flows discounted to their present value using discount rates, that in the Company's judgment, consider the timing and risk of the forecasted cash flows using internally developed forecasts and assumptions. Under the income approach, the discount rate used is the average estimated value of a market participant’s cost of capital and debt, derived using customary market metrics. Other significant assumptions include revenue growth rates, profitability projections, and terminal value growth rates. The market approach was also considered; however, the income approach was chosen as the Company determined it is a better representation of both the Med Tech and Med Device reporting units' projected long-term performance. The fair value of each reporting unit and the Company as a whole was assessed to determine if there was any impairment. The Company compared each reporting unit's fair value to the adjusted carrying value to conclude that there was no impairment for either reporting unit or the Company as a whole. The adjusted carrying value of each reporting unit was used to calculate the Company's book value to compare to its market capitalization at the assessment date. Based on the results of this evaluation, there were no adjustments to goodwill for either reporting unit or the Company as a whole as of August 31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill for each reporting unit is allocated as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine months ended Feb 28, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Med Tech </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Med Device </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,058 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, August 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, November 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,755 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, February 28, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,447 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,529 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,976 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no adjustments to goodwill for the nine months ended February 28, 2023 other than foreign currency translation adjustments.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though the Company determined that there was no goodwill impairment at February 28, 2023, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that one of the reporting units or a significant portion of either of the reporting units will be sold or disposed of, would require an interim assessment for the reporting units prior to the next required annual assessment as of April 30, 2023. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definite Lived Intangible Assets</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill are amortized over their estimated useful lives on a straight-line basis. Useful lives range from <span style="-sec-ix-hidden:f-534">two</span> to eighteen years. The Company periodically reviews, and adjusts, if necessary, the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net carrying value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,752 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,017)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,995)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175,164)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,011 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net carrying value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,369 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,989)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,380 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three months ended February 28, 2023 and 2022 was $4.7 million and $4.9 million, respectively. Amortization expense for the nine months ended February 28, 2023 and 2022 was $14.4 million and $14.6 million, respectively. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,406 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,011 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1 2 2 <div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill for each reporting unit is allocated as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine months ended Feb 28, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Med Tech </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Med Device </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,058 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, August 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, November 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,755 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, February 28, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,447 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,529 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,976 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 160529000 40529000 201058000 -20000 0 -20000 160509000 40529000 201038000 -283000 0 -283000 160226000 40529000 200755000 -779000 0 -779000 159447000 40529000 199976000 0 P18Y <div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net carrying value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,752 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,017)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,995)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175,164)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,011 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net carrying value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,369 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,989)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,380 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 233752000 122017000 111735000 60096000 40995000 19101000 9950000 7396000 2554000 5377000 4756000 621000 309175000 175164000 134011000 239467000 112141000 127326000 60115000 38003000 22112000 9950000 7185000 2765000 4837000 4660000 177000 314369000 161989000 152380000 4700000 4900000 14400000 14600000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,406 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,011 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 5918000 16406000 16388000 16207000 16036000 63056000 134011000 ACCRUED LIABILITIES<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and franchise taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,775 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,842 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and franchise taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,775 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,842 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 9355000 20232000 2202000 2986000 3171000 3731000 1368000 1279000 328000 750000 359000 511000 4992000 5353000 21775000 34842000 LONG-TERM DEBT<div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Company repaid all amounts outstanding under its then existing credit agreement and entered into a new Credit Agreement (the "Credit Agreement") with its lenders, JPMorgan Chase Bank, N.A., as Administrative Agent, sole bookrunner, and sole lead arranger, and Bank of America, N.A. and KeyBank National Association, as Syndication Agents. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for a $75.0 million secured revolving credit facility (the "Revolving Facility") and a $30.0 million delayed draw term loan (the "Delayed Draw Term Loan"), and also includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million.  Each exercise of such expansion feature must be drawn in $5.0 million increments. The proceeds of the Revolving Facility may be used for general corporate purposes, including permitted acquisitions. The proceeds of the Delayed Draw Term Loan may be used for general corporate purposes, including primarily to finance the manufacturing costs of the Auryon laser capital equipment. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement has a five-year maturity. Interest on the Revolving Facility and Delayed Draw Term Loan will be based, at the Company's option, on a rate equal to (i) the Secured Overnight Financing Rate ("SOFR") plus 0.10% (subject to a floor of 0%), or (ii) if the Company elects to treat a borrowing as an ABR Borrowing, an alternate base rate based on SOFR, plus, in each case, an applicable margin of 1.25%, 1.50% or 1.75%, depending on the leverage ratio. If any amounts are not paid when due, such overdue amounts will bear interest at an amount generally equal to 2.0% plus the existing loan rate. The Credit Agreement also carries a commitment fee in the case of the Revolving Facility, and a ticking fee, in the case of the Delayed Draw Term Loans of 0.20% to 0.25% per annum on the unused portion. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations under the Credit Agreement are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of the Company and the Guarantors under the Credit Agreement are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than 3.00 to 1.00 (during certain periods following material acquisitions the ratio shall be increased to 3.50 to 1.00). </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures* to consolidated interest expense* paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* The definitions of consolidated total indebtedness, consolidated EBITDA, consolidated capital expenditures and consolidated interest expense are specifically defined in the Credit Agreement included as an exhibit to Form 8-K filed on August 31, 2022. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 28, 2023, there was $25.0 million outstanding on the Revolving Facility and $25.0 million outstanding on the Delayed Draw Term Loan and the interest rate at February 28, 2023 applicable to each was 6.15%. As of February 28, 2023 and May 31, 2022, the carrying value of long-term debt approximated its fair market value. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delayed Draw Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,807 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments of approximately 3.57% on the Delayed Draw Term Loan will amortize in equal quarterly installments over a five year period beginning on the earlier of a full draw or the expiry of the draw period (March 1, 2024).</span></div> 75000000 30000000 75000000 5000000 P5Y 0.0010 0 0.0125 0.0150 0.0175 0.020 0.0020 0.0025 2 3.00 3.50 1.25 25000000 25000000 0.0615 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delayed Draw Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,807 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 25000000 25000000 193000 49807000 0.0357 P5Y INCOME TAXES<div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur.  The estimated annual effective tax rate prior to discrete items was 5.2% as of the third quarter of fiscal year 2023, as compared to 12.7% for the same period in fiscal year 2022. In fiscal year 2023, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share-based compensation). </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&amp;D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of February 28, 2023. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.</span></div> 0.052 0.127 SHARE-BASED COMPENSATION<div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2020, the Company's shareholders approved the 2020 Stock and Incentive Award Plan (the “2020 Plan”). The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance share units, performance shares and other incentive awards to the Company's employees, directors and other service providers. On November 3, 2022 the Company's shareholders approved an amendment to the 2020 Plan to increase the reserve of shares of common stock available for future grants by 1,950,000 shares. As of February 28, 2023, there was a maximum of 2.9 million shares of common stock available for future grant under the 2020 Plan. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of the 2020 Plan, equity awards were issued under the 2004 Stock and Incentive Award Plan (the “2004 Plan”). The adoption of the 2020 Plan did not impact the administration of equity awards issued under the 2004 Plan but following the adoption of the 2020 Plan, equity award grants are no longer made under the 2004 Plan. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an employee stock purchase plan. On November 3, 2022 the Company's shareholders approved an amendment to the employee stock purchase plan to increase the reserve of shares of common stock available for future grants by 1,000,000 shares. As of February 28, 2023, there was a maximum of 3.2 million shares of common stock available for future grant under the employee stock purchase plan.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended February 28, 2023 and 2022, share-based compensation expense was $1.8 million and $2.4 million, respectively. For the nine months ended February 28, 2023 and 2022, share-based compensation expense was $8.2 million and $7.8 million, respectively. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended February 28, 2023 and 2022, the Company granted stock options and restricted stock units under the 2020 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company’s common stock on the date of grant and then amortized on a straight-line basis over the requisite service period of the award. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended February 28, 2023 and 2022, the Company granted performance share units under the 2020 Plan to certain employees. The awards may be earned by achieving performance levels over the requisite service period. The performance criteria are based on achieving certain performance targets and the total shareholder return (“TSR”) of the Company’s common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards is based on a Monte Carlo simulation model. </span></div>As of February 28, 2023, there was $17.6 million of unrecognized compensation expense related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately three years. The Company has sufficient shares to satisfy expected share-based payment arrangements. 1950000 2900000 1000000 3200000 1800000 2400000 8200000 7800000 17600000 P3Y EARNINGS PER SHARE<div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles basic to diluted weighted-average shares outstanding: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,092 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,436 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,092 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,436 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities excluded as their inclusion would be anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles basic to diluted weighted-average shares outstanding: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,092 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,436 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,092 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,436 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities excluded as their inclusion would be anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,706 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 39509000 39092000 39436000 38959000 0 0 0 0 39509000 39092000 39436000 38959000 3706000 3457000 3706000 3457000 SEGMENT AND GEOGRAPHIC INFORMATION<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="margin-bottom:9pt;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly reviews its segments and the approach used by the chief operating decision maker, the President and Chief Executive Officer ("CEO"), and management to evaluate performance and allocate resources. Prior to the first quarter of fiscal year 2023, the Company considered the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis. Commencing with the first quarter of fiscal year 2023, the Company began to manage its operations through two segments, Med Tech and Med Device to align with the transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company. The CEO evaluates these two segments based on net sales and gross margin to, among other items, allocate resources and assess performance. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates all other elements of profitability, investment and cash flow metrics on a consolidated global basis due to shared infrastructure and resources. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company manages its assets on a total company basis, not by operating segment; therefore, the CEO does not review any asset information by operating segment and, accordingly, asset information is not reported or evaluated by operating segment. Total assets were $542.8 million as of February 28, 2023. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes net sales and gross margin by Med Tech and Med Device including prior periods during which the Company considered the business to be a single operating segment, in order to conform to the current period presentation:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,874 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross margin </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross margin </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic information</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes net sales by geographic area based on external customer location:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,092 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,712 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,970 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,678 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,221 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>For the three months ended February 28, 2023 and 2022, international sales as a percentage of total net sales were 16.2% and 15.6%, respectively. For the nine months ended February 28, 2023 and 2022, international sales as a percentage of total net sales were 15.9% and 16.1%, respectively. Sales to any one country outside the U.S., as determined by shipment destination, did not comprise a material portion of net sales in any of the last three fiscal years. In addition, no one customer represents more than 10% of consolidated net sales and 85% of long-lived assets are located within the United States. 2 2 542800000 The table below summarizes net sales and gross margin by Med Tech and Med Device including prior periods during which the Company considered the business to be a single operating segment, in order to conform to the current period presentation:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Tech Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,874 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross margin </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med Device Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross margin </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 22874000 19612000 70193000 56106000 14774000 12965000 44816000 37060000 0.646 0.661 0.638 0.661 57838000 54358000 177485000 173115000 25730000 25618000 83071000 82217000 0.445 0.471 0.468 0.475 80712000 73970000 247678000 229221000 40504000 38583000 127887000 119277000 0.502 0.522 0.516 0.520 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes net sales by geographic area based on external customer location:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,092 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,712 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,970 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,678 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,221 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 67620000 62445000 208274000 192259000 13092000 11525000 39404000 36962000 80712000 73970000 247678000 229221000 0.162 0.156 0.159 0.161 0.85 FAIR VALUE<div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs to the valuation methodology are significant unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to their immediate or short-term maturities. The recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements using inputs considered as:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at Feb 28, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration for acquisition earn outs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Financial Liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements using inputs considered as:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at May 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration for acquisition earn outs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Financial Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, 2 and 3 for the three and nine months ended February 28, 2023 and 2022.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the changes in fair value components of Level 3 instruments: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended Feb 28, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, November 30, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in present value of contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, February 28, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended Feb 28, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, May 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in present value of contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency gain from remeasurement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, February 28, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Liability for Acquisition Earn Outs</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements, which is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales are based on internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 28, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue based payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90% - 100%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 - 2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>At February 28, 2023, the amount of undiscounted future contingent consideration that the Company expects to pay as a result of all completed acquisitions is approximately $20.0 million. The milestones, including revenue projections and technical milestones associated with the contingent consideration, must be reached in future periods ranging from fiscal years 2023 to 2029 in order for the associated consideration to be paid. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements using inputs considered as:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at Feb 28, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration for acquisition earn outs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Financial Liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements using inputs considered as:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value at May 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration for acquisition earn outs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Financial Liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 0 19059000 19059000 0 0 19059000 19059000 0 0 16948000 16948000 0 0 16948000 16948000 <div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the changes in fair value components of Level 3 instruments: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended Feb 28, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, November 30, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in present value of contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, February 28, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended Feb 28, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, May 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in present value of contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency gain from remeasurement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, February 28, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount. 18832000 227000 19059000 16948000 2084000 27000 19059000 <div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 28, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue based payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,059 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90% - 100%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 - 2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 19059000 5 0.90 1 20000000 LEASES<div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&amp;D, manufacturing and warehousing.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental balance sheet information related to leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-750"><span style="-sec-ix-hidden:f-751">Other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-754"><span style="-sec-ix-hidden:f-755">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-758"><span style="-sec-ix-hidden:f-759">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,348 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,263 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the lease liabilities for each of the following fiscal years is:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,619 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,348 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended February 28, 2023 and 2022, the Company recognized $0.7 million and $0.7 million of operating lease expense, respectively, which includes immaterial short-term leases. During the nine months ended February 28, 2023 and 2022, the Company recognized $2.0 million and $2.1 million of operating leases expense, respectively, which includes immaterial short-term leases. The expenses on the Consolidated Statement of Operations were classified as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,044 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow and other information related to leases for the nine months ended:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,041 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental balance sheet information related to leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-750"><span style="-sec-ix-hidden:f-751">Other assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-754"><span style="-sec-ix-hidden:f-755">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-758"><span style="-sec-ix-hidden:f-759">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,348 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,263 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The following table presents the weighted average remaining lease term and discount rate:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 5143000 6974000 2299000 2560000 3049000 4703000 5348000 7263000 P2Y8M19D 0.038 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the lease liabilities for each of the following fiscal years is:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,619 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,348 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 699000 2191000 1428000 1130000 171000 5619000 271000 5348000 2299000 3049000 700000 700000 2000000 2100000 The expenses on the Consolidated Statement of Operations were classified as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,044 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow and other information related to leases for the nine months ended:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,041 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 221000 218000 661000 656000 54000 52000 158000 201000 42000 40000 122000 119000 379000 374000 1103000 1138000 696000 684000 2044000 2114000 2079000 2041000 0 33000 COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:0.9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation.</span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.R. Bard, Inc. v. AngioDynamics, Inc.</span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 7,785,302 ("302"), 7,959,615 (“615”) and 7,947,022 ("022")). The case was stayed pending reexamination in the US Patent and Trademark Office ("USPTO"). Following the reexamination proceedings, and the parties’ related appeals to the Federal Circuit which resulted in further proceedings at the USPTO, certain claims of the 615 patent were held invalid, while the remaining claims of the 615 patent and the other two patents were upheld over the prior art references considered in the reexamination proceedings. Thereafter, the case was transferred from the District of Utah to the United States District Court for the District of Delaware (“District of Delaware”). On July 22, 2021, in another case against a different defendant, the District of Utah invalidated multiple claims of the ‘302, ‘022, and ‘615 Patents under 35 USC §101, including claims asserted against the Company. On December 27, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal from the Utah Decision. On February 17, 2023, the Federal Circuit Reversed-in-Part, Vacated-in-Part, and Remanded the Utah </span></div><div style="margin-bottom:0.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decision. The other defendant subsequently filed a Petition for Rehearing with the Federal Circuit on March 20, 2023, and a mandate has not yet issued. The District of Delaware lifted the stay on February 28, 2023 and held a status conference on March 23, 2023. A scheduling order has not yet been entered, but a jury trial is currently scheduled for April 29, 2024. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. </span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2015, Bard and Bard Peripheral Vascular filed suit in the District of Delaware claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 8,475,417, 8,545,460, 8,805,478). The case proceeded through trial which began on March 4, 2019. At the close of Bard’s case, the Court granted the Company's oral motion for judgment as a matter of law as well as its motions for summary judgment on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed. On May 10, 2019, the Company filed a motion for attorney fees and non-taxable expenses under 35 USC Sec. 285. Bard appealed the judgment to the Federal Circuit and on November 10, 2020, the Federal Circuit reversed the judgment in part with respect to Section 101 (subject matter eligibility), and vacated and remanded the trial court’s invalidity and non-infringement judgments. Following remand from the Federal Circuit, a jury trial commenced in the District of Delaware beginning November 14, 2022. On November 22, 2022, a jury entered a verdict finding that certain of the Company’s implantable port products infringe certain claims of U.S. patents held by Bard. The issue of damages was bifurcated by the Court during trial, was not determined by the jury and will be subject to a separate proceeding. The Company strongly disagrees with the claims and the verdict. The issues presented to the jury do not comprise all of the issues to be determined in the case. Equitable issues remain to be decided by the judge, and damages remain to be decided by a jury. The Company believes it has meritorious defenses and positions with respect to the matters remaining to be decided and the jury decision, and intends to vigorously pursue all available remedies and defenses, including post-trial motions and appeals. The parties have filed post-trial briefs, and the Court heard argument on March 13, 2023. A decision is forthcoming. The Company maintains its belief that Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. </span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2021, Bard filed suit in the District of Delaware asserting certain of the Company’s port products (including certain related infusion sets) infringe U.S. Patent Nos. 8,025,639, 9,603,992 and 9,603,993. On December 27, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal of the Utah decision invalidating multiple claims of the ‘302, ‘022, and ‘615 patents under 35 USC §101. Following the Federal Circuit’s decision on appeal, the District of Delaware lifted the stay on February 28, 2023, and held a scheduling conference on March 23, 2023. A scheduling order has not yet been entered, but a jury trial is currently scheduled for June 9, 2025. The Company maintains its belief that Bard's claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.</span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:0.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AngioDynamics, Inc. v. C.R. Bard, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:0.9pt"><span><br/></span></div><div style="margin-bottom:0.9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”). In this action, the Company alleged that Bard had illegally tied the sales of its tip location systems to the sales of its PICCs in violation of federal antitrust laws and this practice had an anti-competitive effect in the US market for PICCs. The Company sought both monetary damages and injunctive relief. On October 6, 2022, a jury verdict was rendered finding Bard did not restrain competition in violation of federal antitrust laws.</span></div> 3 2 3 ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NETAcquisition, Restructuring and Other Items<div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition, restructuring and other items, net, consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,681 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mergers and acquisitions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing relocation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israeli Innovation Authority prepayment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,359 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,009 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,052 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Legal expenses related to litigation that is outside the normal course of business. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Legal and due diligence expenses related to mergers and acquisitions. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) Expenses to relocate certain manufacturing lines from Queensbury, NY to Costa Rica. </span></div>(4) In the first quarter of fiscal year 2023, a $3.5 million payment was made to the Israeli Innovation Authority to fully satisfy the obligation related to grant funds that were provided to Eximo for development of the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020. <div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition, restructuring and other items, net, consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 28, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,681 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mergers and acquisitions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing relocation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israeli Innovation Authority prepayment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,359 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,009 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,052 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Legal expenses related to litigation that is outside the normal course of business. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Legal and due diligence expenses related to mergers and acquisitions. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) Expenses to relocate certain manufacturing lines from Queensbury, NY to Costa Rica. </span></div>(4) In the first quarter of fiscal year 2023, a $3.5 million payment was made to the Israeli Innovation Authority to fully satisfy the obligation related to grant funds that were provided to Eximo for development of the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020. 2614000 1681000 6899000 5837000 0 0 0 59000 324000 396000 1062000 455000 0 0 3544000 0 431000 282000 504000 701000 3369000 2359000 12009000 7052000 3500000 ACCUMULATED OTHER COMPREHENSIVE INCOME<div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of accumulated other comprehensive income, net of tax, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended Feb 28, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at November 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,562)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at February 28, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,850)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended Feb 28, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,207)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at February 28, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,850)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of accumulated other comprehensive income, net of tax, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended Feb 28, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at November 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,562)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at February 28, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,850)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended Feb 28, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at May 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,207)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at February 28, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,850)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -288000 -3562000 -3562000 -3850000 1357000 -5207000 -5207000 -3850000 RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS<div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:20.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.137%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recently Issued Accounting Pronouncements - Adopted</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:20.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Consolidated Financial Statements</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ASU 2021-10,  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company adopted the new standard in the first quarter of fiscal year 2023 and it did not have an impact on the Company's consolidated financial statements. </span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:20.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.431%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Consolidated Financial Statements</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span></div><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">This ASU</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. </span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company plans to adopt the new standard in the first quarter of fiscal year 2024 and does not expect there to be a material impact to the consolidated financial statements.</span></td></tr></table> RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS<div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:20.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.137%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recently Issued Accounting Pronouncements - Adopted</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:20.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Consolidated Financial Statements</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ASU 2021-10,  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company adopted the new standard in the first quarter of fiscal year 2023 and it did not have an impact on the Company's consolidated financial statements. </span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:20.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.431%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Consolidated Financial Statements</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span></div><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">This ASU</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. </span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company plans to adopt the new standard in the first quarter of fiscal year 2024 and does not expect there to be a material impact to the consolidated financial statements.</span></td></tr></table> EXCEL 79 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

:./F\O9A!@\%PC/# M6W.@%W!7H6&^JRPPE8,[+'VN2XI+X3OY">%:6PLT38*6*PQBP%#$$%T24T6,!W819M?=JMT_/: M0:ZIR91V(!27=4XYEQ)R8;G4MJ:FH0%/,6C(LVV#5H841"5)8HF*JD[*<(Z5 M-R=4,'4D@@2 M:[NG"# 6@<\6?]8Q% %=8H>(6+IK@H/Z>0-R7[>+4+=6Y((9/^XITS(\#)Y0KN-82)IV23J0 MK-#_ZMHD0*R3VB9'71A3?(*[O.FK>>R99@8:IBSC,2?;F*$4=&O[J'3WW07I MSLU--;L,[Q,+P;UXB;>[[1-H'&_^K7A\/]TPLQ1D6^*"5'O=C^\3,/%-$A=. M5^$=,->.7A7ALZ!G'!HO0.<+K=UFX0VT#\/1/U!+ P04 " +=']64+K3 M:\T# !E" & 'AL+W=OMV&S#L T5=240H4B4I.^JO[R4E>W9>_6+S M=P\*IVKKY+$\A(K9F-=HZ*=7)N*.9J:(K&U098% M4"63\7!XD51,J&@Q"VNW9C'3C9-"X:T!VU05,^T*I=[-HU&T7_@HBM+YA60Q MJUF!&W2?ZUM#L^3 DHD*E15:@<%\'BU'5ZNI/Q\._"5P9X_&X#U)M;[SD^ML M'@V]()3(G6=@]+?%-4KIB4C&EYXS.ICTP./QGOU-\)U\29G%M99_B\R5\^@R M@@QSUDCW4>_>8N_/N>?C6MKP"[ON[/DT MY8IZL>3 HJH;I_=M_'X0AP.7P& M,.X!XZ"[,Q14_L8<6\R,WH'QIXG-#X*K 4WBA/))V3A#NX)P;K'D7QIAA8^0 MG26.&/UZPGOTJD./GT&_AANM7&GA=Y5A=HI/2,E!SG@O9S5^D? -IC&,+P

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 81 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 247 265 1 false 53 0 false 8 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.angiodynamics.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Consolidated Statements of Operations Sheet http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 2 false false R3.htm 0000003 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheets Sheet http://www.angiodynamics.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 4 false false R5.htm 0000005 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Cash Flows Sheet http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 7 false false R8.htm 0000008 - Disclosure - Consolidated Financial Statements Sheet http://www.angiodynamics.com/role/ConsolidatedFinancialStatements Consolidated Financial Statements Notes 8 false false R9.htm 0000009 - Disclosure - Acquisitions Sheet http://www.angiodynamics.com/role/Acquisitions Acquisitions Notes 9 false false R10.htm 0000010 - Disclosure - Revenue from Contracts with Customers Sheet http://www.angiodynamics.com/role/RevenuefromContractswithCustomers Revenue from Contracts with Customers Notes 10 false false R11.htm 0000011 - Disclosure - Inventories Sheet http://www.angiodynamics.com/role/Inventories Inventories Notes 11 false false R12.htm 0000012 - Disclosure - Goodwill and Intangible Assets Sheet http://www.angiodynamics.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 12 false false R13.htm 0000013 - Disclosure - Accrued Liabilities Sheet http://www.angiodynamics.com/role/AccruedLiabilities Accrued Liabilities Notes 13 false false R14.htm 0000014 - Disclosure - Long-Term Debt Sheet http://www.angiodynamics.com/role/LongTermDebt Long-Term Debt Notes 14 false false R15.htm 0000015 - Disclosure - Income Taxes Sheet http://www.angiodynamics.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 0000016 - Disclosure - Share-Based Compensation Sheet http://www.angiodynamics.com/role/ShareBasedCompensation Share-Based Compensation Notes 16 false false R17.htm 0000017 - Disclosure - Earnings Per Share Sheet http://www.angiodynamics.com/role/EarningsPerShare Earnings Per Share Notes 17 false false R18.htm 0000018 - Disclosure - Segment and Geographic Information Sheet http://www.angiodynamics.com/role/SegmentandGeographicInformation Segment and Geographic Information Notes 18 false false R19.htm 0000019 - Disclosure - Fair Value Sheet http://www.angiodynamics.com/role/FairValue Fair Value Notes 19 false false R20.htm 0000020 - Disclosure - Leases Sheet http://www.angiodynamics.com/role/Leases Leases Notes 20 false false R21.htm 0000021 - Disclosure - Commitments and Contingencies Sheet http://www.angiodynamics.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 21 false false R22.htm 0000022 - Disclosure - Acquisition, Restructuring and Other Items, Net Sheet http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNet Acquisition, Restructuring and Other Items, Net Notes 22 false false R23.htm 0000023 - Disclosure - Accumulated Other Comprehensive Income Sheet http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncome Accumulated Other Comprehensive Income Notes 23 false false R24.htm 0000024 - Disclosure - Recently Issued Accounting Pronouncements Sheet http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncements Recently Issued Accounting Pronouncements Notes 24 false false R25.htm 0000025 - Disclosure - Recently Issued Accounting Pronouncements (Policies) Sheet http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncementsPolicies Recently Issued Accounting Pronouncements (Policies) Policies http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncements 25 false false R26.htm 0000026 - Disclosure - Revenue from Contracts with Customers (Tables) Sheet http://www.angiodynamics.com/role/RevenuefromContractswithCustomersTables Revenue from Contracts with Customers (Tables) Tables http://www.angiodynamics.com/role/RevenuefromContractswithCustomers 26 false false R27.htm 0000027 - Disclosure - Inventories (Tables) Sheet http://www.angiodynamics.com/role/InventoriesTables Inventories (Tables) Tables http://www.angiodynamics.com/role/Inventories 27 false false R28.htm 0000028 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.angiodynamics.com/role/GoodwillandIntangibleAssets 28 false false R29.htm 0000029 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.angiodynamics.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.angiodynamics.com/role/AccruedLiabilities 29 false false R30.htm 0000030 - Disclosure - Long-Term Debt (Tables) Sheet http://www.angiodynamics.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://www.angiodynamics.com/role/LongTermDebt 30 false false R31.htm 0000031 - Disclosure - Earnings Per Share (Tables) Sheet http://www.angiodynamics.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.angiodynamics.com/role/EarningsPerShare 31 false false R32.htm 0000032 - Disclosure - Segment and Geographic Information (Tables) Sheet http://www.angiodynamics.com/role/SegmentandGeographicInformationTables Segment and Geographic Information (Tables) Tables http://www.angiodynamics.com/role/SegmentandGeographicInformation 32 false false R33.htm 0000033 - Disclosure - Fair Value (Tables) Sheet http://www.angiodynamics.com/role/FairValueTables Fair Value (Tables) Tables http://www.angiodynamics.com/role/FairValue 33 false false R34.htm 0000034 - Disclosure - Leases (Tables) Sheet http://www.angiodynamics.com/role/LeasesTables Leases (Tables) Tables http://www.angiodynamics.com/role/Leases 34 false false R35.htm 0000035 - Disclosure - Acquisition, Restructuring and Other Items, Net (Tables) Sheet http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetTables Acquisition, Restructuring and Other Items, Net (Tables) Tables http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNet 35 false false R36.htm 0000036 - Disclosure - Accumulated Other Comprehensive Income (Tables) Sheet http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeTables Accumulated Other Comprehensive Income (Tables) Tables http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncome 36 false false R37.htm 0000037 - Disclosure - Acquisitions (Details) Sheet http://www.angiodynamics.com/role/AcquisitionsDetails Acquisitions (Details) Details http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetTables 37 false false R38.htm 0000038 - Disclosure - Revenue from Contracts with Customers - Disaggregation of Revenue (Details) Sheet http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails Revenue from Contracts with Customers - Disaggregation of Revenue (Details) Details 38 false false R39.htm 0000039 - Disclosure - Revenue from Contracts with Customers - Narrative (Details) Sheet http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails Revenue from Contracts with Customers - Narrative (Details) Details 39 false false R40.htm 0000040 - Disclosure - Revenue from Contracts with Customers - Contract Balances with Customers (Details) Sheet http://www.angiodynamics.com/role/RevenuefromContractswithCustomersContractBalanceswithCustomersDetails Revenue from Contracts with Customers - Contract Balances with Customers (Details) Details 40 false false R41.htm 0000041 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.angiodynamics.com/role/InventoriesScheduleofInventoriesDetails Inventories - Schedule of Inventories (Details) Details 41 false false R42.htm 0000042 - Disclosure - Inventories - Narrative (Details) Sheet http://www.angiodynamics.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Details 42 false false R43.htm 0000043 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) Sheet http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails Goodwill and Intangible Assets - Narrative (Details) Details 43 false false R44.htm 0000044 - Disclosure - Goodwill and Intangible Assets - Change in Goodwill (Details) Sheet http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsChangeinGoodwillDetails Goodwill and Intangible Assets - Change in Goodwill (Details) Details 44 false false R45.htm 0000045 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) Sheet http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails Goodwill and Intangible Assets - Intangible Assets (Details) Details 45 false false R46.htm 0000046 - Disclosure - Goodwill and Intangible Assets - Expected Future Amortization Expense (Details) Sheet http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails Goodwill and Intangible Assets - Expected Future Amortization Expense (Details) Details 46 false false R47.htm 0000047 - Disclosure - Accrued Liabilities (Details) Sheet http://www.angiodynamics.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.angiodynamics.com/role/AccruedLiabilitiesTables 47 false false R48.htm 0000048 - Disclosure - Long-Term Debt - Narrative (Details) Sheet http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails Long-Term Debt - Narrative (Details) Details 48 false false R49.htm 0000049 - Disclosure - Long-Term Debt - Schedule of Debt (Details) Sheet http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails Long-Term Debt - Schedule of Debt (Details) Details 49 false false R50.htm 0000050 - Disclosure - Income Taxes (Details) Sheet http://www.angiodynamics.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.angiodynamics.com/role/IncomeTaxes 50 false false R51.htm 0000051 - Disclosure - Share-Based Compensation (Details) Sheet http://www.angiodynamics.com/role/ShareBasedCompensationDetails Share-Based Compensation (Details) Details http://www.angiodynamics.com/role/ShareBasedCompensation 51 false false R52.htm 0000052 - Disclosure - Earnings Per Share (Details) Sheet http://www.angiodynamics.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.angiodynamics.com/role/EarningsPerShareTables 52 false false R53.htm 0000053 - Disclosure - Segment and Geographic Information - Narrative (Details) Sheet http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails Segment and Geographic Information - Narrative (Details) Details 53 false false R54.htm 0000054 - Disclosure - Segment and Geographic Information - Summary of Net Sales by Product Category (Details) Sheet http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyProductCategoryDetails Segment and Geographic Information - Summary of Net Sales by Product Category (Details) Details 54 false false R55.htm 0000055 - Disclosure - Segment and Geographic Information - Summary of Net Sales by Geographic Area (Details) Sheet http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyGeographicAreaDetails Segment and Geographic Information - Summary of Net Sales by Geographic Area (Details) Details 55 false false R56.htm 0000056 - Disclosure - Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details) Sheet http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details) Details 56 false false R57.htm 0000057 - Disclosure - Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Details) Sheet http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetails Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Details) Details 57 false false R58.htm 0000058 - Disclosure - Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Details) Sheet http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Details) Details 58 false false R59.htm 0000059 - Disclosure - Fair Value - Additional Information (Details) Sheet http://www.angiodynamics.com/role/FairValueAdditionalInformationDetails Fair Value - Additional Information (Details) Details 59 false false R60.htm 0000060 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) Sheet http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails Leases - Supplemental Balance Sheet Information (Details) Details 60 false false R61.htm 0000061 - Disclosure - Leases - Liability Maturity Schedule (Details) Sheet http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails Leases - Liability Maturity Schedule (Details) Details 61 false false R62.htm 0000062 - Disclosure - Leases - Supplemental Statement of Operations Information (Details) Sheet http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails Leases - Supplemental Statement of Operations Information (Details) Details 62 false false R63.htm 0000063 - Disclosure - Leases - Supplemental Cash Flow Information (Details) Sheet http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails Leases - Supplemental Cash Flow Information (Details) Details 63 false false R64.htm 0000064 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.angiodynamics.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.angiodynamics.com/role/CommitmentsandContingencies 64 false false R65.htm 0000065 - Disclosure - Acquisition, Restructuring and Other Items, Net (Details) Sheet http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetDetails Acquisition, Restructuring and Other Items, Net (Details) Details http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetTables 65 false false R66.htm 0000066 - Disclosure - Accumulated Other Comprehensive Income (Details) Sheet http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeDetails Accumulated Other Comprehensive Income (Details) Details http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeTables 66 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:FiniteLivedIntangibleAssetUsefulLife - ango-20230228.htm 4 ango-20230228.htm a02282023-exx311.htm a02282023-exx312.htm a02282023-exx321.htm a02282023-exx322.htm ango-20230228.xsd ango-20230228_cal.xml ango-20230228_def.xml ango-20230228_lab.xml ango-20230228_pre.xml ango-20230228_g1.gif http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 85 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ango-20230228.htm": { "axisCustom": 0, "axisStandard": 22, "baseTaxonomies": { "http://fasb.org/us-gaap/2021-01-31": 736, "http://xbrl.sec.gov/dei/2021q4": 32 }, "contextCount": 247, "dts": { "calculationLink": { "local": [ "ango-20230228_cal.xml" ] }, "definitionLink": { "local": [ "ango-20230228_def.xml" ] }, "inline": { "local": [ "ango-20230228.htm" ] }, "labelLink": { "local": [ "ango-20230228_lab.xml" ] }, "presentationLink": { "local": [ "ango-20230228_pre.xml" ] }, "schema": { "local": [ "ango-20230228.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 433, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 7, "http://xbrl.sec.gov/dei/2021q4": 6, "total": 13 }, "keyCustom": 31, "keyStandard": 234, "memberCustom": 15, "memberStandard": 35, "nsprefix": "ango", "nsuri": "http://www.angiodynamics.com/20230228", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.angiodynamics.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Revenue from Contracts with Customers", "menuCat": "Notes", "order": "10", "role": "http://www.angiodynamics.com/role/RevenuefromContractswithCustomers", "shortName": "Revenue from Contracts with Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Inventories", "menuCat": "Notes", "order": "11", "role": "http://www.angiodynamics.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Goodwill and Intangible Assets", "menuCat": "Notes", "order": "12", "role": "http://www.angiodynamics.com/role/GoodwillandIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Accrued Liabilities", "menuCat": "Notes", "order": "13", "role": "http://www.angiodynamics.com/role/AccruedLiabilities", "shortName": "Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Long-Term Debt", "menuCat": "Notes", "order": "14", "role": "http://www.angiodynamics.com/role/LongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "15", "role": "http://www.angiodynamics.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Share-Based Compensation", "menuCat": "Notes", "order": "16", "role": "http://www.angiodynamics.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Earnings Per Share", "menuCat": "Notes", "order": "17", "role": "http://www.angiodynamics.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Segment and Geographic Information", "menuCat": "Notes", "order": "18", "role": "http://www.angiodynamics.com/role/SegmentandGeographicInformation", "shortName": "Segment and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Fair Value", "menuCat": "Notes", "order": "19", "role": "http://www.angiodynamics.com/role/FairValue", "shortName": "Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "2", "role": "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Leases", "menuCat": "Notes", "order": "20", "role": "http://www.angiodynamics.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "21", "role": "http://www.angiodynamics.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Acquisition, Restructuring and Other Items, Net", "menuCat": "Notes", "order": "22", "role": "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNet", "shortName": "Acquisition, Restructuring and Other Items, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Accumulated Other Comprehensive Income", "menuCat": "Notes", "order": "23", "role": "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncome", "shortName": "Accumulated Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Recently Issued Accounting Pronouncements", "menuCat": "Notes", "order": "24", "role": "http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncements", "shortName": "Recently Issued Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Recently Issued Accounting Pronouncements (Policies)", "menuCat": "Policies", "order": "25", "role": "http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncementsPolicies", "shortName": "Recently Issued Accounting Pronouncements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Revenue from Contracts with Customers (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersTables", "shortName": "Revenue from Contracts with Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Inventories (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.angiodynamics.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "ango:ScheduleOfIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Goodwill and Intangible Assets (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "ango:ScheduleOfIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Accrued Liabilities (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.angiodynamics.com/role/AccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Statements of Comprehensive Loss", "menuCat": "Statements", "order": "3", "role": "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Long-Term Debt (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.angiodynamics.com/role/LongTermDebtTables", "shortName": "Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Earnings Per Share (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.angiodynamics.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Segment and Geographic Information (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.angiodynamics.com/role/SegmentandGeographicInformationTables", "shortName": "Segment and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Fair Value (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.angiodynamics.com/role/FairValueTables", "shortName": "Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "ango:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.angiodynamics.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "ango:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Acquisition, Restructuring and Other Items, Net (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetTables", "shortName": "Acquisition, Restructuring and Other Items, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Accumulated Other Comprehensive Income (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeTables", "shortName": "Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Acquisitions (Details)", "menuCat": "Details", "order": "37", "role": "http://www.angiodynamics.com/role/AcquisitionsDetails", "shortName": "Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "ic63af8a87b3a4123948d86cfcf433cd1_D20210727-20210727", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Revenue from Contracts with Customers - Disaggregation of Revenue (Details)", "menuCat": "Details", "order": "38", "role": "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails", "shortName": "Revenue from Contracts with Customers - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "ie9118916c947457d84cca16d49d29dca_D20221201-20230228", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "ango:ContractWithCustomerRightOfReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Revenue from Contracts with Customers - Narrative (Details)", "menuCat": "Details", "order": "39", "role": "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails", "shortName": "Revenue from Contracts with Customers - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "ango:ContractWithCustomerRightOfReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "4", "role": "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Revenue from Contracts with Customers - Contract Balances with Customers (Details)", "menuCat": "Details", "order": "40", "role": "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersContractBalanceswithCustomersDetails", "shortName": "Revenue from Contracts with Customers - Contract Balances with Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Inventories - Schedule of Inventories (Details)", "menuCat": "Details", "order": "41", "role": "http://www.angiodynamics.com/role/InventoriesScheduleofInventoriesDetails", "shortName": "Inventories - Schedule of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Inventories - Narrative (Details)", "menuCat": "Details", "order": "42", "role": "http://www.angiodynamics.com/role/InventoriesNarrativeDetails", "shortName": "Inventories - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportingUnits", "reportCount": 1, "unique": true, "unitRef": "unit", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)", "menuCat": "Details", "order": "43", "role": "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "shortName": "Goodwill and Intangible Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportingUnits", "reportCount": 1, "unique": true, "unitRef": "unit", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i53d7143eb72f44648987049654370040_I20221130", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Goodwill and Intangible Assets - Change in Goodwill (Details)", "menuCat": "Details", "order": "44", "role": "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsChangeinGoodwillDetails", "shortName": "Goodwill and Intangible Assets - Change in Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i4b3faccfdce54b0ba91c30a0b1a6c084_I20220601", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ango:ScheduleOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)", "menuCat": "Details", "order": "45", "role": "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ango:ScheduleOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Goodwill and Intangible Assets - Expected Future Amortization Expense (Details)", "menuCat": "Details", "order": "46", "role": "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails", "shortName": "Goodwill and Intangible Assets - Expected Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Accrued Liabilities (Details)", "menuCat": "Details", "order": "47", "role": "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails", "shortName": "Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Long-Term Debt - Narrative (Details)", "menuCat": "Details", "order": "48", "role": "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "shortName": "Long-Term Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i3f33d28d46e24a33b9b615fa80091807_D20220830-20220830", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Long-Term Debt - Schedule of Debt (Details)", "menuCat": "Details", "order": "49", "role": "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails", "shortName": "Long-Term Debt - Schedule of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "5", "role": "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "3", "first": true, "lang": "en-US", "name": "ango:EffectiveIncomeTaxRateReconciliationBeforeDiscreetItemsPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "50", "role": "http://www.angiodynamics.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "3", "first": true, "lang": "en-US", "name": "ango:EffectiveIncomeTaxRateReconciliationBeforeDiscreetItemsPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Share-Based Compensation (Details)", "menuCat": "Details", "order": "51", "role": "http://www.angiodynamics.com/role/ShareBasedCompensationDetails", "shortName": "Share-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Earnings Per Share (Details)", "menuCat": "Details", "order": "52", "role": "http://www.angiodynamics.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-3", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Segment and Geographic Information - Narrative (Details)", "menuCat": "Details", "order": "53", "role": "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails", "shortName": "Segment and Geographic Information - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i2040080c182f44f98863557acf9ae45d_D20221201-20230228", "decimals": "3", "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Segment and Geographic Information - Summary of Net Sales by Product Category (Details)", "menuCat": "Details", "order": "54", "role": "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyProductCategoryDetails", "shortName": "Segment and Geographic Information - Summary of Net Sales by Product Category (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "3", "lang": "en-US", "name": "ango:GrossMarginPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Segment and Geographic Information - Summary of Net Sales by Geographic Area (Details)", "menuCat": "Details", "order": "55", "role": "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyGeographicAreaDetails", "shortName": "Segment and Geographic Information - Summary of Net Sales by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i3a7eeaf50dba4d44a26ce943fd4a750b_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details)", "menuCat": "Details", "order": "56", "role": "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "shortName": "Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i3a7eeaf50dba4d44a26ce943fd4a750b_I20230228", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i53d7143eb72f44648987049654370040_I20221130", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Details)", "menuCat": "Details", "order": "57", "role": "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetails", "shortName": "Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i53d7143eb72f44648987049654370040_I20221130", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i3a7eeaf50dba4d44a26ce943fd4a750b_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Details)", "menuCat": "Details", "order": "58", "role": "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails", "shortName": "Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i1b16b0d4e511488fb4fe57cebeafd49d_I20230228", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-5", "first": true, "lang": "en-US", "name": "ango:UndiscountedContingentConsiderationDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Fair Value - Additional Information (Details)", "menuCat": "Details", "order": "59", "role": "http://www.angiodynamics.com/role/FairValueAdditionalInformationDetails", "shortName": "Fair Value - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-5", "first": true, "lang": "en-US", "name": "ango:UndiscountedContingentConsiderationDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ango:AssetsAndLiabilitiesLesseeTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)", "menuCat": "Details", "order": "60", "role": "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails", "shortName": "Leases - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ango:AssetsAndLiabilitiesLesseeTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Leases - Liability Maturity Schedule (Details)", "menuCat": "Details", "order": "61", "role": "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails", "shortName": "Leases - Liability Maturity Schedule (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i682095d056cb4fc7b322606efc8b19a9_I20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Leases - Supplemental Statement of Operations Information (Details)", "menuCat": "Details", "order": "62", "role": "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails", "shortName": "Leases - Supplemental Statement of Operations Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Leases - Supplemental Cash Flow Information (Details)", "menuCat": "Details", "order": "63", "role": "http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails", "shortName": "Leases - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "icafcbdaad650457285c620a9e2f28d6f_D20150310-20150310", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber", "reportCount": 1, "unique": true, "unitRef": "patent", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "64", "role": "http://www.angiodynamics.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "icafcbdaad650457285c620a9e2f28d6f_D20150310-20150310", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber", "reportCount": 1, "unique": true, "unitRef": "patent", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "if95eb7342c62492f8d3b2298296c167a_D20221201-20230228", "decimals": "-3", "first": true, "lang": "en-US", "name": "ango:AcquisitionRestructuringAndOtherItemsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Acquisition, Restructuring and Other Items, Net (Details)", "menuCat": "Details", "order": "65", "role": "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetDetails", "shortName": "Acquisition, Restructuring and Other Items, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "ic7b7ca79a6ef42878053d1cb1078c450_D20220901-20221130", "decimals": "-5", "lang": "en-US", "name": "us-gaap:PaymentsForPreviousAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i53d7143eb72f44648987049654370040_I20221130", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Accumulated Other Comprehensive Income (Details)", "menuCat": "Details", "order": "66", "role": "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeDetails", "shortName": "Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i7ac64042857e4cb4958c219a4aeb6a3b_I20221130", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i616f27b636b34bda982b9943b2a50ab1_I20210531", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "7", "role": "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i704ed333913c4d3e8c8a789b585db05a_D20210601-20210831", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Consolidated Financial Statements", "menuCat": "Notes", "order": "8", "role": "http://www.angiodynamics.com/role/ConsolidatedFinancialStatements", "shortName": "Consolidated Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Acquisitions", "menuCat": "Notes", "order": "9", "role": "http://www.angiodynamics.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-20230228.htm", "contextRef": "i74c94accadb44c9c91190877e53c1a73_D20220601-20230228", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 53, "tag": { "ango_A2020StockAndIncentiveAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Stock And Incentive Award Plan", "label": "2020 Stock And Incentive Award Plan [Member]", "terseLabel": "2020 Stock And Incentive Award Plan" } } }, "localname": "A2020StockAndIncentiveAwardPlanMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "ango_AccruedResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Research And Development, Current", "label": "Accrued Research And Development, Current", "terseLabel": "Research and development" } } }, "localname": "AccruedResearchAndDevelopmentCurrent", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ango_AcquisitionRestructuringAndOtherItemsNet": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Acquisition Restructuring And Other Items Net.", "label": "Acquisition Restructuring and Other Items Net", "terseLabel": "Acquisition, restructuring and other items, net" } } }, "localname": "AcquisitionRestructuringAndOtherItemsNet", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetDetails", "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "ango_AssetAcquisitionInventoryAndFixedAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Inventory And Fixed Assets", "label": "Asset Acquisition, Inventory And Fixed Assets", "terseLabel": "Inventory and fixed assets" } } }, "localname": "AssetAcquisitionInventoryAndFixedAssets", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "ango_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Supplemental Balance Sheet Information" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ango_ChangeInFairValueOfContingentConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense charged against earnings in the period resulting from remeasurement to fair value of contingent earn out liabilities related to acquisitions.", "label": "Change in Fair Value of Contingent Consideration", "terseLabel": "Change in present value of contingent consideration" } } }, "localname": "ChangeInFairValueOfContingentConsideration", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "ango_ChangeInFairValueOfContingentConsiderationOne": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change In Fair Value Of Contingent Consideration", "label": "Change In Fair Value Of Contingent Consideration One", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "ChangeInFairValueOfContingentConsiderationOne", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows", "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "ango_ContractWithCustomerRightOfReturnMinimumRemainingProductLifePriorToReturn": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Right Of Return, Minimum Remaining Product Life Prior To Return", "label": "Contract With Customer, Right Of Return, Minimum Remaining Product Life Prior To Return", "terseLabel": "Minimum remaining period prior to product expiration" } } }, "localname": "ContractWithCustomerRightOfReturnMinimumRemainingProductLifePriorToReturn", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "xbrltype": "durationItemType" }, "ango_ContractWithCustomerRightOfReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Right Of Return, Product Return Period After Purchase Date Requiring Pre-Approval", "label": "Contract With Customer, Right Of Return, Product Return Period After Purchase Date Requiring Pre-Approval", "terseLabel": "Days after purchase after which pre-approval is required for product return" } } }, "localname": "ContractWithCustomerRightOfReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "xbrltype": "durationItemType" }, "ango_ContractWithCustomerRightOfReturnRestockingCharge": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Right Of Return, Restocking Charge", "label": "Contract With Customer, Right Of Return, Restocking Charge", "terseLabel": "Restocking charge (as percent)" } } }, "localname": "ContractWithCustomerRightOfReturnRestockingCharge", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "xbrltype": "percentItemType" }, "ango_CrBardIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "C.R. Bard, Inc. [Member]", "label": "Cr Bard Inc [Member]", "terseLabel": "C.R. Bard, Inc." } } }, "localname": "CrBardIncMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "ango_CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Customer With Customer, Liability, Revenue Recognized, Including Current Period", "label": "Customer With Customer, Liability, Revenue Recognized, Including Current Period", "terseLabel": "Revenue recognized" } } }, "localname": "CustomerWithCustomerLiabilityRevenueRecognizedIncludingCurrentPeriod", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio", "label": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio", "terseLabel": "Maximum total leverage ratio" } } }, "localname": "DebtInstrumentCovenantTermsMaximumTotalLeverageRatio", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio, Subsequent To Material Acquisitions", "label": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio, Subsequent To Material Acquisitions", "terseLabel": "Maximum total leverage ratio subsequent to material acquisitions" } } }, "localname": "DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Minimum Fixed Charge Coverage Ratio", "label": "Debt Instrument, Covenant Terms, Minimum Fixed Charge Coverage Ratio", "terseLabel": "Minimum fixed charge coverage ratio" } } }, "localname": "DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "ango_DebtInstrumentDebtDefaultInterestRateIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Debt Default, Interest Rate Increase", "label": "Debt Instrument, Debt Default, Interest Rate Increase", "terseLabel": "Debt default interest rate increase (percentage)" } } }, "localname": "DebtInstrumentDebtDefaultInterestRateIncrease", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "ango_DebtInstrumentFloorInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Floor Interest Rate", "label": "Debt Instrument, Floor Interest Rate", "terseLabel": "Floor interest rate" } } }, "localname": "DebtInstrumentFloorInterestRate", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "ango_EffectiveIncomeTaxRateReconciliationBeforeDiscreetItemsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation Before Discreet Items, Percent", "label": "Effective Income Tax Rate Reconciliation Before Discreet Items, Percent", "terseLabel": "Estimated federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationBeforeDiscreetItemsPercent", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "ango_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Currency Gain (Loss) From Remeasurement", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Currency Gain (Loss) From Remeasurement", "terseLabel": "Currency gain from remeasurement" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCurrencyGainLossFromRemeasurement", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "ango_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four", "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four", "terseLabel": "2028 and thereafter" } } }, "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ango_GrossMarginPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross Margin, Percentage", "label": "Gross Margin, Percentage", "terseLabel": "Gross margin" } } }, "localname": "GrossMarginPercentage", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyProductCategoryDetails" ], "xbrltype": "percentItemType" }, "ango_IsraeliInnovationAuthorityPrepaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Israeli Innovation Authority Prepayment", "label": "Israeli Innovation Authority Prepayment [Member]", "terseLabel": "Israeli Innovation Authority Prepayment" } } }, "localname": "IsraeliInnovationAuthorityPrepaymentMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetDetails" ], "xbrltype": "domainItemType" }, "ango_LegalCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legal Costs [Member]", "label": "Legal Costs [Member]", "terseLabel": "Legal" } } }, "localname": "LegalCostsMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetDetails" ], "xbrltype": "domainItemType" }, "ango_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Three", "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Three", "terseLabel": "2028 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearThree", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity, Accordion Feature", "label": "Line Of Credit Facility, Maximum Borrowing Capacity, Accordion Feature", "terseLabel": "Line of credit accordion feature" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ango_LineOfCreditFacilityNumberOfCovenants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Number Of Covenants", "label": "Line Of Credit Facility, Number Of Covenants", "terseLabel": "Number of covenants" } } }, "localname": "LineOfCreditFacilityNumberOfCovenants", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "ango_ManufacturingRelocationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing Relocation", "label": "Manufacturing Relocation [Member]", "terseLabel": "Manufacturing relocation" } } }, "localname": "ManufacturingRelocationMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetDetails" ], "xbrltype": "domainItemType" }, "ango_MeasurementInputProbabilityofPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Probability of Payment [Member]", "label": "Measurement Input, Probability of Payment [Member]", "terseLabel": "Probability of payment" } } }, "localname": "MeasurementInputProbabilityofPaymentMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "domainItemType" }, "ango_MedDeviceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Med Device", "label": "Med Device [Member]", "terseLabel": "Med Device" } } }, "localname": "MedDeviceMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsChangeinGoodwillDetails", "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyProductCategoryDetails" ], "xbrltype": "domainItemType" }, "ango_MedTechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Med Tech", "label": "Med Tech [Member]", "terseLabel": "Med Tech" } } }, "localname": "MedTechMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsChangeinGoodwillDetails", "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyProductCategoryDetails" ], "xbrltype": "domainItemType" }, "ango_MergersandAcquisitionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mergers and Acquisitions [Member]", "label": "Mergers and Acquisitions [Member]", "terseLabel": "Mergers and acquisitions" } } }, "localname": "MergersandAcquisitionsMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetDetails" ], "xbrltype": "domainItemType" }, "ango_NonCashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-Cash Lease Expense", "label": "Non-Cash Lease Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "NonCashLeaseExpense", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ango_NumberOfPatentsAssertedForReexamination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of patents asserted for reexamination.", "label": "Number Of Patents Asserted For Reexamination", "terseLabel": "Number of petitions filed for reexamination of patents" } } }, "localname": "NumberOfPatentsAssertedForReexamination", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "ango_NumberOfPatentsUpheldOverPriorArtReferences": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Patents Upheld Over Prior Art References", "label": "Number Of Patents Upheld Over Prior Art References", "terseLabel": "Number of patents upheld over prior art references" } } }, "localname": "NumberOfPatentsUpheldOverPriorArtReferences", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "ango_PreferredStockPurchaseRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock Purchase Rights [Member]", "label": "Preferred Stock Purchase Rights [Member]", "terseLabel": "Preferred Stock Purchase Rights" } } }, "localname": "PreferredStockPurchaseRightsMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "ango_ProceedsOutlaysIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds (Outlays), Issuance Of Shares, Share-based Payment Arrangement, Including Option Exercised", "label": "Proceeds (Outlays), Issuance Of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from exercise of stock options and employee stock purchase plan" } } }, "localname": "ProceedsOutlaysIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ango_ProductTechnologiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product technologies.", "label": "Product Technologies [Member]", "terseLabel": "Product technologies" } } }, "localname": "ProductTechnologiesMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ango_QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "QX Medical, LLC Camaro Support Catheter Asset Acquisition", "label": "QX Medical, LLC Camaro Support Catheter Asset Acquisition [Member]", "terseLabel": "QX Medical, LLC Camaro Support Catheter Asset Acquisition" } } }, "localname": "QXMedicalLLCCamaroSupportCatheterAssetAcquisitionMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ango_RevenueBasedPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Based Payment [Member]", "label": "Revenue Based Payment [Member]", "terseLabel": "Revenue based payments" } } }, "localname": "RevenueBasedPaymentMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "domainItemType" }, "ango_RevenuePerformanceObligationPaymentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue, Performance Obligation, Payment Term", "label": "Revenue, Performance Obligation, Payment Term", "terseLabel": "Payment term" } } }, "localname": "RevenuePerformanceObligationPaymentTerm", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "xbrltype": "durationItemType" }, "ango_RevenueRemainingPerformanceObligationVariableConsiderationAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount", "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount", "terseLabel": "Potential future contingent consideration" } } }, "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "ango_ScheduleOfIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of intangible assets.", "label": "Schedule of Intangible Assets [Table Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "ScheduleOfIntangibleAssetsTableTextBlock", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "ango_ScheduleOfNetRevenueByProductGroupTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of net revenue by product group.", "label": "Schedule of Net Revenue by Product Group [Table Text Block]", "terseLabel": "Summary of Net Sales by Product Category" } } }, "localname": "ScheduleOfNetRevenueByProductGroupTableTextBlock", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "ango_TheDelawareActionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Delaware Action", "label": "The Delaware Action [Member]", "terseLabel": "The Delaware Action" } } }, "localname": "TheDelawareActionMember", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "ango_UndiscountedContingentConsiderationDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Undiscounted Contingent Consideration Disclosure", "label": "Undiscounted Contingent Consideration Disclosure", "terseLabel": "Potential amount of undiscounted future contingent consideration" } } }, "localname": "UndiscountedContingentConsiderationDisclosure", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/FairValueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ango_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Number Of Shares Outstanding, Basic And Diluted", "label": "Weighted Average Number Of Shares Outstanding, Basic And Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract", "nsuri": "http://www.angiodynamics.com/20230228", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag", "terseLabel": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "trueItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r385", "r457", "r475", "r496", "r497", "r511", "r523", "r529", "r556", "r575", "r576", "r577", "r578", "r579", "r580" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails", "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r385", "r457", "r475", "r496", "r497", "r511", "r523", "r529", "r556", "r575", "r576", "r577", "r578", "r579", "r580" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails", "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r280", "r458", "r513", "r527", "r559", "r582" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyProductCategoryDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r280", "r458", "r513", "r527", "r559", "r582" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyProductCategoryDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r378", "r385", "r456", "r457", "r475", "r496", "r497", "r511", "r523", "r529", "r556", "r576", "r577", "r578", "r579", "r580" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails", "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r378", "r385", "r456", "r457", "r475", "r496", "r497", "r511", "r523", "r529", "r556", "r576", "r577", "r578", "r579", "r580" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails", "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r281", "r282", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r514", "r528", "r559" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyGeographicAreaDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyProductCategoryDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r281", "r282", "r485", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r514", "r528", "r559" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyGeographicAreaDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyProductCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]", "terseLabel": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28", "r526" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r203", "r286", "r287", "r501" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowances of $2,030 and $1,939 respectively", "verboseLabel": "Receivables" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets", "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersContractBalanceswithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails", "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r6", "r7", "r32" ], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Outside services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r6", "r7", "r32" ], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r47", "r48", "r49", "r204", "r470", "r480", "r483" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r211", "r212", "r432", "r433", "r434", "r435", "r436", "r438" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r46", "r49", "r164", "r476", "r477", "r499", "r537", "r538", "r539", "r546", "r547", "r548" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r45", "r49", "r164", "r212", "r213", "r433", "r434", "r435", "r436", "r438", "r537" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation income" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r16" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r386", "r387", "r388", "r546", "r547", "r548", "r565" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r131", "r133", "r145", "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r133", "r141", "r144" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Charges against income for share-based payment arrangements" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r205", "r288", "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r71", "r97", "r102" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangibles" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations", "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Securities excluded as their inclusion would be anti-dilutive (shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r524", "r561", "r562", "r563" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Aggregate purchase price" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r181", "r191", "r220", "r267", "r271", "r276", "r291", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r411", "r413", "r427", "r526", "r554", "r555", "r573" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets", "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r43", "r220", "r291", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r411", "r413", "r427", "r526", "r554", "r555", "r573" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r135", "r143" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r157", "r158", "r410" ], "calculation": { "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration for acquisition earn outs", "verboseLabel": "Contingent consideration, liabilities" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r157", "r159" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Current portion of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, liability, measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r157", "r159" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration, net of current portion" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r26", "r73" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r68", "r73", "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r68", "r175" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r220", "r246", "r247", "r249", "r251", "r258", "r259", "r291", "r317", "r319", "r320", "r321", "r324", "r325", "r345", "r346", "r347", "r348", "r427", "r498", "r536", "r541", "r549" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r36", "r111", "r184", "r196" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 14)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r546", "r547", "r565" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity", "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r123" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r526" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.01 per share, 75,000,000 shares authorized; 39,976,422 and 39,541,173 shares issued and 39,606,422 and 39,171,173 shares outstanding at February\u00a028, 2023 and May 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r50", "r208", "r210", "r216", "r466", "r472" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss, net of tax" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r62", "r215", "r465", "r471" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r80", "r81", "r173", "r174", "r284", "r486" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r80", "r81", "r173", "r174", "r284", "r484", "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r80", "r81", "r173", "r174", "r284", "r486", "r583" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r80", "r81", "r173", "r174", "r284" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "verboseLabel": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r80", "r81", "r173", "r174", "r284", "r486" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Contract Balances with Customers" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r350", "r352", "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersContractBalanceswithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r350", "r351", "r371" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersContractBalanceswithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r350", "r351", "r371" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Purchase price holdbacks" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": { "auth_ref": [ "r512" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.", "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination", "terseLabel": "Additions to contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r58", "r458" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales (exclusive of intangible amortization)" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRefundLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.", "label": "Customer Refund Liability, Current", "terseLabel": "Rebates" } } }, "localname": "CustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (percentage)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r12", "r182", "r190", "r343" ], "calculation": { "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r177", "r179", "r326", "r440", "r507", "r508" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Term loan" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Principal payment percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r34", "r124", "r125", "r126", "r127", "r176", "r177", "r179", "r189", "r223", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r440", "r506", "r507", "r508", "r509", "r510", "r542" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument term (years)" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r27", "r178", "r557" ], "calculation": { "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Less: unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r71", "r151", "r395", "r403", "r404", "r544" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Gain on contingent consideration for IPR&D Write-off" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer.", "label": "Deferred Income Taxes and Other Liabilities, Noncurrent", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r71", "r106" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails", "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r370", "r513", "r514", "r515", "r516", "r517", "r518", "r519" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails", "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r217", "r233", "r234", "r235", "r236", "r237", "r244", "r246", "r249", "r250", "r251", "r255", "r417", "r418", "r467", "r473", "r503" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Loss per share, basic (USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Loss per share" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r217", "r233", "r234", "r235", "r236", "r237", "r246", "r249", "r250", "r251", "r255", "r417", "r418", "r467", "r473", "r503" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Loss per share, diluted (USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r252", "r253", "r254", "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r431" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r142" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expenses related to share-based payment arrangements" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r123", "r200", "r211", "r212", "r213", "r224", "r225", "r226", "r230", "r238", "r240", "r257", "r292", "r349", "r386", "r387", "r388", "r396", "r397", "r416", "r432", "r433", "r434", "r435", "r436", "r438", "r476", "r477", "r478", "r499" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeDetails", "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r169", "r419", "r420", "r425" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r334", "r379", "r380", "r381", "r382", "r383", "r384", "r420", "r453", "r454", "r455", "r507", "r508", "r520", "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r419", "r420", "r422", "r423", "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r334", "r379", "r384", "r420", "r453", "r520", "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r334", "r379", "r384", "r420", "r454", "r507", "r508", "r520", "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r334", "r379", "r380", "r381", "r382", "r383", "r384", "r420", "r455", "r507", "r508", "r520", "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r167", "r168" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value Measurements Using Significant Unobservable Inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r171" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Financial liabilities, ending balance", "periodStartLabel": "Financial liabilities, beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r334", "r379", "r380", "r381", "r382", "r383", "r384", "r453", "r454", "r455", "r507", "r508", "r520", "r521", "r522" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r424", "r426" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "verboseLabel": "Estimated useful life of intangible assets other than goodwill" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r303" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r103" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Remainder of 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r103" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r103" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r103" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r300", "r302", "r303", "r304", "r459", "r463" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r101", "r463" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Gross carrying value, finite intangible items" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails", "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r98", "r100" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r101", "r459" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net carrying value, finite intangible items" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsExpectedFutureAmortizationExpenseDetails", "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Intangible asset amortization period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Intangible asset acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r79", "r486" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r88", "r90", "r464", "r526" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets", "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsChangeinGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsChangeinGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r71", "r89", "r91", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsChangeinGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsChangeinGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r57", "r220", "r267", "r270", "r275", "r278", "r291", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r427", "r505", "r554" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyProductCategoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r71", "r105" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Fixed and intangible asset impairments and disposals" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r53", "r180", "r185", "r198", "r267", "r270", "r275", "r278", "r468", "r505" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income tax benefit" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r305", "r309" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetDetails", "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetDetails", "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r221", "r392", "r393", "r394", "r401", "r405", "r407", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r222", "r239", "r240", "r266", "r391", "r402", "r406", "r474" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r70" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r70" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r70" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r70" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r96", "r99" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r178", "r187", "r214", "r265", "r439" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r39" ], "calculation": { "http://www.angiodynamics.com/role/InventoriesScheduleofInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r42", "r526" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.angiodynamics.com/role/InventoriesScheduleofInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets", "http://www.angiodynamics.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r41" ], "calculation": { "http://www.angiodynamics.com/role/InventoriesScheduleofInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r42", "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Inventory valuation reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r40" ], "calculation": { "http://www.angiodynamics.com/role/InventoriesScheduleofInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lease Liability Schedule" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r450" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r450" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r450" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r450" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r572" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r450" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Imputed Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r31", "r220", "r291", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r412", "r413", "r414", "r427", "r504", "r554", "r573", "r574" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r183", "r194", "r526", "r543", "r553", "r567" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r33", "r220", "r291", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r412", "r413", "r414", "r427", "r526", "r554", "r573", "r574" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r167" ], "calculation": { "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total Financial Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Financial Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r149", "r150" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms [Member]", "terseLabel": "Licenses" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r12", "r182", "r190" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Borrowings outstanding" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee (percentage)" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Interest rate at period end (percentage)" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Credit Facility" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r12", "r182", "r192", "r333", "r344", "r507", "r508" ], "calculation": { "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Outstanding draw term loan", "totalLabel": "Total long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r34" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Long-term debt" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r34", "r121" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r119", "r120" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of another entity's patents that the entity has allegedly infringed.", "label": "Loss Contingency, Patents Allegedly Infringed, Number", "terseLabel": "Number of patents allegedly infringed upon" } } }, "localname": "LossContingencyPatentsAllegedlyInfringedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetAssetsGeographicAreaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the total assets less the total liabilities of a designated geographic area ( such as a state, country, continent, or market) when it serves as a benchmark in a concentration of risk calculation.", "label": "Net Assets, Geographic Area [Member]", "terseLabel": "Net Assets, Geographic Area" } } }, "localname": "NetAssetsGeographicAreaMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r219" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r219" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r68", "r69", "r72" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r54", "r72", "r186", "r197", "r202", "r206", "r209", "r213", "r220", "r229", "r233", "r234", "r235", "r236", "r239", "r240", "r248", "r267", "r270", "r275", "r278", "r291", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r418", "r427", "r505", "r554" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows", "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss", "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations", "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r201", "r227", "r228", "r231", "r232", "r241", "r242", "r243", "r289", "r290", "r293", "r294", "r373", "r374", "r375", "r376", "r389", "r398", "r399", "r400", "r415", "r428", "r429", "r430", "r452", "r460", "r461", "r462", "r479", "r480", "r481", "r482", "r483", "r500" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": { "auth_ref": [ "r74", "r75", "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.", "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)", "terseLabel": "Accrual for capital expenditures incurred during the period" } } }, "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r60" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.", "label": "Number of Reporting Units", "terseLabel": "Number of reporting units" } } }, "localname": "NumberOfReportingUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r49", "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive loss, net of tax" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r267", "r270", "r275", "r278", "r505" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r570" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r442" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails", "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r442" ], "calculation": { "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails", "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating lease, liability, current, statement of financial position, extensible list" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r442" ], "calculation": { "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails", "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating lease, liability, noncurrent, statement of financial position, extensible list" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r444", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r441" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease ROU asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating lease, right-of-use asset, statement of financial position, extensible list" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r449", "r525" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r448", "r525" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r165" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Consolidated Financial Statements" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r6", "r7", "r8", "r32" ], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), before tax:" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": { "auth_ref": [ "r161", "r162", "r163" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income (loss), before tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "auth_ref": [ "r44", "r47" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "terseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r51", "r123", "r207", "r210", "r215", "r432", "r437", "r438", "r465", "r471", "r537", "r538" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive loss, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r161", "r162", "r163", "r207", "r210" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeDetails", "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "auth_ref": [ "r161", "r162", "r163" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "negatedLabel": "Income tax expense related to items of other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r5", "r6", "r32", "r526" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r61" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expense:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForPreviousAcquisition": { "auth_ref": [ "r540" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow representing an adjustment to the purchase price of a previous acquisition.", "label": "Payments for Previous Acquisition", "terseLabel": "Payment for acquisition" } } }, "localname": "PaymentsForPreviousAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r67" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Deferred financing costs on long-term debt" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r63" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Cash paid for acquisitions" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquipmentOnLease": { "auth_ref": [ "r64" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for payments to acquire rented equipment which is recorded as an asset.", "label": "Payments to Acquire Equipment on Lease", "negatedTerseLabel": "Additions to placement and evaluation units" } } }, "localname": "PaymentsToAcquireEquipmentOnLease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r64" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance share units" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r135", "r143" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r345" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r345" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14", "r526" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r24", "r25" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r65" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from borrowings on long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows", "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r107", "r195", "r469", "r526" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r218", "r296" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Change in accounts receivable allowances" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r66" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Repayment of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitAxis": { "auth_ref": [ "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Information by reporting unit.", "label": "Reporting Unit [Axis]", "terseLabel": "Reporting Unit [Axis]" } } }, "localname": "ReportingUnitAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsChangeinGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReportingUnitDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Level of reporting at which goodwill is tested for impairment.", "label": "Reporting Unit [Domain]", "terseLabel": "Reporting Unit [Domain]" } } }, "localname": "ReportingUnitDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsChangeinGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r148", "r199", "r581" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r306", "r308", "r311", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Acquisition, Restructuring and Other Items, Net" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r128", "r193", "r390", "r479", "r483", "r526" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r200", "r224", "r225", "r226", "r230", "r238", "r240", "r292", "r386", "r387", "r388", "r396", "r397", "r416", "r476", "r478" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r263", "r264", "r269", "r273", "r274", "r280", "r281", "r284", "r369", "r370", "r458" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations", "http://www.angiodynamics.com/role/RevenuefromContractswithCustomersDisaggregationofRevenueDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyGeographicAreaDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyProductCategoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r284", "r551" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue from Contract with Customer Benchmark" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r377", "r502" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue from Contracts with Customers" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r372", "r377" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contracts with Customers" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenuefromContractswithCustomers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r447", "r525" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "ROU assets obtained in exchange for lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r7", "r28" ], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales and Excise Tax Payable, Current", "terseLabel": "Sales and franchise taxes" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r49", "r568", "r569" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r152", "r153" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r34", "r124", "r125", "r126", "r127", "r176", "r177", "r179", "r189", "r507", "r509", "r545" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Principal Obligations" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value of Assets and Liabilities Measured on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r98", "r100", "r459" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails", "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r93", "r95" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsChangeinGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r93", "r95" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Goodwill for Each Reporting Unit" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r9", "r21", "r22", "r23" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r307", "r308", "r309", "r310", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r108", "r109", "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringandOtherItemsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r56", "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Summary of Net Sales by Geographic Area" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r52", "r85" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r82", "r83", "r84", "r93" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyProductCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r135", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Delayed Draw Term Loan" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails", "http://www.angiodynamics.com/role/LongTermDebtScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r260", "r261", "r262", "r267", "r268", "r272", "r276", "r277", "r278", "r279", "r280", "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment and Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentandGeographicInformationNarrativeDetails", "http://www.angiodynamics.com/role/SegmentandGeographicInformationSummaryofNetSalesbyProductCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalStatementofOperationsInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r70" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Amount of shares issuable through two stock-based compensation plans (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease)", "terseLabel": "Approved increase of common stock reserve (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r132", "r137" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r13", "r14", "r15", "r123", "r220", "r246", "r247", "r249", "r251", "r258", "r259", "r291", "r317", "r319", "r320", "r321", "r324", "r325", "r345", "r346", "r347", "r348", "r427", "r498", "r536", "r541", "r549" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r38", "r123", "r200", "r211", "r212", "r213", "r224", "r225", "r226", "r230", "r238", "r240", "r257", "r292", "r349", "r386", "r387", "r388", "r396", "r397", "r416", "r432", "r433", "r434", "r435", "r436", "r438", "r476", "r477", "r478", "r499" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeDetails", "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r224", "r225", "r226", "r257", "r458" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r14", "r15", "r123", "r128" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Purchase of common stock under ESPP (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r14", "r15", "r123", "r128" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance/Cancellation of performance share units and restricted stock units, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r123", "r128", "r139" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of stock option (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r14", "r15", "r123", "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Purchases of common stock under ESPP" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r14", "r15", "r128", "r134", "r140" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance/Cancellation of performance share units and restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r38", "r123", "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r18", "r19", "r86", "r526", "r543", "r553", "r567" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeDetails", "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets", "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology-Based Intangible Assets" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "negatedPeriodEndLabel": "Ending Balance, Treasury (in shares)", "negatedPeriodStartLabel": "Beginning Balance, Treasury (in shares)", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.angiodynamics.com/role/ConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r37", "r129", "r130" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, 370,000 shares at February\u00a028, 2023 and May 31, 2022, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating present value of future cash flows.", "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Discounted cash flow" } } }, "localname": "ValuationTechniqueDiscountedCashFlowMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingtheRecurringFairValueMeasurementsoftheContingentConsiderationLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r550" ], "calculation": { "http://www.angiodynamics.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Effect of dilutive securities (shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r245", "r251" ], "calculation": { "http://www.angiodynamics.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted weighted average shares outstanding (in shares)", "totalLabel": "Diluted (shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations", "http://www.angiodynamics.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r244", "r251" ], "calculation": { "http://www.angiodynamics.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (shares)", "verboseLabel": "Basic weighted average shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsofOperations", "http://www.angiodynamics.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r531": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r532": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r533": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r534": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r535": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 86 0001628280-23-010093-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-010093-xbrl.zip M4$L#!!0 ( MT?U8]*B_T2@< &#,Q M,2YH=&WM6FUOVS@2_GZ_@NOBVA207Q0[3>.D ;*.%YM%T_:R/A3WZ4")(XL( M)6I)RH[OU]\,*2=.[&Z=7=Q>X,0?;$L

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

?Y*"\G155=M0\2;Y1!/"*G &G_VHG_JW=:F[*1KU/R0SRZHF,Z:#\IG\J5Z8SN0"YO M(O=QD_9"L'83N5X(J@1!I9"M5O(]4(PG=1E ZK:=$ZRQV#;#>1: M,2A0A4&!VB0'7TX(^> ,B!? +,ZBR8OLLQE.JZ(V"4$PDS":I(]E[D,Q[WO9 M!Y8WP&@&HHYW9[0]&KT!ROY'(NR'>'!%UH/K5/V0&F#=X4RYI90@&, [2\9=S#L;UPK,TR7CT2.Z#R,\)(KM_3/-9,]I!5H1R4DS=9%JDD[,I]6)<-8?/)^&\'&2C\+P3 M>KT[VXB-?(VTGZX3=G_D/R2RIKZBY?OPU./N(G55'E#1QY<[C,1ZK>=5(3'M M/PXH[Y'88236:U>O"HDRE:L!(Z:'8H>A6*]-O2HHJG2,&2U_D+ZE,>=VUX<\ M&4_,,!O?J3[3=&SY!5>*JCU;XZJVT#QKZLG;0GIKC^D!HR^MA5@/V&9R.Y8% MK$0 6#I0+Z[I3@_89C)!E@8L!G.&YUU]CVI_7:\B5,&#X]R,!'(S<^#V^!T$]EX>IHHB9W MC:0[[;)J(_$&A89>,FQKL.A7!UNVM<<'Y)Y<[1ZV+QRV-=CUJX-MVH5$ WI/ M'YP>MR\)2;@-N:XO9ML.P?*!-?I;?,@_3/JQ#_6(?\$<]8 M75WS?I"=&.3+24L[ G&>LM$6O-DGGVV$%5=X(XRE%M[DMXM\/9D M3;BA1EK' 57[1M:/ :6V]O ]M8M[0'4"4+5O--T!U--L^73&>*#N.=?3XZT3 M>*M]F^B' DRAK3V.6B+ 7LY1X1M^X/-MS?YT4F,Y68F [\>C\9? M@]_^9RC&]_ ?WMK[U[\H>/4O+3J.U..OA:;I0R'"'R#Q#N+2T6!U-V_\\1*_ M!UJ+@;;"/92G HUN[;%[:A[T0.L$T%:XZ?%4H+&M/7%/'E,C0'LY64KSHP?U M6++]3F1;0JH/,.53^)'7%&7M]\F[A<[5&<%/0:< LT3B7S(CK\Z"_Y9"^*88G\_*:4UA)>81U%V*K-]'L0]C03@Z=8*]?+>)@] %L,P%7;R4L#L*J4#(*X'0!\ M.?5 WX?)\XL&_<")?;8S\F-NO&\1&V7&?ZG-$[LY^>Z(H$ #5Q&D#]6>8<:U MXYQ3IH2P&.Q[M$2J49@\N]R!EFEK@:EEJLL\B:(-!Y9ZGNQY8+K<$4\(\4MO. 5$U M'&99+5?^P*/V>7DQ-)=I!N'[C-S?^=P[>Q(T?F?G=T>K/-&+4&3EF2G"2G=& M'_&,:R*-@MSRXZD=AILR;9G']T/FF($ZU8NWEMA],JZ1=^L6[RUAW9(#5G?&^17]GS3IKD]AV^6 M#*K6P#IDA7SS<]WZR;;Y8,?-; -S3QS5)Y?CW?]'RS;KY9,C99 ]^P MQ#?W-/3=^((Z[?;M7N?#Z23X5419GN]P=WT'Y.D+T#V)LS;/<([P^V0.7]HW M?#(E&TYG[7FRY\D6>)W?X4FQM-_9\V3/D]WAR;5YM-_A2;FT3]OS9,^3W>') MM7G+W^%)M;2_O#:>[)-&&K^S)T'C=_8D:/S.G@2-W]F3H/$[>Q(T?F?G:WW^ M9_5#\)F!(9G3,,OE++/Q=%).S"A-HD6-B+]C][:H?VX_RO6/\N5L!#X_R?-E M5]!X,'PPDWBK[@FW$+3[,SG[?GIN0_$A5M&#\L,W:3O?=W_BT:!T8$\/.+H; M^GMBG[@:ZVKTL*P?EK4W,5XI+#&J8(GTW>A7#\LNP;+V5LBKA26N8,GNZ4+4 MP[)+L*R]8_)J84D EFJ@>9N4^,LY/+5,@MW+;@S93LMZ3L\[O/EDMJ1UV=;M MRQ?O@=F ;5T;,%E=UG4/S%8#>]7^&OQZG-3G.:C6:$> M?0E+D(W&$W@Z$"B#P>0PLM/"#+,+4TRR<,A4$ GA[\2EO6F-YM_I]$F4.>,>D%0T!('S8332G%D"(Y*"N&% M1'_'>FOQI;-B,8,+8*YM6P3SY[:),,%=,_QB+LNM5S>Q!\"[M>ZWE^S!A8GQ M.0NC'K$N,Q8 )A_/6K/L EN&(MT%0S)M&4IV5B01^96Z;STW1DICX'J?MS^\>:CT!;C*?P#%\FGO#CX= 4Y=V1 MUST^\BBA?--0J-3V-U53;5N[-."+,NPN/ORRR"S)1]7SJB_],L?^7#\EX7H[ M%)8H,KO\3>[NH)GLG8?DYF^>7]ZI+MTR7F;7F-@A0CUX&>W@9U[C].&7?N^; MWQLLQCN4B'ZP_6 I98]Z[ _"U$](2OGAK?K.K?=X=C,1NA[7[H>6"IH9[$4( M,^'U#FX^*V>?#\%B>4S,NYYE^>YQFG4JH\>MV7OX339;K>SF0LULLC4C[UK8 MX@F=_=H-RS?!9D0-LA2X>LS6RV,F_E(7D-3!QQU?HQYDM8*L\_G1K6R9=!L_ M73NZ^N3YMSNHWHX&J$O5GL=KZ)QTCU1LVLX42QFOHH=1S9\^= M+>?.=C93PG@=W91Z]NS9L^7LV=*V2F0=;97J8L^7<\SQP^0L%%E*,"G"61B5 M^>>0Y161LY^20_[S(+,!*!VRB?FZVW3SF?X9&_2,OJY"XW>^G)[K;T!$P0@R M-RV*,'*7V:2 IPVK?*&L/VRRH<&T2CL=7%=.WPR0.<4/Y@0_2?2>C75_Y$^^ M47_?_\^TG*2\Q]\K179BOC[9=DDG&0=X_@S0DXM07!9&L/#] ]1P5Z M!'<"P:L+RK0%P71KCP\(DCV"-P?!ZPU;K FW=Z&93@C*NR7:&S[LTL,LB;\2-6 G*QO,/0@[R3(&_&U5@)R.7R/D4/\HT!>5N]D<=!^RYZ52UN MQ[H _'+V(F:430Y'%KY> +5#5IV?#SZ;C+-\$LZK$Y?C'[DN_;;%*EF\]@)9 MWV/Q[S,WOJFX8OXU^.U_AF)\']?K=#A6PBLO4K6>M!)48_. M%X#.VDMEK0F=N$?G"T#G6HWW&M%)VHC.?BOAVE;"*,S*;/5;"2]O*^%]F'R( M]<:?*.UW$GJ,MV@G81489_U&0H_Q%FTDK +CO-]'>$$8;ZLK\BADWP6O>(G; M"&UP0^XOA7(RGICA+3Q_UG"6=%U*\IV%@?]BTM@5JM_QKAZ]VCQ!< M", GZV\)-BH=(%9#]..C%P4:& M .H4!ZFRC!A@5]/*@EP<-%*^I41XP!.Z"'H"@ZH(\Z!LC/:8QTD/S MWOO5%J_V^GY*UTC#ZNBGE ZL+]]/B8J^F5+?3*G>9DK/E 1MF?N-GDN_[[_= M?W]PF!W_^^'AR7'KQ]Z%!DN#+'QU(6GRU&8Q UUDKB:S,6V.)-VAF/=M$P_B*XNPSMSF5'<[:X.]\]\ORS#9*F>#K7U"'EV-O5*!EE34FU[ M*3^KK#+)S/,1T($2ET]*S&YWCQQWU24C:'_GTS^$W&.U/#DQ1 MI$C.?YCA-#PY)(>KXN\8WZTNO?$'>WJ.ZBA'><&I0E@B9A@3U%@GM-61(8P] MI1A5'$40I[@)CB);>V"\*W*WG4)K#R-UH #S,H;>M2C(_/O;Z>9=K"IYTH@' MX!S,;E)F17 !D&F'X2J/T0R'XR]FY$(5'OF7!E31_F($;\;%Z_'43N)TN!CQ MIZL!SVW9)S,0!08:((KN\$]E1SUEOG4)BM7.MSKHH:F^.]\BE!?!I?V.X>4] MO5V?F$[>\8SQNK!]AZ[OP^2YI$WG&]! Z;L)$,_+$M_0@PS=1EYM4J9.Y E M'AE0=#<5KSGDO1RO_VCT&8@VOK$?UI<;6)'$7BSV);#+D_E$;NT).N!T:0G= M/O^W1UK=$GHII*7<:#R@R]L"O5_8G0%WJ S(QR)5E;=6U>I[E@I\ M$:9C72IPOO:'LZ7?'_GJN.ML&_&Y%J3>VE/@AM]U2WO7I3/XJTLQK@!_/"4+ M@^],NNK!M+L6Z_PT]>.VHQ]A8+[D6@9U1::68B<,[,3)@,NE^6G#>CWW*%UO M%&LIE*9V:XP.**MK]ZQ]=34V+27I8S&^@+%<#C)P;I(N +,^Y;%!CH@"85X>+]7]&((+3K3W&!YSWEGV'D5>?95\C\EB%/(26%N[M M,^G;*[^/1A,S.LW3"8F9&?]\F?TB@L7U;4LLUGUF$@'#''YUPVE:NK^.Q_Y+ M/AP^F8-X*KC#!JB+^7H]!.O?KU@!!,7,D80!M@B"G;?"%^3J;>U5R^UG,T8J MAJ;U0,N[)7M[P[HS,*M+-C\;9FIKCR \0/QN%8W>BEX90F9-#I:/@W>;.>J2 MP=>VC]Z/1^Z9P41=[2!)LG2@H[>5VPNYNN1Q+9 3LTU++3:HJ7VW&N/,S)0K*X]@\?1KV&GI^? G@-7 MM#_^9 XDP(&<#"1?.O"[%@[LO#_X-CE[R@4!MVG;K*[7T++3.H]%+LA"K2K/JR MR0:*M:F$2M=V5#9NP!UR+Q=!@XM9\]E4TBMQ)$PB_39UWLA]F+4'BC9)E.TSTUHJ39=(RQ5 M.O4OU0;E+W3(0YHEF;DGA)%?O,%::\99#>:J3L4K:\B-[YVD]F*NUI2SY3$G M4<*06I<:J &I9&M/ ML@%=OE927S6CKOR@\>AT>Q**A&]6/99$_F3M.B+2I'73*#G'[Z257&, =,=S)#JT5BW^%XY&E.=##% M$T[ M/)TWN[]MB]S<.KUJGN1N;K?VAGD+MU278+IJ5Q6K-H5">P.^I1I@O$=O[=$!:E520F_7MU2JUP<[A;;V MV$#2IRD/AFCJ?, 40,BZO(=V[>'NFGF.SAFY_DD%1N?U5BXRHMWJ>K"3^_'DY!A M]G--918>)M*"JUXH'_ZV-2E2M_E;+>J_+4'J5']] ;Y!ER9$W,)L M&ZI"U+FB3Q$1RZ\H>W!%.Q]!/:ZKD,EC56,'JE@\CIH^_[QX\/S[V^GF7:RJ M 35![(_%8BNTJE\SR"Y,D7TVPVG(_N5[S/DQ%,=GI@BUV)I'[]_DQ@^S!J5;7R_60IYI2N3^=G(T+P)Y_G.EU;>KR.S2[=R(K(M?2$TDM M?E,RQ[T)'7<).9M;9JY>^$N;"/IA.BDG8':!G+JY$#'_&OSV/T,QOF\-=*N( M^;Q):-2J21R5Y?0V&K\_?OS4\:\424\?/SACH_&/.>CQ/)970YBU)/X&B2N[ M!E1S'Y-=:7OB:Z"H5.$/T?#--=?@W_SK7Q3!Y)<616+[#8"6!H&6!!MK(]C6 MZG6VT$])3OMXU#(G93:HIQKZNF$/Y9FC7H-[LHHI+FO2ZR?[)JN U]*S ,=$ M;J9G1/)A72[1-7C,3=3;IBA!J>)KG\K: M9335Y?,\!DTLH:F#Y\PVH*[//@PX+;89@N^2^^U\E#ESD4_,\]IYOHAP0&T% M4*_6_B,L_='H8+;PUSCFB:DBP(Y;>UR+ 2%+)W/W\:CV K"V4JCU Q"<<:[$ M0,DV=39\.67:]IV;GD^'*6X"E(^YRR?9"SM(]M-:)'D)\X1/MSGJ4Y@8&)$_ M-,4(UJV\1H_7,W(\F:-2[V:E!U3=;:I[)[^LM[0W$87/%^?K0Z$"%'(U8/BN MC]\("E]Z>M1)$4PY+2X7&P\-A9(6PZB,A;G=,'_A$^-(3T[.J"WJ5]L<<(IS MRJ<&LM\>,7F\Z.S=L19#K2Y_K :H MD59![64Z7N-9K>SQ^441SL*H!'D]K^?4NV+K<\6N4:0Z>'MPG1ZSTCIOQV7Y M/DP^Q!/S]L^$L[^_/3HKEBY]#=9\] MF/I -H87]^$-HI/R75VHM"8_/%;:;I.8V &IIF<7C+ .D[NZ>FE?FOB!EPR9 M*0(0O#OS":VK1<8C<_GKC5WL=N\7M1TX#[A]\>XWZ&BXUAXJKUSV[ YXF#B[ MX(QT)-N:A^W\]%_8,HM\(/*!UFHO.^<#/EV9DX[@RVD=A\H'@K+SR]#7XA_? MVLS<*\Z,91R<4/G\Q$."HG+C$FV\[U+W[GRT=J\_]-I*";_N)07,[+H,L8)E MJ%D\O'&5"_6,_7X%[V=>]'3/%/!0Y?-W0CF3\_G;JIEU-R^G*HOW933J^EK]RHKG?[CE^ MJ\Y^F=N'VZ(WGA#%YQSFO+AC:_9?'CX?4&.N/- ]1'P='X^!O_ZB+U:=_8O2J%A)HY>]ZZ+_[@YX M?&&J3O*Q9\YK>V64584M=#E;\W!Q$;>ZO 8:"XR4S"L1+[JHMY\_??O\V\=W MEU?OWR7?KN"OW]]_NOJ6?/Z0O+W\]A_)A]\^__>WM:MJRRI^&O7TR!; :']N M_UR+'@B(_@C&L)6'@NUWN[JL)C,/PG#*TX, -OZ90>5>CW]X,V["7O3"*\*7 MWC14U@@"S\86;7V_"?7'4PYWCFHNU_@C6GITA452D_;S:-X/"HY M5I_@-\GO\-A-E;P'J6'GE-1M-V7&=MQ 56WWCGUP63*.=WI,);=-"OB=V@:2 M3:CMD"IP+@F7NNZ"KFZ2O-O_425YV;]-^H/0$<'GE_H(N6"+OGZV^IL'4=+R MQ$)R/KEATNU72]6YMXYK.'Q?V %YLS:)(1+,**:-T39C\*-1&"LDA7"<&JP% M_?N[X,Y*$7ZU83 1T-(T5F-C;Y:O\( Z2BS?(1]RK%#$T;'B*'589QX?4E%F M"<^<01)C:2G)>4I5P!$>XX@\%XX(.KL@J$/DLE/XD'-0#D"47MI_C*JFW/FP MGY0.R,448+OW&AGK?^M_-EXK&U6A@>GN5;*V:%U[5ZS:'LG2SV"9V>PV7/7LZ[/@>M53\M7.=RZGE(^_ 5'LT\.37!?CVO']?-I07TN'WL? MX%1")8;/^:0AW_#M[(E\[FVN-0FP=3M(;MUS-NKJ[:7'W>KJ^Z5'7]VK@U"; MBH8^( +&08$P67<_"3_7D\]%!6_]T"_? M]4?9,!]U+YO#604=7QXQW;K]0[2%3I*/;TILY.PB70YR./CJB.UFTA]\7\L0 M*E3TAL"OB\";J\H-D^)V "9M'5KF'_"62K^"4S\Q_?PE&?;'R1E\SG_K]ZY_ M*[X[>^F/I[KJ_^K>A2-Q]G.^"E#^WIEM[J7E6%#;\4[_G8]]J5\ D$F:9]?ABD'CY MCCY6<3\*VMJYF-N(ME(0:RTAK=.Q2VKG4;60K!(4D6",=*=UK9Z6N/)8'?,E MQ]BE=$WQN>!M/O'+92?AB8G;5MP# 3OTO2[<.U?__;$W/IBODW-9Q26%[Q;? MIM:"40RW7@P_CM8VO.Z19Q=IA[%MKGM:*K%;S\(_]KZ[WK _5X3L-'PV+VHI M+<-HYB VQH^_N"<=PK=I5!1]ANU5'?9WX?, '2Z1&D.^)?%R\]36.@R/2^'^ M4CK?6'Z<45C;5?WHYGIIYMV,^@?#^.\#93)QCQ.2R8':$#K?4,?N)1&>@[;TIU?"!6.6KN^^M>B#-^M*BR MM\K=\J4^-%^\H3ZUF5+^&Z.0!A2B9?],U.F/@D"?4ZG?"X'Z;'7*G M4T#LTV-J@\5NB6V3&W!LOD)$B+&TSOYZ][?*1\Q_'A_>Y>3L-H8B!RCRCA0[ MB,5L30NGV%*QY6)FC_2.*@Q>][Z[:227*9B?V5QQ\ MA[?]SU <_& 5DDN8L$=GJ%PZ*+TZ,KSK)(.N[@V#X>K^.2H&/D0UNBF?,7-( MWX5,@*O^I8']+]V7YF2^^',!&^#]^%0VYL^AY(+@+4G]B)[+%BH-ST:+TN>* M$KY\)W7PWLI#8OI=;4)WPIK=^\H[>D)DT4WYDEQ_@JS/O5"<<&. J;,+UE$K MJA)&1^11D.#^F?VV),B1K^B7;N7>B)[&IX1T>],O1!S @8&Y!^=8MX@]M0H M[6+IOXXJF&%5N>J3&W[._2DUG]A5Z/$E =AR28"HJQ\%N>V??=]+;AMR='3/;/#EG"Q2^^! MZR" ?]@DV] '[%39_P$KJ!+@2]U^[_K5T)6WP%&RIUW$':X_[(4K^(5#^0!G M\K&J1KZ"8EVJYPI.XQTUSL@+V?AK]LY_Q]<@S5EF 29Q=L-9JBJ[:UI/>2#/UQE)?[ M>J&O_L>5_55$)\^ 5TN"R9L6%0(Y'8U]TDUA:LR9?C6,&GLK;MP^YQY.8UWI MK3^851A2OI!.2XK51S6\[5S[7N)Z-.-.TF>7^ M=*4IJM#/KPJM6ON#.OPP1!S>#KK].^>:CP:CTMSXUML^!/W$;*$7Z_(W/J_/ MHR$0;37U,(36FM6TP6;# "_+TA>,]#]^[)GNR&_TYW"F[YNSWCB\(,6^A1$6 MR[(X%K4[&JK=;2_ -E M\>D4=$6V6[3 GC%N8]!Y[DSX=K&_6GJGGNE'KK$-"74@0R#2/*F3?C!)]!^AR/N/3&9*A9" MV&,487V:G_/WS5E^A:/\W// ]O]_/SVZKZX:EH49.AMBJ'MV_ABZ_3L@M(=%!MLGXBZQR9JO8@:%Q%+?K)-&;&?$Q_5 MOENY%'7*G9M'6^'S"ZRW;Y<+R#6.CEE.4'.'C?52X3UT1"ZG2K5NDQ@NE M]I(FR8Q@+D/8:M$PGZUOU6[]*(X_)?]K?]H&% J"5(<.$YJ,I8;D5%"4I2ZW,@,*ZT" M ]JWZ;#@55#J9NJW].P.D^T?ZRE\R3'6((V\%-): M/<;I6#VA:PP@QE<#-'I0>/2$7H2V& )\?.]W,PKI3'94>JP,;]P3S: 34)2. M4Q?:?;Q?O^?Y\>?RBRZ'S3\NIZ4H/SG_R]M^SPUU>5>WO!N7IYMI;P0?C&Z= MQ:L4(7IV@5>$5AQ\+86(L4/"6#NNR?:/-G9VL>Q.;V,AWX-+_FKIA'\9^J9S M\+BN2]!\!H 0;S& DE,YC\]@\>KA-)L;'JJ&\(N0[WD^(?'% M?6A>3O&Y#PD:]&NHO2Y=5X.IX=[\*.SP9BR)9[Y74_-K-/V*SF .H^'ZK[1E MB]/YS9C]T\_6\XJ"49L2Y)3 3K'4*"DYT@3G4J2I307Z.S"U\9=N)K;*0%^[ M5UGI]!^O= X+?*V[/_1==?;+/.D!W3438J0.Q5K^YTC\%4])MF4IR4WHA])>'#T@ ECSV/4K>>OD5XL3TQ:K#?U$B M7?(2!"*][%T7_7=W(" +4W62CSUS'GP!WT995=A"E[-90>UC;JL7]?;SIV^? M?_OX[O+J_;ODVQ7\]?O[3U??DL\?X%^?W_Z?__C\V[OW7[^%W'+Q)GG_GW_[ M>/7_KUUE6U;UTZBG1V"%.OMS^^=:]$!F]$BL/!EL+B0.8JSN4C1UUS<2#NN3AXT"^OEAY=X:JJA>#S M.'0>U)_K$*'^[6V_EWSS%4D><5'TF.N)LO]C,6;OH+9DW#-.=X.6$CH+%;WP M%K./*FISZMX/2W;A> M57QWX3=%#W[GDI^Z_:I:\C:>$%NZ\JD+H_)NIXSIOD=7BP1"MQ$),YYM*[H^5(KI%]PF[>H M1P6<_:J[OJR8SP[X7=\E%'<2?RM[$L4\%G=HPQ"3X VM%B[ ,;(N,U:ZG*=, M<)'EQC%#G9;&8,?QZG2RCY\^+-YWUVSL\VA8#77/;]GCPFC1]#Z;GUU0U>', M%QZD.TK&:4TL_ .Q<_NET><+/WD'2@W"=$T%&>IQKDQ:<8(UDJH7""3I@X)C!59 MC\HUD9D[@*?TO3QEA^%E/;5]Y;8B,B,R]Z*B9A:#E)326L9XEF?<( &H9!G) M0H2 MA:^AU15NCO&M3R#:^F;Z6_/"S=P=$H'-M:;Y:)0A488%Q=.0[O?CHGZ.M MVG"L8QQ8#\K=:QM:*YFG2B.4<89R)S/B\WT%D98CB\A\3CU!\M%J!V#B8PB, M^PV L3&/\XGS%$R!;52.]J7-QS%:/L;)\P-LL;0*M(),&B9-+A4U4N0,R]Q@ MJ?%+\0/6+GYP/$%%:]H(K>N)>BQEJ/<1.82D)99J9@U@!\"AE/0F/)$.1"G\ MZ@'LK HA\EOO&TW?"FD1[6-.Q^_+&?;I_>>O_['9#C1JO M!Y>3\LB-2NS)::OF9(<'J&R5O P@W4&D$ @=%B:^=LE8P5- M;88P,GL3/&N@LBQY%-B'3+;#Z])& HYC'.\8)\^O' E4'#\DFH=7VYIRO&!VMK;J88:V-9 MJG*0]40R)7*IF:69Y3K3+J/&M5(Q5M@;H1U)MNZP&QUET2'SH$,&8Z$=B!V1 M&6:$T;GUR2X\-Y(Y)UY<])"S"XI).UPR;23@.,;QCG'RS,EAB8E#PG*L&1)( M*4=295*9FU2E>%\768]F3K1%S.G8_<5?1J6Y@4,)]99-79EQ[!^VKDS>?_OR M)3J)6Q,U\?YVT.W?N?KJ97QV7[JPVHWU8=]N).U(M1R3=#Q^XM,BT&5.OR5U MKHG_7\/@U]+F*A[/SRZ.^8+BU EO![$R.R&\S>(T5>KSCD$C.F+*C&/$,2+G MVFLHS4MP+E%SKC;)U&._4@B']BKS%JVWG"8F[9/2Z [-B1(=,2U4DB[M/T;5 M,#35N^I?VG%/@2^ZL!][;^M& L&.S!;=,%]=W29Q>T@\C6)F;T-LG6L?D5/N8W,'UPXU/GN:3D5#C MDP?QY#/= [ZD4/_LFT0EE0-]]MHZ@"QM%G4DZ2<$$E4 MEDG).&893AE7QJ)4N]2FIBDG^8A@IRV[3%%$0IRNP.O\V@\3D*Z,4(M0.T6H"9XC@VANJX=*/(!O%)UE-S5S4/$8L3BBR]ZHT06E DL,J&X<$R3 M3&68\,QQ(53&J=;KP;BO9@,4^XNH-D'M5)T3&S:'(KE%EO \%YPQZRL4 M"4U11I2S*>&$WN.=6",7=M4EBB+Q'%VBVD2S43P([.#4V %N%3LXGNB?V YJ9R$^F*6$"B((49P1!E:! M8JG)J6 IAU^+!Z#S$NV@*"9G%YBO=*[%A-.8V+A;\UD##KBBG#JGF?1G04$1/*/8QS:&*?.EG:@\NZ!+;&VL:5C=^'% M/E [TX1IEF.EL@Q3@1A&6&,A*7)2Z1!/ M1D*-3Q[$D\=^M19KX$9W9;MN45I6'I+B4 .7KJCT$>]DXABG,<:I,[F=W\FT MCLFI]C&Y:"/$)P_BR4BH\#+6P(TU<.,8\2KFR5$"ZG$-W4VC8K=#9:BAJSH*+2>OQ*IL$9#'#&]I)(PS'3* MI%$6I2G@4:IJL7YNA.,1P7$#-')J@>ZIRP0! MG0T4-27!AE(I9R"A$$//Z,;P]7.1Z"B^K,"UT8UQ[,4W8OW< QWCY&, ''5< MYI19JBR8GUP9SCEE,DTSG G:Q !@4L< 4/A9/D?!3&"A%ZK#9$LN^]M(NG&, MR YV[XM2'-0;RHA)?5^ 7%J:$:(D4:G!J= OQ0YPJ]A!#."/3Q[$D\<3I/9R M1>^.+U]QI>O7$(T)UY)3E#.:NHRG2*8D306Q6.7J <[_,D7O*/%R@:HV%9IL M8SYNS.G=@6Z4(JM,+BEW*F6IS$$I$CDF0N*<6^OLTW6CG=25HG3+NE(1 W&, M QWCY'F3T'F62\2!(5F&J-$RSU%F!5,HQ9J^.&]B[>%-T7B+3Q[$D\=^:?)E M5)H;8!Z5-]A,B!&9&&O6E#;O_.U2T QF?WI0NKW=AJXV"UD8[H$AA3E7*:,\:L)B]'> +8 MGEC6@H^'].(8<8S(FO9ZN[HGUB0]:Q(M8DW'?G,5ZRA'EU^[U)RVE1BERM=[ MD2M2 N/=7ASC-,8X=2:W5(UW>)42&.LIT!W64Z\U\36'W;7^4 M=5TR7M$QE3':+# *9&3N#,5(YSD33*@4,94;;3G/*&-U0:U'Q4-M6VB9T5!H M68FTP\B.*TYN>_*'45=E+_3=-N/IJ857MMZ/ MC6B.:(YH;LI%I4TY@;EB::BD5@]U3U#"F-='K\;ZW*H?,!XE+U:$[K) ; M,1\Q'S'?8)XHYA 5W"GL&/PLX5^,$H4)M982_A*8]Z6&.W)%3^L31?SSN*,. MTR.U86%M9:BS!*1);B4SABMK!"BU66I8EHLCY'%D?^(DIT4O[RCJQ=X3[<'/\RU/!2^-L6WR_^&OZHUY&5OUQ, MUO2H#\=+;DZ;D7/!@2(&_2K$=[\NG:\O^-V]^5'8XYOM;= M'_JN.OME;DFW1>_5PA8NKG[M&O/\*6N4CUAB35L D'X9POE?AQHC_BF8DF[+ M5)*;TC..OQ2,VI0@IP1VBJ5&23!+-<&Y%&EJ4X'^#K;JE:=\'UKYUO.?L#70RN M\ NJ/YZ>]3FJS[N)[6C>W'Q\'CY:X#7U9X2=8T76?HS.\=K/[AM6GDNV_IOW MC7K_9YRN?^=3Y\K/*7W:#CS_7,4YH?1 YBK/&3J4?57G7!S*7,5Y*@X'6PJ+ M YFK.)>/'+6)HEM08; (%LYJ ^E!KY]:>G2%V5)K+<^CGS\H7(/ J9UB2="9 M'Y%Q\)@0V;+_8]$1>E!;,DUT#)KO0(,F7O3"SZ;.>;QOH^Y9_5%OFC&CVQ&H M_,Z"<987IA@FD9X6MR804=^'*=?D-!NK''Y3A(#E76S<@?*CL<=^IQSIOD=7 MRP)"MY$%,WZU#Y'L0& M7/47=;P32KOY7=\E%(>,&[R#C)MCB6#8+( AQ6E.1);2-*,LLUI)DBG%:$8T M1SJK+S$QXA3O)Z=FYBK#9Y?*CB*HH_C6A5PW/=O#N*0\\3O(4[IB?!(NGYCY MPGWJZ/9E(B/F(N8.&7-464D8=<1(RI1&2J2I *PI0=(,)KD-YC:4A?3L@@O: MX2B",H+R^$"Y29B=[WF$3(Y2+CC+G5-<98P99E+$>.;$>E3N+O> )A,.BZQD8)G*0,]5:-,6)HJDEJ-!7+/*"ZYS_# ?%?5 M-@\%DB?LY=@T3R.5#%M-!#<90UDJI2:YX!1EA-#,KA$BN\_3F*'9=/=Y&JTG MV"A#3D&&;)1$\21@[E>[$[M.HHBX;!5]GBHN-TGCS8Q@+D/8:39Q>,J@[C!^,*.?8&GY_<,-0 CG5_#VR,DZ_H*1!SEE*J, 5V M1ITT4@NI,BZYS1"O*WIBE-85/3&2CU8[ !/3$IX;\SAU=I%VE&A)ZOSFM]DVKFY1CG#I"M$ X8Y+I+#<$"9MB38S,3/8 =#9M M4AX^_%P?R_B\[,:XPF<7$G52NJM:HCRW2 J'I",L?PZBVY 74M^@C@AUQ%09QXAC M1*ZU5_/GN;D6"UQ++E^9MK:MYL%[>_UY^I2+7][Z/[O=4-O$VTJ@E@_+PO@\ MVMIL\J3V-*/I8+T-&T8AV)2AS*0:I8;9#&E".4VU<\Y005BZ:Z/)__GK8L/; MC3''SRY 3^@PM;79%'V4T2?W<%7%3-I<,6T0@M&P9)QPQS(E*X4,E8*R5.E,^<$:37O M$JWB7<=^Z;!6JQZX,AR<3W(.2N06:O7Q&;$KU6JA],BT!<.:%A+FRNH3Z =!#5$PFLMX3UK4,-&A.?CN-0Q\[PX M1APCLJ:61"YLQ)K(V85:D=']9=X=YVV?B3_N2;#!9=S_=QR?CD_M\,A)J?/(@GGRFF[R7%.J??<^E9*[?4E+W6NHD/3?T M5WQ#_6WLW"= M%G[XY(:?\RO]YRI]E?OPKS8Y"MM(K<34*< M75#5H0IU"-M[SZ8V>9[W2)UMLTAV5RYU?NV'BI-L5R8RC0!V$AO&/.8>A;^78$VWL_IC8A M<2>^B\-T7VS8C,FWEI \MR)%DN%,:T.1P)20'/Z="?YH_\7.FC%)$ILQ[9A( MCU=Z')8 V:C5YI. N5^-CL9F3!&71XC+33) THA-9&THUC1':P7:F1Q.=.N>$E(QD+)-&8LUQEAN&"$(Z?<@C]3*%Q!7R!FH:N_-$)\TS MW!!GF6%".>92QC#),FQ F3::,I,CJ\73G31/Z7"QC 5?&7(YZB@Z;N,81S_& MR?.F-"494HSF!FFFE916F(RC3*4.$2?,2_,FTA[>% N^Q"[10ZVA;:6>5^FQ2A)93NN,%1QSC M-,8X=2:W?Z3KC2.O7'YJ/*XX1_8:[ M5H0%(\Y22U6>,\8QEI0IHZ408.\C[!Z3-+N3*MI*GEU(W*9N2VVDUF,:X]21 MMW,3]*G(4VU#WO&XZ!^L7_^I_]W=9J#@4+1%!?MF_:=;P5[9'%-FA.$G5;!G".^D@GV$6H1:6Q:]20(-U@PS9;FU&J!F M,FEISDSN)#*:*K8-U#:4?.3L@DO4H717O9 B%B,67WS1&U6PSR3(.\*^4(1\ZS$0'RV4)N7&J2 1D!.2++WH#/$II'"(9 MEYQ)9K)4$VMD2E.B,I%F*G]&X>@+G79XNG4A@T-"XJGZ+C8L7\^4MH(1YF4& MHYQ(!7\8FSJ"E*12/]IYL:OR]0SQ792O/R12C4+CN(7&1EK>Z[S5I7JE]L%4-AFVQ]E73=_!"]]D1ZGN(M0@D=,\1@,C!5A!APAGF'. M7&:895H32DRF$+(*:<.: !],ZC #_Y]\AC+8#$EO$"N^V[Z*]QWM <4!O32> MXA0C5]ISKPXFC,NXT(I:EMLLHY;G6 %;0-BH<9+A\W,E=2A*6F)@+\PX])FFNO4 JJ8T,0*\@"J7J)N/\/(NS96>1I/.AMW M@WSMIQSZGU7QNE=T_[^S8>ES"[2Q7[ULU4/@M!P@;;B%N:^3P(9FFP]PDYUT>[.MQ1[$=+>,]Z8;41X:FS"R5VE9G51M*+8\0Q(FMJR:W5)JR)(,^:=E5&*%Y= M/7/[C$-SUT677PO5G)95EF<$GUV0#N5;*TSQ7B..<:!CG#J3V[G"U#HF1]K' MY.(%27SR()Z,A!J?/(@GG^DFKVWM,WS2_-;-,P[-QQ7'B'[#G8?WZ)PB@IA$ M.4W!,.8*(<(48XZHE"K\4'3N/>$]CROFOZ%2ZVM!=A!-MZ\B%&\YVC_&R:-S M?TGF>T$G:Q4ZC\?1_V 3C@\N*T>ZO$N(#$TXR#8)*4W>?[V9BZG_?D7'5.ER MPT*7PFAKK""ID@R97&6.Y]9:EDF7BIR'4EZ/BH?:MDL'X:%+!R>H@]'602>[ M/?D7]H&_)'VWS7AZ?&V^'6_.88)^Q678DQ#_Q$8@Q/=UEUO7D8AHCFB.:%Z% MYI031K5A*N>4"<:D3 5&@EJ!C. LWP;-&\IOX7N-T$[*MD[KCG"/<#\AN&^4 M6*L-?$D)3DC.P(K*4IXZD-X\)3YPG*W'^]X*81,?),Y)!Z\ _E-+M$7,1\P? M->8W@#PVCN9@$F=Y[AC#,J/(4I=E4N38Y@@]HXA7H,V#A;[L#CME ?\\GJC# M=$9MV'8%S%(C+<):6,-(9B6G6<:-SB00/]+DT=ZHG;5=H6@7;5=V?OI'*]^B MB-MP?PX4_BLTVR=A?Z^:+<7;MWB)T(_0/T7H;X)\986@AE''##.(2:$%4U99 M3073(GL^!9>2LPO0HBWB:>OJQB7:^ ZW;N#_4EZ_2&, M#OI= I,I8&;7I>XF UW6X70WKG*>Y,+F:E_I,"]ZNF<*>*@:PB]"D/OYVGUH M7L[(N> PP4&_"E'LKTOGRRA^=V]^%'9X,R;\F2\VQXZF7]$93&(T7/^5MNRQ MG-^-V3_];#U@"D9M2I!3 CO%4J.DY""H<2Y%FMI4H+_34'LZ?.FF'*]@H*_= MJPP4]#]>Z1P6^%IW?^B[ZNR7>=H#PEO8]\4M6[LQ>?Z4C9&/V)<: L! ^F7( M='@=RJ_XIV!*NBU326Y*SUC_\O !"0"3YPP>)F\]3^[YTI_Z8M7AORB1+@6, M!"*][%T7_7=W( 8*4W62CSUS#AS )M]&65780I>%JUK,W58OZM/GJ_??DJO/ MR=O/G[Y]_NWCN\NK]^^2#Q\_77YZ^_'RM^3;%?SB]_>?KKZM75I;EO+3J*=' MM@".^_/R7!_)0MC9^K-K^*L*&NI++!"?)TFCZ7P:W<(89EZU$_9+"9*M M-PS__)Q_& NU;Q.9]JZH3+=?C4IW!7/ZM0L*TE39H;4>5O1&SEYZ'=.\+/$@7]=C#@0Q(-S MN)\.:A07P I[P]>$G/-G((WU2LK;69UC>BJ>VWX>N)IO5X%C#>]_>BZN,?$A MC5ZS#=\: K-W88P>S"&YA8G=5(F#';"3*+I:=VU"Z6AXV--=9_FUXQ"\;S?. M#1,=7KYZE!5?7IBSKFZ2#]W^C^ERNV8F0>\,CWJ5<\+CSI.E,U^UG;_KYJ44UZ&-R0_X "8/ M1PN::=F_39H!']99DVSD+0J@6E"!0?,UW9$%8NAV$SM!?I64/A^S68'7FT<> M=->P,/A",>C"$]>N!^38[8;/W<"_KNB%U?ZM5TQV/$S_,D!9GX.T#0_T!T6O M*24.F '=SD^L$^:@IQFDR4]^+4457@R/]KQ=UH69F5'IBW',/OMSTG/&594/ M_QSVZ]4FN2[*;GT TXT8J]6=Q-SHWC5,L&CJXBV0@ZO)P1_9?-Y-$6*$.[X* M^JA;DU-_'IG&DW$>R+@^/__+,5T-0F;K_23UT_@+?DOJ+U2>J#SG!L$X0VFW MVKKU5DC+>=T$!L$ *XO;1U#O#GC8A.B'C5$X:KC".MVP@(]_ 'D ,?5_]'S5 M^QEET9-IM^N,M^JZ=S6+.VL ?]9)SGXX_V=_5)XE,'60T6<_@P9P"0<;%MV8 MI$E6P[YA[27L;.U$J&8.VW4+L''\WBP<^2\+ = "8&.U\7L@STT T*QX^;PMR,A8_U.S4:P#[VALE WWGIMO$& M$:,U%X82HEAFF>)$YLAD&H]F,(.5:M]2WH%C",6R\8I"@Z'Q=M=WQBD'-7("#5SC] M+4#E5=\^*+0_8%+/NBN@ /=??W7?';#>K^Y6@UH>BMR%]8,V\CGK%M>Z+K]2 M%M[K-P>9RUNO.FV\73[X[R&T>"@,^MZYZ/6_?#0$X=M(B6N/%#,[CR1XU3TC MZ\./834)C./@>$&2>QNKJ&IN5^-^S.6JP/DN1^5=W]ML?3LRPZ1FX#-&9&"6 M_U8!SX>WN6M0.0:@JH$B: M2LQ!-F>:@_*(M!!:.,F9W%@&?2B\==SUAOO'R73KO;ELY#'>=).8CS@Z5_=O M4D-N2WOT SX&\\*37#D$G<0F_>\@]^_3LJ4U.48&:>R+X_%,(:!;[$"KQL+ M*_VF8(7!C'XU_F'U-ORV:ALFC.BRGE& >%T/:GYG0)LRKRV@U^ERNA?8AQ8O MZM&)?Z9JMF M&P'0!E/?-Z"K^YPM\I) :9,=F\/\CQM7>SS<(?BA_-Q9_T>_/,.#(,A'#%\<+ZLMX+A\T1_N">/#2T( M?[OQ0B8$W;^)UTB\#Z##KM('EHT\1A9-E$R"Z,TRAK C##0 Z;!AVJ;,*252 MI1:-O*_O_^O]I[^]3SY\_?R[OZ6Y^GKY]NI;\M\?K_XC>?NW;U>??W__]2F^ M[X?G,3]OB7)A4H:!ZPO&+=;8Y+!9( >P2!V3#_C*7]"L?#EZ^-+O%N9N!54L MW88@IC/*X:7,:$8S(7/+N4".8D%)#A;9(E4T#&:FSMT6'H"5YNI*JGEXGO/K MQF$,_7 M?>\3!YE:U04CP8@J>D')KE7GX0WHS:7+O6>V&LOE&5E?&^/^]][&&(+L_7-0 M/^IM".-J3S_\MKXF:-3Z/AAO2V_V:D4?E+ZA*V^]+WJ\N'**ZMHU4I9^J-J/ M'>8'TVW>/OEV'9/DJ:2Y3:E,?Q!<)Q,ZG_7A#&ICK5YAWN]V^S^\H9#[Z5=# M-ZA>)S\5/\-!^O?D=Q,%Q1/C3]7/-3E.M_P-/+WX^&!J#\*)C W":GS;,QXM M?!6^.]V'X*:?>K)KJ]<_]OUG?['1-]Y%M/(A?P@;O=KK43_!L!-BFAQ"H*F? M_.[#:F>.VY<=K7+OO]=K7K-*!SM$Y^&LD7GC[Z-ZP0%QZ^_*QKL$MJW3MV,/ M54U-E>[6UW?^^J.QI.Z)>%NS W5(B;^H WIZ(?7A75&-?9*-:Z%ASELMICTG M?%G-\01_R ,XV:(_JH(GHP<622^<<1_L>,\\ AQK.RNP MKG"]G(POJAJ.D95];1/O10&N4_3]IG9ATQR\<-2S19Z[,CAOO'DT)AX/:YV M5>S%OKX18%#VF JEY6WT?\YJ@VF A;T/411)C=.=V$ZQO/,$"7I MVGON#V'TSW MP"]SNFM^XO"O[X4-1J>KPDZ&[2YK-Q ,!S_Z*?BQFCF<)T 8U99T.>\84 ADG*%9;%TJ:AR#?8=Z$\\5TRY5.;&86&HY-PA;9?B MK*[FU($0R@VD< LG WM2A:JA-7^'PQT?;"?\],YYI2:0%7QV[?K7I1[>Y 5/.C":=C!&&,AF\0'L>A!Y5Z/?W@S+K5<],)^AR^]F1_.D^)B M)4!_%/7'4RH]1S6E-H4(FS>!TJ0/UD[ ?.G9%=F?M1+P/&F.#\HJ5-OC/G+Q M]SI@\?UISP6-[VKECRG,?30[^-%/J Y8U=VX@T_A//WAHW;N)#Z# MMNEK\L(5FQZYU,>7;%JUQ!;-R)ASY61%H M1PHT(3A5DI$2J"EOMRT2C(,\R@31(-<9SI+7) MA7+82,QR9T4K@:9\RU1)M^[Y%G$6(,RVQ(D9E3J&<80[_ MS]J(,XX 9ZJ3XC8)M!U=X!R(O[0.KMZF,7&;&KKLP2!38(3)C!)K8$=(RH$&2<844AI+ M:CDSJ>'&8>=:29D$&#[J:[X(((Y\:FJ3<^] M?;DM#[_IWNZ9$U6(6.Z(2ZEE8/AJK][EV"*BE!&6MM+2$&<7J>BD9%>W"R_? MGN^9[B8BBX@L8F,6@52FB"5((IDQD2*MI!-2IL):1AAI940-]Q?]M(.V[^ 9 M641D$9%%/, BGD45$ M%A%9Q-KH"J.M%C*UB$IF&? 'J5.$B;2,49FW,KHB16!HD YC6_OG(HN(+"*R MB(=29 PE.'UY8]UJ<\ MI'I_<:YQKH^/J!G%RGN4!&K M\$6@'0K0I"\HFV9"2T(994@Z3A3.D$F=S! WK00:.[N0';FSK(*(LXBSO=<& MXYQ(05/*$6,R)UF>2VF(P5*DN;2HE3CC9Q<"=7 L*QN!=C! 8Y1H;FVFG23, M8J,$YBF22N:.&(UX'7@R!EI+ D_2LPNF.H1M72LF BT"[;E,-)E;*5&&N1., M^9[<3@O%*&+(4J.S5@+-)Z1V)!<19Q%G!X(S*[@#5&G,A&,.HRF3JIQ3@U.B0(*R:H8EK*'*EV4J9/_!*BPV0LWG;$ MI,F1LD(X([!-F2):&BD4!Z$NE5-"M-+O(WR-8$8["&]]E1%)L[VDF3L)Q&EP M)FS&@%]*JITR*+=>T:3C=-F6D28-\ARCR#2/F#)3PJP"HF248&8SHKG,A4TY M,Y@KH7 K*9-Y>4X[&+>)-&/)RWN7&7/(GV^#CH8[J51C+8$W.8)8)J3$),NE M(C*7AAK$6FEMA);'LD-VUB+RY9/(8YV)R"/:RB,RK"2W&<^)$LP2KA$PC=2E M*65"@S782AZ1@FZM.@Q%%A%91&01>Z]6Q8QBVACM#1VCC,+81RL(YUV96M!6 ML@C?:)J)3BJVKNL?>43D$9%'/*1&L)P9X &.<\[ Y- Z599+1)1ESC:]#]OF M"/&ELQ7I$+ZKL,'((R*/B#QBK;/4:-_)6TJL'? (GJ7,6.>0H%0;)4@K>80" M4R/MJ#36SHXL(K*(O;,(AW7F30BIJ/=&9,X@B;&TE.0\I:V,U90(3 VB.H1L M'536&AZQHNRE7YH_JZ(W"G51[B^$.?N^?\!F%_G=WJE/+%(?&5?E^%+V[<@, MDX8:Y@N3/;R,HF==;_B:D',>6. S@R@LX^K&)6_[M_#FNW^KDD&]H,JCIRJJ M8=+/$YW\**Q+2MV[=O[?M\[Z\^TDU0A6!3\ENF<36^CK7A\.Q !N?(1KE8R M[I/LS@^: PA"S9ODQNGN\,;HTOG??X>1R\H#(_FN*S/JZC+1!KY<=<(OAS"[ M8>GT\!8VRK]\ *L7M^%WT_F6KDA MD-IU=9ZL6;F?V;7K^5=T[^HUP&"W1<_#%'Y3].#%Q7?72> 7U^[5]:CPI>K@ M^\;94>E@Y-_[])VT-4]7XG)K[:ZZ9=#_TBWW[M.AJZ\]:/-+0\6W>U623&!/_W,&G"VPP>K F4F0O_4B?X!@#,1F&NE8)9FN M"7[RJV0P*LV-1W$004 8/VX*H#T/O3 :?-1@LP\2IE=SEEM=#:??!5@G^KIT MSC.+>8#_ZU\DP>)-M3BKZ8SF8>^!U4 %9MF]Z]0\KI_T^D.8DQ?N,%, 9>DY MTN3X^M/CFT 'MK)FAS!D_0W0 6![/8S\UL%$+P&7N@PLPV^3#CK#F.,Y#>., MI]V9Y2F)^ZZ[(U^++3$@=#7L50[/>"374_0;XI\?KW*R"SHKNL7PSH-] #SE M)YB:*8&M#V%*U1\_GRE;O)YL$YAF%@ M''#+S/#U%XVBWRPC/2U?MYB#B_\KO1**=?RJ+A[I?=;M^$1?D- M.";TSRQW4-8TG\^+O>'=P#-P0-B4 S04!O\J/2V?3[2JLM:J/,W<@H 'V6H] MH#R]Z%M0;P,\QJ38;.@L.OXF[@_@55X32:H%PVYEAXILZ)1 M3S#327JN5H-@R.\:<.L5YOFWPJ2LJT Z99XMN6[_QP;4VI[S^^AUO?%QA!^ MI<"Y)9ZSPJ)7([/F#!Z^_GP72< ?GJX)OE9V_,/WCG>>3,7C\$9/)I+Q6<\C]'?A*P6 R>7*[IU_-+"]=2NPM9QEB&7<9$B U6U( MGDF3GAT(8V_L/;#[3/^Z5_@-.43 ?YTRV+)>R?\ [?SPUD=@ _WN#*D'E@Q/ M3GCF%,\3)>ZGXMR==^H1ABNTKWN(#WZJO/S_>:SY]8T9>;UL" QHT 7MXMKF/R M->_SL7?.B@:FZNJ+>4Q]SQ,_M^;L!B_+#C%H*Z.2<$SJIG#7Z<1 M%H%BRIKS ^&XRI],4'4;?7/^J";$XT\U4,[@YJX*9MZ@'S3AL/5==PV_&1;# M;JU%>46U9HNE^P&L,QQ _PI '-"LVIII4T?O>#ZQ_:LS4 MJ B0:D2>-RT>UK$3;XJLPL]40#7'5].\5^D:+^RG$;RY, L)DXYRK'+JA,R9 M1$02E6>,IYAG.3+IZFJ!M:,5=+3^V,LZHR-/5>0O]4RN8")SGE787//:CDJK M[Z:N5.R3)L9>U&:J%YXF[IN]Y9I:(Z1CN69(2L4811)3931BPJTNP;:/V9.S M"[4\>WBDJF%44P!@=AZ3M@]$X0W6QM$65-BJ #:? ^EX#!8]F%5@8?UY _W@ MX1'J5@>_57_&)Q 84%<#U8<_ R5[%M(8TN-+A"KYR5,^06_"O\+/^,W/7A9- MN)67(6#=9J/AW)Z7KE:::T;5,)TP2FU4^W_"\O"K = K /,FO(ZF#A Q#U7PSXX.5:*MCY0:% ;)WZ7W%OFP'*] M@5-[3ZI@L-4*[\P4Q_X/.&%W"R:/=V/V!\$8@@&[P1<[=MZNG#F,_K$W7GH9 M',MAY,[$Y)M11\8C^0K88W5D9J)>S'@:GQH9"^U!EJX7[KUP: B*D7/A^V3! M6X)V]WIL%4S;8_VO>66U 02:?D5GH%&/ANN_LO>V*X_$C4]RG-NRF3]ORO%L M!M[9G95.__%*YS#9U[K[ SC0V2_S[ %XP\(>+BY_[2+S_"F+?+!L/*RQYE$6 MB*I&WNO:4(.G8$JZ+5-);DHO=_Y2,&I3@IP2V"F6&B4E1YK@7(HTM:E ?Q? M[((? O#@K64/GK_^HB]6G>-*PTWGUG%G,L>Y8)9*G5JPS:BVF1(,V7S1<$LI MSY!C&H/!QBA62J0B=:FA(/PT4^)LS7L>-/@6WI-E5J?:,K >#<-<9E0C8ZDS MVC&F.7TQ _%> &5N^,,U)D_#FKH35N;E2\T3Q[^QHXED %$Q(X^]%)KPN%H0 M 3NO64_M+0R>#)_G->7'];>>*K"Q?+%=^^9;&G2:16MK:[NN=I$/]9]>H>UW MNRYX!F'UF;O1W;S>G2)HHN6P:.X$7+AN]\+"JT/-/A^BQ_B_Q@[&M[,.QD-4 MQKXZ?_'AJM?CR_'Z;,:.A-#/(IR=%_7^FM.K,YZ\>^-N%XWWZJI]RT$9&8[*7O@A"X-[ M^O1ZQ@^ORS?>23]&/PC-W3+.,8:PA^D'F=>VDT;7FYC7G:JC= MW;!.'6Z^O$84KDY,5Q>WT\<"IX!_-IOK9UN&A\"&#G:?KB8^BG#+=)A^BJ\S MQW$Y.8[7.@$S]TI.[/ 2 6E/@[;_L.ZR" 59;Q]+#'^STE M:+_;0!>CB0D^N='HC7VQ1=_.'=U@^>YCJ@O/.XZGE%M-22=$!(2;Q]N&BB?W M;@U:PDJT,27(W'!'TO,WJ\V,X/?UZ%Z3]SS(1P"%B?VJN\%=\.W&N>'$/%BS MC3"=4;?Q\?'XE'"E-H!FG0/_ 7UK03_#.,48E#^7"\0HRC2A@N0J5=I*B14_NYB&1 7F M.8_*Z05[0P,S]^])M[@-[<5JDS&@Q0\!9SN]$ QC)L'^N-=U\Z34HAG7S:J8 MOJ]^7I_S>F'-E)I_!!Q?^EE]:(9PM!3OJ0LL'0 M^ZQU0T0SK':\JZ.>ML"UO+[@GP2[3/L +QNV-/B3@5]Y37[XLJ3WNP]%&]U^ M=;/W M>#Y=:QY>?0')432:E1<0"QQXJI#-W];/W&DV'#Q(@89,)T<#-#T?+U3[^;U< M]=\HIAK?/H3LW$K,J"R!>7=GUS28XT? N.IXFB+$//J=\I.'60[[97V/,?]\ MT:L/)H0.>+A.[DYJXV< %YK(D>U??C@4EW+?BK0DB@M6!PV. CU6J M1B,=8_T@0W\NFQ";8'=+OC M",7U827SFS8AA6HVSFC,/>\:?C=OJ%C7K&F!JS_:4'E(>]^/)!^GB:P2YCXE M9'C9L[^-%QYO,Z2D; -2# MRKT>__#&NW6[^NYUT0OK#5]Z,S^'H-/CR@IY*\!;'%/J^^2&;VN_P,9)O>+L@J..5%OG_6]ZKB]#1<8)^B='*3L0KN M&!1J<81M$2-2CA0I^Y27]R*%>--SZ\:\N^Z=LURM;28ZZ/X;R>8WWO9MU07E MDP)=9F^R;[3U&0M%77=BV%]]*]G/DW]YQG+H?","_-@SI<]*>>?JOS_TR_'S MEZ8.F_W8^]6',[FJ@G5G12_7:#S9:I.X%R[(<@BN?(!73^T MW[ 86<>T9&G*C%"YYADU>5OC ML:HZ,_AS%C(%^F7RH0YP2?0D*FM2E"8YQ/"LO_DD M%$KG>).N+D#C680/\O$5]\(F^1(+V3@R?R:&)\1?3&LF^9"E8KA0@,F7;?/7 MV)6K!UM=GZT."H4W^UH%W_VCMSY#H29*7_:P2OXY EF5US7:C!Z$W*HZ5M\7 M%C*N22RN'_9!8A:8F1F&6+3NN Q1DR)C;GQDY01!>AR"P/6!_IZ9=L"Q\7-9IL.67H%?Q'^"L6JBO6*1=UN%78U3K) M^ZZI"QD"3B>Y1./J/G7)D_(/%W*L)VD;DP7[J#B0Y,T^-*L M@JK#(&DOARF M2^Z<7JQ\L6%^=&M(>C7'>G*>ZH.<:S8F6#<7#DW]S:8,3!TFWK/U>0%!?*_5 M@!FJ6U]]L&IH 1YJHNO6EM8+ISV-+AR7B#I/OJV<21BWLS(><5+\LXFRQ@<1QF#%BJ.S&_@Q F'U34SS>V7%VP"0:?!*:_;Q1UTJ=2TZ? M&'3-&=]+'#,5>PFZ)ON8K)!I#+J.0=?;!5VW;QM^UW?)4DCU,UX'OURS^*_Z MQR0Y,\92QUC-Y[H^GJA/0("_C^EOTR!-[\>AK,-V=JT<@Z@C,-NT\!>XK=X- M,.79!:@5A!\,,)\I>OKE!/U_]\L_O/\S]*>JED3]9,UDLS6O9" '#:2=2SB_ M\Q]]H2"_[QLC29U=B(XB6Z\*"ALG/N/-[X?_?[OC%4,.@YN(.I:%&TWHYLC$AS>V// MV]$<.;O O*,X;Q'-[4A]KDE'M9E1S]QOO&!#[B,SVV/'\N<3>$M96H]@.?3L M(J4=3KN3M ;R\UDLB]$MR[& MCP[<:T?(Z\.Q,7-U\4-D<-,YKG3?"_?#AULW!!/B*6'W;I*^#Q5TE7'CGO3= M?M5T5_#=1N9KY-[J/URH>#FZ'=0I,3KK-XVQFIJ7UMWZ4?SXTU#F^88GDUG MZ+_.=#^HW.S0"QVPU]09KJ<_=)VZ3O$X.K3J]G^\NNU_#S5Z9UYW-6FK,MV* MIJ2^CY59G4(11ERJS!5R,S9)7WFBH%_*]IF@_K_&O%[#?@ V] *=X, X0WR0-:%_CXR MOC4]>\SK7R@ZDN\_.M+;T3_@P"Y[]F-OJ'O7!?#X4)*@NB=>DB.Q&%^H4VD, M0KG$7#)K4(8HR8 TC:"&8\878_G^_?/G=__]\;??DLM/[Y*/GZXN/_W[QU]_ M>Y]G,!B/RXM92ZE1:EA3&AEE;!:,B%A4XW-7BS3*HRX MJM_1:B(9G^ A)E6-YS[I0%AGX/C> ;XK9*E],?=.:)GL0C!DR*D"N5643>/) M7MW4!'X-7_4-DMP_1W6M>9] -7T25@L2.]2$UV51@?B=O+MTD\JZH8WYG][S M/RG*/.[M6'=2:C*PX$4P\+SL];&?8P#5'8J:9K%U0>_>]+.F$F^3(NIO%D.- M[:S)%/4)6^-4T<4[-,Z_MV[<9EK5[=PJD\PN.[#8>C0KC@7]4@@(V\_S,HT'%6.B\' HJSTUH MELAFIN3;)826/.^<\8T[RX1BGTYS">3132CR/P="])P3Q%X2M.E:-UL_XB2; MJ)G0OU6@*S9=L4,27F^L?<'..:.K8=./P%/J0?:?NII;;+/G'N-^80L@;Y*C M GG\"%E>MP.OF(;N4/#A>.]KY3'TNFF:;$Q"KN\A!;J8R]G38U)H&K(&9;Q: MW_/%_["@K3F6JYSDF-NE/TJAL:"JUY=E%O^>65;9R/&I8E>]A75L> MF0,"ZLU4O-]P-^'[.C1=K+=UDUVMW/5M*#XXM[&YXBX3E!&3$J9(+BW-"%&2 MJ-3@5.AZ8X'&5B>JW[.QG\?==[_5+]YX;Y7O M-?WMMI6]]F2741]DW(:7^K MWHJ<,%JSY'ER GO3OQR8X>\ K"OG.ZMYLP_^\0ZL9]^?L'(N^=0'3HAQ^#=,):B>[YQ=M_B9&[WK MP/JJZBY.UGF!XJL;K-9@O([TO;"CT'EU[@3#R$$Y HVFK%/*PPL# _[?(QBR ML=WG\3\:%MV0OUH/;WQ+CM!U"_:A\1DL_-;K>G-]&^'7_ZC3Q$'N@SM_W M_PX)Z<%/ XJHYZAC[XV='J4>NX9">U=3P"J',[T6JT"_3=9_F))U&:P=)E+X M//YZ)75^L"[OQH/=NB%H<'[.GT.'I=FFN[-NJW%G\W&QC>NR_\/WAJD/ !:7 MPWN;;B7-V=8^J4!B@3YA6O5B9K_;D$LSFPFY>#R$1H7CHW/V37(S6W%@D<"" M"N%K*/2:J@'3CC1C?'CQ'SH@^NZC7M!-3(1)T_G@X?-?7L?3%A#T;S.$['6[ M5[5N-VWY4M=RF ?E.G8QAWD_S1\W?3 LPEX$5E'C8HKW(I!NV3S2NYMA+HN] MNOS?GGNM>#= 969^C7ZE[3]C*,K22F7P,1U+30H#== *]_BQS\]J>*P)- M+2RUZ;FSO-)FSNM>O6;G_*M'S=: *#,CGTF_P JR?O^/V06$S1CW:VMH;Z%@ M1L.#%W3Z!0=L(SFJB>APW\?^M\YX9^J&7\VJ:C'E.VN.Y<$3]FFL((^N?7^^ ML7MU3]TX'\C!CR,]]T@G6?5@L:W'S)^Q@,&A%S!84Z_F 3_N@M\W3RU7AA*6 M90J>MS*SECAO5RG!$,1%^[()<]J]C?*"-R_Y]3ERMD,*AL?38)-)5D]=^ MK W'&#]'2NX^G3P]9XSN(?>=2A8GRQYW8(],U%\;'(SY$;;9^K2J>.+\I?\N M&F^UJ0''GHHA/!0.M!SM<]]VM+!PP-APWN]>/*+>PBGL=..5B'N]Y[V^"B%0 MIU4(HVD7W)ES!.\L3?FH0WDW6_S1A.D*3 S%#/[O;3!"=)H3E65.XE1S9G03 MS096U/UANF-K8],07>P3@5+4X43M.\O^)?+2-N?4$9T1G1-T*DELGJ>*:9ZR ME*32:FLH(5:BS%G#]HY.>G;!CA:<$8(1@@]"D&4TU\;DUCC.,I1IA0U%&F58 MIP;)_4.0G5T0A#N(RX/ X.DDT7[HE\Z'%(8:]SUS5QBEUZ76S2M]D>_<:3X>\IEA99)CH/ MB6Z)WI:<16VAFJ: ;@?,*>*[RF6N\FP\>K(CHAS"?->.0\\!D&V!N?VAMFUG M2<_QF]A9L@5CW1PPE+'M.,*FMA-2(@).(T\YKJ,2TM7BHM"N(ZCA<2$)<1%6'$;1:P$",/912[#CLV+1*[<.JY1W?JM7Z]8_GU M6K?>^C(P$94<"$D"25%*8VXK[GJV%\@VPZIM M72FUAS*$D5***LDD%9X;19%D7NP+]"8[CMH"="?PZQ'2^O7.%8R[L$ 11('@ M >.^BBD)@]#V7.F(R+%#/?BX6Z#:(!;X M*Y@K ^&'$?6X%XK8X@]:UUU)J M'90:1:$2D8@%6#>4VS&SW<#S%9/*]? P[^B4ZK6NO9866UI$6@0M.W"HJZ* MQ)3Z-&1A8%/F>]0-;)O:1Z=%'UU[=B>HK;5%Z]I[=M?>P;;L&;.255-L-K?8 MQ4R/N:"^LH4;!\ MB,V]P/%]3N%[7PD:;2CH=C0S/;BZ"8)E<7[.GLJ6B,Z) MB':@(2(CQZ=,!+[K42[MB'@>BR(W#H7-O-+Q^B0-G<+Q&EZPX[6EK7.BK9T$ MU&$51X\FH%B#!-1)_/%<4\MCT:>WGFE:GV>QH%T^7 M ,83.Z"9KF4#+!+8ZVI98SB\@\'^<.K%BD9+4C:0B=DQ0)3DV$W".X^X^$Q[0 M4GE+Y6?4LW5O*L?*,(QU6%#S\?-SD?E\Z\9IQ>=J;ZWSJ"SZ;>LJV;H;TZHZ MA*LZ$*:ZHO:X!Q.*M_33GV7'G;?WRA0@O.NM*WJ_4*9]ERP3H@+0QKE/J$>E M(#R./!8[-'9LXH&.KMT%MD-<[2[0'S8T*"GI]_VT4/Q6CK=9%3MWC0$B,TZJA1]HBH/ M6=$!RNWNTECR>-2HG[A]&[\W*DY@_LKZ77?AF#5CM$PWQG/D.>^7FMY5N.VL MY5NF9HW_IAWVDJS2VV22JWC2M_JP-#EV5, ZYQG'-UWC6[%C3))WK3^JEV6: MN'2SMKG)8U^CZ^3[=2^1L$*OD%70HH^17F&$WE,5P*7'72F"4-&84SL,&:6N M'3HN$]RF@1);5 !_IW=:;_1"TTTS@]^36"WW8I*3;-J+J61RWM6-7G %S!U[ M<.6+PGVAO<>JWL6F]8J1;_!'$@/586,YCFQ(-_U9LP^Q[HJQHK.A;D-D^B(7 M'-!L?F8^85^7R2A?[//VT%-#;-MB8><8<[GAD/@.2R29F SR,3HC\Y+CSEJ+ MK.@!4G;E6/'F 7_4_28C9#\"(8?Z4==Z'Q?,:FY&"[=C"?-9MYFBS9.9!S:N MG.^BO-#Y3P,>V!EVNUOJ-;DXA?6])O5H%M20XQ2MAX5(*Q7K%WO$ZM+]R^7K M7?],R]'.*4$'G$'M?N5I*MPWKX@S& /6T@'7#@MRD>7H=W!4-'MW?\M2 M;+(\)VSK6H!M*J!?S$+>@D$\T%W49*G :ZNS7HL?$][ S,H_+X\\^& M^YRE)P2QXYM&CI!%(2<^)*(D"M* MA+WM0<1Z6S_7@FCG PHLD>>ZG< CYQ+IWZ;=M$1ZI#C%$U!I13/]<(8V!U.'5S MC8'7NJV];J%MSO7S7C)Z:36U=J%6&=K492KV71L/$5@4L, /!&4A<5R^==!= MW5HPM:]N?+MCLX.C=)J757/AZ-M)O3L^_&I2[ZB)#F5L67Z<<_;DA6.Q65#< M0V^A.ERQX]A.X_E@ZZ9\NG%HQJ4:\.S/_;21%=.]/!KT.1624NI0A$BVS@.J71MQKVY8AWG+G2OVLQT:9,%?./AV*B][?/35I8S0JYN@ MXZY0CG?V-+50?)E\R+4,%\^)6V-@6F^@Z]< M[. 6*QY3Z8=AY+. $$8DE9PH\6R*B']UXW7V"]L4W?B8U07LI_*K7U!X MP<&KSJQK59QPEJ#C\X=.O/(WZH)?\73/X[N7"/3_\U64X> MEAP+O([C+[O3]@T7;)E!RPPNG!DTBQ?LX43W'*![EW9LYV#CMLG$7X.5,5_3 M:$.-CS9%^\RRGL]JL&V*]LG3)3_P1\MU5G2U:U.T-S/R9F]M4_.SSVL5V^3L M-CF[^:$&1TW.?D%FW8NQVD+%.(U$;#,F:>#9H4NHLBFG$KZ3L0G#)K8W7V#R M^!Y63; M'G5Y2!AQG=A_-LW7TZG8CG-PZ$(;Z=E@W>X$\*M+M_.O;MRP8]MN&W5\/EAL M%A3WT5NP,!M8%,[!==G..RKY_)V2;2KV%N40B ^T)C@5+* AC<-8VD0(YKA4 M.)ZOGDT;"=M4[/,$WTYU88Z/OKJ4$>Q8W''"0\K"M%!\T7QP#UW$MS$5._#K MBB:_&%7DW)PD;2KV1F/ ]46HG(A*GX$- ": 1V,>QW9,_4@P^5R*B(\%P3JA MVZ9BGQOX=O**'!]]-2DB/D$\^OZR8MPZ11H+Q68A<74JMH]'J6=0<:+-&&[D ME>W"-D4W;M.OVO2KT\DKZ7MN:#L!QAM0W^61\%G$8FH[CG1=QWXVO9U>W;@. M[;@^N^0$K);\6_)_5LOI!/1?E^7D@8+K.QT6+G.$-A6[908M,S@#76 ?)[H/ M=.^1#@SMDC6!VE.Q%SK0GTGG[ZJ$L-3W$;K==8=Z[/D][F5*60-X2"^W%(Q6 M6N]4E$UX]FB04'8+MOA0ZIQ4ZX'GUG_L0 ,Q\U04N)0(GU!&XE"Z$2$L),P7 MCA]PTZ,=QEKMT5XA!F^1&*H36F[IX<1WF2^C M@5"1%W#F2AK+*'*E%SN,VL (!!-*S]\'((^UH 387) ME(GB?)/A1(]HCHT6C(N2;H#U*$9IGN UKTPD];V:E:% .5RYL6"\]NP6'H&0 MF8S7W[*4E_M,_-EQ%Q:H\F\OFZ7WWZGK*%/\SVL>PV!?\?X#?\RO?IX70R"# M%M9PH+%H:>S8D3AX'O2S^P_Q?^$RZA4<0H#60824D42D\6>+8=37700A6I@6/.LXROHJ?DI*_2 M^ G-\]UD/,E4E;N\-=)!+\XW&,^O_53\.>, M?!0AH(&V$83-HJ:/\/YO#ZI_KSYHO\#.A(1A-WZ'VDWJ@/L2Q"Z P6OS@II% M3"B)OCVD.],0U33DAB]0&CTW#?FM0&H@#>$YQ\Y4I,_'.\1N4@SH"Y%$02N) MFD=%[]+)[G:1KXG(=NLJ>M.*HJV)*-2'3^.>RI0^-&@ET[%H"J@G?8*@2I]S ME:YN<4?VIJK@ZL9W._:*!H3G*YI.%XS5QF/MND MI1\U)"L(F],=HZZHK/D( MJH78J>4P@.W.2\TB1-G/"Z>M>)\^.]UX>HLMR;;KK7%<) %1TD_&BO77_YX^\;Z_?WMK^]_?__M_=NO MRP!9W-W=(NU6GJMO'.>ISM4_QC-?JSP:,JY,G.1Z3+QZ" MO[+.[J@[(-V@;?G2]L_K298!O]C58@H= MK(?G>C7W%3YU+>VVW'U+HTW),JN?1K%WC-TA[L&58T]%I!3]\8IF M5.U90-TBKS"9IRN^+Q&Y6/(07MD@3W];Y*JA++PNS%'$' LOZ72I\:SYTV2< M)U)9U8W;<8*Z3G :9'2TT#L2 MHZX+>M@9I!.X38+>Y:O2*E<\$SWM6I/J7O73T0 VK]6LCQIE4ZHXQ>K?#N6; MV=KO2S_!U8W3^!\A4W(->N. M,SX4O217UIA_;]7NXZO=>NF!1*),R6>90ACH-Z1)R2RM8MTP M[KP_N)A]=1,TJJ_2V96.?@&Z?L3'K=/\^+*A;)X+3X4E+(^@'I^@7@=$@].42ON:Q/W3K= %\-_:C[TK8'U M>%?5/9X(V*QLNIGBQ83*SUF0Q=CRO?D0X5TH\,V2IV M(^6Z2ZFAOW_Z^-OUM[=?/EAOWO[Z[>F=C/D2BLW09<2N!;^$F+".=Y&/\7F1*)F.+WV5*X0FQ/G#4V7%* M8E7IU.+6$&;PVEQW.[WN1WSYU>+75S]9#\FXIU_4QWX+6=ZQ_L_G#VEV!TOV MNL=S9?W*AW]VK(_=VVX':T_?RD$RA-%DNH ^/ H>TT'6H:PH3?_,)L.ARCIZ M7/K+ON(PS2SCP[OR>WPBIOC>:AAQ\W#]R_]5C_K'CQI"O&_=YGDJ$OV7?OO7 M1U@?80"F7YUW%_H!G <\OB$4%O=HE*7WB52F&#C?K4D(JJZ^S7W@C31B043" M./)"SU/,=7W/*819B!3W5&^'WV&DGV(SLG=<:'_F!_X]&4P&OZ99II.Q7_,1 M_#)^W+73 POQ7*R[[F"L[&^1*S%!-&?J/NW?5T ?%^,IL/QE^GLY4$ S@FBW ME8O\V"$^]2(W<*ACAY$*"*6,AW[H.385VZXXE# DKV4^VU0(J MJX1'T_;&59(*C&Y8)9GQ!PO(?V#U4X"Q69HWQ8]O\$>4#];O\./53X;\8 (I M\ K1GT@=L0"K(]+!(!D7J9P :WQ#K+BN9S_N\3'RJ?0AG^-@8_V03"&/T*U_ MTC$0;&77]#-Q,718Q,^(:2DU=QKK" EX.>;YEV//X7$X&GX'!'''QZI@C-8P M'>/+U'>AU&ZM3PA WV.VRWW7I@XC4>R%+!*V[7J^XX@0]Q9DKF^[J_=61^CL M0A)8"B.3,*IW9O%VW'S?MM>02-D,I6M08+W%5@'JN\KP4!J7,9_H+Q8W;X 2 M*%(:)D-#$/;9LYH1T4"@J0QO5V-/(Y2W$/ M\W=9.GB?YQ- 2QM58G9><&,>O>NII, M]WUS!DN4@:1"6HF3(:ZM?@O(J@FP3H"#H2!\8!4>0-_U ]]#L!M> M<3UC&D^) -S0.3C#A,0K.@$7D:CC#,&BU,>A2U]CB8U''ANW#G1MCXZ/W M6L\#@DZ'ZU"+_'T=KAZ &A!8$6RW!%$PKK+SOP(H1D;-PAY3EL890 $ 7CZ M,?E)7_RUD,V?P.H;XII;[S32< Q?\(X?K[Y^>O<%!/&H/\FMM;P&"#M2V0*[ M"2.;Q7Y$A(PD)0$-0:<1G,02+&(J8F<#NWG_\=W3&_(KSY/\ZP@DEOPT_#O0 M"IJE.&IGREBNR6Q7W*L;N^LLLY8?K!_S2?1/);14XE;<3U/=6>*Y9JNEU(+Z M@6,JX8)37#E#"C-D_BJ#Y/.=0\;6$10"D#C+P0@ZN8 ML=M?OUA3H=C1TKP/@Q@B-!!V!E8:@ @SQ$I'0P4YF>E_(^!'<^=HU =5'_T5 MAMOLOL;4XW[L^HZ@(:6W1\Z.\[+ MYJ"@ G.*"7%H& >1$U'%05LE2J@X9">>%U9D[:X(>/L!@;0C58@XHJ%23AQZ MU .-PW<]!'4-55MO]#VC5RPD@72MN*=P*?TVO+5@US]"F-SP?Z6U8JL2%2@#" M?LJB=UQG)F%]B7!5X-$XM"-L#Q8"F&S&/,KH]NN\@OO@7V]4S"?]<94'O2^L MA94K#;8A6:''_6 $":[OU >B#1UD)(5:M23LM8$C>)9A43%>,41 +<;>6_IQ MR&?6JW^%I62-$_&G;L*E5&?5G:M%;;X[JXI9Z+&8J9 QE[)0L<"38,0SCWO" MED&\._!7V2VOITOQ3JG/8#W )X#LRAUA*/_(JBW9&6TB@FF%3(B *^H [^). M()6*0+/BGA-MZKE9_^0<6T]N!6&C!@][#],HZ7HRU)KX""OM@@%VQDKQ3-.+ M^LF==J+EA:=QO)*.,J5] \#FC#L.^,W=A(/Q/E:H0?XS!>[4-TIGKKD?7-&Q MHL<%Q1)46!@UL"F99*@VX?6P*.8/F<(T@99>)QA\G&0Y.N.2%/5N\PM^ M*%FQ=E3@:,?PZ$2O"KIQBR$4_?PV#JA[MC!:7+ZI*TGH>$B>:>\VK!32G]Z> MCO6@/<"ZRB,NA0"!!W;#."_XK!"@6V:%FQ [^RO47 'GM MN,^(2,T2_.EL3C^$^=7!6[ ZH'8/+JB$B&$L<8JGK$4S4/2WX#)&\.=0Y?E_ MH6R=N^;MK^^_O;G]+[P7E<<[-+PTP&&>#5+Y2C2C"I07T_^&T_N]6((ON *K MX$RN;MRNO<+C"2OAP _6C[+P7*ELS('S@H!.4IE7.J1.Y4O5YZ;9K5GWO,>- MYZ/T5\N&*?VF!:O2=N4NG7I6B,^R$ORJQ+ MM I LQK!6^!"<[8)5\*CL!\+CK4JS9^R.0IYWL?+FBW,DR&*([U%K_4.O4XW MB'2ZQL]9"IU=0C9.7MY94\E_:<<2&!S8E*,T,#?H;IU5..ULAFAA$#V!3F.@ M L*2&"/M0,/7(]-7KD9789+)PBVOOO>2*-'G%>_ UK#"Z_\+1D+?..'+,*6B MFO69.CAN]1:]4U$&9M"C(?FR3GG'M*P"(S3?+7P@8L23/I"7'5"/1U$D0B6# M(/1YX'HV61,A_F10S:X'W X&A6\^X:[&CCU].KA3; R)4=Z!&.2$1J[D/"3P M'U?X,:>P.-N&R!]RPN_X^R[ FF/0TA4SI3)])L7':\!3/8?"*!0\HT(@[<:O M]X/2EH[/JI/]=OQ9VT=OAW*EXQ/[?'6=%8Y/H/NG:$@OVP=>?%LRBT[A$,^R M1USX>]Z?:+6K#QM^K2-[D#_B$F8I6#6&NX',C'F2X:G>GVIL;EK%=4[7/&5> M_.5+D;2^$RXU33F;1B0A['=XI-X>VSVV[>UQ'DTMUO;VN/@L\659V;:R:,OD M'T<]W! V]KH0IKM$#[LS0<506^K8*QRJ;87\YT'4:C6TK?QS;*.C3K(B=EUD MU=9NV1XTOZL\?P50X:;+,68[H#61%)'C)I;YA=5V^?$9,MS?J%AE8'&:6%_U M&I==]Z1=IA/GZL9AR[4SEE3E!I3-.'_)8EC/T__J8\0%>[S6/.+U&L)%J[UU M+DVS.XWG3?J9WXGY=/U]*X MZCWL/^[H=PWB@'M^2'WN*!I'3DABY2IINY+2D#F;PFKITTKE%R750&?-P,C% MAIA38F(QEF'YPP:'M0X&+W4@G2>A8[YG\5X)#(CW^\6"W6, Z].%!_99E%I2 MG0@UJ4[6RE0G$]EC1>HN&0XKCGRXMI\HG6/#K7@"JZ&S7M.LB L?)=EC&7"I M?RD>].,'W4[!^*KI3]T=(EUV)J4M"U9X32Y8$1Z_8,5[3#7&*LI/-(3WB;=8 M%B*,7&4KX<*X0QI*'MJ4VGY,;,=C<4B=1>_\^X^O/WUX:WV[_?\W=8)?&0"R M\77GKRZ0Z'TP!>K+3$ UU(W7]0F7/AQ+!E.2+#.V]'7YN#C* 4U= M"5T& AYDSM'B@BHUF<8)LD%-[!:7_YSHWNZZN &,1\*/F<(L0QWAV[$>>@DV M/\F4E6$ D)R=;Q>CT)GH\#<0NQ"3K&L5*N[F([KQ#&_ZYF2L M!OD>IWDQ\U04N)0(X&B,Q*%T(T)82)@O'#_@AA!@"U9+E?D.$&_+D4YI \_Q MOL 2#-$5K6'YJX)54V_TN-7X/0Z[$#8K)8V/2='+581^P'" @D^.>TDF2QF" M7U;WRAR:QD^\1+,AH(%7D!9R!58AE%KO1BAU$[M!U@'4HOD5,N$3GY M$F%F%^FN$L8E@G-X?XD\P.'"^A"=C[MBU2I1_QAKY02_Y*O *!/X+@-BS-*! MON>/[M'IJ.)0>G M %Q@:,C;A-B;N'B8*:C.<@*#00T6L]7Y4 >,:$KX42>CP;XO7#=0L"FS4C,8 MACO095^^*H,%QR<_#G[2)1IR@QHUS(MAP5T+C\M[@*EKPU.JURX%HYX?D\W4 MW:3/42G#/!#\GS[O+BI#XQ9FL)9:CX.O9>%8T; PB2-=+'F#';Q _=$1S/IR MLY0F!V+Q#KCD7Y,$ XERV',=(@0;"K,"/50' _US(N],/O][K!N";H!$JUE1>8K,M,L]OY4>,0"RT#A[:"-94[ M&8/AA"4M=.;8&%G=$*:5CG0.D$[Q1#:"+GMXRP,'(Z*SXIXO_\D'HU_>E/6! MYJZO,CUX]"IXZY7M<80E('R0(/CZ26Q06F;KYI,19O[IM2H2VX;\3V1"M/)V [)&EGL6?B*PILUB+1=367JG]Z@H#FA],4XS[3W#^DA7(+B8? MYY,8F$&B*TLM;J+)IM7!J_%$5XHITRK@C<6:#JUG]J!$4^ M\^S.AW32ER4#*19[FJ]1BK+A2JD)+&W2-RZ AE82F4'(VX'F7&@61OOM_:>/>UB!FU^]4%Q1 MV8(&L>>YRJ&^'T8Q W0PX@@AE.W[9V,U?AI:G\0X!:7>_7U^.TLN5?S MP^GW\X8KWGF'J:0FV+Y\>*Y?:"K8@*Q A7.F2R_\B*&2 %D]_J7Y6^T;0-7 MFC]P>JHH0FAIIRW\! Q)^[N0E^K%*.]9^J$JBF8#YD9*%3K];&'58-1/'Q6J M[29!&G.79P\H>CF7:Y)A:2G8KH^P_&B$66:[R%:[IY2@ZU]J/YG&+)4YBP0CE,9$V MI2Z1(0$B5$X$?-B5S"]*MSB.+L=D/E3M1WLIV'/*?:K\Z=;4I=2501Z7&)1& M["<#FT^S^&(38%M6LWBCRJH6VYQ3S+(D",,FCV+E6CL1 Y9&>.2)@'HNY2#I[$ &A BI7&%O&^>^]QJ7.='ZU_QV,NZE M&9[W[QHK[F*81G==[Z9I@80%*)F9L GV8KC!\7:I5[SE39%1M$%U IU?D#A4"J:"2$=@U MNBSPR$RU3N'SU*N>6QZY3A381 0QX80&H8HGYY9(/2[3-4N/V(1AZ)(AY$D2M M:;<ZN,&Z)0!)Z)^$+) 8$TV$4>2..1\#H+?%:;S M&-8:G?K#<2_' U^0Q$_D^YD4OW7'-=/TY%WS:@\\/EUF]+>@U ET-*WF^&_- M.'?FWB[FL2\W"2]K<>^<3GO@F>C)YDW1BJ)KY]TIZQWHPP10"4IP#0%VSXVM MO9R9S[#&'H;;;-(,=@68KQP>X:1"YE))O$@).W0[YKZL(ZY>2?#V ^ M-L=9)JRYR2^A[#S-JC>F>-6>Y%$]7=.JW]1#67@S];6KW9>KO!:ZO%A11VOJ M:=3/&&@3;AH>\FN*=B_\\:9T0L(.?*V\N;2WT2;6&=Q@*YL"8\P- 3R+B<2V9?=38UIZD7#\#B'7B]T=&/ M.L&6$G!OU_C@MP9^Z7\RN"C:+BB>#4T=4"YZB;HONCI,7Z3/8+?8LK+G0^56 MD27ZX%-#<(J]V6LJ%>ZF]XRQXH[IH%+ILE+QJ< P#(<6C\67K9O7[^4_K6M MP%M:>*43!NXO[YL'.0;?CD!8SVK/R F ^1&&J[)K#)T?%7/6U1VJY).KF7NN M,G'K PHOZS7/^JF5)X-)W\A^S2&64%[74>^I<;^FQMA&R^(8%6WV3-!8T@O> M%B3TU4!^M7;P,1W>*PSYU#Z57&Z&>WE8,(XOZ/KK ME718P\DPF[Y@M9:9F7-J'?Q0T4B++(2R?5FE@TQ>9!]J4L:GB.+VR$2O%B\K M@O'+V*9K7I0VFW'UEW1BC%&,H\\5C M^H7@&/1)5\):"L\9[AH,+8\?9UNQ<1N7^SCQX.\!2&*%9@!%QIDRY$>+EOTM=AA2$D<,S!6%#9D98*&HV7C^\__O;5^OSVBZ7#/O:(\=CXTG.1,MC80FCE!===5[$W*E%5XJ)0 MG\99EKS(A&]7W<^%/[I240N;1,+?NDP=AAU,#]]&*3KA3*GIF;+0!;,!7_TCS:M, H]\G@[I*!1!5)KFE,1J<,M(VK+P#G=2)/K:$,,7^QL;ZB5L8;3JGUE MHPG@>I/Q+/:W6%,='#E;3YY7P\)-O%VD%@:Z6[3LJ>IN_:/ XJV!XORQB_;T M+C,.NM2D]MF.2RN'R=HKG14)"4J3'*RXO7UBH\8.)KR>#"%Y#4 MP2HN?(U:D-4*LHNO7:;M\4-JDQU64/2,R@BM# $\-$1DJ:30DZ9F)9A2[]NN M-8>P(H3+.IZ]+O2\<54W]R2[MUJ0%-W^:2P!70+Z#J"YTX,: J #CO,.QN5X^++L;Z='F%-3[5FYT=M MO>]GU_:+,\DE^KO5E(PMSZ[_K;)T%?UYII>>0WYI4$GP/4EK+Z'Q M4L!Y&LV]7G#Z+3A?!CA/HX77"\Z@!>?+ .=I-.IZP1DV$9P7[RTO]K#UES=; M@_X4KR.VGW?K,6T@W0%NO$=).ZS5O(=T ';]&2),S M]9N7 RGWBFK UFVV;O&,RH07FB%59WS(&]I1GOTH3V2Q/BNC_#I+#E+?B\P= MDXR39)5U-NS6Q?WQ;;^BY+!Z]GR5B?XL7\ MQOVZRGH8E- )[)JUJ^UP<7X:U@O&>^VV\//@'6,6.G1%"[P6[RW>CVHH/P_> MO9:_MWA_%BOZ>?#NGR%_WZ+%[G-T"O7I5B5%GJN&B'/\&B)?U9WIL8N]B&"7 MG^H8Z@6+U40X\:GRHY@))Z3<\\ V""0LK>/YPHOM:*EOS-O?/KS]^,VZ_?C& M^NWMI]^^W'[^[_>OK?Q=:!$6P8""S(OA7KG*[?B)+XL\9^II.; MZ>N7FXG.RK/IOWWZZ^LETS*NT^!NGT]Y[SHH8G M5A_17]@P-/R)A(KZ:4CTTD2QCN)05I@D7/=X8V;,L\#)9%UX\6P J8'T#W/ M!6Z&!0Q&Y:;G3C+JZ>YPT]]DDNM> ;IWSA A<_=HJL[=]=,(KM2E%V$I8%HP M!%&6N=EG12)U9TH,FBTQS0JG+L]407?+%"]2C"PKD666CK3/Y5; M4Q!JOERJ"Z3]M%374J\ ['Q/L ^?U/8"@[6'_]XHS=0-[1# M*3Q;ZW$&)#KE$Z8A*C>=9W4[/%U5)P*JDA9*@CCM)REN21\K(P(]@MZ@>ZGJ MHD&Z+&268JM1#4AN&EC&J= $6:)I#",;&D@4+RH+C;W]-*6DO"A=>#G;QC9L MVZQ2%%8Q0A(TG VTLQP+9"*GAE7M8$U3K,-4= ]5 VPRN\1F#/LK8L,E?(=ZGK;!@!XI"2%C;0!?GRT?(=&M5K=>U8UM\ U5M63EXW"-.RA<@))0ECUV5MR8E ]'_"+19)7VMZN>BGC2 MDRJFJ9LJ/4?QSEO]_ETK;?KVU8U'R9/U\)_L9*&L>(^M241-"(J.)N<#XN]<03SX?6.XU";VIX;>2QF;B!]&L>VD%LX*U8/8Q,O.Z?RB%XW M).P8=?%\9[_';BCBYZY_:3O8)@YVRZJ++[D\XOI"@"]K,=JBB"^IW%I;KZXM MBMB"K.D+N+(HXF&1WMO&96SQC-JVKAWD90ZRII(^)J*';58KGB]!>>KX^JC& MUE?TCQV2![XRAJEQ\>W_<= 4SS0\:]GM[OA$Q1[AON-R&G";,V6KV%=*"!E+ MW]DYUKSP]9H@K.$8A_"/9-Q[/&Q[E(<.(X)%BMDQ=3SX_VCG(/=3$!KVB&8= MWSDXZ;LEM);03D1HRO-(&+B^Z]F4AC&)XC@,!1%.&/AQ*.V=H^M/06CTZB:P M.PYS6T)K">U,"$T&GJ*NS1T:**IL._*E)_R8,CL2U*:[A_6?@M"\JQO/[SB' M9ZTTKP#6&1B:O^F("Q-09AV2)'Q).3,G,,KTNG_6R[XSQ?B@ ]).<+BQ]01J MSR"-Z[(15[MU<@CBL.LUZ3#?:Q%WN8BK74T_!''AU0VEG="I*Y>U15P#$5>[ MOGH(XK!"9-"!ES4(<1=UX+$VJ>\IS;2(!6[;&1B2,%]D$D.VNR*EJD=TBNR9D'ZC4[XMLM^7938[M:Y]Q1L^X M*+-S8YQ=D5/:1MJ]M.-2QJERX]"GG$@:.R2T S"9>>3)*"8LI$V,M OHU8T7 M=$*W(3I<&Y?0$MI&0A.>&Z 6*$*PW*60S(T%8S$!@\>/5>0V,=(NP+@$VG&] M"R2TEVJO+"/393&6S_ )=VT*0H#9'J.!RR@/P]AFO(FA:0&>_P=!AX8''\ 3*AF6KG&)0V5$N!?&@?0]*AR/!..> 8/0BO;HC7"=PF':.W@1M-5^@/01S3B/.=@Q7U%G'-15SMBOH! MB OMJYO0[=C!P:<-S4/I]LAP7#H;D.LT.<_W6[]H/4C^T"=?E]DNX#LH(W;:)%]/&0? M:#OLBVP*R/;;6+L6V<=#]H%*_;[(]C3/;K61-M:N?48;:[?H)3GY#_^HFM#M!6V>K);2S(;3:N[:?@M""JYO [;#@X//BEM!:0CL1 MH=7>+OX4A(:!&33H^$%#/!(MI;64MOG4LNY&]:>@- Q((:P#.FV#**W.J$$W M6$$]U2:*UTZXHM55(^((VS#"D]EI!T0(,/OJAMH=SVYKW%TPXFHW6 Y!G'-U MXX8=+SRXX&^+N.8BKG;-_1#$$:RJ&'3"L$EA4"WDFJ["'@(Y;!_@@&H:- ER M=1Z!-% U/2 6KPW%>^+P^T!]=<_#;X8)^':W(><"SW_XW89U'"'(]#"]>%]D M8\8[:9'=(OMXR#Y0_]X7V3X@VVE+E;;(/F(HWF%J_K[(#C3/;LCAZ?,C6YL2 M/X]YU%DUPCY+AA.M%^=O/,KF_^1O\4X[2J-G79@:OF(;WJ1)L! M*KW+^*B7""L9&BL/IC"=[,:)S!D]A'8#3T_.P.3C9 #C%#7PYGG3]*OH*3GI MJT]Q</=[-LHDX/.[T]WWK*TC"S(M5/'ZQ\,H M@ ?D MUE"-K1PCW*SHT;J;;2.'65D1SY6T@)NH8E$L4:R*!=/4>_RJW&3S_))F3;=< MF%^?CW+UJOSPBTSR49\_ODJ&>I3ZIE_FX>"ML'@1'>;G7QX2.>XA.75MP_@* M6[QX<_%S5_^TP$G,;]3K@M6U]F>[ZZS][:G'.B"RG?T>^_1OGKO^I>U@FSA8 M0K=Z[ 9/TD9%ABU=ND)3:5Z']V^]3"GK US7RZVWP/+E%NK>I2[&1_AF_5IL MB9!G#1'9;IX_)D-KW$LG\ B9_[2-?K]-O_6SV.)W*K)(V+%0#:EKXML$]E_B M I(Z6,6%KU$+LEI!5E,H4G,S7=;FN.PRV]H =V(N)_7693:2GB/)=27WA<2&$'SO2)HR)0+I-S!MC[.K&#SH^:8A' MM@VR;PEMTP,;N@Z1#:4.J M$+2$UA+:YGAGGSL\I"Y1Q*91$(8.B>*0D3 .A2MLVL"\LWF M6TIK*>U4(HW&5 E*<_S*% MW8[-#@YN;#,MFHO,0+C$B17UN8JI"DCH1Z$,91!S!?:-;3?2CJ&8D='QR,%V M3(O,YB(SS =;E@ 6FDHNP#,OT.\YLDS3?HR664'@Q6/0WF]LKY M*X^>'=@8 T072-S5QBO.#8M(3Q,PJ>B M;,*S1[.Y9=*'Q8=2)R]TK*1Z-%PD]W+XGS6:9N=;:6R-=8>+6?[O@\J4M5L9 M 0*C!Q5;."&)*8U9&/JN!UJXB!E7U)/;%C4JR05H! >8Z;%_2?(_9_4$G!4% M!6 !KVX2T(V)"]:#S_P@B*F_;1V;O2># M$17>BKH?/W2L3.4C!7_=J_YCU[)*= PQ>["QX(@I,H^X/ H95Y(1!1%/@5D@$A0B@/9NA$)1!1N6S!C M[\E0C?1E%K\,#IW+ QL(LWRT4@"( !X_SN#S9)PG4FGD_-']VNW@QDL%>!@ MCB06 ,A[R6@ PX"O<^!9>G0=2P)['Z9C>-!@E"6Y K2 @ *&"! 9I9E>/L#, M#"W)T+P\UN_J\WQ<,+(XP:E9CXIG>==Z#Y>!L# O&:9FL&6!@4R-8&(PEAP0 MGN&H@7L[]@_X5-@:+70X)EK,7KO[MOI,2AJ"%10XOK"#R'<( P1M MP"@Y>%N]JYMP^3!=3[*?#N^N^UAU O8)RTY@3093=P&^>@ U0N?4PEY6$TZZ MRY+1FC7)72S$L5Y0WOPMRGZ^6;[1R"]7^L16L$**45\ W_=L3AP0:;XO_<#^ M7S^X>M[Z)4]6*W$(D,F1BXN\XTGV=]Z?J#< ^7Z:3P#,2_5! &P&D+!72MZB MSD>$4J!]AB!W7"H\+W2X$Q$03/ :3^+U\_5$WMV^_V+]_?;W/]XN*TK5O5NI MAVQ^V?S@F+(=VW4"QJA+76Q(&7-JAUPH3U(: )AWJ/)"NL^BEFD$? +. QQ& M3+(,=%6L\:**[WS!*@J'*@M!C8X5 @RRNI$;C-[,M^PJ.D M#[P,^=#8BF'[K7O<_Z*(RF0$B_ZO28J4"@OS)S MX*5"P6L?>BA<^3U/^JCQ M=JU_Z"]676R!X$]AF/!O!%._US57DN%H4G 'Y-+3!\U/B(]&?1P<#LI 8*Q$ M;YC\:V*D!3)\Y.J5H7>M=[=??[5NO[ZVOJ4C()*0V)UYF^+4Y8=6;R<2FZ6I MS?I@]FV@!0=N487^.M:1A_WD(&&!85>2O(<(,?+PN@_V8;^R);U$93P3O45"!U* RR:Z%U7U0*-RE6?)O7DKC'?!:D26KAI+D50QKB9X^P&PL M,WIXET8@2N@Q7IR#09?$8-R!'@' PALJ YZ?"C#B;U,S1S\O+]6&V0 0V5+% M6DD!E25.^S" _-5:J;;,> JC]!K=-J]GIB"/-K MXU##E7_76^M8UZ"D:>Y2;.0,'P,U[J42AGAG-F@ENT(4)[C&:.J70(3O*NCK MMMMX[&TD.VSC&NF"AF/AJUJ_TWD"T^+9ZGW6_,?<D/ZE^3!'86KP 37VCS/T=M M5R7W1B^"8GZ")_;QO3"4=>OSA#![TDE=[#8EVNS^993FVA/R2K\1S/Y9 MI<,?YNVJ JWV[!8>Y6E_,EY_RU+IG6<"M1,L+%#EW]ZT)_D(.,IUE"G^YS6/ M8;"O>/^!/^97/\_3+A#NPAHN3G_M)./X*)6$D 'KI99*I 8=KR; 2S*\"H;$ MFS(4"_3M^/^[^LMF3TX G$A3!A \'F$A$?WM9WZS:A]7^A@V^@P6? R4\YA[ M) BEZU"A(OA+Q-3U7+C#"62PEX_A5(5DIUX?4R@62\?.F$-AFLI/PR\EF_H5 M'0^K:\<&3M"8VK'&XM*B&<>JN]/=HRNY4NP7WJ<(L8]W #O8L,$O<[4J [EA9-+3=HY1!W>^I[6"?:;"^%YZD MP*SCG6=1U77N0*/[%2I>J<-IG]*KM1G4>]65W+M>HUUJ5S8O"_%- ]_S!%5NP#SFD=#GCAL(6[C^_[[?+G?]5SP*47G^.AU$19K/#'6OJZ K MQ>7C?%YJG'Q7\OK?*DM7I:2&)A+.(;\TJ#;PB1+/6]IJTMQVH"WA!30D(.T# MSZ'"YI'K,:6D#(/0E4*0AM 6:VFKI:U&S&T'VN)"\5#XDC"FJ.(TY&'$(^H* M$L:**7XRVMI<3X'86-B^8S>JKGU+7RU]/=E]C =*\=BS9<2II)037RA&W5A2 M'GAVU"3Z92 MKDC@4Q[ZG#//(;:(! ];VQ^"[9SP!IF4#+!%HF\&RNB9J9@'MQ3$ [ M-W[6[;)NEEO);VZ<67R# VQ:'\U,60]*=T>WQAD\*E89=BD=/R@UM(I.QQV+ MZ&YEKC[('4][4N-W0WBH-8 W]7)+P90D-L+))CQ[G.^&HR]&."ZT@3QN][DI MG+=H-?='I=>E;@4+/Z=# 7=IK]QR$SJ7+O;G Z'L1)XK"8LE=4 NVVX8N9Y2 M;NA&2I&EIG7GTV[5-)B+5#]]L$:9RG4R#T)!]/CP3F&_U6JS.I$.1NE07Y3& M5MECM]*?]96%__<\[>N T79MPVQW[5\7.EW7\]?^O'?C,K]+Z79M\0Y-*+O$ M#*EOFAU],%SH;UW//*GUHWZD^(=.4OR: MS!HA5X5#V2A\V@AY;EDO/"3UZN97WN=#H3K6Q_1>#2*56:Z]D(FXI6+W LR6 MRS0\0,4)'+ XHH#$E/HT9&%@4^:#%1+8-K6-X>$XKOVTX3%5SRK4]X]DW%M2 MQ?)Y72R?U]RF!Z;Z63O;*UA (.R$+JG)7CG!<>H958FO: O%_==X\2LG? Y] MUL2I:I45-=9"DRT[+,?6VD;V)0AJ':^/2OWF+(!I+_M,]6$T]^H7E,+7;G>% MMAOQ7)D$@1^=GU;H/-4M)[MM^4H6?=9\+&8>\#"7$N$3RD@<2C$I?&5B]'TZYVJ=X383'*B[D7]T0$IQ/W<\S2MS1Z']6 M56FU3V0U>1[D#ENOIK\$;:N6I;D8[N:'Q&:>M#U?1#060>02XMN^BD48.8RS M;>LU-4-+"XY3YND@K-3C3][H/[YJ'62M@^P@E\=']-*W_K'6/];ZQTZG]'W@ MC]92D:[6-7;9KC'I>VYH.X%-.:6^RR/ALXC%U'8V9?#.4KCV3:5K7 M6.L::UUC9\W']@J^J,4UMB.+8E?X.-O9+=5]7 M$"*U@1 /]E^?3D^H791?@HMYWI;=U3=VZ5[FFE?G8GC913F::=T]^&J"2XV^ MYL4(Y@V^YUK1Q[:*.$7P%:&UQL; S=D<7HN*O34S83 \M1*3^I0-DV J^A/ MT#6:F )5<%VNHY8QEC5+E;6B#\:#QG:&G ]FE'I M/Y6&CXZ$?0W/XL-':Z0R#4M@W?H=?)#"'O[;# :NPZ'/6V!@K0I U[BKMZ^Z M.#=',<"VC VVYB5,TP*:@Y6#KA0JFS(+'=M^6RE2]A8W]5.U2%DC9[AZ6[ZF M U7BJ,#<7P&510T*A'19A *A?)_V[Y7!7#J&L6--@S+4OX T/BR>C($KKR>B MR2@U1,=%+U'WJKQ/ '_BVJ60RHD _H=^X72D?X:Y QVE,"HK14+-DG0"'^$I MV1R1P)NDWI>\:WV>#4F_39I?8-!+1 VCA+_Z_CA,W&WA.B(,I,X<"' M=[,!5P8P&VBG8!5X)1_CA?@I'X%(B1-X7 ;3&P+%]G&:>EJK)CX&\*@QS&9M MU3P8?H:E/Y$G\;$>\HSES/,U'8@_>\Z4#55G6L!:PNU=Z]L2:UQXQ(JA%/K_ MTX.!WW 5X?(1/TM1S]FWA*,3KBP0)5_>]G,V7VGKB/@MG]>\Q@&^XKW'_AC?O7S/,T!P2VL MX>+TUTXRCH]R/$J>+LG\-]Z4H5B]#"VSOR34E3ZQ%0L%B!_23VB-; KM@%*#]3#7[!.D, ME8ZJBH^L!'8%9!:R0@X_/R(?+>2KD?D63.I/^ ]>B]^:9T\UKZ[U?BB .'*C M$L'^%G^ +$,FC]RT%&Z:'RFY4U_JSM2O-6K.A:1\0 MH+752NS&I!J[,9/Q\)+5/L57VZM))X]<8ZSK^FZX?I; MGWKLT[]Y[G;A<#L--N@Z]GYK MK'%E\Q;A[U-EY)L2O6'RKQ>]&LM1D"]X,;Z@J^9EA7Y^*3Q_QD8HO7#':RU^ M8>>K+[>UNA,Y?F1+JCS'H6$81S167@#6M.*QI$QN>X)Z@B+3U#VW?NLUE7#; MY1G[)@.L(MY!(F5?/1.&WZQPQ1[29.PY%_>4(G+'Y;6 *+=1G-IU/9#U G^+ M5+981X^Z(@C"P"-A2)D3,D>Y?JRX;7/I,4I61\@VW4OTM<_8-0:ZF7RT.**/$\2@]:AX MMAM';5=SNIJZ6NLUGO1XNV@4S6NK>BY7M@O;+NQY7;E%3/F3H5&-.79?$]*R M,43E=KSF;+QCXBT'VJ@'"03"8.9!V10_.^X5D95E/!]&/PJLLYRB*,-#>5X& M=V!06[^O0U?["A]>B?',,:Z.CT99^ET':/8?K?\X?CJ'-Y>1]D=EXFLTR5U+ MS/LSM3) ,=5=UBO-9@!0^O!7U])AKJL#=\L@W<7@G;$^QD(EHA*9S/,\%8D. M'IV%L:[9Q8XUF.1C*U(FG-CD$Q0[;T)AW7MU^7F>]"O-8*%K?Q1?,#8]R-I>M2H8BD$8EY1*3P;*(< M,#Y=EY]5H%7)7J>AQ\ P@9T.+9XA918Q<,AL^[AS&-,.C$.-JLDYN#S(=0HF M4SZRAX%3Y;Z;VW--OM$DZ2/C 28TRH"M93 U_4,:QXE0%JP%9G%^^4\^&/WR M!I@('TYB>/Y$!X0A9WK@F<)@"OB[>XZ!ZI_FE\72)S?7:7P]@3]^Q.9AQ/[E MRZ<_]"?GEY^0VZFQX?X\(00" H(7?A9J&AL/&?\ =+QY:(.4N4T6,'@($@MQJXM\@16+=S!6C\.JM9)RJQ%V.Y258%/#NW5,] J.S1898TBYYW.'"=OV MJ,LC+F,L]\,B^.0+(9;B49^+ZA?55,YC?4Z&YRPL.DWNG(FNI6L?+6X:UQ1(O/FC0 M*"&'!']L%;AQ2&3(R:)+SF^0-549,I&N;KQ.@YU&U2/L26DEI!.4;.Y7D)RKV[\ M#@LNL+!I9+O%*'%L6RKEK& MHRG4TV>\^"+AQ]% %\H0[RXYL95>A["Z"G@V2 5MH7=U@Z&%@4L?SUT4F MG;'2=AYR]F,ZO!9'DK7[*;.-EK7AYDM8*6O[Z?#N6@<>U"MMM]4S7WS+@"-+ M6R =L1_7\^VK&[=CT[HRPIN8]/WBT7=D@7L ^IRK&]H)[(,]CN?:>^(Y@/,M MQ6BAH]BPQ\A]VW1?VU/YN$MS,5SPR#)X9]ZG3UO@:RDLY M 4ENC1]'N"S]1VN8CC%R7V(BR#34'U:D8QK"8&"VZ,VE TXPL\&4]A?9-&([ MS3(3UZW?/Y?^4(W?YO<\Z>M([579##C<6SZ$2;%0 >/C[&!1YG:D>2=:>J;SJ#361/%6G%, M7!C>C7LXV$H&@F6M3H+:'+L_'^OO",]63$;$M@EU"5P7AR)@@>]'KN=C_Z$G M ^UQR@9-N!Y (/P.,U<&10.1:KX) $!62T.]6M_T9^7,-H_T?*+V0[_KA$>* M+=_NL?774CJ+D-RUDW9DN^E#NB?_P&N^+,*57HS'XE)QENTTR-HE5(;_ 9GQ6F:@VW:T4V/*]JQNW6Y?Y M?Z!N_QP[MZ+J8=6P6%"9VJY-*RLBL+9K4Q.&IYW#ZHAJS8H0<*R6, M']?D;?M^8_*P!V:D16.Z6:Y\M:0!)MSK+HIEQ8*I23E7+"8YPQSLL['FGN\( MKDT3?G[;\SE[2*!5@U6?@/A7)0779E->VBG&RVT?4=>IY),BMNBZG$\!^BE^ MIZ71_VC[>OG I04__ @W%-UB;CXD V &W-^D:0T)N)^@AO_O:@^O?J PRC ME^]\'!ABI+'#G&:8_B]#-B_51&XC!)^1A%#N?'M(=Z8<=G7C="@YV&G6Q@ON M1#E^*WP:13F]3&U9>'=&.UC9U>DX[@7FMS2:=H*R67BFM.^U%4+'(B5=%_)) M.OJ6_JH^\T3>XD94*&F96!P@EN!@!>UT8N:HU?;/7X958]YW[NTY'W7WHN-+ M7TP$Z:G%^L[27$>/^TY=B=(G"!J]9#F/V_S*>C\833 LXWT1*=F*^F# MCDO.4QJ7=9M&:59V8=C(;5H)W>SZ0(%74WV@5E+O0$ZSZB$U2>O5F6OV4\EK M+TN$KMF_]*_VJ=NG,&#-/18%+B? )9=BJS8T(82%AOG#\@)LH M6AAM-8IV58O&U6A^:_H][=J-,0BN;NQNL(1?J^C#J-=@EVDR&@@5>0%GKJ2Q MC")7>K'#J!W:CF!"Z6DZY33)J:89;I@FZ(:+)<>*#EH=[-J)K3R3>]5_[%@/ MO43TBF:4V'QN@%TZLP1,V;P'BF9%3F*2;05W0VRU=7+8[16\??S]8)C)M:$' MZ,[8\Y7#(YQ#R%PJB1. Y1&8L]WF<%>.==382^T<:[K7$OK 9C7@\"C M1_;#>UZG^7A-]'[H+&9BFXQMA]J">M0GA OIL$ I8!F!ZTJY&.V/@??%2N1E M@X( %VJ:^X9X+W3S>4\GC(G5PG1:,+1CK!^/% M'V:A<86630YVY?;^]C:A\*4F%(8J=-W 5ESZ#HU=$86VSV@0DH J,&2]38[& M#6[SJ1=DR1L>DJL;>/"Y) W65&6\I<"6 A^/P5B%)M35W)42X$M!39IXKO4_W4(C3F5*O+Q%$I$U(X4HT[D M16$<<;[IU&-_"J17-[[?RL"6 E\X!=I*DI@0Q7@,% @ZJ7(E$;%T(DXX]=6F ML[C]*= #"O3\^Z)RQ3.L\(R%D=6]ZJK \;WN&-A=:7D@CPGU7B$!2YE 6J=@C89"2TB;\3CVI.."UFA'H2TB8%XL *TQ=IWC>6<9 561M&SK@K$546JS*)!A M$#'XJ"(G(M155(:"^JYTCZ8J,A>P=7@YEC8O=7M8_*:&V%_.]-R3V/TN'V>Z MTT?K7%R;AF8'W NXB+A#*'P(6C1R; M*6%+&G([M(,@#..Z=,;=$L"9KVNJVG4U]FVAUT#HA3)DDCH,P.=0D)Y,BDCY M@#N7^$Q&?ETJY8[0"TPYWR8YO@]U3NX95])6$SG! ET,.1]:B&%_+27$IBHU M1Z8\8ZV0ELA;(F\JD1]:AF1_(F= Y.'!IDA+Y"V1MT1^Y-HV1U',0QOKO71L MVO* E@>T/.#H/L<#:SX=B0[V11L&F4JQWX-5CX9C?JZYA3O6X+G/2N&"_5!5(J=?JQD: "#L]3MYY6T MQFE9V M[1*\L"7=^/:$#T@W:,D9=GVPWH!=<@>;+G(6/#.Z6UN%K5LZ9H8*V2]:E5I5XF_Z]=E?J"X_@4_Y&K6V0EGPI& M\G[XMF C[])LJ\YQM_JRQ=)1_H%4B"D#CDEP9)B%;9:HGMI,K60<2V M3%08!]ZD6-RM3DV6O]]TCF(F$F4_W\Q7%,;[])D*=:5/;,4"1S'J"Q:&GLV) M$X>![TL_L/\7^]UNZN=D=]D)^C4%*T]?''J*UB5WO/^!C\@CLU M%* 4+C4R"6U_J<^'C&S;(]R+):-*B5"1,.!18+NV4LI;:F3R^M.'#^^_?7C[ M\=M7Z_;C&^OUIX_?WG_\[>W'U^_??EW7D62'/5J%B-4G;AL'/C]1[CO$";CM M^PZG(6&,DM"W?<>E$0]8&%UM&F!S^H!]JW142M"5>Y_V[XV5<,^S))WDH#\" M+*Q1EH)JC0P@[Q0>7^W!2P>P/R+A??QVK/I])<832)7!6(:H0_2UL9* )1--!1.& 87Z:/%<8^/X>W305H]#J]2 M:HB3Q6YXT@P;ML@\W1+P,5+P#IZG0WC&(\![G&#O(;DP-.RZW4_QH#.?B-YT M$ \]I1WF,%L8";P>-749X4(RJ&..UN!(_,X2\+YI%HQYF([QW%8FL"7X4SH9PR8JO?AP!=J II>E51S*CM(QP#0I=B"> MZ.V97=;=A3+7 W\=^VX<)W[=_=*U?N49X.']4'2M^ZYU.[Q+TC>/P$T3D9NO M:V)7Y\)&/@VM_\.'V+O-;GU,066&G2"T.N >F#]> 7_7OW4@:^8QSJ^XTTW$#Y/ M]P]Y(EQ!@PZH%' 3_'OUTT\% Q3H6GH 1IJ/^2/LZ$@-M=3(JI.;[OIT)/C, M;QF7"BO>6)_B.!$*'OW'U\_?/EWAL]_-XE!Z:N%I0DR;C-\&%UG MBD8-S[P$):Z>67_3A4WO 0A;T)&E;F"G)1!.90 W:U2ON[^8W ,,'#E,J"6O5CR6EP3"1RTY S\!6F&A7HLH%>#!(T&/F=P ?K4/()-:+ M,8;]BX'L@!%V5H^^@*$FB $@/1GUU0+\--WXOP!#Z)2?=3].Q&+Q-R*TP & M$%;>/8%KMX7('C=^W3ZMH6>.$_9PH4(IJ0;H"\: M=,4$KWFEV5MRKV;1;#_,FR2E$C&[A4=Z-=;?6*#*O[UL%D]T MIZXCH.D_KS59O^+]!_Z87_T\KU+!5BRLX>+TUTXRCH\28 1S-%H=<-W4-.Y\ MI*%?_FL!R $LOU>#/:JP)4LN++ZJGN.Z7_)",>RO9#%SY M05>3)G;)C;25:B%; 7:CS5@T^1X5VKOY9&J%\P(N2D^?LKOYOHQ M:Q&,8 1K74O;0O)6!N2:R^%UMU8N>DI.^C@5'1LU-RQMN6J>@D9V-$'Q]<\) MO'&LS5RPC8MV]+!.Q8.4B4"[!=G?MPC3;Z+=.:.[? /VB M\A; #^C9>R8;NE$6I,&-HX'L>!UCH"#8](?/\%S0_!#\?^>YF/1Y5E!-U71< MB>KG,14%CT4D.9>^9U,O(*$G@%%RIDA,0NGK"AV.9[N.?5U^6*-L3QVT@*B9 M5_:Q-!K[?76G9/_Q?3%4:?3R[51N5H/1&'9HX'4H*D1AQZ/PT;?Q8VC#QR"< MLP8+Q5LSF2R=W/4**C>V5J3N 'I3'D(U%!BR$*,;:C=:J:\5UERN'USZN5#7 MO@.MO61CLSU.$3J#=,I=_SF1=SI&%1@%+YQR.EZ5/^!7#ZK?Q_^BR]'<97R+ M^60P0'8XO;UHP6W.3'+CI<,OILIMN88(Q:G-!P0 RA0RD8YF*R7.#.+QFX>D MWX\G?> 4T]^ZEB:3QY)(V+QWKQ0BE4G"K-)LJ. W5521A3V^'O/O&NK3-N)S M&OM7);K [;UN08%:)RZ6J-N%K[FB91N\"43* M%$'%MJ"7M5RC)_D -/))U>K>>*ZXX$@A[X M$@H $=!(%& '%9^9A3^O%\":I\.[OO;*\[L,R6*J795F:>%B*9:Q,I>\3'F: M*0]Z.#+5@X4M!HT$[7 86;'.Q7UP-0RU,IL"!,B[NM;;?P%>]-(7EQM'T/0N MDKNNZRPTRYA<@ EH!ND/.II4D/%\#)J'/>K1VFA>%&E6F5KWR5T*C#.'_1A-,D0++AV_YTE? M+P>F$-7 G_*RAGYHM=17%PD0#LK*LTLIPH.SYB:9+-3UM-H"%B M# (,#LG2E>E)7:XMMH9H'W#8; M @(0PDT!'.&#="-D"8'?%R0Y+<4D\@$30'B#4BJ.YH35VE:QK2FV=N' (JFZ MH>HJE(CENFN)/=,L^W7-U2;O*Y #N'E..(MIH6\JYDZL?%JK4_5>IV^ DN%T M^JK1<1R=B*3XA#1P/!^=A /YS"HZ+'R9^,RG.3/'*YV9W9D8Q,S:RV,I5P;_ M$PM? 9Q-K._.E/E=F=6K3?"#6>!_SX%#"/N[U]V"Z_WY#/G="PN$+XAZ8S!\ M)NI;;.08K'<[\7,NLF:B&,(ZM&9R/TK[ W-8W*G0ZR:1J\\QQ3ZC*=Z%"_]W MG'Q'[A%DR!4V0XO*KW/INAPH[':29GR4KD@5 &ES$PG*%JN?WAX3;I"*Q0#K M &D74OH2T"EH@)*UTD"5V">^! ("*-P57"(5:RCXR=2%7V^NKE)*BPKBD!4B MR9=LG^'NDSS-T'M0&!#$-'"I+J>U(-CAN@NT$LC-"]HH]WW4J:L0N!CR0D"G M5\[HDBFZ3(!AQZ"0C^*(9R@;"BM Z-9_Y)%+STZ(YPJK\8N;Q2BB^S,V8V$I MHKF58,L%BG1*LY&@Z 6>9,#83!RMOV+Y G\V@$=WBYC6-'WMQ"DWS/CLK\_X M/&*^9^_P^9[?\$1!722[^S+RO@EQ>HG80Y5 'T3>6I[P^?1/=%9.9T7:FJU; MFFFK-NN;/8T/+*?7@Z],W5.9HSNSZ9^75__X_>;VYN[FR^>.\NWZ]N[;[U=W MOW^[^?S7#J6#?KG[V_4WY>;N^M-M1_E\?;=C1NA!SY">^!9,]S!P-SC5Q?&M M]8";!K2I]BW3US@;\)ZI#SRF:8SU!J;7]VQ'MQB UOU/'@CC'4!;/V;B$5\H M$G6#O&Y1$O82L+[(:+/61IN;L)1GC#:OI:X9:NRI?;OO.XYO T-6C0%S^I[C M>C:'_YI\8)?U)(=BX[?2(/OB+V'H5W&:+4C@Q]RNZ:WXICUPD.<8JFIRP[(' MIFOC3$&?#P:F;8BF3J9EG$X'JG:QAUNLM<_>7DOKO)W3; ]UA^%TY5-,7>RN,>RXCUY9 M)PJ,S^A16PJ+%]S];9L&E=P=>OV;9M+S"-VNKU]]T-_%P:_K<$^W((UN2VZM@X>0NGREO&P!M8WL#5;5/K MNZK9WW@NSV$)%FA-L;[NL6-WL8MV@Y+L+U7[WL=4-]/A6#WU$QULP:J1_,9?.+)/18Y4$E! M=?3I*;H1]"5NA/+TVL'6#,QG9O6-G@T6<\\:Z'9?TUFO#_:TPSWG.:SGE4U2 MM?X9-TEM\;# 0Z-OJ:KNN+;;!A7^6NI@,J.IIK MJIXVZ(/A;7J:ZFM.SW?\0ZGP\_CF@);>I&$P:[3P(AL-%LM78V=[Y?25+6"/ M ]C]SEPYGMW(HMQG198IV&E%B=$)VHW&4^S&!:=W?O)IH [L/L@CQU%UTU)M MQW+[O3ZW#-,!3=X^6-1U3C[IZJOWAKZOL&J#_+HMKI4!0UTS/*VO&ST3^]^Q M@8L1?]\V3-!_=-<[E&TXCVL:X)K3;W'M?'&MIWJVYO<=GW/L&&PX \VS-'.@ M.JZM>29O1JQ+US$XK?;U%A7/%Q69-_"]'E8F&8[I]KP!X*7KJ9;3=[FI60>+ MXLQCF_'JO=GK-0C76E.E*:;*28:X;M*$@:JOW$11_"",E,L\&\8)-L,;)WPL M!GZ>HN5BMA&O=9:+WO=-;KF:HSJFZO=9;^"ZKJ\/X$]?U_I'CWCIYSP6L,7# MTJH9>*[GV8.!I>FFUN.VS>"KOJ?VN#/H>=;1(UYZK\7#%X"'O.\:_1[36,]V MS)YK#TS-M%R56;9I:[;$P^-;/'TPO3L]\\F.GA85FXN* Z89''BBIK*>Z;F6 M[?9Z [7?LUG?Z0T\\SGRUE:SQ$8F 9S]3'46 : YWKJF/X?&"Z M^L"Q--_V',OIJ:JA68/G\\7;K]Z;QKXJ)EJG5 -QS= -335[IJ^:GLG[W.'< M\E7#M7O<\S6+/Y\OWGGU7K=;!^@9XYKJ.I[!@*5QQS4M^-.P'-,RN&&8GMT_ M7-W)'*X9ZJOW/;6-,9XQKIF>-7"-GFW8@[YIV*8S8,!B=,>@CFB MO;?4)LG0/?F$!EB]/>5_KD_3#BRRZ;E M"2U/V'_I@6FY?-"SF&-XIN\-!H;7\S7'5&U5 MT/*$EBWW#:49[!Z/WZKW547M/=M$VAB>0(^07ZF_^OIH5L6=T<3;J[_Y: M>Z.(YH[E/-O:9+#:%# :#12D."@L#3Q.(W3#K*YW_CO3C9@"G? $GG9JC/#8M9-'3H* !8/'9B[1B)F5D- MJF,:EFI8W%"YZ9F,]7N>XPT,YGLZLUQOV7O6SWB8?H_'^P/>TSS=\EVSI_DV M/,#IL[YA67J_;WN49JG<+)HCLVRR3!WF2SG<40]C5^"N!Y:8\^4'29HI_\E9 M(F>.^P&*#&7"65),>51^VD(*NM; )H[T%3+AI6H4C5V MI!34-&-JUOQ%;W:HR%>1]9M^C).O"7_ X< UV;B9^.M7X@\3EKK+DN;A5$/< M7Y%IC+/(1LSCQ1RVE1G*<(T8DI["+ZDO)B3'@[#@^37.2&/AX>IR2OLC3VA. M] ,-+(8KKG\$HYAFKWG\ ?C26,S^%7-#+X'QP -#!I@&=P4X%D\LL,9FBTEN M*8?S\58N&2J6C]PT]%PTE["1^"I D> M^$V$$T4_Q]F""6B&-Z.M,]UULT >WJ]T^_ M_W9Y=UU,.[OZ\NGKM^N_77^^O?GGM7+S&3Y?KYY[MI /K5W(\\TDNG3=?)03 M#9(&O0"\O\5I2C.;%L#8/M&90U=#L"G-Y7(UKJ6RC/K-?MZFQ %<_NF"A98S^*F.S"= MGNWJFL-,QD$+,P;_>[/0_$(J@GW"7W.*5 ;JT# . 9+I-5@9V621=Y'2/^TY M\VJ.G^WMR-KTJ8W2]&?TNA 4W;I6MU,6_^D6OVQ#2*II&/V^Z=AJCYNJP9C9 MMVPP1K0^9XXYL#?("5I"45_)BNJM9NJGKS.ZSON;.EER*TK3M MGOITQ6L?A[W?](I5\9C6$]QZ@O.X-81#*K5)S91#*WU ;]D'_ V M30$T3?<VI;E]!BJ2W=-]714N8+5G:(OS4/>H"M'43J/WTF:* MM=[A<_<.&WW=MQW=]AV+FWWN.RKCIN%SIVX M/''Z:>4$MM[H<@+K\.4$L-1+UP7\@9.X_YK$$?SINV9@T,K? >]V9U]N[ZZ_GSWV[^5F]O; MWZ\_*)=75U]^_WQW\_FORM=O7S[#WU?7G^"*VX6DLEU]Q7JH3^_%Y:[CJ8;3 M\XT><$70\?Q>SW$-0^TQS>];2XOUUL)@!AML]##Y?<^QNV"2-E[$,DPNJIV@-B4VE5U:_^KU;N:L=EC M%VJ]FMZL2,UZMDTZR#>.0BN<*#=I"IBO5!Q'F68YRH5RZ<7CC'O;Q"].;A!- MN^#]++C!X79@E*;6VY%1JM9F8?&M&>7^.9IVH-7J7=-8?NL.N0$-"^PN9I2W M&8L\EG@;1+-/:E\?0/-+@C'J2>>VM6O?YRY.N%(^L(R?Y^Z46-3(7\41V<54 M!_LQB!C8/2Q4 &LS(;^WRCJ8,L?GXY.[IFLT;&(;LMS+V]_1?Z==:&I'>/0. M,YRM6@X]\6V0P?;=#1;XUQ@ %E'OA,LT#=*,_)"O[^(QF)RVH;]YJWP(4C>, MTSR!=0PFRJ^RZ8YR#7I<%L"7;!#GF;+P26N&NFV-$WC$SX(QQT"6NV&0*H@Q M0>0FG%'3': ]2O$9,Y'O$_O*?05H5AU9%N-M82Y[)7GEH>$MV':)'C49PT.Q MK+V\L:-@UR+8+,?CG/PYQ9+W0D?']AK4-:-V.38KPL9 ^#V73,*?N0K91OV1 M?LDQTI)CU)H<-0TM%G/CXZ4@_#V/N+(DK6E+H)T](8E2>918(WCS1&'"JA0- MQ.#QJ52TBNXO:_O[$,('&5"4IT1QI@P92'S84P#/KPM(>AW@NEL7E1L@_A(' M\;H&336;1^[=U+L66BCS$SC+/."?I[U*$D/4ZA8V@+7GV?);#IX"NV'3CAHA M")#5_ATFE<9USR\&P$N_7S ?%ON6A8]LDK[Z9=IF! MO!H:SVU^Z2=\_2+(G M[%&0E\?=.*$C?YM'0)IB7.I?6%.6H@P3=$C_:8-V14"79(@#C5VA+YNT1O9^ MT3FN;QPS@X(+7;*[NG(W<,VV+H47Y%)X ;[7SR#8_LU!Y,Y\X?W^%"J5Z%^P0LA@&<*24LEPX7 MM??F;9U1HP&.RA*FOJ!;A6>B6W#YW6\!&P2A\,-0Y]WBEU1Y#+*A?20I;GC)R*:7DTKU[AJ'G>+KD;+@X-TR1^D,ZC&6<.M3]-@)TD_(%'.:>D MA!JZN 6ZH'G,R@;;F"M=("OZ .&T$O@:GPJ' )=C>U>X8TPI6IC(B#9SA*9P MD&;DN*HU=TW D+B/1 ]6]$5%U;**Y2BAQ.L)/:IH-POL>B0( /86)*7_":"? M#U+^GQPO*K8F7_-_\-C!I&K^FO!DMK]VLQ"^P=XGXTC>I]-T/8'M%U'?=/)! M[>R!,D4W^1@6B?XG;"3OTM,2\OH. *^5$=!6@LJ!]$K);L?K?5$K7%&;= G? MT%J7V8J:O397\26[M&:SO&<<(ANF+B6!5%[RJ?6 1( MA4SDSRF%"'/0!RCLXRF7$0LG:4"1ILIN@IAXS@AE>DCW*AHZL4_NHHR MO0>O.LZ9+<#S8,U_Y)&H*"@W4H4_,$8%" B(H0SGGW7?W?*'6VV]^E]+]LA MG]K,UGWXGYN&JH@Z@.@>5 $$.NS@$?Z\^"V.O^/G!6;^21'%.JSKR-/$OP(,*F[>(40GD*-71$ M9)?8-N(LPE]EX/MK$CS@6)Q;[N:)L,5_JT89?<,BY1%8]10HUQRG!SAZ&4ZA M>E*BP65T'\0?)A$X<9K1C6-T9XB110!"S/R@R[S-=8:!70;*<'$L 9_"-<=K714GBH9IG)[]?4S #D' M,+&T#BDQ&*J6Z? (1@-:6\ H[E@W(]H@\!2EJ/_F2 8&XP MAD?21UHA_C'@80"V(_V=!"Y]@!P\,%'"! MP; ]6H]8&NX]A4M#4.=A=60XBPWB>2[%MRXRY735%?0 - GN@)?EN"<*H /@ M<=838L8#O1]V7>#>B$U ;( YGI2V") ]>:068G1QR!(@.%TA0>,%3L#K*A_A M/;@">B<^F@E#7QCQM(3BQ042H='9DXV0P/1.RJ(#< "/),'V=M\6+: MS0QPRT=/$)X, )L(E"1(+K^X>*S,.*H]!6$2)+BR1!#T.B#PPD,?%DN'Z^^1 MN6;UK8@543(%^FXR)$K"F7L@6S2$X8#C/''QE1*CF100TIOS\<,E;E+H0Q:D/8# ^Y2G4G"'DLJ3-^((ZL+B>CB M/A8#VPHAU:F_A;0ZN'[,"T\"(, %(@#2>"H*T/$(8=U_P(,R!=D!\1RX)N+B M%XJ"#]!2(L2=64,*I)+@!KOX B9U1NIH4C'!B 8HN\C+,+ZPX5GAIPN%<:66%O 1U M[#O/:B<.,I%'B ^+?I)?,=?E8YE:Y\]V]^(_Q-X47!O(#EU,K0]0HR M#;V\R'+1 3U6QD ^0Y8*C+T'C>7_I'RB11="O."&J^ 4#VC<7XW(W)"CS$&^ MA8QFC"YGV"?JBF)2(2F9IPM24-US#=0%Z,&U MS).N^1JO>W5[??7JS4E:JI1YAZ2 CR3Z"N M"*^+8KH_$R@0$/@&M3X*1PJLIE@;)^$P&^ 1B+C6#-.W4; M M8WBZNXYB@K?;L;K$\ 3J Q?9G*P CID O\"8C_9)"CS0 / +67X9Z O<*3 MRR!-+D@3X4_T)?BB@!W204T?)_Y*BCJ!@78OU*HN,(/).AV4)@ "MTESA(CT M/6]K%(GC9T*51T5GL1J*FX=_79E\0YI61WE=LX1/W9)ST**"$*.&D(Q!*J-0AG M6K6,%!3>C& $AG#1X7I@]@GW2GP']/6WQ6>#WA#^8-FF>7WZ60TB,.N\K?X M$?A LH)Z)AY,E5H0*L1%Z9((DB;PLX6@=XTOP>]+.M0,!E6\,@FG6*(>P4H1H1O"G!92*3S[=S*K4-/@OC](8%B5X3.1#^ F M+E1C4$]=&0VO_U;"T(V3,:K.P@($@8A2Q47Y(/3Q5/E'*$.7\\1:8QXX) R0PHXQ6. *KED:CQ@'Y$3UB/E<'M MRN"Q'[LYN450[49!B(\0MNM$&8"@\,BW5R@: T#"/Z?* TO='!U-Z20%"4+^ M%2:,5A=%)*(ZF-?">S"NK &1,X*7@994F %AX)-H0J]$(%Q2RK\XJMB@_W1J MP[^E$X6<=4#7'MHKJ#JCFT_L$#E7(OT=&,P.V'T4DVGN<20O4#E3@>NP#E]X MR.!:L5\RU>7LWX1VBO)\%X2 98>0-(9")AZ1+ ]Y)A M$+D"_L+\EFM->8:L DV4/"F7BLN1AETX$0O'6>A@-X[H&U!= Q [XWPL#K M?4Y#BV$'+O?0F4K1,\'\A7 @8XF>6V>?H(9)%) N/-A@1"H%Z7T=R2!^ MIT)OZ4BKB+RQI5V*!9PCGMR3X@'O>V!A#IC/D"757$OPW$5LNE,+\$I[=O%E MTNRE@E=/2>*P=,3C [#1$W+7NM<6>\:A@+@8L>^%8,4D0MK:.![GA6N5C6+4 M\U#!IL &YBU*CQ@A2.*H#(<5BH$4.>^$N*KY_XIGR!B%\$M.5C#T MAN.\\ =+/Z\/2J/T1LHS8F&*X94QA? HTQ2TWTZ1* ]"4\A0B6@8;A&@C^(' MH6G5HB]361B (.0*Y]&0E?4P4BLO0SC%S5WE&M6IM CRU:0W? 0='74%X:^@ M( 9*[(0<;BC6DTAJ/P!W\:&X5\:-\.6=NBXH[)P"Q2L/-6@9Y/" !?VKENU-6#J9X&,J[]>_>V6[NEGH$-J#?U!*%2EX$9D6N-2#H, MQE(^( * QI>4?D>!DABX$:HV6+T!Q20I!6#F1U0X:[]65@8HRIRB$7FR].8I MC5KJV7BA"$.@:] 5K^!*E"<4$$"TEGFN<4T@"F1")$)0 UH,E_*-P:1F^L : M[Q,V'N*+PDD'XW@KRPO:%KL- M)R<9&;A;$?<&M: F(>OG06!!XZ/.5T#OYT5X5(1TRA#+E#J!\*6<"6%87@/" M5%>.\T&(;Q92OPC\5B'C 8>K,^!@D2@H@%,25)..*4]-:A @5'.I8E01.%JI M#/^AA4@+ O)))<@;G$FBO+NB:XAM+5707J2#FIQ8KGHLD=!>M1@.!*541P MD->[1)([!=<1+R&Z!@XSAJ>\D;KC(BQ9"0.L=2)G,=)E+2=H^IQ0]2Q\Y1)B M92Y8&/P'[&M<;Y41!D'**'Q.. MSBBZ+@+I**SGA?KV:8JR+Y%RF=\#!!1#%3U&.G5 HPN$!4**-+5K#FKJ5KN>40DB@#2.>\EEDRVY:_+$SNFK=_M'0%>/QF. # "[%Q=HF+M,8 M/>#W+)*,%A@.(6_-UBZ4KNPQ!A#?$ZPZRB> XAV7NC%^^$"V&=7WH.^J6DW= MR0O'2XD(K'3L"GZD#)(8Y!3JP3X<4DS^5@ Z1GV HBB3#C4H.KQ2#2&B&<64 M-RC'&X&5+ME](9QJ0K;FVI"O +B$ F'>!EPJTX\@JCNLHE M")41O*#(A0 5"5.5*JH<@4**$8/2CST$GB=R!W':(\@NG/;(BVF/"QB36'0B M7,<[/4(GTY6ELA(@?7N2"'1'V]X 8&^7[DY6&XHRQ9XYL[N+6AG;,VZ.&L!0 M=+9_Z)+V%4MX-P4;S10'_4T24^7' _O+Z6H_(R[^9*M=JY!\RZVC9@)=/S[0 M]25 +P52X57Q%:W?[?\\*Z"JG_M=\^<3.P BZ>,> 8K%A[ 7TEL"+\#.J4E MZNNJJ@S&)*Q[:E=O(;X_B-=1?A'HM5X)^KZYF!06GEB_O,V$-[4GMK\3PW%[ M.%IO6C3\!+^6MA"*"*?ZO)W>VA[(E@?R&U% J;=.'XO:U31A9-"9@284BGKVAAD 247.LKEWDR*:H@T?<_&N1IW9T\#EE&U4K( M1SZS*/[O*/ Y-CR )0J7BXR_B"J.%7$(&=PJ,L^B\MV7X7C(_LG7IO#VX2EG&$_K,4(5T[U5-+8SR@K M!LD:RT" G('>"P8DE8\B[D3, QVR&_,.Q4L"3)(93&K\XXHJ93\$H@%.1_E* MIZ^DY0; +-;UD)B.;"+6Z]"6O?41)_+H[O>(K_J_?* MA:*4"U%$Z03*D*(Y!N&/D+Q3F:Y%KV8_H:=A;F%"R80A97J#7*(T,.R-,Z < M9W%3EB=1+:GH>6>D@$[6585>MNV0%,WNJKW]#ZC6M&Y?L;RES9N ML;9N['^Q>E=7=QO]?4:0;1<+B]5[^QP5K&)S\=KSJA% O:8/%%G6CAS5ST]" M>;I&Y6F+D2E/A,;*@4C/Z3K8#%04,%P(J6I&P.[#CYYO.M1FNWU-5F>*<_/6F+]:U1@\1&[4W7 M.[9ESO0LW6&;!$=+U^1U/[)X]TYRL(-1P!TI+)2V5 M@.AW+/4E4\GY>GR<68=/RU=:OO)<&JMI=?K6MCZ-LV(L+9FT9+(^C\/IZ+KV MDLGD?.6OO3#@\@N57K[?N,I^IF+GE*H];7.W,K8UQ6B]_FZECFL**#7[=!;K M]'<"):W9-+&O MZK+ZQI]2)77* 'Q2C=F+!> S%W^>''Q:"FTIM($4^DRUH$?U!+3EH.TBVT6> MSB+WE%[3:)XD?,Z;_#LU9[NM&SWE*HV^U>GK.X;[&Q0S:)'NI)!.[YCFMNFE MS4.ZEM>5=S.:QF[-JWY64CMN%T M3'5;A;7!B'VFI]3O./TS$A)GQW[FND:U[N]-_GWFRM39:.^9FJY[!%"SV>)Q MZE-G@=1P7TU++BVY'+-0M6'DN2;.KP=6TJ*D)RENOZC+;: ;TD.'X9\3[,+Z7 ZW-:A8S M''&Q1#F-N?Q1#,C]'#_PT8 GBJ&*[/HM)JBOQZNE]/A<"'<'H))C-XXYI7BH MI/Q^!&!:C#I&-3Z;Y@S_I)E=K3JG>-'2CP[:.B7CHCFOT9Y#[0K./QC/_WY]L7>^_.Q[ZOIN"#: FT?E-B;Z7>3*)H]HD=Z.& MO(3.3M?9A ^N/?UW*V:];W^ 1Z>@AI[L7Y/X$4A)G@40>#P:Y*D"[V+WG)C8 M.&09D-R(3ENO,2]?BM)&,JQ],*A%&/HX#$*^'E8>+_F].L7=MU2)MM8DIL]S MQ)%YHJ8KEPO$%8\FU3J1=98,4[D,QT/V3^;6R%OOJM/D7=,XGD3>'7B\GX* MA/>FL9]%/*5[+J/[()Y: _Q/ZW6MG^G]=E?_^8EL!1^SG+7,*S[GQ6R.O+9U M\N4SB^+_C@*?5^=_3%T.J%>?T=;V)-X:>#:OWA-_"]/[)4C!!X"!^:)\B7"_=Q/:KQYB275P'-< MQ@NV,^^.RC*$,:A5WF;0A,VI3_7?ZBYZ4CW42A=9)'M37AX_B%D.' C D@6D M459V8F55-_*,_\FC. >T_WIS=25(X5/@X66I1-IC'F!+,$<@F&D24;O]6:(P M%Q/%:A$KWV/J70N;RX[C-$!3ZVW"0X;W5SUE?Y[N52BM++6ZA0W2.,RSY;<< MO+WAAN#4^S,-#6O_#I-*^;CG%P/@$=\OF ^+?!9=P*PG"RVR\+'6Y M4^G*"VR^1>Z(YJC4C81NRU9>!ELQ9FQR9\K@L#=E*W/&AMC2^[\,DE_>;QZ] M.9QU0$]\&V1@B[A3L+%F8:/U?J:\!N 17Y/8#RKO\"G-]'!TYQ C!_K:;H]= M,\S!6/[2QBW6UG<;$7&4Q1KV00:0M(L]&,[JO4T?NR"GO> ]44QF_YE>^=2Z M]TU&>S2].J"=@'*("2CK1J T$9O/CGEIQ[PTBJ9; ,[63&].HOBT,CMP#L,7E%X++>L?I[]@Q]U1PN7S&!EU' MGX;7#3Q?L[MM*[%G.-UC0.(@;8=;-ODRV*1I=FRMWSQ":G&YQ>5M-VY8';7? M0*'0BOQ]33?J;CMDY@6+_.;Y4!KAEVE2A&S#TQ8)1V.1'G/:![1M\;Y[DD3HF/:DR8\ MGYEG>=$6FZV&Z+V.9>PXG*A!PPQ:I#LQI.MKQ[$%6W-LXU-2N]OF1+766,N4 M3I8IV49'M8[C?VB1[L4BG=[1->ODD>[,):&V=<[=>4O"YIG!=ML=DJB*EV M>NJ.O04:5'_5(MTI(9UA=WJV5RIQ;J3PCK-Z>C6Z6/=F M*31MBM4,@N@M@C32G=PBZ@RB:FT_CA9!5G.R-ENT.5RHR?KOP73J7VC$VONC MCI=;AC=:;^5@YKJ^?*11@#3N3KE0IE1W-X[2(,UHMF_$,SDL,\2YF3B_T(U3 M&J5['\=>BIW6O([R. Q<&J(;YAZO+J-'C%@&ZV)AVL$7>+D+7X_SQ!W2=%$_ MB4=P?9!X8@RIG.&)C\4QI#CC$S:8^\S-\@30'X:2QU$&8ON YP*R$8Q+/W_Z 5=I8IC-A G]2K<>H6S M*J.)'IO/S M0\4\7\6E00YT'(!9P_+Z1X:G&@#2P6X4+P&\C>!4WRY%3REAMAB?_ES 6S$E M_7F6\&X*-L4P]%OBC ]QF(]XP03'<1J(N:AR[#B<200<0R5+,N&+",E,D'S M%;56^)OA6>0A78W:*!^-PW@"^G_",Y2=:P&-L<3$.^?_/2WNUF0M<6<+3:\Y.@JE M7F^5^N>WT"KOV[17[JE6VYS"H2]5.-KSW;/1!N? TS1/I#X/1OB69MR,5])< MKBN>B1W7Y$,]@AVG5@X6@0$U:FZMA:.;L)LH MZ0NPTSDA)9UV?<1P";V_P>&28S&$UE9HJ*V@S?NNVF#.,8(Y>S80S%E?\3,$ M"U[\J>['0)@3P&V?H%S9JM7= 8NV".*HT]V@5K//YR"Z;>M6#%[X0( MB*.W"0\)G]X]!EXVE,F>]1MEC$"M;F&#%"1.MOR66B(K2AZ>'(G)Z]8T..K_ M#I,*V>_YQ0#LE^\7S(?%OF7A(YNDKWZ9CI@$T<4,#&>WOW23OK_+)NU-I,B* M_,J_L*8L10%;S_^O5W\*3,/KZRIW+(T[9M]U;+NG,EWS;:O?]_J6^K\6V)N8 MT(H$[_H'(\3SJ(GO@TR0&]W"B;6PN32+V!> 3A I%__&/,H MQ61-)/XOI)G=1&#"<>4U%[^]V2I>1YF_%972 :,C&*7];_/&NR!P.(EH< MW?1N^G&(RS.IYG26XN<*S;NJ0'59QR??+'_NTD\S"?#B-UWM]JW^TI^!+R[] M;=5C-:UK],V='KOZMYYV0HNU5?UT%FM81KO8TUJLM>EC3Z)FX@BUS6OK5K3> MW+4+RI^$(O4\)4%KQ;UH6D8>W$_"3WF-?LH-2H3V!(V5Q=_/J8EN!JK/F/*Q M$%)"GSDR:AZUNGXS"+XF=W:O\4*.[!8 D_!9:[J*= \ M(OO(!TKA[W_*KNL;WZ0*[^R@ISB<'P)^5*PH7[8.SGR-\FD:>IPS ED(/ M3*'-4YT;T6KH!/L%?^,I9XD[)%>2QQ]X&%,-[[8]M383\V?:VV[#S3>[+4._ M8_=V;*BVL8[7Y!Z,+0:?.@9;'=W>L3WN26#P1DUPUFUH(X1>N*=1X'DA/]+9 MONYUG3EC?6] V/Q@CPJ$HW1$;OGBJ?-%7>^ 47G&C+%%X1> PK9USBC\HF6[ MT;5:V=ZZ779UNYQ@A^=C-G4^*IK;6X^2?%*CR\:3= ,[H1X59L[6LVA;_'BA M+9V/S,><%D];_%@*,TU]WH[.9XP@;4?G-G2Y".MN>1@6Y8DCEGSGF!S?3CX] MYJ]CJMN.2FC>X*V#(-U1.?R!D>ZH>]/5CJD]*]*5VSV6!_$$1V3H9OD2BTK([3:T5A*PJ?-0?,[IC];1UPK2A\;M^"L;7SZ;Q%8?/L M[T;8]&U<['3\A8;6!L9:A_(J^\=ZWAF29XP@37G&>2)JR\E:!%G-R9PV=MH@ M+M1DE;<1:O0)AL;^RB.>L)!"8\P;!5&09@DU9VOC8Z?L%+0[MG$QL=,A:4UK<^E;C_)J!&FKQIKH46X1=091]9:3 MM0BRFI.UL;'F<*$FJ[Q'4*.;M^#VRO;*%OG;*]LK]X'\O]!,I_?;3\4Z\L#& M5;/+EC4X5N2DK$;.C%8NE*7K?DV#"]5WW_X?&XW??:!/VKLWQ7YP1FN8>QS' M-F<\B606" !(?!!C([.X>*82P9+'8@1LVE%X-&21R^'Z(*5A8]5/#Z R>BSC M= <]4USKU:X1M=@1N^>*"]M"31,'$M[G(?R@/'O!?CDZ?G[@[-S>]:6A/>YD:YHYSTP\PNWQF/N:> M)ID7()06Q8G,NETWO_C(:UL\(!7/*PM&R)MB7W'!GF5PR,""_H!#%>-N"]:C MP$%C!ER:QCA1%5#D,8#3182(H_L8'U%>FLGQN6(V;D5+DLV65":F(ENS8\J7 MS%]]MYRWM:AR<%2Y LX AR9FZ>)!#7C$?9RBR\L1FK/G/35%DUX">(.BR:*'X3P#$0$4BJE-(D?@I0&-(OG75U^N[Y5+MVL MD#?9,$@\Y3^ (*!V%5=50FC+L>3> S+0RNDRHU_G<4(Y1GU\Y0P@09K*.[ MN_[\7/"7 *[;* 6[[775:5GJU(BY555;5?6$]8]+^ YI%RA\R)GGPO(RQ0>* MIH,>Y$'H7<1Y*94N\V0BJ6#$\9R%8CJ$&P: !?%H(M(_9CA!QMFH5&0JRG+7 M*3]2E76FR<^H3,=95?;EJ#:-Q*8[$C"=0DB0Q/%X.HR%-R:F.?"I;(HWJ^#6 M.&[-6"F.W&FME^:=]Q1:$)/8[<*9IGJ JT0'[90SZ;D#$ MWE%XYG;?+#1M]%FW4&\%L>_S]!MPR,VQ5_2N?5![I357-C17EM=)-L1J6;' MPGCY*^G6E\OC /P'=W.Z17CF,8K0 3R)!.L((L"6D5 3,E [(MC=_:2C#'.X M'/$PSA,7V4UIS=2B$1TEY/?HX\<%(M+,+!*_!O3S.5E)9?AAWB,7PXKK)LT) MQP3D@2A'Q9UY0ZONUR+FK]>"!,+1U4#1^.I]:VBUJM+^'+U3!&',.7HW1C 1 ME5VH6>WF-&Y5[:.KVF"*IX$GW'Z@?#$PUD4 "4^4Y!P=U,W=:ER2S%5=K%G/ MZU(%9.0J3;UKP:+>C>.4G =OR9L(][Y[#+QL*',GZS=*4:A6M[!!&H=YMOR6 MN4'D1U+7=7L:'/5_ATE% ??\8@"P_G[!?%CL6Q8^LDGZZI=IQ0"T@AD8SFY_ MZ29]?Y=-KIVKOD;]_ MKRE(4X%7^?[WZ4V :7E]7N6-IW#'[KF/;/97IFF]; M_;[7M]3_M5Z]O\,L(;02KN"%@#WI7WYA[Q>=XQJMC;*-*B2F>6X B)"-4_ZV M^.-=D:T41+0?NNG=]./PJ&<2FVFKXN<*"[JJP 29Y"??+'_NTD\SZ=;R-[OK MZ,[2GT&S6G[KJL=JW;ZVVV-7_]8SEK^T<8NU=>-T%FO89KO8D\)9O;?I8T\B M3_,(B<]KJR2TWMRU"XIMA)[Q/!6U:Z4AR8$[4M _"07]&A7T#0I2SA8:G]'T MV1(8SX)W1ZW-W@QVK\FE$.?P""^=&V6[J"1IB^FUS48;,&F5PI#=U\8WJ>DZ M1P#J+0!W .!/RA6YZO;!O,\1/BV%MA1Z,A3:/.VX$>UJ3K '[>4HAL7\G_#) MQSZ6(P$.!(,%_6O6;7MC2CC3)FF;[[_9!?]FQ]JU?>TVS/"8W=5:5'XIJ&P[ M.S:@;%&Y1>4F;?RUUNO/^2Q:)&Z1^)206#,[AKWC@-@6EUM<;M+& 9?[:JM< MM+A\!KC\6M>U4U$NFNC[-?GIF;B4/U[2<;#'NI#!.U5J,:S'N M.3'N.,-_6X1[L0C74;?VI[0XU^++U0%F2>YF>4(=O,JF+4'&L8-/Q+-M/67GS$M.;T*@T3'Z MQYD^]YRN^1;GFK0WO6/T6IQK<>Z9=29MVSE6+TT6E@'+:,KD6ZY]R; MU5%[>HMS+\Z 1#HG=4B..BEZBU9%LB[6=SZ'U7S:0 M7;RVC"VRMUMO>8MM3\(VLZ^WV-:D$SEK;-,ML\6V)IW(>6-;1]?M%M^:="9G MC6]:1^NU_*U19W+F^*8V2IXVSP%P,*?"SI.5GP$YUC2IW:"/Q_,O6(Y('B<\ MQ0:T8O3 B.8KP1)9?F+#K"A(\8W.T5@_FPCH?F1S2PT?BK]S,S5$YWI,4J M[K!KI56#MC?+2\3@!QH3L6P7U=B'\NHL5GB:!2,::N+G69[ Z;/)B!Z).,R2 MB(:]A0$;R!%..,2'KL<9;_G]4&%5MIB8\L9FF*]W/-$ L/R).4>'XQ(*IX-&A46<@%!ZQ@'6,3?X". /H6VE6S<&X+S#JFFBRPNE-C M"SCU4YL=NEN?P@N\JIE4D.TT=+=SXL.@7KA8_8U821FO3A9.53LZ;JYBFL58 M(3E6,<)I>^%"MKE@K-#,=%ZM&N+6CFH]BJJQ$$D_L2CW6<']08;&[JSE.J7+ MC>('827Q) .+%@]=B MWO$P;RJ=)U5>HX,$)%$*ZCV-!I[3$^/DGD72HD0V),S7-PN9SU,1;,V O(T1 MK)T\?N3)X\/2EU%PL)LT83P,E)LHBA\$K[O,LV&<2&OS)Z,:+5WG?O<)CM7S M87_2Z'CDB9Q0[(DKA)T+?\@QL_2ZRSR9H(\#D"F1NII<2,W6*72Y% S!:&J< ML1^D+B [JG>(4:K0ZH OUY=#*_'S$,@GX6,6>*4='R1IMN)Q!JX%AT^FOO < MQX.P4 ($5:&:2/; 8P O'7#D\O0&,>LYGK 0P#8@4D%1C_HEMG%G]R0F4@9& M^H&&,!\;X5:8[LM3%1NT ;+.9[BP'+V, 0:.AF&U!V!]<&NDN'F2\,B=* &8 M)FZ&TY59]%WQ.1KFBQQ_'O=Y@C:,F-N,"$26^U9>FS.+3QP;=3=P \8E8AS3 M"1 )0V-^2JDV(^(;"&411]G%[*^;1]L[ 8(IPS[G>%^E',U2M@1O?Q:\QF)K MC7[.(WA8"(#PYMF"'Z(OB8E P,*CJRE4[8#9YKMRQ'\JO8BQYL963&8!K]KIV.P"W7>P!Q[1N/*KV M=)*^GC!2U3G-&:*'F:AZHL!H!ZJV U7;<8U'!> FXQI?.HQ:)'L&)#LY#>4L MFN])RRL#RVLP;7EMVE%A_V-(C@J08XXA.>K&7ZO=+>J6#S>&I 3"<_9W:9'X M;)!XB_+4%HE;)&XB$FO=1DR;;)&X1>(GM KH.J>"Q&=@>BRN1&XT:5S[O@C( MDO61L(S+K!#,W,"ZK81GL@1BJ?FH;P>2A3RC>;2C=9^UW?Y1]_KS)KZ5;;LN M+,"/4T0#8PT>G.EQG_>IFNVAGM^A:GIW=4/2,SW5AFI.F_<2F:+PS56B'>L-T!E/N=:@8_Q,WZ"4^7FNHF_7U6QEPY9PB]$SGS]VC?;M#EH3)+8;\%_\L##X@G>)6G79. MB>;_A65O]WG($JJH> C@L; ;)9S:*HM )@1CJ@]QY;83#E&J! MJRG@9."#' &$RR-900A&G(M7U3<<<>X)]E)L'?^&-86KTP/Q99ZM_X0QQ2(X^/ MS!6(21GABZ[] .^]7M<^;)KBOP6>3T^:P=OOZ9@MZH;FAJ],AV]3%\TJ*:K/*]II5]DS96@#"(_EC MKE#^E67@H,._SD6=W9NW._G0MXFY;8)BVT:"#[O(9XJ@'0\=OHQ)N<166JCU M4;?$9YE3L-OM2OZ\41[#IB,(&XA?=D?7ML_';%"VVKD?$#" GK$% ]CC"9V]@O:Q M;$/S1 9PNHE,>J]CZMN.P6Z>5G/FIV1UC)YYO$,Z>TU )#JBVY__D'V/*.I< M],6/H^5QG)>F,9AJJRXT]W0,PVIUA4- ]C//:BW1-N8&Z_8OW68RR&4 ]+TX MQY!9L:,76VVQ?P UFW2UCF[W=Y/Q^X-1PYU3+;6TU%(4+YD=W=*V=HP=GU1. M893>J_8FHD@;$)ZXZ[CPG"#,K*G MQ*N"/,WNJA(AG$J.J(:089D->'R;W&"?? MJ6^S3/6D/+ .I=4EP2"7J8'N @HIFL!JO;EY(+TJBW%VRS)K/2W;W*Y(C&Y1 M<4M4_"A+ @1HUW0BGCUY3'G,(Y\] (<3OX39+# M+_41@E5:?OU;Q!:K/BNFAI;U+L:-;/@,5$C5"Y3$+%OQE[W586?';*7]DZ;/ M=V(VEW(=$/\!PXD"L>^GP+T6'S PFT8>A$PG/SK,U8K)-1).AV["W_+:#7FM M?BQ>JVEU.;R0V\*OH%4['W.,6O "35R.LI/ M9F7!'%.E$&AC=ZVMT$9.H1J'S!4E6U3,6A7/YE%0QZ?6W-H?WJBU<6(+SV9V M%AA.O,;YBRX8_E@S'08N#6K9=*;7ZJ%SK5;W]",U:N-REA[I/_Y'^<0]] @7 M['I^WMNZL]3;D3AU?##4=B1.$Y9R3B-QGF('U*M^_%5IA1 (@$TN=57 PG0PPR\RK'JG8OP0VXJ@P$#+6TPS19O;K-?-SX[+%2T8'N>K M]3?5(V0I_71UOH?E^"M+]+=8"(V*QA&F=,TP2+$?! E,]#*$+(IH;.3,R-)Q MGKA#)OT.FRBV.&KREG/E_8; I?5^ ."^4E X@]0FGP>M!"],BVX' M&,[$>#!M2%(YK =;U8@^'ZVVO%=MV:ZK5LN&AVZ,9.WA[/%PEC&"!7T]-E5P M-U*76XOFT">KU8:1YM/DM "@R%Z"?U*(3%48X"*A[W )-[3.$71Z)$,4U] MQ[9LV'+)JO&OKM@U076!AB2WZ (" #(E=-Y !3C8G#QDV/PGP0GL17#%C1\X M2*BL&(+MNCR4&1 =!3%Z%!5@YP^T,R'=6![*$TS%<\M6?AW/<4T)*=_:!83E"WXH&I*A;X)Z>6'',8;@DIYDT*22>T[7)TQ40 0QK@UA M)]5. "WPAQ[>KW55M4M $\O:ZHWBG$.^Z%7WU ,M$6\SX"W5V^AU"^\%!5(D MLN1C5!?R!/$#\!MSV!YY^%#:-N)NYOV14U[:]:\W=Q\NE=^IW]5Z/\M'%82&WV/>.GP, VR-6.E*QG82")JAO MVBBMRSNT1NL-X$1WT(TTP&DHCIC'43!MIVK"B?T!LFCZR%9IE+"^M ^>./%&Q]Y M5LKY=\&0OT_%&P@5!#O3X<=?/"( M30JF#Z(63CG"117VVE89)HUI:HH/OA29%7AP7Y,XBK%EYVBJW.>4NOC=1'!H M(T'8J"4E1+?(UEBUS_'4/E& 256(^"+Y3S2KP.NUCA&!-/"0?PCJ!S'XC8_C M)$-B_@BK433UXA]MB&,JQ*$M#W'@<@/OOUZM=[O;]JLV+M+&1?: I8O9XPU0 M.&CI2-C .#*B1I)\\$58?/X @CZ,TQQM@UEH+-,J5R5_"IY_DJ8*G 6Z.%+<<,K"*9!3QJ9T!K"H:IK_ 1OJ)C)EVY5= MR_'7ZSR).\JO"8 #5-:OF% E>[1'S -[4-[953YN.26@@T9H$O\(0)_ 5MZ] MG^E$X(#$FA_A],%&B&(0)J0=P":*GOS59J@CN!>3^3]D#[S*)UU[*^J[N& T MI,/I=Y/^#?^1N-*AGV"Q/I"Y[/4,&DD-V4N$KN,IV@?HN)L!,J #7'N//KVT M,_/2^P3K>\2;A'X_0%7\G@F_:9F^*TRC(M>*-&C:/=DHXE'U'-T96& 1D"]- M'?2Z5"!Y' 8XO"#!(.$(;($<78H )_(0)*1WD8I'J*F%2,$;9:=_N954I+JM0FI^H'BE1]'/% S ;$ M>3X G*+;"B$,[&4B)7;1K\<3_"<3M&\N"D8Y$D+CH6^T^?P1A,)20BN;BV_ MQ'52D"=YY3H%-Y$^B#^G,I;1P8-Z=- W<*O$Y5\=LIA>8,YBI/"+1JDQ,0I(O*(;!-H6;AU MIC4!]!0,>*VR8#!1]*[Z\YII!?0HX&O4;U^?PZ%ZIK%PAM.H4'I[A4/I;LE0H?!2(:>IY%U M!E=)MXIX???;U0,V!KOFV%5]EZ3IRA0&(6R7$!:>&8$.#JPV<"RD"&F4CP8B M@%$JG\)(+4(JJ/G@B*_:3#-YB@#4S\A"HGMX1W%W%5%.P>02T?)(04T"\9/B M+61;S""$G)HD#Y=V62$FWHH'7U>/+Z=B[^5(-B('EM"L)<)!C.ND9#X8%'MU M5,5C$[D9P-4X<$D'F0IYQ5Q*?AG)P"_KK++*VL*8_^S*0APV<3]<_$@9B@'V MB>9?BF0SS85K)[PH&:PNU!><=:>62HEQ6M)X\ .%DD7@JN;1EN0GC9%J%ZWO MNNZ[UO?ANW:TUG?=^JX/[+LVN[3T))9S';]B0IN'KNI&:.LK-W!=1>@QAZCT MLHM^+,6.QN6.3E&@7Y9Z'(_*/E*RBIYRE8IQB4$J?5M"D887 Z<0R1DB,X<& M+^9PJ\BP(MB40D*X3#&R7G,U70T#[BO7/[B;DP+Y!:/S/!&N4_JMLB;D;YU" M ^7"1BP'GA92&;_T.,HO48I?.*^+=ZX_1=0S4@RWH"C]E@/Y:0:[T'JO!V^* M%]S"BA/A-2PC$Y>BPZWF&":YZ-F('+M=Y=?":4!*3*5 2PF_ @;5[W-P('53 MQ(O+G(H-ML:V/FWA8J[-E8U+'01="W%$# KT@CRAO"=:C;#>ZV%P2EH@+_" M%PL5[R*[0[X,E* 9S96"+4%I#L*+=K%#G->1^PZ):]3.4=/>.7%NZ0*(],M M,J"IH@>2@@HL:#]5LMKM]962Y(7_69A$%$=)4>/)1[F8VBC2$T>C/ +-*2LB M/!6=5,.#=\9^W"Y&!,#F1:<(NL P[9/6'U*W"I'>6,L\*(%?X4?S6>]5%0>[ MB62FBY0C"N)I#3;?"H_[KNS7.J:M+KUM45QK?UMSPX<%*8M=5ZIR%61 +:RRHRH%$U>C"LEPB'#B,:17N"!1$J2O"=@JWU'[")TGKF^L]UJU[:#-/ "D-'KE>B"/QQI"U\OO]TI-S=OE2]W?[O^IMQ\_OCEVZ?+ MNYLOG^<7OB'16:\VDEFU_1_9IM.ZRF^@7H3"F./D[-W&5SZ]DVE&KW7[1Q/' M9>FJ9BJOKJ9K8XC<:+0UY@ L*&6-BE+633,VJW3/KR"QE1N@!P3NC5#+=TCF MW S=@!^?'+Y==BD>AF$;=,F>9%RF%L@0=5F5>32#2S5+>Q+G2CJDY"R7@9#( M4?$J)JL+K4^ A)3[/)7MTJCX47U7QRNA ,Y"DB[4WA7&,8NBO-36ZNCVWZ1E MXB7UH@*A8L[-:Y>QD?JNZJ9@*/HY(PQ&^!XJ98(U"3+#G.@$8U9D\]62T^J: MIP?:9CE/^MOCC'=#&.&23MT%$6Z:; MWDT? ]HYLT-T\%3$SY4)U%6%&21G^,@WRY^[]-/,C 7Q6Z_?=EO MJQYK=_M.;Z>GKOZM9^Q_K5;7UNP36:O=U7O]$UFKIG;[ZF8+6C-^:OTT,&WN MV@7S881I^CQS4-9:[&*$;9KFH =\K==RSG'QJ1DI3X54;;K/%I-2F@W%.\RQ M(+'_F5([!$^.??KJEK@__?FUY.VOYR?/[ JA%P7I2Y$\*J"9!"X7H/[* H^^ M PU8(8"WT-T#'BLK4)@^L528]O*ZK_D@#-QP0A\N(U'_ZOG1G9F&#$*O_F&7WQ*U]PEK]3 M2/)K"$L4STB4I8=V]@-=/W"7$P44%O^%4GY5> &>,KCU:7/FFC=.C:P9_=V6 MXP>W!<:19[\>]E!/>'C@UOMO-C)K>M?:=I+FB:%RRZM:7M7RJC/@5)'W.+'+1%IN-=9K1[9LG MCW,M:SB)8VI9PRFQAJ-CW=G[RHI(=*4$E<%II8A+/\57=H*L3N]8>F\WG?R$ M;,AS9G2+MMALG-/TKF.=/,Z=.6-XDKG>H&-J6<,IL8:C8]V>_$ "D9PF*T,B MA/X$GX_TR8=5PD_+ 2''"S'C_ &HVM>RB MY9T;M;3L]%#^CA9%6A1I/(J0,OD+U2HL*"*9'MBG8K- M/-MBHB!VX\->>+7>O6QZE%[5):]LG">:B8M3JY4F8>43YH528V"J3WQ"K6[_ MU&IUC:[R00S;(V2_Y5$0)[5JB9WKVXXZT^=S'"UJFK/I*3JG=HIF5_F$(PIN MF<^S27W R(YU_K.C84_Y.#7]U(ZSUY7C!&JSJ=8>Y,DX%"=-7 #@$N9F;T5/MLERN!V[*=#4:OF/83 (LG?'7M_!.P4M.J-W MC2JO[Y]<#;?=U;3]E^^:<*.^6UWTRJK@7M?4#U!L?,#'ZL]2PSQ_Z9$+X]83 M#:'K]?_\[>;7FSOEYO.'Z_]9&GIQ&K^[)17:$7#)<2PFQ ZP4Y+/<4[3=(7K MAF??M"TO/M#/<7?I,9[JGC[PU$T"F@7TE/+7IM2L;IH:!KKX"]KNM5"BE!>T MY8]!B&Z^#UB*O( AS9@NFC"M=@7)4PJ^7\1#=A<#SDO3>8N^4&]!)_*2<25UMG,79,AW[([R>T3#_6ZQX76J7,4>[R#'H8=I M1D\5DTR\>(Q7U1]17.2H_7+:#DL&+.+IQ9 M],@W$1$6%Q;OVP*@+86V%+J&0F^O_G9.%$J4_ MG1W!7+'0Q?F@J"_^%D3?,9>_))^TI9]C7WI.]//A^N/9T<\=^Q%'\6BB7/_( M>$0SECYP/XB"Q135$M2Q+STG@OKM\M>S(ZC?V("':2N+&GCI.9'.UV_79T J68A!B>9N8RU7%AGUNYIM M[?VQ>K>O[W^QE@:/=8Y4$77T2QNO1EY^_NO-EP___GSYZ>;JMJ/QB!K_-X_L<0=KA^Q\AQ **NOFM4\ M@<#TBW*K_"+4I_E__W[YZ?I6N>HJ5[]=?_IT_>T@[8LVFVVY;(GU?QS?&3X,D2[DHQ%/.N1Q"M!(ZRRU[)JR^"4)PHU?]^NO21"Y MP9B%\XM_LYRN]JH5]/=V:2N_6_F](Q 6UT\?#PPKY?/MW?77OUU_5BZ[RMVW M+__Z]=O-A[]>+^C9V4K!)O9[N,WX>,@C.KTD?APD@7?/.S7^^T_@OG7AA^&* M)Q-X#_#;!2^ M__]02P,$% @ "W1_5C]%T58($ GZT !$ !A;F=O+3(P,C,P,C(X M+GAS9.U=37/;.!*]SZ_@ZK+9JE$LRYY\N.)LR4Z<VUG,GN:@DA00H4B M% "TK?GUVPV2(BF0 DG)B7;H7&*1Z >@7[/1: #DNW\_S@+GG@K)>'C6!J MZGSUJ/SF^(+/G*]+!Z5QQ1=W#H>V^\_OC- M*]H_]+S#_OC5>-!_.QR2_<'@N,/^X?APV'^[ M[PW[ Q ]&/N'WC[((.BC/)+NE,Z( QT+Y=&C/.Y-E9H?[>T]/#R\?#AXR<5D M;S@8[._]<7EQJXOVDK(!"[\52C^.19"6/]C#VV,B:5J* X7&/<6(9DQ M5[YT^6P/^SP8#M^D(@C(UE3!0JE(Z"ZK\)3HJ\607^PWQ_N M]QRBE&#C2-$S+F8?J$^B0!WWHO![1 +F,^H!PP%%#@L%;CVYH+/J5", MRKP[UP!30?WC'CKU?NK2_@S(^"6T)"UB5%"T1[R]!R(TN,AZDLJB21SW)- 0 MT%@WN]SQN:!-.PXB$@853?3_??]=$C3M/XBX4?#WZ+Y'_:;=!Q$6LA:]1^D[ MN.\P[[AWRB$6O283:!U>_W)S;HD^=-V95 J=@F>M>C_0__:=?A;#]ATMZ:#H MN[U5@16H2%+O*GRO_UZU]40X*;)&<,5(:LL5M5LJEEQ,U;E6R:'D ?,P?K^% M3NA@4'+_"DQ$-TTVU+X5SDK+$+A8RFI>,LSLAG2X[V2PSY3YIWP&'9O24+)[ M>L'E=I@S4:T$'M0GL(#N('Q'B3PA 4;/MU-*57OBBBA6H@[7$95@.3'8,RU* M7A,!O9I2Q:"=V^&H"&DE[+?ZA#DO"MC_ZBB!!5=&Y/0LX ];KQ"28\>+-$C5> MUEGB=HBQ\Q#TH;A@M!DW>3DK"_NK+.2D.Z3K3YQ[#RR $-8[ATZ 8L*R"L%+Q:I4 #]362DX?J$!T? MB0A9.)'75&AM-"+"$+92\'J5@A3" 8R8CPXI_Y9.<"H*(<"S*?,/0]] M+F8M'@H+EI4:8P:=(.J(*,-T>*SN1GVFQ*4!O4RILQ8\Y!_^H4 MP#6-&M[1^+\Z4$.GF'2C&;:"QDHNK'W'87_3.;45S\I?V20[14W(*J[1Q\ = MHNV&NM#X8'$N940]4 ]NJP1SOA8\A#_=%LL:-2&MY!ES]138B9&=#-HI8C_S MMZ+L:QZPQB->0V@KGT8RH#:?SHNTEBXM]%O70.[(.&C,:3U,*YE&6J'6ZHKS M(L;O$HVY!8\6A)G25FJ,=$,.HXL$K%DS:4&('HI4O(X%ASV]WD;]ERKH%4ZNR5DZ,I$26].ZB[N.,=)O1)"]H MU;JY\J_%NZCQNOG15B%7(V@K:T;.H&$"MIOT6C.G[8+IFJA64HW<0;VL;#>Y MS#83?Z"*L*#]7N94WLJ/D4#(HS@O$IPNT6!-FX&ZR&0BZ$0WE/N)0!O*-JW+ M2J^1?JB7NM-"N8KQ,$@J^6P3)3Q])@*/[]X_C148Z%;>C:1&7=Z753WS7,9$ M>C4YH;CRL#X%][5JM-G#8;L#$O$I(WTK/9-I9OD[:":Y)#N^:\N+ LK]W,4V MAE 7TTKUNE,8F!1(P-&E%Q8+NLWC1@Y\'8Z5+R-M4^2KVPYYS0K,1HPUP;4R M:"1Y+&L\SZ16*O]T"C\I"],B6^:V"MY*L9%1LE(<5^6P,"OZS'6!C-7?6^:Z M"M[*M9&'LG)=LHS[3'5>]Q\?Y]3%D^^1 I6.9EPH]I=N+MX)Y;9]>.WZK,9@ MY*^LQI#6[<25._G:G:3Z3MJ'N43?+LM5A6+ELB375;+2WT%F\FOU&X55:X&L M_!C)JI7E_Z['37GM9G-$_+4I5^5H5L*,+)-!6'ZV&6_AZ"!ON6.T[6:7AKB- MF=^,?$_^,&XG22@_4]N&C_5(5FJ,_$S5(=U.TK2Z6:D-05485FJ,5$S9CJ<. MDF+9H+11R- 4VTJBD8VIL0VJZY&%A83;:#8C8L']SU3=DH#*\>):<"]RU2E1 M=,+%X@F8KU^IU22,[$TMDT@:@*$+[B[1;7#&"R=IA9,VX]EB:I&7E1L)2GZ, MP937:;47(P.TD;WD!+ 5G327Y<;)Y1_19^@&TDB2(TI7S>(6V$ [9$G&4['-V09YO1?R0Z MTN<$OTC0SBV;A,QG+@G5EY"/)17WN&WL/)Q'[?+)VZK3:C%&+JK*8O+U.[H! M3JX%3KX)3MR&;AM+XH5OI_P!=*6F=/DHE5+*?2BR?".#PI>J,B]Y%7_Z>+:* M;GY(@ZQF9J34"F:6CEA)VQRH.>=YJHP0?!@6S-KH%!JY]&K=#(R6I(X\3V.2 M(!ZI+@N0*U2-/5[9FU0EKY-/*#2SXSQYJ"9_GU M9Q*K-/[G_A/0"*#/1#ZAQUV^Q3[_P:6MN]ZZM5BI-A+'Y3XX^^Q"X8M/S][8 M8";]),G6*5\#;&79R"R7L[S\\$GG>5WS'KTV;-: LW)HI(+7OIVODZS5/=>Y MX1FU6MA6/C<_--I)AJWG.UMNS:H+:^6U];G1OS>=[_:*GQF.?Q<^18P?(DX^ MA:[)QF^@_GE!I:0T"3G"B1ZXEE'H'3^AUX1Y(U]1\5]*Q-U44-ISR%CJLS_' M/9\$^&E5_,PRCM8ML$+@A6(!3[F")Y]M=E0 M3!IW7_FE;WBZHX_J).#NMTIMU >PJ\"+XHBP9F<])?KXESQ2:2TU>@P&!XT] MU5H](ZYF[7,T&U,!5_D]#8E^"605^?6DM][7Y$JHZ"0>)2R]3!9I[Z@[#7G M)WJ9!YN9[UGD#B/SP@+:_0G/7#W-7?\;_G0)8?Y;JC+)R'[BWK@ M#(/(@X?S-!+XZ<1KW=9*4K<#WD1-/_093[;Y0C _LB=CD+O _0IX',LEG2B M4C?UA'?5O<6G4,[#90X9G]+2M86KL-KC-T39P! \.GY"921G6?-F?L,F4W7E MWU"($<-+&)-GT>R&XD,9O_T4?<(%\^DU-%[<\;A=!4J)8+I3X% M^_;T9R"O([!^_/XY=L?J2^V2N^!4+TD8^229'MS 0^WJ"M=WSB*T"_WZS$-, M0NC(+#EQ4FFRI65W]0F^I.A]F4LM%*T6VP523L4)$3AXKF^[46P7VIY&>-

KN+BA]!&F@6'2@"HCJRO_T^-&/*1P'F+6 *_'IR%\$@5P$28T M5*H;Z *P(_!YJ>QO0Y0GI!A \,7;-7K^)?1@OHTOY:9>Q>B>3<@K>]X095?C M)D"2\I*("0NO8PV2276G*TKO!*T7=$*"4RYM8[99;A<<3]D6&0RNS)U7.#\) M<3Y*XN1B?A_?!O7,I" W8>1CR>UW5*%)3CJON,$^9U['7)@B[T.,SS"W3"W9/5T_&IX?3 M\X?2EZG:,QZ):@>X"6;[8?YI$P*U\QI;2(WL[JRJ&*VF65P\Q@M!S2/F*^ZX M(L$%O8>N3.@--K%FZ%L7[(GB_CF,,D^D@%MH!?T>0?D[?@G1O& DR+\[Q.3$:L^=$D'YK\T(W3 M0TF:0_R@^PR\"YT\I:/Y7,"8'+3/R+:O\>=G:.$IP?4J:S(L7V@7'I%LS?0S M5(G@C#U2#Z(+,:%X>[.!UP;YD$15)UP( M?/LWG %Y06UE6OP5S6TV85VP7FTN$[YWS7]VJ- MP [U!T)*O0D@$DZL@S3H*OSY'7D=]5$Q@-!\.! M=K$C?",IJ@VFZZ,'(CR[BZXIO$..+=O#5.:A?B>"84,+*=#1#!>&;1YO ^!= MC;6^4GR P83C65<:4\=S#IB*8)N\9)'0Q2V&+(BP>**G*J/9&/:)A@Z AUKS M>M'[U"7,UF?D_2__ U!+ P04 " +=']6+F^AQ) = "/' $ %0 &%N M9V\M,C R,S R,CA?8V%L+GAM;-U=67,;.9)^[U_A];PNVKB/CNF>\#G1$>Z1 MP_9LSSXQ<"0L3E.DMXJTK?GUFR!%613)%^CZ\6SZ\U/V(WWZ!*9QEL;33S\__>?'-\0^_=LO/_SPU_\BY%\OWK]] M\FH6%R/<,THE-3;]]Z>?3/ R.N>( M%)$3&20GCB5.*/ZJ"%DFAK]3'CH93__XJ?P1? ]/<'#3?OGQYZ?'\_GGGYX] M^_KUZX_?0C?Y<=9]>L8I%<_6WWYZ]O5OU[[_52R_S1# L^6_GG^U']_T17PL M>_:OW]Y^B,=PXLEXVL_]-)87]..?^N4/W\ZBGR_G_$Y<3S9^HWPBZZ^1\B/" M.!'LQV]]>OK+#T^>K*:CFTW@/>0GY>]_OO_UTBO]]--XEDZG_F0<^Q_C[.19 M^=:SE[-I/YN,4Q'QASG^663>S_+19^B6N'L0+KGQUW MD']^BH^>D2)URKDMD/ZRQ5.??8<=_20N)LN?O\7/9\\N\%J, +[-89I@-6]K M")-9O/2E29':K%O_YL0'F"Q_.EKTY)/WGT?_F$UGJS=,/_V*"^D$7G_[#-,> M1BI';P(/Q'IFD<SOG^#LX#* M&7$M$-IW=?P"\JR#U?<^^F_0O_XV[SP*9#SUW>FO.(\]CBGB;^(43Y:C6JV! M4>"):YLH 2;0.> >B)<^X/@L8S0*XZ1JI'>:#6KOM7E9]@7CR&9)P>5 (*"X MI7+(+BTD@>A2%HE'FQHMR.M@[JFCFZ["H7#SVCK>4X;5%N]F7>*H,PH]=;0[ M NT.58J$C&,,C$G(&J)5X2&=FH=5[T,E5AUYUO,CUEC.4/2C7 Q10*D''I'E M/J%U2DX3X)8GDZQ5MHU&OP9EW[&]AQYPBHZ?3],K^ *3V><2AZRG6WHG@Z:2 M.,E0=(8K8ATZ<%E$-,:46>MIDW'>"FM(NGD_;EPE?CUI5"/_!UBN:T3TF^_^ M@ M#11\07)3>$ DFXV*DE%B6T5O3P8#$11Y$FXAQ,Z8A:=>ZU*@DAVJ\^#M, M<7@3Q/,\G8RGXWY>!OOE7%-+QD!D:@D8+U#K X("&8C*26;-I 5AFI#C#F#; M,$0\2H;4E$@UFCP_F77S\7^6LW&4T3LHZ; P@>=]#_-^Q+(,"6TVX8PB)E"< M. !!,.A+5'B:4Z.DT^VXMB&)?)0DJ2B/O3E2$K"CE\?X%WJ8;_RX^Q\_6B@'A4=&D]]'6H\C_^W&/?C @ =HWFWB/-%M[*!RQ32*OR ^2@[#U$;031W MR-H4$)KVE(AL8LX8AN00MF+%MF_ UAQJ+?$SC:,FDELSU.,$?X#NRSA" M_V$V22/TV9@241'4QQ0].ARH<]JC+C8:?QYI9KS)\#9C&M2FQ:Y4N&H-*XF@ M&L7?8] W7< Z&]/Y./]]/#]^N>CGLQ/H7G^+DT79^B[6&O^7/OIO(RVRSI8[ M5,DE_^ZE1[TX$QT%*@4>H2$Q.O9"G;*'XL M9YYHD!QM%OX_MXD^-P :E/;0W,7(A% 9=EE8\1B?$9D-B93 MEKGAT(2.=^Z4[N?6!\93]%D2S@/:813Z*L-MF$\!3:.UL8W?N]&M'\CNPHZR MOY8BW'&N&VZE60PE?UFIFTN0]JOKO/[PYN6==XRG4I7G M,EMSZ57?:82F]BBCW7M7$L%([OF\&X?%W(<)?)R]\QWB''$JO#*<$YV0(-)% M4_8<@00/23##HPV-%N5^P*M4#&YX_@OATO&[E,M769$Y$5 A9&$>]B M)* 2YTH'87F;+;@]0 _+5 ^4KC4%?Q"F;K6^P$L3'$02*!2WU6M2=CN(Y0&B MT+C*U.'I>G\-6W?FWN#;QY^F+Q<=OBF>?NS\M/=QB62:EI_.ED?Z]Z*?%U?D M'/&(1L8$^DK$9Q^)M)22$%PF+/D8J<%80*>#3^@> WHLEJPZV^^C&PY%F&IZ MXX9QK'7K" (#J[@AC#%.I X)=6>I-U4&++5@J&FU6[815-UDO8F4>^DS<0E$ M*:8U)*28B8*$4: 3/$$\=++^85=6+3Y<*SW>>=X/8B*W\2=$I#8):D@*62%H M0]&?L)88R[6T+*+F> 3!V\/FHUO1ZY"R/6S2YH6?E#/$'XZAU,_MF:2Y_+ F M29E;\%9*PGR8S^(?Q[,)$K=__7^+\?QTY+D#8;Q$KBC4)XJ5'3+&"%.>%<<_ MB4:^UG4L^VJI=P@/T'M(RTU10,4=AD21#:$IHSMY"=$*%- M+DUZOK3FE9)^@G[_PX_3I]Z3^/YWYR =S(!4,S&DH2-%N> M $O$.9%) @D6E _.MJG1NQO;D X!5*9'9<%4+&V;^_$4TFO?3HUL^6L0_*1%S!7"EJ2J:E@9PL$\QXB(+ P*4FN]9A-R#[JC'%D-&CT MHQ>YFJ3?=? 9 \6SLL#U2;_+ M(Y14*D$S$.70&9"<)6(M,T0%JY*CI8RTS0;;%N"&%)G5XT5MJ52CR]NQ#^/) M>#Z&[^-D3 >I,^&&&U)V(8CE(A&1E'%:)1Y$&W9 JCI'74+2#>,$*,3 M;5S&E>V$)M*A $2)+I3PE M.90F/!JUL=?)D6"3E@XL!].PC&HW1AS*7ZK,B!HBJ,:'%XM^/(6^?SD[">/I MK#+H!HX%EZE35&/1;'X26* MTVI4\+BT(6B>G6><-XH[=E.G#^!SW4OR5QF_YXS78_)L^NDC="=O9WZZ]OQ& M1E]F7;F48#!M<3B[A>DY1J@@Z>&G:U'G?A&:@[M5^TM]WUJO)_]59. M-)760[IE%R S0[4J)1%4N+(M93#>]%:0D#S3U/*419L]H;U@#]0YVXMMAY-C MLPCQ AX#QD0C'%%9XDP(AN:5*HXK(P;#5:2ND<>_GXHZ5&_#6J2I)('*&\XC MZ1$SXXHP7T[<)U2)7F9-N.8T L-]H>O&_V_[!;QO>2\K5GY^^F_CI' U[V;-> M=B$O.U144&ED\B0I6O8BLRAJ5SYM?Q9#+2V6H3DR0Y6T^DI)Y8@1]C#B98Y&FV;1R;;= -R2^N MP(WJ JG7H7?]]L 29PD<"<+38KE*+V)9CB3$)!B.$*"-IW,?D1_*JZT@\ITF MMD6FN73)O5XQBM&5#QF Y&0"D;YT,@5:FLCKJ)VVT=LVW3;O0E8SQRYML$YJ M],98B24S56AZI2=".F6R1L/+VO@^&W/L@\E"[\^*6U+3]YKXJD?;QLO&!V5T MYRF'6 YR24H=,*XB C(*UJNMA*$*B&YB\(ZV^Z4VP900W*"FS*CEF#J79!T M?7S1&B>T,4C6TEE'>XS9A,S$.6>]%8IAZ-:$('=IP,%DH.OS8D\Q/&"'0]\? MOYG,OM;M;'C^T/8=#6_&7^D0?7GZE=+YY=44XX@PSDKK+__@PC??08 6KO_'SREE&KWEY \I[',SKG"'.1REH7R[-(L&;B$Z:5<1;[I&03HA, MLT^Y3>+_L..LT)VF0'C7S;Z,4<8O3O_9EPVA\R:CS^-\_&5EO2UGW!AG",]> M84VV7*DJ,F,;H]Q2%[5@/E^0ZN<%B2H>=_!3?A*R7U_!5_* M H2D0(!R7=)JG.#S#,D^QL1R\H$=E*0W8!R2@_?X2;HO"5J3],UXZM&GO80O MQ"0#%9XD&W 1)2Z($]P1*ZFUT4+PL4T_A>TQ#LG;?/PDW9<$U4BZ&N)1OCCL MH^E>$SP"JK@U*I3=+$ZD4H9XGA3):"HXL.!8H_JN!H,94H+Y$='^H6GU$$K< M:,4HCYGDL#SG:TH"UWJBP'D92H-/UR; V%6)WW\VWL-G?[H,#H_RNLCP%03D MBHR@7> X=E%NO2JW I5#/5Q8D94/7.@VNP*;$ WM5J86)+K>[J6"=&I6&T2 MM+RKY]>^7Y26?%=P450L( PG$7(I'S09!QL<,1S5CF:)A]1FQ=R-;4@^^8'H M4UE@=2Z*78,Z6LPG_K3_CNO#L>^@7_[Y @U9>K>B_O.N*_:F_.>Y;3OZ7";Y M]3?HXAB_.8HR^91L)$EDAH8-I\LZ7 Z@161!>(1P)23<<*=L W!#JY419*F4X*41!I"UM-'VPQ @J'+/: MF-0F@W$GM$%=C_-0C-I+7NUHM+&\=^1I4AFL*H*HM02$L0*C+V)YJ:1*01$O.;I%62>*WC!3OLW- M$+ONQ>XT&Q?N[PA@N4RL[#:6J[68,21$;Q!A5 I'3)5KF-&++[=>H MW$<,%4\5?^X@COW9I4;/3\JU&O]9?AQQXVPH?KQ+Y8)I5@J-K,./'AS&!YE% MTV8K[190CR"95)LEM414)XOTC]ER[V'I+)PU7EOV0_ A:I)E0!0@;*DH9$09 M%;,7,J5\Q29OR +=\/!'D,6I)? J\UNO8O,\7U3:$R..%>,2C8PZ[8DSIC$AO M/G5^-"V!A?+"]#$@Q'W(0YVZ#;AD3N3T:BZE)KR*=U5_LR9A%=CJ)T*2_'\:0P MJ!%SZ<.$KGN($JQI=&?3K;"V2LG1/SV%=A540^Z<=;Y?^V&/0OU?.Z*L15S-2;8-W*[8]]!9O>[95%^T!3.)98\R2G;S6 MAWQDG1% T7QC'%_:TEM#;)"9)&^BXU*RD-JT!-@-[U8T_).EF \@V7HL/,'E MT2VWK)<5E6_'7R"MEL7'V0MX->X_SW"2CO)(@ <+01.>G212BG+YJY"EQ8M- M 2)WMHU?OS7$K;CV)\ENMY5?^Y/I%[R #_$8TF("LWSAAZ_*#:&3G(L#ZC.Y4905I1XA/0X)4+N=&U@ILOS=IC1._] MU]_\'+JQG_0C'H)4I1[+*%,N-BIWDV7I"+< "80MY31MAW81SI!VUW=FP,9[ MP7:>^/I7P?T^Z_XH3MPL0M^/ %45E+X:*6I:KEI0)+B2O^!H&F5FFM)6"8*; M\ QI][P^"W:?^OHT>#.>CGO4K*4G&4:-S%A@3A$5RGD[C;ST%@0)5GBA0[". M-KX;\!*>(>VIUZ?![E/?WHE8MZCSTW2U0>'5SWOX$SN\I9IKL>\(*WD9A01S M6/J6-W2"'&F-CBH:"1)UCJ74T1+D03F5ZZ)3@@:FVE21WHYK7_5SR],OW#E] MJ8(H&1NMD*4:DP4B,]I-FZ@F*4F+$1R%W*@^^_Y8!W4$H"+!KFJRQE*L9NQN MP?GWKE0T>A5+.$TD=.FXF M..)$\AD]+Y"NC8/[8?('?9M/Y<3^R60MMP)/()2XOG3 $ M8>7F:BJ%23DGZ@_N96R!>TBY@HJ\NX^9K2S<0YC<&S"_AQ,_QL7?'>4WXQX% M^;_@NY&3-GN#F'DH)3B@)'$L.A*RI)9;83 &P K;P3_B SWX:BYOY@?B)\% MY\>OLY%--AK.!,FA7$CJA">.H[?#O##*BYBS;),JW0GND+(G@^'@+J)\0-:] MF2VZ$;,VNBP4T:DTMZ",EA4BB/:9L2S!!S4$1;C&.Z2C#H/BW;V%^9#J#HD$ M(YF\5J S$8ZC;J8BHEHN[>$@IG*EF^&T367.CH"'=(IB4-2[OSCK'+W9C'0= M)5X$_#S/H3M?*9X;[6TI8>.B]/3QCGC-3+DI(@OF5$AJNX,X>X 8TEF*!H0Z MJ(S:)V:NE_[LD6[9_+!J290M\59*C5Q_V_IJ0NL-M592LLJQT:R(CTP3:K2V M3GO!99O<^D9(=2ZYVSA@A^-U 31)6>%:,923$% 1FJ!R,)$AVC8>U>VXAI30 MJ,.6FV_"JR*7>O>YKN"\GYWZR44PTH<4F-!$:!DQ1+ !0P3%RB4F2C@/N97S MLP'0D'(*;=A10Q*U:?&NFV7HRPDQ/WD#WS&A"P51 9 8328RP3V9% MO2')6&V2X.@YM5$F=T(;4KC>AC%UI5,G,%JK.NC1E8ZE"_HK^ *3V;+UU!H6 MC1*=>NV(3B$4O:>)HQ )! Y82+?CX[ M@0Z#G<7T?,RGYY@L*W=$8[Q>J@)E#@KM7G(D@M6HX[B)O,VQE-MQ#2DR;J,V M*LJE7K,;/UE>M_?Z6^E[_-%_.SOWL@:5-"T)'O2893EO);PECJE$7*8QN9R8 MH&T"FSN #:FS0!NVU)1,^TS)Q1;OWT]6E$][9$SN?FBUS,D]\5?*H%QJC"^% MM#8X38"'4K?M::D!-L1;'SW5$@)KK?NRKANDERTQS=K[D>@-#_UA&6FYA-8PHI3C/.7*;VX2]&P -JCER13[L M/_OMCJ66OMSU,QZ9'53,86V&M9"9^7Y(-TO,OT/E/\(_%22@U M+Z_&DT6Y;7=YR\718M[/_;3<93'RR4?J7289/)2VB1A]!L.)P*A4"BK!IC9Z M]IY ]]4I&UYW[3TO?#_&J$U::E0&XK/2Z%\G3QS@&%A,W'-)199MXIY[P1R2 M.6K)NZL:JITLJYFP&R%NFHSGZ=\8[IWU_78J.6&$M"5H&IGW. MU+9Q['8$/*1]@0>G8&7YMC>BYPTPS_]CEE>;^GYZ,4;]#7R_0)=@-O7O(6)0 M>;:X]MGBKO;N:F:ZS6S4"O^^O_\S@F4$BF?!G2&6E1.<("0&]TZ1 M(*VR1B@E6)N6CK?CVE>-KN]R>3D[">B.%L%NZ-1ZGB(;12.S$]R<55=ZE)X5UWW?4RVCM-;I*&NZ\A\X2S7R5[8-;(MRK M?N36EY3^=._\.)W7:J_*_[FWS#AA2.0:@VV)"M11P4@R48/'*-S9?!?3=GWY MD&Q7$PI=*C9I+9UJYFW;J5@?FZ,0&#>EZ,%J67J6,>*<8H0#F, B0WW=YJ3X M/8$.R?0UI=LA!'E8MMU\2CAFD51TFFA73K&C8T"\]Y+0&!17&307;7JD[HYY M2*6XP^'@_N(]N/*[UE(A,>T\KAEB095[SA!RH$P3KR/U%"17NLTF^*Z(AU3C M.QPJ[BO:A['"2V=!9Y-"SIJ8S'&]KL)G4TAXY5/7!MRW'L;(,BLEQ2YH*0R#=J O@@ M:6R37VT=JV[UGG].$WH"I=:M7"-1FN*>5;[1I*A6QA/ERB4F263BF!5$)^]X MX$Z;1LL^'*HAF"UMXMG/RQ\!W_7+#_\/4$L#!!0 ( MT?U9?^_03 MKD4 -_; @ 5 86YG;RTR,#(S,#(R.%]D968N>&UL[;U;=QLYDB[Z/K^B M3NW7@R[<+[VF9R^5J]S'Z[C*WK9[9O9YX<(E('$717I(RF7-KS\!7BR)(JDD M,Y&4Z.Z9I=*%3GR(+Q*("$0$_O5_?KT>_? %IK/A9/RW']E?Z(\_P#A.TG!\ M^;42FIL^K\O_VJ"E]$Y1Z2(G,@@.7$L<4+QGXJ096+X M;\I#1\/Q'W\M7X*?P0\XN?%L\>/??KR:SS__]:>?_OSSS[]\#=/17R;3RY\X MI>*G]:=_7'W\ZZ//_RD6GV8(X*?%7[]]=#;<]D%\+/OI/W][^S%>P;4GP_%L M[L?Q;@ /W3ZC,_ M^=$($2^>,+_]#'_[<3:\_CR"]>^NII!WHE]/N8!2!<[_*$_[J36F*P0RC3GM,7][%DF0_ =O$@<@W7 M :9=0GWPW'LXUR W$99'^O'E<))NQ_YZ&&=_B9/KGQ887TUP,7[O+^%I?/B$ M"2FK*N7<+H#<_>-[()#MX7A8%I"W^./J"66L%G#@ZQS&"=*//PS3WWX.$TS%3$^9G>VUI89 MQ+]<3K[\A.,@Q9S]ERS?DN6W2XZ?0+"4^'$SN\"'IO+@UR-_.9 .9' XE:QD MPJG02#SED:0 /+I$I03:>BH/AGR(_4Y?+J;K6:S>H"-?L6(75.!Q/NE"A$N" M$/^//TRF":9_^Y&VX7(]N]?#6?2C_PU^^AI_,QODH!)8!<0)0#LG<$V<#)KD M'&(40GN5?6<*NC'X&?#;A5@?,\VZ8_H]3'']7((*.6MM;"321$IDQ"_>XH], M0(A9"R><[ICK>\.?'=O'BO8QW[P-W[^.Y\/Y[2N$-?6C-[C[??U_X7: "XJ2 MGAEB&8<"*!-KI2&>90K62F>=?H9\!T)X)]3+9L0_;ODT]3 M7P(='V^OPV2TL!RH%,H)@QXRBIG(K!CQ@%]L#"&Y*!.WJC7/6P8^ XK;BO,Q MNZJ+[?D3?G9@HP4G62 Y!M0R%7!QD6@5NK)G /<1:.YL1RXCG@&?1POP,9&Z M"R+_UXV?SF$ZNOT GR?3^2!2&W5$#,QYCRM'HB2('(B.$)G5EDDN.N-T8_ S MHK>-6!\S;;I@>FGPK7>(P#)7B1LBHD%G3OA$0O2"> >>9AN]C^V7Y*U#GQ'+ MQXOT,<>VDV5YZL>SA337>J>%M91Q0JFSB,DEXJRF!%02QAE0PK'NENB-T<^( MZ5:"?4RV:^\RO1Z.X/>;(@YTU[5A1BN2G&=$.C3T<%:64 $"F*1.1MF1MW0W MZAF0VTJ06^(>K4)<2S ?X'(X0[]M//_=7\. 61:L%)9D!KBD.&UPVT ?SDN: M!1C#&&MO86T;^6S8;2'0+0RW"FTM ;T9Q\D4EY#%+#_.<>-X-;E!5_WVU23A M'D)U9, 8H5I*M @SX/:1(LE6)%O J=Q^6VX Y&SX[T[<6]2A@\C7)__U3<*I M#_-P>1Z]6HJXB"DDQ,.$1!]/!G3OM)+$6^&9MDEPT54$; >$LU&!+D2\A?Q6 M(;$ELHN4IC";K?Y3YLL&,GC'I:1$LER<>X> T!5$HU)RQATH;KM:\K<,?S:D MMQ7M%L);A<4>H'J%W[Z;?IK\.1Z$;'P,:#BB]X\K$((@@1E!$@]9@I%,=! " MW3'XN9%]I%BW4-TJ1O8 TV++>3=]/YU\&8XC#+3"/4>X3'SFZ#>@ZT]#<2&\CX"W,MPJJ/0#V?C*;^]'_-_R\L#2,ISX[W%TB MC:B0.27B==8$ +]F+ZWT7?EHV\8_-]:/%^X6SEN%U\JB.&)453I&",5*;1F=7/4,V"UE2"W9(VTBI8].!0= MF,C1FH^>X+B\G*YHW/VE(=EP[:T3G,?VE#X8\@SX/%Z$6\AL%1A;:]:O7^.5 M'U_",E(G);-2&")D.1O-%@'9* CG5&1K&5KP[;?2;2.? ;6M!;J%X2ZRO);I M*LL3E*)Z:+K?S :>"BN39>BKE6Q#BTL(KB-HP'.&SII)DFK75;+75@1GP'AG M M["? >!KC?C.4Q]G ^_P"]^[E &=#=WOQ;J&]@Q#7QRL8C=9P-+71 MV)+6Y'TJR:9 O(^&@$C:1B=!RO9%&(_'/1N2CQ;F%FY;A;)61L3D^KH]&KD9[-W>;$Z77P=S@;*X7(D'2=* M)'0G#&JLDQ*M#PM."1M%=F:/ MA-2AQNSI;/"D!AU!]J2&T#LLQEP#NX_GE\7JV0C18*/50J?J\!A3EUO$KFX1 M=UK0,6F3*A+O1Q=$]"%0U'25 NI\"((XJ@51EI?BX9!=W!>\>_XZ\* #QPE5 MX!!!UZ#^SE#];6$\#2B3&CR7)#I6O%!'B4M1$1.4X,D%SNB^#,46S&]"Z<\^ M[(J?3;I;";?#7@NE^?-L2#-NT?+5OFC&>3T3"5 M=F3?%KG99"F6J\D(1Y_]^E\WZ-4\!->TIT[CIW?7=.>X"6UTY=&&)F^M=3$@ M32 ]UU'RG#@'Q;W4@P/&Z_^"RC15V*HEB@L&C1HA-)-E&$9YR$?1YZ M!P;Z-RQM-YPWXS@%?%=^@>5_WXP?"_##9#1Z/9G^Z:=ID(21-@A#J"C>-(] M'&.<>%PQA=!<"[8O!^#XJ1\(M/_UK*6>;&Y6-8GI<"O[-OM'834>HXBRY#9$ MBX 4FFB>J40"1Y%(Y9.B^TXG6KPDIPMC]D+>IDO;2O(5;-C'4QTX)2F7DA-= M>J%(G0-!\SR0%&A.TB>0NE9$8_M&=[;*T$[V'78=6B/Z5.9\,[U=(%M9X N- M'3C+- T*"+:E M?O :WDYFLX%P4GL.Z- ;5%I4T$7'%4% N M#BD3IY,@*4D;<5%SWNS+6FRYGQR$];P5J3)W';95>@+QO_O1#6P';)E@(@=% M!+!2ZB0IB@;724:=BDY[S?9VR>M@- MV8XXQN1BXD!4+I5@#K_SFB;BI>&"LF"8VY=I5&EQ^Z>Z=MAPQV MV3MLC?HB_9^;V7QQUO1IN^'Z)NC.6P$[YZ?+1FR[SZH\NNA C2.^E%5) MK2D)24>2 X_<9G3>3:7@ROY3PDZ.O:2Q3G*TS:V'TC E6.)"6+RX$5U"9LW> M/B7UCKVZ/,9A4?)4BJ,8*^43K,3SC,G$.\$Q3HN,CV6^<3(Y M21KQK52E8$B@LH:0)3%4*ZN3]TG4V9$?XJB=M5\ICZ&%,)]=IO[R52J+[&1< M=OI% BK@,N5=#K@GEY8. /B2*PO()WZEJ@ANW^U=':C'-EA]9^QW0?<26++?5]E M[0P)M*&5 @\]*D33%/Z>].$0D?>2R>_+;9)):J*7=CN<;Z9E2*%'8%:%9 C5):"JX(+ +;;G&> M@G,/EFETN[)4L*\BO,4"T13B.6A)'3XJY$1N"6ZL@#$OK,^!$L4B;G-29!), M06? 1.N4"JR.O[D3TCDH1C?RKI =>5$BP^4:NV6UJQ(>L@X$4D(P5)3>^@&= MZNPCSSEZL_>BJ1:KQ'T89Q!<.%ZL%7:)[?D=%]-IZ2JY.%/Z^?;N,^_];?G= M8@9WTQBG-Q1U8)Q+QS??XCD=+ZRQX+T=[GXB[/'/E/83@*@[:;#X=QOFJ=/P? M2,CLP\=_K/;^%*G@7#.2,I0;VU%:%DJNNF?21V,"R%I^VAY8)ZAM/3GSC[R] MKFBK$ EZ#]-%RZ)Q7&9NKGU1*X6.CFJ";@7:*\8'XO&-(U1'3T'I@ 9J%6W: M >B?>M0)53UVB[B(RURA4N;P2PEXC&8/431K"['M,5WU?W@2XD:C!W3,C,S< M&.ZR=*%T3(X2K -G-;[$W>SW5CWWM/?OOMK)N!ISQR3L!Y0Z2WFCA7 MND$:&Y4I:2FFCGN]#U5K)W(V@_F]!Y?F&4-4U657M7+I[K)]RB F$Q9-RR,K MI8#!>!)TB,3S), 91[W=UV2VA7_9$&'_:U9GVO+(!:U!2H7M#''-2]/S_QC. MKU[=S.:3:YB^'?HP')4K+X?2)=GBY(.,EI@4@I7%+4%>7T!;@T81B X4^&RV7U%KOT4DL/0 =LQ$A M,Q4H4'3XZM2Y-D%W!@I3C8P*+2"6&-]NP_AM(<3E;3H?_O=BJ5M6Y+ !%\I" MAD",YQGUW 0TP:4F1CN3 3U6[NO$;XX$?'9J59>R&AT@XA6DFQ&\RULD,_OY M]MY/RR/-()2RP5#"2Y*2Q)63!)"2<)>4##IJK2LUS3L0:5_5"-4TJBHUSZ5R M8<]K\_/M;_[_3*:++KR+DR%G!)721>(DC>@89'0,1$B$*!6S4DX$/!IT@VJ*4!S1>N,O6>@=)(; M%XPONL#1VHP6[4X5 TG9&L.LR*I2BYMGH6Q/9 <\5UT[A+0*.O8)XM5X,II< MWBY.(A]!7IX2NE@ZE/M(E,R<2"Z!>.J! B@@;GH4IWT@$;P^C?_JY*\F;#9 M.4,U:D(V(BB+UT@G8T."1&1*:+4"8\3'@-\)_(]V.&M6J<".=P#6,TDR!R M("+()"#)9/9>W/XR5.&I),:>-.$067>H 8MP^__ZS]\@#:,?O7W[ZI6_]M/) MQYO/Y8KY5WY^!7.8;F)>E[@9W,A*AI(%BRLCYY9X_%JJ%#0%QW%EW,C9V'&\ M<22 _NV,+LB;]"SYG=9%]UEBJT.](K?UD?#LSWMGPK-?AC-_>3F%Y?'>)*_^ M08N,LK9#=I5]UNG4-S+5N.$YYA2R2AXM#K!1)$;O=X^/!W MZX??14L=@,N!)J)*/:2DE.-R*3)A^+K@KXS1E1KU/(6L?0[WXGFO[\G]?@K$ MKU_CZ*9T>"IO,?Y_*IVPHE?H=)2;430P(@WSYU4EQ[G;M>EJX(?MT,>JS*TS+/77!*4AR!2*TJGRM0]5 M7^1<4B>B=,3;TF/+ MN*B"8BXWZ_:) ]S3&_QI4V=V(3B5_]\=M9,.1=RA27\/S^QBG%:(9BM3M0FH M0]S\0_A_#*=?[[X;IA[3WI&8>],!F3.48@?"F,E$*L-+JQI/K&+14&E\XHVB MQ\^1^QWN?(_4'R+=KCUY]"9+>'I]\ZR%R#+N@!!"B5PZ2FP2E)B8O9/1\1": M):T^>&Q_1F&'/2< *622(]NO?4I(1:/)J@/ M)C/5E+#[#SX'RHX65,?+ZK=6$'^'R>74?[XJX9O%4I*53I0K01PZYR4;59#@ M\4OB*H"R(D7H;EG=">.L[*INA-WA(J>RQ.4-E"\]\W4@ ;0F.C+0G(9L0J/F$<]1 ?986'WR?XB( M.^0]EN*3Z>W@'Q\'-!JT#P(CCI?04.04YV094> YE\&QO#>2-X/XE\O)EY]6 M3USRO/IA0?."X+OQ^MW$.Q+\I)74*@34?I^,__&M19\3:(Y 0&,_EQ9]7A"? MM2-"2D:!)[3\ZE20W@/QDEEM*],>^Q<\>4+RNY^6\K(O5<^B'@W2V^G3_NEM MG#>9I'C(3/"@J+3 0T)G&#A+,7'&,GOZO.G1<)5/F)*20EIC"9BB>FA1EILO M%.HQ6IC"HI-1J<%)K1.F^S626TLC5RU*/L'T>@ )_==,\8UE!FWJP'#VV2?B M=+E=VX(U.3RENX<,^ R/A0Y1@&UUJ)W*N.LPP;;#J@_#RZMY$<3\9CI>>=RK M'Q852!=Y#M/U!6:_H%FVN.UI<=O9%"X^?YY.OOC1( 9@C$H@D$KZBB^=JW.Y MS1$$UQIM,Y.;!1RJ03PG77L>/'8=5,567BI4:K(V4KG&"(MEG>T,%#?U?:U$KN77=@>!+M;TC%]<&,8,&4(YP2(L($I"0LR3 <09@F/(N=J,]32%]5UI5A:<* M?:SW]B39O!_O]62Z_ORZ6/S->)T?_FIR'8;CY8=-)I9OXVH66V?TK87*XL+._R[X5PE,JY8[ M2PMBX%1(R;-(T!C(1&;O2P,O1:+*(:.G9UEVS1;,#M"]&E5JI&#,IOC')&=<2&:A6H5$7B4;G'M^&?99'G@>1.&DKS(Y/MA8@ MUCV-&\#H_%#S'H#^CS&/I&"3Q!;RJTFGBQ3 HDI*AZX?DXFXD!W1.@D1>9:T M6:CT>="XYS"R8Q8/$%O'[*T\KA60:!VW+*"]$)TMJ122.%&28!0OF6S6"--= MXNZ#H?L]JCI:^),N)-=A"'+;D>3Q?_/IFD/X>CD1\_:@?0Q;GB(8_OZD3QZ"EMG"5* M;V)P45$3DQ29V>B3L R_H\)IZ@>'#%2M?>NU";H6B<_W)2WJ!BJI<847='%]17ESH&2-2F7'33Q_=3$1?_7!:(+V= MS&8#'Z5B'#)ASKG2]%"A1YLC$1#!VZ #C766QNUXSE C.A!\A88QNZ?]CQGD MFU$Y^AD$P6TP:(\QFDLK9B$)_BH1RW3B+DB))E[/^^8=NC-4E^[,5UALK2(1$5VJC?=>3: M(XAE4!4TXYR&A(P6QUUK16RY0\(8X5D(G$E91V6:8^SK>**ZTE2BY7D=6)AR M44!2AEAJ9+F5TA&74^D&:(*,06NYF0#WD@\L:E&Z]?CB$-%6C'8U,I%6)1JXB0''3W"CZ3XXNC*3Q:-U$[.XL?Q%U MMN5&8L5+R_2D(TQ,IT">01FKG>=5@76>'%NL'?IB,1J\GTW(=\\!:10-( M2YQDY6)29D@H%PI2%FB*P$L9:=79W0/3?[R@'=N[@H['RK?"P<0:TH!Q7!>M M$X0;AJ:/L90XBO-B.AKT0AAGHDY4<8W@=.0>3<<.>@^29<5#!9P3#"_'RR38 M>+NX;GBTB$S]'<6SB'?C4@I9>$&<*5<[VF2(0X<3=UP>N<;I6M7(1CR:]:=,Q'A?.'.PW.8#/.B2BP C4X>N)%R;H-R6OK4_:I3O1O^VK0)M*Y?N(R MV()^G.;@@ A/=1$P(Y:CA9A%Y@!.456I?'D'H+YBF-UN9%U(]]31R;M6M?<2 M!191 ) LZ* 9T;0HOY(*E7_1I4'X%+Q)3-9)TG@$Y?31RQ;\/FH)W$;.%;;) M!X!6O3F:0*IZ-<<64*>YEZ,E7?O(;R'KGM3 :V:HH908'Q.NB.72(I<-L99; MIR5WRM;)O^B-_B?NXJC/_B$BKMN[$W<[3:-@B*24CR2(!"%9--Z3$L'0R,Q& M,\'GU;NS,RGO[MQYB(AJ=^Y4P46<5231EDP^C\:R!42E=,Q *5BS:9H^M\Z= MM0@[6DS/(P"Z^7.= .BN47H(@#::X$8 -*9RR['V*DHO ==>ZT0,T0F!GB#8 MN"\ NFN\'G*[DP(3@[5$1^_1?S1H*&H?B&(.(-M@<3(O-K=[SQA_GRZ\>".L M\-H0!M'A&.]O[;:0+9,\TX>H0;3G@TM'#R:@08-V#[R+& MF^N;D9]#NI\V-@@Z>]QL$TG.E19##O< 83))*BD>OUGR[S ?("8MI$I$9XDO0'2!.* "T3$*$5B.K.]\X8+K^U*=0XFH$-P]("6M M%$4P8)*P5%+2F )BE=9$I.R%<*6M4)UVK2\T^;.-TE2BY;F$5P^Y?)R7YJ>0 M'?4X0"0IP_)=JLFS9>P5G3UN^UMO8F\"=RJ ML=T# 9\F[EM- 9HK6F?L/0.E8S$QXX0E.0 E$E(FZ&](PJUVWCOALN_=^.I/ MV9Z(,C]773N$M*YCTZLFCR7X.IZ,)I=#6/=[E\RKZ)DFACE$Y1(CH43@C0#E M([.&F6:]IW<.\:Q,\O;,3#H7:X7XP+?.G[!,!9E=#3^OH5G$18WF)"?*B=0R MDI!QW@J8L5'A]*%.9N$>4.>I(UVS46'G^33U":[]](]O]S\PYZW(BD0H:1N6 M&>*<$T318#13TEK;Z.:;@[5C$\EYJT0KN5=PX]\.(VZO<'$Y!5CWS%]#H]$P ML,&1P 3ZH5)HXA)"R];CWID,%Z%.Y' /J//6CJ[8V%D3WOT1W-O)^++ _ 7" MO(N>27N?U]6Q6G/0&P=H0FCPT6=W[/B*CWPS MGLVG-XL&$]_"14Q C"*BH1'*_:>1EEP*@SL)8]IHRF5.E9J];@?4?DD:P[O\ M:@II.'_MXZ(I[ZHKS 8A&NTM:*)4 MZ:S!6;E4(28"61MP3N;@0P\ORQVB\]"-3N1=P=%XF+]!2T$]9/*U1O&PUZ9>$ M"MV2'@IC<>D8RS9J$27)S)3ZGB!)\,(1+I@(G(7L8AW/Z3&6EZT<'[$9ZCAG3$1X?W=BR6N0TS:3293-^,YS"%V;R &UB5$R#F936@M*FT MC@0@*;B ^X5&G6^6C?S$0"^;\LY%^9AFW2'-Y:=?ED>)]Q&N[S4:,$@6;6)* MO..XD(D4<2'SN)LIG;,1SD;6[%ZT@X8].Q7H4LR/%<+4B&J\FEQ?#^<+_85R MDVG$[_PE#&3VD3$J2#8.H8(&8G6T1 0KC3/==.6J#(",)I%2)$CPQ $/VCD0>2E6YL(I+;0'QT MBEA)O4VVW)B1CMA1FHU^!FI17>A;(EWMRMJ.0?SQ)LS@OVZ*/S7Y#7=*-))' MBQL59PN^9@/(QK-2TV^@M+HW)9:UQ^?/=ZQ.MS0*L)9"'=[\4!;P7R*AJ3H-(*AB5B>@<04#!B.QA>KE7IPA^)E MZT-KN6XAN76L]$'47S*M@@Y(@P^VU($GXH$!R=K0A"Z9UI4JT\[OC.5HN6XA MN75H=)M5?=\EOUA=H?OK. VBY)F!+,%Z46[;3.B?XSP)\RJD;+4(IDX'I0- MGHF*5&)EBP:UO]SXP?P_0(+KST7B[Z?#>-\EYT')E#(GC$N#.!4Z90Y7-Z L M^AB-TI4JRQH"/ _-J<'&%JTY.N:ZXY!H4;T4E8XA+C:\4&Y2T8@IAD! )%XN M>L[1F1XTI-\+L.L?P!TLV^=20%@VROEJH_R$_V91#:*TR$+S2*(J$Z$T$ M9 M$Z717J(V*MZL,?91AL@FFI-=BMV6X2TF22M)5T@'VL2T2MEM@JIJ+=]V7*D[;$,BD(C=S(5+8U5J=G6Y^J\$1!75^: M<(BL:VC /<-XG6O/0D@&!!'2EDMT<+K.EZS[$!1PE7#'K'\ =ZJ"ARY8VN-[ M'"'B&H5R#_R@A69'9W$FM)A'G.($\8L-Z#OC5F=L"IF&4,=4?(SE7&R EE*N M4._T$-%*M9M@JKK_;T-UFMV_+6-[%:"%N"NL^UNQ<8XJ37.I!(^:2)-+RW2> M2+G9-T'"/^GXPE7@B5V_#PTX1,I5FO1^F8R^E)3BAPG'RYT)G,1_@LZQL4[A MSH3&C35>$%ZJ%VA0Z5%.=V?M>O? ZM\.:,_+-M'0]#6L+ M13D;+$UHG"C+T=)UI4TMTX0[)277G"8AJNC!(RAGP'T[\=:XEW"QLFGKI?8I M$Q-+P<"B^IH+3;)G:)]*I;)KY.:]C&M$NS+OCI=AA^47FS>]-8%QKO>%'D3! MCILFCY%?Q?M"?;F7+;%(M"Q%/=%PXJ5:7'7-:;8&@FAT./P\:&QT7V@7+!XB MMJKWA5J1K$V(P3.9<(TO%\+X% FUADHA/(NIT<'N2[HO]"#A[[PO]!#)5;TO MU+CHG,N6!,92"=%88AVBL8#[-DN+E/GN*'P>]X4>3>'1DJO@W]PO>%JL+)9K MKQBB2$GG8KF5]OTJ$7!<)FL,_E"G;]PFDI=N^70BX0K5B/?QK*SU)HBJ!K4> M8SI-2*L=5WN(;R'HRB_]"IFCT4G.'=$,E5O2R(E#1XL$HZU2CG&@=3J^]47] M$Z&LVLP?(M\*C*]\ZG=?8#H>7E[-7P_'?AR'X\L"\>,D3[_]Y/?_K/ MY2]K,X-ES3EZ\]:41'$E\K+QF!8&_T]3D66=$\Y6L/L/A;3E?7L@I ?2*@3) M?O8SN(=&H"6J8]3$^"('JQ5QUE(D/KM(&0B?Z]SW^A#'B]>)%F+M\;*E^SG& MZ_[AD[PLN^VDW=OVA];H^=8 _D;C-VN]24$9FI61H$00F5,F55*"9;3M!T\_ MOD[WMP3..!E4$:LO5JP@7J,:HM/!T-T(WN0Z"=25NK]M5+#XZ?06%\=5-ZFD M%8#S0("5\@4C+?'X,X$8&9,A:W!UFI3N0_5\DGP/T87]"9XMY%ZEFUN&*6Z: MR[T27DUFRRM0)+Z2X',F695FR^6V#*?*YI@TE\$!X*M921VV CH736@O[4J) M>M]*7)**3M$2&:/6E6(U2T)F@K@4G?#HUJ=*Q_3/LW2H#=U'R[5"=LZV, UC M5#LE*/%&&2)S5,3S*$HWEQB,""R:/OHG/8L,_NX6^,-E^[PS^+D!%[(GEFI MD]D[X@S5A"8(U@FJ%*M41O;,,_@/8KA1!O\!DNXQ@[\!JN\\@_\0WAIF\!\A M]/Y4 BU5D#1YL@CX28'H2KMN@GZZ-4+PR$,_13W/+H._>TTX1-;]9/"#UB(: MD$1P35<7S">K2/;6ZL!3X+E.$M]C+,\F@_\@EI[.X#]$Q/UD\'-GK!4R$08X M-\F$)CX'2Y0*BCMF@S#?8P9_&QN@I93[RN!O@NG[S> _B+%&^=M'B+NO#'XJ MP4?C&/$TZX(-2 BBM !U02GT87.EKB+/.8._1)9,-K^,-OH0,_H.8.RB#_Q"Q]Y+![WAB*?E,.,^22)E*20'C MQ(D0%179@*_C CS7#/XVW+<3;X_GE!^O_!3*D6IZ-;G^C&OFXNZ]%F>4^Q_8 MU?GD ; WSB:E-]H9QB""ES:R@(8=Y<:@":X"^G2#_8]N^=9M??;%=%J2*A>M MV&_O/O+>WY9?7?SII^DNJBDR\WJ1RI!IL4^91K]$X@Z%4\K"XFH2ZV0GML?> M>LTZ%L&[10>>V;N;^6SNQPF7Y&7WIG6[ZU]@U?;:.POHIFFB*2UE5>BJ6<\] M25PD06G0M7RBZE/K?TWM6=OOD_$7F.%4%N*9+;I+W_][2?7X?3+_WS#_ '%R.5Z\-99% MIB/Z$YLRE :*#LTC*H@#2YWW,J=0Y_+0?N?YS_?C^:A1A5JQ=7;R MRD+:)_;9+KDO#Y:4D%EF1PE:5N@NR.")53D39H%K(RW7E9KD=3:%OA*Z3FU+ MGX3RYY(Q]G[DQ[_[ZV7V ^,JAPR,:)/13J,)W0&J$DDT)9856,WK9([>1W&J MT^$3Z<'FA<#'\E'!*5MC6:=(-$!3]1SY(9[3G" ?S\\.HEL(MS[EX(R**4N2 M6+G6S615[I%-A 63M*5>(J(72_43)\6UF#Y$IATRO+@"YP+%33_.)_&/BW&) M<.*Z-?P"BZ6KH%R=766(X(+TB M]%DFU(T%)2SAHI]%59[3A%6F-ANO?HFY# MR*2J-#N,&R\0?C/>"\CW-]-XA3O6/6R<266R#X0:B=:VA$ \M9(HZ@$HR&C M-F+ZB8%>+L==2K#/<]ZE=>C'Z>\PN9SZSU?#^&:<)]/KI;_FT9@IRMKFY/? M(3H["VXSM,8A"2410?!*N>-U2E%9GVP(&P<'#I8VRR-R^4M(I\GT_EP M?'EOI#M?1TO+5'* 'HX71 HI2"AA5723?9!<>V"U$C>>1M?6_EB?3[Q#P]V7 M05:#S@91&&:X*TV?%)3J*U"M4J!/ZWPGI!*&@KO5CTU3I1OP5 M3C\O9C- %,X)IU+VY6)JW$M%CL0*]/,53TQPQIA.=3+7E^.?(>-'"+9&LNID M83U-%Q/[,)S]<7=S$AMHSGAT3A$=O%Z4\Y'@J"19:^6R-D[1.N?4^U"=H2IT M1D*%([Q[P9G=8OCY=O7'91@&@N&>&B#,*I1%$I;X7$I#(X"UA@J6ZE3 'P&V MMUAK;26J3=2IXZ:EG^''N9\OGG9G$_K1(DS@;3)!*T56$62K U35)DJAA5(*";.J$]4^C-$^5 M:9]49P[AHDX!-XQOX#5*!:$BSCC_C^'\ZM7-;#ZYANG*#HJ.6UU2(]%^3B@! M(X@-7A(M5!)&\V!\G)H*4A10LBX.=?Q1?;!.C,]Z8Z"?DS@;XVO@LU66_2J M %3I3V SL4>1">5CQP$,4K@NT%-(KX<+C/C=$Y40XX]F;8G;CEX"OTX M1/@5].)N'WP$P:VR;%$ M3FJRL--T[3V/\>/--1INMY.,=M='/X)9N'T_G:2;.'_EYW YF=[62W!L/G9/ MF8]'"F,C)=*A&ZVMX-1$+X//067C04?./4>'&YY*B6R.HH=K?P#)EHU@:IF@9!%O*:DM/.\-S%D;'L!DWVE$CLO7Q9T1G1S)\)MF3 MSHA(+[+-2E";J.>0/;FR!M]-5QTE M%MYO]MZX4EH9P#A<]B 2)Y@DH(4%R0*-IKOKM+$FQQH,8GW0H^8ZSY%9X M9A?CM$(T6_FZ34!UGBZY$T[_Z9+MF7I,>T=B[DT'1-*,:P$DVP34]UFB> M-*?$)"1+)HJN+%= 7&11):&R:-;)\3DJP%$E*MWS?XB(GT_7D"U'.P_3G'H] M;-L^].G.VAJ(8K/[2([&,D6%5DHF)[P5QB4O@Z6H428=<=2V'40GYTRS"QB$]Q(J>S2)%&04(TQ;HPN*XDQPAW(4BT.%/8;+;U/9W(]:)[79S2 M'4)CC=LAOMFU!TIL:>+J:!G^K]Q<#[FT_RARLX985)W$;. ZUZE3;(>[K[C_ M2;2P1TJ?P[' ;O-+>>H3 T^" 4XD[I+$98%N='8Q6?3 !&V4L_#2/=;Z:M#( M>3V$CO[*ZAN ^CZ=UX/H:E9??X2L>U,$)Z(SU!L"BSY%+N%B2X4C*05F1=2) MYT897\]1 8YR7KOG_Q 1=\C[O5)R9YVR 2C!V=AR65$DC@9.1&8NVJ!2ROM. MBU]J ?Y!@G]<@'^(U&I4I]WKX>"Y]4Q(A8N:9$1"DK@AH7$4?30:G#%)U/$, MGV%?C&-8;2O3'F-*K_UP^N]^A.[4^IM)7AHH'DV6H0_E#M8AX"S\K-RA.AG[ M#^4VU2DZ6#_[V7#6(JC4V=A=197J"&,CK"10>YQ4-K)$I9?""Y=-,J M#RGK M-.@,1;L%X=OHR[$OMH[];OQM:/P ZOOT 9([5TL[[U,"1;)F:.@"S\2Y4H7K M':>.49"F3ARETVFT763O#?T-UR_#67'B$,9%F"VB&0.CK;4Q6))\N>VOE+CZ MH!S)P="0J0/NZJR_S?#U'V%WLV&"Z2HQ1X#M M7P-K\#[IE[0*Y8/[I3((DBEE5"8Z+4Q:=&Z""Y0P+JV!J%TT=0H2]N,Z2^WI MD(H**>Y=+.#+B%G*(+16 @UPKXA45!+O:2!1E!)_%IV.=7J,=S:%OL+BSV?3 M/ W[IPZ;/YK]S[??OOU_AKB43^/5[5OX LM(D$47$(49B(JBY+652( '29@& M+Z53H'*=%A_-\)TJP'XBW=FEP=UQ6&$[_@9M)9?%W1"/\:XB&TW 5FT0RIYJ'M MG3 6TCV=NQ2G)1<5 AS;H/%U!VJ@FC,:2>((J.1_DJ"T(D$8)J,QT5>Z@6L/ MJ.]-38[AHJ?51*R@*8?NMA$%BRTM2ADM5V;EDN2+3KC0U$.=(.L>4-^;FAS# M1@K_=0/C>+N\8C:*;(4W1#M;FHS45;!O ]173#2#V[HYM@#RY$]8-P0T,Y"[8Z9)$QI(NGRDGB@67T<5,QE>VB/:@>QZF42M:F_CE;3CIL?'C-^RK(J>/5Y,_ M$?3\"KY-8.OT)AD_\M2I9AYN9%TIZEQQJFE)> M 1=:HK,VZ 7AZ4\6[TZY; 0-H +) =T/R:0G@7D@RJKHK>/&V#J5-L\J3>F8 M3 1CF)%HK9- +:Z$N&N2$(,H71J"*">%E-;QCUY$^LCIM+2++)-#N'T>V4SW M%J-%N&&@K:,D M@<68K/4$G(^DQ$]),"(0W*P-+TV&(JV<(O!]YKZT4>#3L/]<N.=B%Z^3'4@_1C4H&G"FOG-ESK[H@- MD%6-E^[&=IHP:3<<-E",%@3TJR(^68_]YF.^>"VH*>,Z%Z1M*D$T3Z M8(GW.9"0(PN:*^]LH[Y[!R\93T+[ODW7;IFK-^B">[ ML+%+:ILI3DM>^EN;[@'53 23E"=:\Y*-F16QT0L"V@G@U(*J=!O(B13GZ8L< M3ZHWA]#1=??V51LJ7%PA/=QA;H)?GC0UH6'G&;)WBV^^E MGJR-T5*!P\>:UOIZZ<.2@YN _6<]6?>\MRKW.8:TD]>361.!2N#$LJ!P]X9$ M;'"<9)MLIDHX21O=/?,2-:R;>K+^%.P0KGJN +$J>9$I[N,LF%51G;""9$FE M-V@!1E,YI?_E58 <1.';1B@-^BQQF4J; M#>.QOD%UOA4@'5E3G;#W6,%D'XG[32#^LP*D$X*/R. _AIT358 88;,7'$BF MOMQ2C.\2;NR(/&1%N9;4@#@O!>J@ J2V_AQ"RJDJ0 0W#H1'8Y B4"DB)PX< M)5H'8,+*X&./AO6+J YB-9C*D .X:2"953P+6-J$*_&0YS[XFW12J:@A"3& M4;0#+'?IWK7WG6K*=CS?M_W3 4>/-4=UKSGKD&P#7%7MG%W( M3F/<=,'>DPK10O05-J.=^ (5F8&3N'SRNJ%1R7/B6=[&M9.:&Y MTJ=&'"+Q?C1AE28$Z96?7;T>3?Y<;804$5$I%-'4!R(I<\2'6'+74G2*XL^T M3@)&G9_\&/+YZ +G(C8 M.F;O-Y34]RX:%5LVXN_!T/W>&G.T M\"==2*[C[?0W__4>$(46)6X%G@B:!9%. VX-P1(AT9PP@3'\57<4WA_Z!5)X MM.1ZO.CG+1H&,/MX\_GSLL3/C[Y=2C;)[SZO$J=F]^XO;M&&X_C!NNJMT=%T M-QIF* O6FLA54EKRH'W@7ECP@8GH+).#XX=M>1%#N>D6%J/_ K,X'7Y>R6U5 MP>HSMS)1()8J(!*<*^V-% D./%<0G7-URM^? -;6?5R)='RY&.'7KY]QTX6! M9E(DX)((5[(;%FT*32EKXM13Z2-+ODX8>RN<$UPWT:$V;/J&[25>(4B]?<)+ M)P?'1M_4E0Y*)64371YBO9 D"J\D_BG*4$<9]H#JJPR^IB)T)?/G4JK^9HR; M!WQ;KM^6?U H*=9YDL937NX+%YSBGEX*H#PW)/.48MD2\']5=&@/J%.%'SKC M?5)'_A6"E#N@K2)M3*D!(G5$*8]KKLF1 MA%)ZHD+R$?^$QF2=6IT3J,D3YQRGT9)#"*A2S36;O\L?_0C65\-&D0PXGY&X MY BZ_[AJHJ]/!-",1I16G-=)UWD$I7]3M4.J'I5IM9%S!2/U \R@I-)>C-,O M)?5U\KG,>&5!?PM!*)5]$D3HO.;G_X!Q>5ZB"_QY)-!.TN!1I]+X3)9RN0)T\'JR*)7E6[5>0K9 M.2E*IRQ4*"[_.XS1'Q\AOHMTC7(N-TG.AU]@0Y5++Q>!WEWDH(FT21&O&+KG M.B?K,F=0Z?;E1O#.25^ZYV-G75_W,>)7D^OKX7R1A>C'Z5MM;1Q"FVO>&SRU MJZCOH1/8".^"XU'HA,+G629NO??&1,U,9,P(DP<-GM\RD#4IK2[O/?8N5F.M M]EE:28J+C;XUE"Z6-)#D<[9))L%UI1#N3DRM"M5_ORFOPKO\'E]"E&=)9IC. M(;V>3#\ ?$5BE]T^!]'P)+2+),E83D8-7YZ1)J6]%OB5R?"4"AXRX G"M=V0 M_J!ZO89TN^[ M('Q'Y^O8)3>?8'I^^EP,KV8SG'Y@BF*!&8#Y]#^BFA]61$E MKLDJ$<^91(LL*TTU8]398[1@WZ!GJ0F=2;F"R?MP^K=KW1V-X!+2Z/;-.)<$ M)DC+*:&!'C18=.4\+XEMRE+B#$TD,TF%XBSX2@5YA^%\\6K4 ST5+.-'0EB& MJ#/UP*E3:-R5:E/!,[$YE 4/3$XA*%,IV+(=3V\G07VHQ%%"/O7Y3\G@>(LR MOUPV%_>S5;)U=A[=NDAPX4,G@&I%K!.9&"E3+#705#;2DT8),(_'/]GI3@>$ M3CH3;,=9:@_1W&\2U !3Y_FCN]#TGTS:EJ6=A+<4<6_T&\>26;0<0,66@2=B M4Q"$JRPU*KR*H9$A\0QIWY-\V@OK!TBVZTYHGZ[@%QCY/_T4+F+!]JW5!%JX M7')2?'I2[H @WK),A/'1&RN!IV:NQ(X!^DU@[$;TDX[EUK6K^&KZLY^F-^.X M[A8K#57)&I*S+F4G4I&@DB'4N!B4L_31[KR#PXT'OW3NVLBIQV34B_A?-\/9 MXED?8(;679S?%-_!C].[^15,%X;I[S!O$74\=(BN0I"MIK81C_29*R1?.6>\ M1,?T M:'8ZU#42+"_-OB/GH4Y3I2;H6JU!NX1]L2'L04*&N F&,)XCD9D*$A+NHDR% MI$V.U!C?:'%J.F+_$8;.5>'!*E9%TA5.]%=M06>O)]/W4_@RG-S,[D$?^&AU MYEH3L(#HF"I-UKC'#1-_UH(J:&96'OPJ[,=U1MI2@8@:)_GQ"M+-"-[E36W^ M@'96J:E%D:P<;9\S[LG*$5T:T,CD>'&T&=I<&?4\H34>ZYS4'@"RKYA5=;6I M18YQ33E-C8Z/B MT9>@)BU2G.MIR2$$=!UV>PN7?K18,-&NX"<:FX M2R$XXK,2)#)8?%EN.S?S MJ\ET.+]%+_GS@SM-1(C)E$ QIX KCA&.6*"4".<\DT&EE$PCSIN/>38*4$G, M%2[T6$3/'J8B1_ B)4D)+UU+93"(2(,GQB>J8C( M@.N,"3Y!G4Z)AR)MNYY=O'OUYF(^GP[#S;Q$9SY-WOLIOLB_P_Q=_N2_?IB, M1J\GTS_]- T1>(=3U+@Y_ACR9XKX:1WXV&^;ATDJ8K>>^32Z#&&C2 M,0+1B:,0<+LG05E-HL;W)G$;G6K4P_!PN^HHO.>K43WP5R%[?=]BO,;]?C)= M4+0-?M#,)X<*(M&_0/A>$VN-)CP+%%FF3- ZNUU+X&>LASTR6L%UW+(P&WQ' MG*#E%<$U62HG$!$+)'H=36;::U]GB7MJ0ZQF8B^/ )WR@AJ&?F%8M";QB5A1 MVK*SP&V )&VE;E"'H.SKD+Y? [(63<_EQ/Y;*&*IUF5^D_&BRJH<&$6:G BL MG#@GB4L SR4@H0E%408A*4C;J,_Y$2_<'EBG.K6OIPR/;-*N2*E@GFY@6H6N MFH"J>F"_%=9I#NH[I&]22_:]*09BX%)21W*BLC2U*>69CI)DD@S:.XH6QDM7 MB">.Y/O6AT-$7D$/[BV3GZ9^/!LMCRC2_[F9S>^=3 2AO?7>$JUL*-??96*9 M0M.6HJ?CE0K"USD':(:O?[^@ S)W6R]=,;$S\G7D.<$C&A<2 TC7/_U:PN.S M(6ZFOXYOKE>=K-\.9_,&YP('J$H9<+:I*P7 8><#'4SDVWE R_=O>4M+*)V M8IW-=F.(+D(/RT?^/AF76V.*85LM5O!HI/XC %L9VNJ_[Q++H;53JU^7+\'/ MX-_^Y?\'4$L#!!0 ( MT?U;EOH>6'"T "(N 4 86YG;RTR,#(S M,#(R.%]G,2YG:6;MMO57%-X7-3ST,* ,0TI)=PS-T-T@+0U#=XNDT@Q#IZ22 MTB4A[=#=(9)#MP*" N+X?K[O^ZSGKWC/+_?N>\[:>^VS[CWKJFFH2L#@S+@E M@-\ P!-F.2B;' F;,@F'.B6/&BFW#JV )CVK KW0"S(^0P;1E]PR)FS2EDSB MQC!.97J8':V4.Y5L\#.90#99>R5.90->-7/A%\[BAGXR/B'27M3R;]CEW7F5 MG"6U[$0UW5D4?;DT0KG57T-?O!76"Q-5M=$P\WJI&*QFX.:I$&CJ%!*D8%S! M(%;#(/&)0;J#0;:<0R96RCA'RKB&1[&/7;6-2[D)IELJ:UXKHI<@Z5(MYWQ" MK3O!I3O$J;G(:[C&:[+%9S8F^G(9:KHN8C4G83$K8'[ 9G+":'3*;KK';;;# M8;HC9#T!L_LJZ; G"C\7<=@5L"U2LFY7L^A0,:]0,$]1]>PV<:G7\IV0MU[2 M\KY0]/ZN'W)B%GZJYMOO$##F&;YH&T*M&$.EFOI<.XWK11*G5B*O/E+(*(%1 M)YU-/X?/*$W$+%W8LLA(.=K8)]*ZC9+*G?K&GY7=5S6=:>6#J:US"363G2TC58U;G<\'EH MKP/UHWGP[O-H^_#&P-CL_/+Z\>CT_?#B]^5O?Y:V+L;GA^?W%C=.E]=V=O:. M;O8.'W=/=H^O+J]^/E[]O/QY!_C_ P!@NL?% @"J ;S_ _][$P @!F!(2*?> M5-P?#23CM@RZS*I0,B\\SE7W+E3:Y;B\MBC=5D>_WZ9Y^]C^=9>'56W;I/V;(G M/S=N?XG (6+0[FC:B4Y*V;#R>$E4-IC&HO5>N_/3P63NYT/XU+,?)89Y2HD, M.EVM)XM5R[LG4VO\[WNK[2??ZW2W7ZR7/&O;>O)+]/LV*IKHN6Y/T+1.3^;; M6\^>SI]')Z5'1FQNR<;[=[*HPF]W_J2J/$=R MF>G?/6H 5/<)%0W&J$9HZE,^S7<[J^]8B'$*%FXZ/6OD!S+5/M4]SCUK'F.7 MRK"[NGTX:ZG_#CZK4).O.6];=>+1R[ZZ 'A2Q<18Q!+W?6+DJ[IU333F"ALB M'>GVO=/7#"B68![M#5./0G:%APN-TOR(8QIE^5-3Q1BH(LTSS(GO*Z3^9#[J M@?F+,0QR.?Q#.V]_VD9^&QO"<QE"N057_X%-=Q:SV M2F.'.]RSI?Z M]<\Y=Z,B$RZE+Y-JR&[NH_K&PK ED5HI""0< :L<@U8K&!;_ MU\EV8;6?)!'J9497-R0Q??6_=3],T8]P#%_1B>TGNCM>;7":AU@-]/'_36<' M_X1ZYB-?OC'<\S>4+=Q7JO7J,GX7G[S;/T&XXT[/07HM @G-P3QHV\Y:??:I M^WW^\,-00^CU"CKR>OSG!^G=L9LE&^R_/QG"D?0D??Q1!CL\K7R5/\8&C<+& M_:A?OQD??4="P>T2!M>%DP2 MD,HXWXS?9;'/ZJT2A,;7BQH529&+ M0LTP]K]$^FA@!T-E":XO63/0@[W[Z/@/%Q[Q+Y- W R"\7P/3/&#"GC/4\9& M6#*8<&"FV#^^VTF9N.ZR%58I$AV:\'XXOFWI3;5U61?D4#F4H=2/G0 MQU'?&0TN8UH_TM8/,(;$YY7&:]Z"?&2$&1UE:VPF*L MYQ;E!(6!1Q]-LL&<"HQ+)2&WM;9X* $$"58%5F-Y5^CI35 R*5MK)PP=AK0 MQ/V5(!R""Y^NM>XUCR",0-=Q6T53&?J!/H,("=]7\00E\\:4YD'(G%*#"Y_.6? O=,?#'3\NO2#!BU])B>],H3KR5T"^.+[^C,O+@"<&7]1, M!3B6VYH1+PS@L-P.!ZB)H-;YD3VN^RJ'S)9-S.LDL)%E% G5B%D:_)I0(R"( M71G3/#K7Y)!K=(=*V?L4 [M&D[[?J>6Z4\*P0@5UHG.QR7PP@\\W]**>;ORN M)81&4P\T.5L$^K E B_?QJ6)H2*B2,P92NB@R,P7C%W)^(Y"6B.FAW_36QA3 M+AWHV#W2U"R#GB29$'(^@ATA&89CO,]>5?\Y!)9-!S%6'*\.SZ$)C KV(23X MMYJT!5>Y1( TCR:GKW;&2:)E6K5I\"& MM=E-72Z;-67%)LK>U<-BHG^='_Z2[U4RTI,DE.GJ)O>MH8&/Q<+:(+3Z3D+N MZM2(VF#BEE+C'"-]&,\NI^CG(B&J2&ZMU=9>OOK7J:Q!RP!$,)A($JVL\M&= M*][4+VSG'[_&8.@OGXS+@KQ$L829>AG%G*X;+S41'#WAR(Q/)V@"6 067A2W M&59$\6SQ8XLF]B8S*SA*0.W=$\\+"ZY C_)V:M&%O%R^F<"2^/S?[DY3AVZ_N0TQQ0._G M7S>;M MW[]W?NT?'2[R.0Q!'L'0_Q8G%C_:^(UJ0"C UHL=_LJV&1>*!J13F!"C;#[@ M$O(J!%)%X5;N4Y;^-U>7P^@B09/1H.+B<'PJ/]!.X.YH.+V@N(L>Y&;4B!,! M@7&^&2T'S[X4^CT*F0RPPTL/82L3%%I]*T$=-D4 *1%7D)'0>XB*:7C]AF@G M@LT(\@X=0QGKIE1I8%T>Y<&*#4C#YE:(?*V/*X8.#68#/+>-\@C +[F,C%KA MC453FDCHG5:""T<5K.]B.9OCM47#Z'8D,*Q70=K+\:SSL;(2;PCU0Q]_0A2 MRGC] ?A 3951TCR@9A("3$HN%KFJ>DN@Z0*(-D?(JKX.^L 9S+^J_88%7($0 MW,4'N@;1F_^.^SFBZCD'05Z:7.GC"EV:F>]$*P%C4JG%1$PA,:8(ADC$FNJ+ MCX&+@)HU>^$LK%ZY/HD3S8J!E";/(]2=&".YKA*I=K&=/U.>2>B]XD@X0@B. M B'3QTFB"!A3_YM4]126$L36JDZ*4C)+^MN+UPE/S(3<(Y"R8Z\/)#+&.Z*Y MN,*8L3)<8C&QV/H)Y+'ZQ)UR=@! :7%JSSQN.BLHU!9@6P&P55-TM4WD2P=2 M,>/RHJ!NI,CXKRF$3"G<]_Q")_'<7-D@K&3&*R1N13!N)*CE+INH.88-)QKL M',U GL[S#$((>V&> %XPS4X8"O1^]HX(GKX;;QF28&*-F\W*"N IB4O:R:P3 M G\$ XG0QMA0@*<1M@ <*&0L3U!-J3OFZ(!..!7+/UO$2;FZ,Z\M6/G5[Q3*[+R%DVPUS)(<:7MA&>(=T/<= M4W\A=G11H8;B52ZX<_P_4IG?I458F4IEN8#H:KJX8'F\DEQK42P\/ "TA(!H M%WNP@]*C$]^*W)("_\.D:X>EI'OTKJR(LP2;Z?US>-'TQ]+B*D__O?1^ MYY)^1[E&SFQ/E"JCWH=Q?37C"' $8Y:"HQDKJY?1;X@IU(4'+>-&&L<6[7\7 M'URE6E&J'D0T'^(_F&$FH8AI&27M4%5$NX(MOY%Z=);KY8.TQ!53)<'X$@37 M!-52XHK_R NH_*N)KY#-ZO:7P8(R7TN2'P0I\EP(;DG_<2 9],M2A/V)]3T6 MQ@CTS$/^L%3M"L#)EA E2S?W-\5-PL0@\'/"EJD/' M!7'K_#X"X2 N@!&AK;)3;BJT'P\#EV(QK51WJ9T_ED [@\.0PD!@P1^R,OKF ML(O3,&1[2>,WT@@NA8(J<$5QD9(D>*3K]8ED]N7]"P9N7R[?IJ?5X$ :)QPB MY-I]$[X^Z&RO\FXB8!&_5JFLEGB]U!(GYP,JX%*RBO^$M!!9F@ER)Z=YZYJ' MJ6 FK:8B"\83)+3U479&UQM7TBUU8:_D@R-M =B, -4; ""BA=\7-&7 $*>1 M9)9>]B4V!P>KD"T?S!!:R=;<0&7OSO'02.!;FF .3IP )T_4"5BT41MZHU7; MF>:;Z@=)G1)K.)O?3VM\@A]6-QQ+T!6\:W]5DGPL89@(Y@@5_+/V*24SA;&D MF2':S6"-E)FH#5M?X$ZH _L*2?20L=220(=2C4)E=C>W9.>!\YH BK2Y*CQD MK?[T<1J5>?.Z-A9@4*A2"@_8+S$HZ50BFP>BLI8?/U;2TB5G&_P9YZ[F56T M]22I:8$@)SR\O@#D30O-*'BWTMXC/*_[>;(I%^,"J;CKQO'M^>Y0VK-&NA%: M(+$C$2@%84"IAJ,ZZW"@(RE%@Y==0@KRJ_!<7$H:K$1!EC_5*3][B'9J MKQ=) 8_)S5+@"?=&I3W2SNXFCO1&UA/2%MI"SO[>0LI>CO0OU#][=F@_BW60 MC_+TXI#VKW7WQH9"5C@*:7_U>DF5P>;%1;$(1-V5_VA!;KK[ZJX[05B$K%D M16.R9#]Z!11W!QG-4!ZJZFM_M(3X6POP1N) 1_4 ,6D["*N&F[0#SOAVA:I& M<73 [DR":[W,[:2W?QUE4$?62"3P_;1&\^@SAV"WEC8X\<^7%)P!'M\1&DVR M],M4M9MAH/Y@7;\,AB=BD-"W!N[C!)C#&M5GJ&C%5J*C<4Q*8DM4\3?L)>C/ M.0GNU^L!ISX6^N]]X7+QU#T/^EL+:1QS?7HNZ,T[RG^6KV38YS?>+=,\WDTS MS@;W9)$&$]%!J^DJ\@K!Y'5DOKQD3_2R_I!-,.V,%LUCUS*/$>@/^2NU B*R MNC)$Q*5I+K)&E%HF[:1%%MP]UWJF5<R-!QCGE?7(7AVBH- M?>))MOX9$:9)J_5)9H79@'7A-;JIZ/,!J69I,7UL06U%85[(V-2SB1[LUT-@ MDT=^>X#1O"89X>8S!O!6H0!700L M$)7,*B,;6'=F=I.$N7<6!-,7?))F]PAG6:YR_M8MXOL.2&,MB& !:5&J81Y@ MBE[JQ(VY%2E%Z; X<4'.\7[LR+VE6IY9(M*.[9Y9BS'P:.BFB=6[!%Y6EH/#]I%D*B=,"1DZN, MI&NV[BN.]&)X8>!IJ8Y .OQ:';#89I7+L_[,FJ_7B*]\26MOZ6?8=[[^GIKG M&Y]&][R6F>^!HQ98%+ A346;#Y'&N#/W*] MVG;->S.(?6 4:1MF25 M/M_J=WAYH,4K==NYO[[1>Z(;K-Z7;].F#[,I+ ] M0P3!A.^(O2'#/$$7WNWA\6]8AV]9>.Y*[4S![8O#$E=Q4:H!2>#5:6JBY.4B M]F_RL6-BD2(].SA?!J9\2ZSFC ^=,,C5J=F=9#2+SNZR"QH[?0']UR],YDA4 M9Q\?/ARXWH,9RM_FQZP';=4ZR1[/4>S[;"U$OMFOLMP?*EJ'L^SP*XP)TL)7 MLR'TQ:.J^Q.X);#Z'>R%)\A<#OQTXV^".P?=)9M]!CC:[I2Z3@+/W)1=4X2M M_NYZO %C]T(4&8Y8&3K2K+\.3A3#[;?O"X^;5M)[WE^"Q:>T%ZS,IJPM[S_W6K1]+6^VR_;UJ(M! '@P(,+<1Z@&1 M_'-"ALS\R#9_E4*?]Q=;9ITR8L+HH>^8(^4*-OV3]L=5OO;N=.CD<^^OD,:K M,^FK:E3O>][%-UY#G%@;]?D_O+__#*^_P5= SY);=&-*QP7UE M['!ZL9[OMCURI/1&G6IDUULTMM]YF&Y.MCKN1+A.PE M'M,= =8&SOGZSR.)@:W#&)L]]4;PZW\(*I*;-))KMI+;P?H[0M(K =+^!(<& M8E(@0&^.M7RW6C[W=7.+:=_-T(9P:=^!X%MZ]:;-7UN4*8C?M$]6I;SOS=Y> M],[>6VCLQKV]T4L%#]O:+.MI2F+K,5D&_,QBVKV LJC)[88\"V[4,N(=5&S=L]-[OH M/]G%?LQ6? Y $:%35_(K/_7@T>5Z$G7ZE17N%IA>*>H)SLH&JB^E:U/K6/&!"$D%=$=<&(01O?OD%J-5U4?(%88VW"=9GLM&3/& MEM7D.T>"?1V8FY*^M'U]ZTQNS11M&(;1@-L3Z E-:/I[%5^>NIV@ZD#DZ@IQ MNBSCJ?,/2IQ/@8)"NHS[R(*Y:C6OKJ$RF(.B$L^)Z1F4Q:@!!_P)+6O(J]0* ML8<2'TK7S/>#'+EC!Q98\Z*'*?%V!\L@P"!>Y+4&!? ]UM!^W<#GM_40S*W6ENV$%V;@V)OT+C(JFF8VM M,M-7B<*[E+#,P(O[NIW(OBY35]A*^[M.WX-1W8BHJ#_YH/*HY5PZ#$/K-XM@ M)K6-:EE93:G2Z0H[&Z=8^,/%*52#RY@F^&P'LHR* @C+:+]649^H>?1A-87' MLYF8ZL(@4&YLGEZ$,F8WX*=>TL*^R\*" W*0Q8WKTZ]Y+?>)E@H&@0<]=CWM MK)7UG$=+?4Y8!)_8%OS'%-#\E=)U"ZM&I9U)M7>PE1Y$[2YMS[318=(%BW7V M=*7,T--1RUC1',^-^/>UG[TV.].;20)H+R#HY9J7N5*&04*&H)GH.QTP>YYN M2NNVTV*RRW[V'_OJ@Z3V5\<5=XR8Z8G#-(;^,=MXL%@KF^P_'<1NCJ;JRQ/5 M5ZJ^F[G9RR\/8[L&)!T*V:X&%4ND8X%@ #MXK\X_07(8F/(U(_%I"6_#)QS# M3](J]9\W%:/P'DLO:0P;+$!GU@[S='/"-<+8^059>U(VYKXV2J%E8R/H'[POG\\ M?^H8.2X(>E;KD;EF0=!I!T1^[VF8\NO;7S_]XST4,+OP.JJU=BU@J/NC[W4, M_A$B8%0PVM(M5<^W78ZP/Y7S*$WSL?,GT-L\.2QE1&?MS\;YE_'#!@AL5>:I M?I6]X2XFGT4VQJ&!:730.N=&+7U.99^D)$1[$+H;TWOO":+H-K5F3J_067(+ MD:RRAM^0]?/N_(C &!+.TI3V5S_3LQ B7+J7R)2E=E(.Q3&S"!N*$\C88$7\ M4RHVQ&V\^1O]+-9=D8B@X&$LY!^RKV%ZNQ\\CS3)CIZ3"EZ,<-SE? MY,LD&H7F M) PB#1V?>9-8MT+I*8'*00BE/<*WN4EW\0$^:,'RB80M"8PJ];-5P9B@<>K8 MZY'1MCM]_C^=!RU#G/GJ&?MIN"5P'?.$]#64:WXU8X7B!$6&$;]3(5TU6F4A MMTC'1)^GN!S!1UHJB9Q[D;T@._IJHI) N5LLK*D:O+">^BXNB:0\4.M+K-,R;8VLL3=/.J-;6KTZ*V M6N*A*MM$D?GRF9_\\K^R BDU\G,)QSP #@&GZ9KG3X!^A./4( !/M_X8 MA%T:KJ[69>S-$,"CH0,TP%;K9W;B!&2@7X@5N"1&:&5IEN@05 MH_K:+VD'Y% &0Y7JRXZZ.?EI'YTJ/I('IUME/VA6^=4V2O&..],/O.S*4/[$ MQ9; 26AKI@6;3$^YS 2"%WN-FG)Z>"+G[WEA9V21YB>)]S[] M?FNZ@7(QD3R[2W>Z! M%P?!A-F0JD.31'6)S1/GK4MC4>9U7IJ$UGS+2-E;YK< /8;__7$0CMO]2 L M;WJ_.'MS0JW'= ;? TWTB:6@X$Z1/G&_^O*9*FLW>4DYBTH!N(?_,Z-+AX.. MM58:ILQNOY,DZ]^]*!]O MF[N.O.\J5Y*HSZ43#_=Z#FNP7XFB4A4NS_'54?W0L@($Q6K \^ZP67EW,GP0 ML%]T83K\H%-'&@VR2]@5I> (!/[>(LR:=-J?]CF<3*:%J-0;K3"UFQUA*/>< MEP!S,T+XH.B\'CNWKLS =_@N"4QV#CKL^.2I/D-L:75I!G<*3QL/<>B\[_XS MG19$Q)Y MZV:"R5SF&H:P'VK*V@I0M7?$:O@54!F:/W187B>/.F[9F6B,P6] M><^)L087H%X=YFC"A'3ZGJ$%<76;S4^H30%V<-12&V"D6'GCG0(H8[75,>83 MEF9YO@JLYEGL2C%C:[BWLK!DL%_971&^?7W9 >/9G;$9VT?3",# RT-B,PN M!KXESP[@Z1GCEF50:7DJC?_1@:= 8/:-8+NP B67L4+FJ&1Z4;C&33L/A>+)J=%[>6V__0JT<_41! M:<%0'U1*IGSP[T)<\0.QS[^XK@T3W(F!Z,7\CV^[N6U&U6>ZS3+ET0PBP8.0US\=AK&7H2TEP./PG5?YU! M?\$WV7=,/Z5^!(;5TV1EG&!DF-X%/1QD,CM'#BE /GK;[N]54[_OZP@WH J/ MQ%GW*;[$^B62+;/"(>"C_W5_N]**[]HX]:1X;.>6@6N8I5T&//,;J1P6(:6H MQY30$+]S".3" DQ$T8M(#"0YAA= YKCCVD"RLI5SHOFDJ1[#'YYR^EX.LLGJ MU[P(VR4-NY.NJ^WK 4EP%L"RJWIM?'$UCK]H 2EA F%9LE98EC8BLJBDE,568J/,^,S&C5@YBD;7M M(H7-VSW'W8=H0L$*AP-XE,?& M_KL9; N@,BF'F@>#S^H;K>K$"> 8A P8@!41H:[-,% %2!&.L.5)=@3!Z#M( M,A(' Z^52ZA1$U*-LI9U)[7#1VC8\<"@M0="DIZ-) ?=[Y MH>9S$GK8GA=Q7J:\F3@BE2B4)Z68#>R#%?;<@H8<> D-H8"KQ0A%AZC>>P@% M8PN119(.NOAED@I%U*#9?J*!NN*+&$6IK 8,9F+P[MNHRDF+:H"4&QU082_1 MNWQD*'=$ TFBZ5_=;$@2TY/@-#446:!.PUJ%G300(2*8.-28>-FL;C167B4% MR)60'<+>-(_DJLH0,DR"AZK00Z-"'EE+5.E9P3'.2' MC9%B?335]QU%303X[H#?44=:V8N\E1 M^>A1NJDF:=2SL"%,RM!0O?34\-H@TQ59>+EJJQ'QMX'$@$(EH<(R"B P!C9 MG3=^1]295H-5=*[U)6:J1)*JM/!#%7'%4W="OPWDUWVEA!#AI#I"O29M9!E8 M0WT&5P'O,D,=83OFMI]Z5C@U8HF8= :7EJ:Y7F9_^? \A4FI_#I>I>U!$6/O27#"DV7O;NJQLT=LR= .6NHC%53!KO MF4TCN4V)#>:P"2@Z1:62""G(.MW3>VC;3NPU_SRH#:/U.;F?&$'GF($D!E&N>ACU*?>FRT%K!N'MR2[ M)WU88ER\0]/3TR-,?^:;1$^)!L5H12U=?%M*HC91+ -?+-$9;"*C+**]C1&N M>-IR"%DXB>'TF&_O7\L^[IL+&O M&0C#)7GVYKC&0:L=D_I!&)^"9Y4'V,1&DV!3GW*+MPE^4;,,H/;P- M3WNE:($9&5&;/35(Q3W96:T$2UNX/+86*I):>3R91,_4,JIS8S39\FO;)KK*!L&25:OCP-HT\NGJ.A-L[C-A%%7:7,:< 3\?/S0=2[-C\[3-.L)WY6QY MZVYU<'YSZP?>]J4HS'B8J&_XZ6?8\& LT*!)@N 6"SA-LD>^?5^QC3TP_S"\ MG8@22HF8?[S=_H>'!JX-[.&EL>4RL%5A9:S&_'IE(^"Y!8A#GTUO 4=L[.F MY15HXA7T$_:$K"$BO,&GDA(E]&FK"-N8_MBMMHY5BN,H@D,TU=8X8=S.1?C8 MLZ(=VI$=*@:]'D8 8402L D@VX6-:,*5ADH?QVY34,?0.=D-9V)VV',V,J:X M.#_NNQ"H?*Z\#VHQ #J=.PH>8/OD,'DT/Z MD0/N2$=+S*Z5T\??5BV*>H?N[39J(X?[47M0U)(G_I&/;JRZQ*B3F+.IJ[&K M+H/X5"J$\H@.'[(:1 7#X+H;[K_&S&2\6)W9&CYZ\\9!'[KE+W:$A\*U,W1. MZ=00>.+X]OV._-^B]E>+Q6GV<2O(XUH]O8KC).M].4[G2&LM@"D@-30WNCT[ MS3S29N682NSI42UAX$5OU@QD]>*+[3?RMLB3 DHG_=Q])\H(B.UPC(1=!F62 M.1Z9^\@),:4:6H"G"_AIYP PX[ MWML84NBC=)'7K!P.[.=#(W""=7<4H]OC',7PB$U_7))F]CEB56]/X7SRT.,) MY,/P_-+W6*!^VY_O5W$[Z;+']-0.-ACWZT KC=Q3MV\>+3EVUMD6O]J] M+^I7=56CK$V83GM__%"1$>;ZP?2QL M+((R)_PJRXAE1:QM1?S;!^!%^_?PAYSF=Y)M+YU@]9SPF >Q*\K75V=%RR]% MH@@(,KE-CZD^V.1MH2I&KAA^7P%D8XO9^=>V)B'_KEC4KEE)=K]3.W^DZ%N@ M?7G-^>Z:B^"<\>TPH[K=,Z@?]]$U_V\_9(JGTT,DZ;M$_HAK ;6?(B]_.K#; M=P14/LI6'$%44/#9"PN=&HO-$DL3%:\>H0'6 M)+_LU7XY4&6JI$7NC:1RR]L[OOOE6AF801TKJ;[+J1 #\OU5:+L@';N_N&,!HY^CLZB7#_*/["S.CJX,,\TM1':B.CY*C MBZMZB)^C88BND7V(NSW,@5E.%B0=)!GDZ>/I& !G#/+T\/*7#))AACMXVSE* M_K?_W[$ ,^/_6Q+@+L.L\+\$X_\TE;S]'!E%^<7X[ 6%)1C%8?R"HC )(1%> M1B&HH)@ %"8@*,('%92$PB2A@HS_)YAE08S2?@Y.D@;*JO]'[#\DP^P2$. C M*2#P^O5K_M?"_-Y^S@*",!A, "HD("3$]U\%GW^P5P \B,_+G^5_%/\?A[*C MO[V?JT^ J[<7X_\PW,[[58 ,,[/ _T0$_H_*?_8$_J^__\#_[9"CUW]M\?O/ M/]8_S-_'/P_W=[]_W=[\O+ZZ_/']XOSL].3XZ/!@?V]W![V]M;FQOO9M]>O* M\M+BPOS<[,STU.3$^-CHR/#0X$ _ZDM?;T]W5V?'Y_:VUI9/S4V-#?5UM375 M594?*\K+2DN*/[PO*BS(S\M]EY.=E9F1GI::DIR4B$Q Q,?%QD1'14:\?1,> M%AH2'/0Z\%6 OY^OC[>7IX>[FZN+LY.C@[T=W-;&VLK2PMS,]*6)L9&A@;[> M"UT=;2U-#74U515E)44%>3E9&6DI29B$N)BHB+"0(%2 GX^7AYN+DX.=C96% MF8GQ.0,]'2W-,VHJ2@IR,@@IF.3I$V(B$"&0 !\/%P<;"P"0^G\ 4$L#!!0 M ( MT?U:P_H0,?\4 ,4" 5 86YG;RTR,#(S,#(R.%]L86(N>&UL MW+UK<]PXEB;\?7X%WIZ-W:J(1!4OX*WGLB'+=J\C7+9&=DW/1,4;&;A*W$XE MU62F;+A 7 N__P_?SPMP#=>5GFQ_)<_ M^;]X?P)\20N6+Q_^Y4^_?WT/TS_]SW_]AW_XY_\/PO]X<_\1O"WH^HDO5^"V MY'C%&?B>KQ[!7QFO_@9$63R!OQ;EW_)O&,)_K6^Z+9Y?ROSA<04"+P@/_UK^ MF5,/"98R2-*80\08@B0F'LR" /N>A[PD9;.'/R<$(YIE&40A#2 B*("9SP+H MR5M#(A#SY3WJH8M\^;<_JW\(KCB0QBVK^M=_^=/C:O7\YU]__?[]^R\_2+GX MI2@??@T\+_RUN_I/[>4_CJ[_'M97^U*!7^N_;BZM\E,7RL?ZO_[';Q^_T$?^ MA&&^K%9X296 *O]S57_XL:!X56-^42]P]@KU&^PN@^HCZ L_ M -# 418+?L\%4/_]_?[#69'9K^J*7Y?\08WL'2_S@GU9X7+U$1.^D-K73UN] M//-_^5.5/STO>/?98\G%Z<D[^I85PO* MU>9^LJ5C'Z:?K*G[5?(#=Z_PCIBK56Z^4.^6;*SO[D;4U:J[U]C6UZ)8X<4( M7XNMF!V5%^J#C_*G5HQZ4 ^9UG):ZMY1E?]8\27C#5ON/1KD[%_^)'^:KROX M@/'S_*:J^.J&_GV=5[EB[IL?>34/>!P%'DN@GS(/(AS+-U<2<4@RPHF/190% M8K[:?*_G? E__]*I4,NY+.1/!A:NSLS4DE?%NJ3;=]S3XM2+2[ZSU%LN_76) MGWCUC-L;I*;*'6B4_]=:1["C)/A#J?G___.O6ZL&PKD8!:3%Q/ IZ)XN"^4: M%.4A 75 F [W2JI>VV]P!6IU6_OEU $_J]\L:JZ3Z#Z!'I^ZSO\8Z^@7X\& M]Z;L+, EO3 "[16_TD)Z1,\KN#<8RH/4-W55Z'\O&FBE\#^!HF2\E+[N"4.. MOJ4?)04M?L,K-:]NENRV6*ZD9RP]Y)Q77R5YO)&Z_FV>Q)[O^TAZ7XC$THD- M.<19FD">89J&J:!Q$IFP@);4J='";?'TE*_4VJ ">,G GM9FW*"'NAY96,?2 M,7O4^H)6X6,@P1]*:5!K;9%1C%"R2C%ZDD?E'",P#DG([.9AK/1A^4U.LZ)\ M4F9,2$"U.JW7)ZS?OYL/_E?-2/O+QY6WQA//E//11 M@*A<8_E!PB$220IQD#&894$8449BSI )-QA)GQIE*#U!K2C8:%J_:C_=_#OX MH]'9<#EC-AIZ_.(,8\>T?\&R])H?#<#T MWE^#87#\?E((-(J!GY1J/X.;U:K,R7J%R8*#50'N<"DISMXKZB025E]!^Q)& M?<6<-.[P%7+ZHF&OB,_/\H6C5M4?Y>N(WZO3Y<_B]XK7^W]S1BE&49C!@$5R M,I,P@)C&!'*!_3#EF.# R-/ME3:UR;U1%BR4MN#^\^\ *T7-9GL_PGJSWQIN MCME@"UFMZ S4JL)"0*DLN.D%SY@(M$"Q2@S]$D9E MR=F754'_]N51LG[U>;U2T1HJ &:>(!%F4>S!((H#B%! (>&9!Q-,/"Y=4S^, M8A,JN2!O:F2R41=42M\9J&J-0;%5&?R4+]N/?S:CF$O8ZY&,140=T\P6S"\- MF(VR8$=;>S2C"8M5HKDDGA?%"^?W?%%'8>28Y(M\ ME?/J=ETJAW.>X8P&$4J@%TF D>^;(R/4.\#+8>PUB%T#''=+K"#KH=;6>@U=<>RVA#8Y5G+DL= ME6FT03CD&OT;AQX2JN76EY5\N-JOZP).ZS@;Q+-0! S!+)0K(^GEQ!!C)F @ M_V$!]05),[.3PK.RIL8P[<)_HROHE!T4Q=0'LNXAHA7HG)\D#D1MP$'B13PL MGR:>ES?RD>)%PX_/%2_?,O!P,5_F*_XQ_\;9AZ7T?AYRLFB67-4-I>NG=+IH/A^81HQN(1SIGK)6'M?9@JWZS9R,=GEWL;W2P M-S]Z' R?W?-'3P)YD1856NYO?R^?PW_D1X.?>")&1Q'$'* M,((H(0DD<9K !!$1"3]E)-9:F1T\=VK>4:V:80C$(53]S',% ([I1+U'\VJ5 M4Q5_N3WHMABQ<,;V/BZ0M^SP@/SMD ,.GSG*Q#YC2#=;S_W9; K*!Q3SWWCY M(+_W>,EV KNK]IO&,Q2% LM9F'IR4@9Q -4&"O08(Y2$/J%<*^[ZHJ2I3=-6 MUWJ;!.]HJS=A+P/;/X6MPN5X4N\BM:LH^*-159/C+D/&VL38QOL:!;H]D5.$ M4)L8M6%IJ%)=KG@P]((@K5GP\@-&X45M.SJFU+]AV#KN"UYP%8;^[@?-*_X5 M_[C#+RK(H=L#%2AF68 9%-*_@4A0 3.>4$@R'&6$<19[S&0CZ(*\J?%HK6[] MQ18E7M)'J3-8X1^F>\V74-9;BUG$SK6GM(&MT15(94&KK8-]9DU@K"ZI+LD< M=?VD"<#A8DGW-C-J83R??^%T7>:K%_GD1^7G?9)?EGG*!4\C'L(TJ]-/A =) MXF.8R863)^(@R4*M)=(Y 9,CCU9'T"D)E)9ZS'$6Q'ZJL &-:VXP0T6;#"Z9 M?F+V5YS^\E!\^U7>6D_\OR/U(VQ^K&?[V8>.,KTOF=3-YXO7F4_@=\N5?)C: M/RZ?B[)V(.MMY-MBO5R5+[<%XW,FEU(\PRGT42A75UC(FX1J[]833D#0.\&RN$]X^V9G-%V;YODW#7#=D;N^3>^ M7//W4@^5HU]BNOIKOGJ\75>KXHF7-Z2J/YO[./4130D,&(D@$G$"L]CSY)(Q MY5E (IIZ1K4]-.5.C=!:M9L:?YWB3?&_3G7P1Z>\81"-[E#H;:,X -@Q2UK" MUGA?Q1 IJ_LKNK)'W66CY2:(\.6KVN?9ELH).$VP MEW HZ4NZ7BAC$!,:P43X01;1./"X45SQ !VF1FB;>?8&+U1QSFI_PAGN \9 M%#TZE%@C(>>L2HGN-%D5/CQ:W&X%FJ#/,EH(W2AO4=+X.M M1X!V(73,=SOH*6U5Q:567\5Q2N,F_.Q6AKPL=MPZD=HP'%6-U+_3 M1KKZ7[E*8>7LYIO\]('?01'$(1:A2 MV"/L(6Y$0J8*3(V2.HT!;E0&9:+E6DA7;UW* M1][S19NGTN[JBE3X*6(^C,,DE3Y7$$"2AA2F:8*SB'',4T\_BK-/U-2(;4]9 ME>_::FL2D]@+K<;A@37 '%/3/E9;10<%)XP8PZECR7X0I]8= ZN0%U6U+23\1BCF,$DI!0BEE%(J(\AY7&42 \R),2L'+F1^*F1;*,5*(1ER?;!T/I_T#$N0=3PF+(L)^*((EYJ+;-]&L%7ZN0 M$8V,4%ZXF3!TUR#I #5E4%5!V)]G@-1FJ128 3QSS=@94-)((S(*>^W9LE^3 M=C,8TB3I3#5&.2]4:PMA^^QXC5+C$ZD%"$]RKHWG#LPDI(^0ET:_LW+]IH[_*(^N_F.2U:?YLYI*+@?JPT^$C*(?$9A MEA B:3M+0I8(Q,Q\.&N:3_%?^OEBK M@JM=MML]7O%W0G"ZFL>^H"). I@*0B%"80)QJ++2 A8'<>KC+ Y,O/QQU9_: MFJ!3'?S$6N5_!G7$3_58Q]_5/_"MP891D>-^-?3>,-,=<,>O(67*#*A_P8Y% M,[ UMOEC$W>Y_]G>#0T(8/O=Z7#XN4YE::#8YO\J,$"#AL6(S5<91;O!GN.: M,&ZMH,30=^WV^X.UI$2(>33/FP91&!"(OP_)]ES*8^3&C&),P M";E9[O7VX5-;YK3YP4K!2^="EX'K?P=<"X=CAC9 8D!"]+')5V8_[SQPY%3G M8U..\YI/7#/,P7W+R>K#4K)$':%QSQE_>E8.]IVD#2Y9@JJXC0<^SP(U4^1IW.O\%57OV^+$C%RSJOZL/R>2V54E#(N^J=@UN\ MH*J0KOSQOE@LWA>EVBN89RC..)6+;A&' J(HB6"JJL;%!-.($>%QIE6_832- MI\:,V[ZXL]W.'%VQ60;DO-Z8#6J[9V#7IS<-&MVIO7K-'AV/0AGFT([%SPTV_-_KZM5 MO?W]M3B3Y%7OBI/#G?-[WE1AY5^DRLT[.B^84OEA63^E-GN.$8L%$PQBAF*( M4!K"%%,!"4UYE :413@URQ5UJ_#47H=U;EU[PD5WK#'-,W4\S'KOK"D-GN-7 MULW=A]O9Z?/)[9'3;+L]+.HB;U7SCFIMLIG_.@[PEK-G'2L]5[3,ZU7?QWS)/ZSX4S7/N!<'// @YUR=9#(/XB#)(*44 M>UXJ./:,XF NR)L:_3?JSKI,TQV5P1]*:5!K;;B$N82Y'IE;1-(Q%U\+HGFB MA1XT=C,K+L@<-Y5"#X"CW G-VP9DU^[O+[U?%$7Y82EG,*]6ZG!JCOR,97$F MH!^)5+4NBJ2+&A"(8YKX1/JP6"3:^;47A$V-9&H%0=YJ"$JIHD&>Z"5D^]G$ M-EYC[S8WV'7:UL?X%K$SR+*UB.%(>;9786F6LE]%H=-Y^8\C2*:^@@FH?3DD)]F,$/(@RGF"'L\9A)LHTV 7G%3 MH]==;55T:[[1US!2[ +*FFMP:]BY7D$?P';4N]+B\E@+$[N+VWZ1XRY-M/Y=WN%RUO^ST??K$U8=/Q9*OH3+/TBZ M8_X\8D$0\U! %D411%Z"89ID'B190(F7QG$8&;7RMJO>Y B+TG*-%_6>5%O6 M#O ?SWS)\M5:"E()<2J;D0'6U,A8/7(5OY 7S(S0+(^R'@&^WM@Y)LS6%M4N M0ID&NM]WC)L!:1[8L:^E4M!9"'[:/5]KC3Q?,0 M^1U)&?:F4)N0]3OH*Z>/R_SO:]YTHIUG4>@'29! 7Z@"@4DL_$[0U-A[HR>X>7XN"TR;8/6-UH:-BR_BK,>Z-M!SS)_7 V=,AY=0 ML4IL9X6-2E&73#XDFXO7#]@,K!T!!&)(X&T=P1U)$Z-2#IEZUG MNH:[&]I :VQ06@; M/M=+UT9=L$%0*@QV-+[<_G,@E ;[A;8A'6G3\'IHS78.36#JW3[4>M!X>X@F M=NUM)!K=.,RE^_#TC/-2/>^S^%@L'S[FWSAK_,BOQ1O^-J^>BXJSSV*..4*> M'U(8>XJC/2%@FJ41C$(2QQ&E:8*-3H>U)4^-J]_G/U3IYR7;V5ULBF&!?&-3 MTXV8U4;@A>'FH_Z@Z#F$3J!VS.M;G=6&I-(:UFIWJ^A5 0@'G>KR&GN>HC%< M5EU'?>FC^I+&H!PZE^8/&.1M;I;&=1[ENJU_*JFS+E=3GVW+1?.<8\E8'E)= MU*@/$?4(3%&((0HXSWB(HI!K]9DWDCHU)MO;K2IW-:_9JZA+0N5*^1E8F M7JH97A<\5FMFMEWX+$:WNR@@XE\DU#5,%B=M;?9;/,DHC%C];9"2B$2 M/H.$>P)F#"6I[U,4IX&U#B8G%)@:\Q]U,&&MS@8128,'0\]I=0FQ8_J_W+6D MT[\.O-EDS8[4MZ0'O/'ZEIQ28CI]2WH@,NI;TO><@>$_RU7.\L5Z)=WG+RJG MJ3[@>?=#50'AK&GU^?2\7K6Q N]PJ=JFJ.(A=>3YS9-29\Z2Q,."9!![J2>= M7E&W.&$0!\R/A4B].(N-HH1L:#4UDMP: GAKB5SGJQ/X7(5PRD\JY7E\+]8+ MIA:C6(( .Q3 3Y6RS+0%E)WAU6/8T0?-M=>]8P_8&;S.HJZ?\<8FM;/06:4X MN,DAFH'&,HLQ3S:!MAL:946S<2.H;()Y%&AE]>'7%K;]L/PF7QA%^=+N]1[T MZ^4^IB3(Y*"&00H1\Z4_F_@QS"@7L8=)BE(\K&YMO^#)\?1..=-.\]PTX%,; M=3UN=8&E8_H\!>/+YHS':;MC4[0Y +]7Z^^JG0PX2I&?I!SZ048@2F-?.D?$APG&J8C<=/C&W0Z@T9I@X,'#:PU3G+L(NB8="Z -Z3-IP:*!@H]IM%XS'@'-/HV[1W-&-PVS!5\LZ[R)5<=^9Y(OFQ*_B^;$_Z= M8Z$;4JU*K%TRA$Z*/3G&PHWGMO]2Z[R:*@#\Z]2WZ+\-PL^K*&*HPJE[Q:@Q:KR;TPR2!@6 MJA*87''%F,.(QQ%.(NGV1%H=S ?(GIH/M%43",[!3]O:OX8[\R;XZW&;(U0= M$YO26FT1-7J#3O$9V$%:ZNZD$O Q.P6?C&0/VX1&'-@C@K"#'C$P UNM;'. MV>=OO%PJ]^.]Y,XE55W*\8I_*42Y^,_OGS'S^HOK8=,(I1D:8%$#,1PX#0!"6)2B4QJG)XE3938[O6&+#1&6S,:=J>_/3E\_O[GW?^7AL% ME%4&!57LC*3F3OI8X^-Z>_W:H7&PRV4%6[N;\5=I-.X.O0WPCK;MK3QTT&Y: M03EGU>?U:H%?J@]5M9:"NV9NU7&[MFUIS4T+FL]U#;%W/^2+(I=72C<4B2#! M!"8888A"XL,,>QZ,$Y8@FB5IA'V#[3?K"DZ-O3L3FT %WJJIG*VJWBPI:O6; MU!+^]+PH7J2?U?SIN=M'>99/--J2LC_L6CN!KSJ8SK<.VW'\J;5/]2%K302? MVYZ;E5[)VK9Y66,LV%C[RD-LM$WYJD,]VK[FZPVYZ9:HL_&XL(=J7^Z8FZ[. M4#O8I74GQWT?EVV4#,I(ZF%$H1=%*N ^1A G"8,^0X()2I"7..O-,MU I?73 MDRH$].6Q^-[5CY?@%/J )BM/XJ*OP?+5F):\4.7456-59?EC_)[N+A[+)9=LV!!(Q8%V(-/H:XV/LC?0!8-6;."EH5&^@S]3#MWGOM0.SJYL*NEV, MHA\&(F%43O<81?(M3 3$7%"58<=PR!,J0J.ZMON/G]I$OU#J7P"QU%$H_DW7I)"^U7=(\[D*[PKU&78XXZV MH)3J@N?+ 7GF.&N^P2UAY_I-O@>:TG/F)(Q1!PZ[[_4^@>.^WS5,/WK/Z]PS MC$/^4A3L>[Y8R%7]85<55;IE4:B-WNWI!PX%3S/$(4%J?2ZXRKA7F:P$J;36 M+";$R!\P$S\U?Z'3OHY'T6\99&,@]&C'';R.B:@?6;!5'OSAY+QI&'!6*+YRLG"51-%:!HYGF>^E_S007P>O58 ME/E_9#PNIZ#OESPF+$J4BA MS]4Y8&. C]UX&AW!XX;/&$!Q%"UCH%5:5G& M14YSXXI")]'4(Y7K,7),(YV"VR*/+@H%]8%@N3;025$CEP/J,_>X E#OU0-; MUBQIJ4KMON7-?S\LI:OSC'/VMG5XV@I#7 MF,& B#0.:)!A$<^7_$%-)CV.&*:(UOS(FOFQJXY3+UUIW?2=K7BU;?Y@V+9F MV,#HD8U#L$=J:-,: '[J3/@9Y$O0@=^5,MLVB+#=>?LZ!.WVN!FFRK@-;ZZ" MZZC[S75/&Y#0>5")O(F)Z?)(/F]W*E3H,E4EVE396WGY]NP[QA$+,?0#GT$4 M!2G,B%S(A51%J'DH\B(MC\J&,E/SNX[:)[1[0<8;0%9&JI] Q\;?,8T>M5)H M;-GFV($=Y,I![/4QQ Q0N5/ M202CR$<5-[8W6YQJ(HF]W(1DW#8XI^A#5/+*SAYOKPHE6T MQJQ3=;=PG\7S"RU,[!YE](L<]U1#R_RC PZ]NP:XSK>/*A_DPW*3_/=9;+-O M]Y)OYYGO8T8R!N7_*$0$!3#-_!#Z81I3P>)0!%II=89RIT8OC>9J/?LL'ZN( MICE4+02@V[QENFN"@?=E,!X:OK ;E!V3T1;@G31Q587O3%:X&W0-W%@W*(_D ML7Y]Y-UN&*#2>WE02[T'G"^K%>#=7K(<"Y67_\S+O&"J?>IZ4?=\JXOWJ.3] M30Z_:E8LU+"=FA3J>6KA"!8[B>8E;S;UY8T[;^O*5@]+\\'I]7H-'C>>@VMN MXYXO.^!V:V63SPC:%'K8*0_Q8?F\7LT]Y'MA$/M0>)D'D<\1S#+&U%"E@0@S M06.CN$0+.DWN#77F-33;S+N7&=B=L[FRPLP_MC&4>D[TR /D^.5VJE;V[.RK M;5N20X[8CE7@0^^(V2BA/11CUW6UC?5Z[6+;0X'4J, ]^-$#%@I_*8NJ^DWZ M!_ERI_IS%,:BT- M/,_3\&FX\%>#XIC0&CP:!;522'2Q,7# K\9H)%_;&"LS5[<7AEZO]O2=XSFP MO9KO^:K]5UY5I/LM)ZLV*"B(1!:3@$$'LK M86JL]E8NPE[D(NQMB;^#K[Q\ A\+W>*JYV'4<_"N L2*^-E3H6.[W(J$Y'4&Z4O#8DZ@3:>HQ@#<%7#7?:('I_ M&5$+$4[G(7(U^4GY_KI=ORX:-28K-^F_,DCKCJ_4$Y#N7R*DIA%M7-C;A//)(&A JC M4._ANDS-8[G__'N3<5*!HC5#33K>&E*?9"[J6;FSV6P8,7[%R.D1W4CCX9C_ M:BM@(:"TH^WY]GEG2-[M#LG&&E";HU'1USQ,_7I0[<:R7Z'/N 'OUP-W%!5O MX9%#2Z9T_9RJFR7;[)11R0+;E.--T)J( T$0]R!EQ(^KO9>0;QA<.&QL]*G6&N.O3;HM@#ZC.,@ TR^5: M3#08N7[+ '"."[H,>[FFY?V MCW4-]WF420>3A*IY04*EAQFF$$?*X8Q$PD46IHD?&>UTF>LP-?KK3%#!"ZV> M8&,%V#%C!LC+YHJF)KYIR>P!(Z:YJ>9V'%QONSD9 O/MN>$@VMW &Z#'N%M\ MPX$ZV@2\XE'#:+.+W=[XH>VSJSDB28I3+X )%JH$+HI@*E1$=9CQ.!,B((%6 MC>J+DJ9&@6W6@IQ]Q6:]5K6ZFC'<>7#U>,P*9([9:HO6=G7[Y1):QF1T$0FK ME'->VJC$E3(T*/A5+2''UV)YEMIDZ9G/_-)QZ M<_]JD!S/_8/SQ%E77,;>U.]%P.K4/RUIU*G?:^SAU.^_>$",N?RRW\KO^M[7 M-,%^3.1['XJX#M*B#&*6(!@*FE#J,X_Y6D4VSPGX?VG"GP6Q?Z[;@,;U%HM$ M1:G71@U$91Y\8:3(T+Y9A5WO[.:L"$ [N<,YF0-D M:B/L.5&#\;/J8)EK,:KS-1BD0\=L^(.&%BK^QI=K_EY:I/:*5"C#7_/5X^VZ M6A5/O-SV,@G2.(O\C$"1H!BBF 60A%$,/8_% L=!0D.CSMRZ@J=&;*W>3?V$ M3O,*?)>Z@TYYTV!5W3'0(SP7R#KFN9.@[F/JJ(>,*5B62R5K"A^Y>+(9),?E ME WO-V])_;9URG?B"C[F2_YAQ9^J>1:C+ YB#N,P%1 1+)DJB4,8(JZ"[^/( M3[3VG2\)FAHS=;KN!MF /Y2ZH-97,\#I(K[]+&03-<>L,QPPHP;7.F@,;G;= M^_#1&E_KF+C;!%OK>G-:^%1\+;$JW?CEY8D4B_<+_#!G3.!$!!&,$B']%E07 MG?$3F&01]3@F."%:1_AGGC\U$OA4@%9'T"@)E);Z,_\4A)@W1G<=]F [>/69W@C5SNL7>6TB>@9XE[*(Q7EG%*( M,I3"+$Y#2&+,,A_AU!=:>73]8J8VC3N'F"A-P7.[[C/8-#T/J,:&LA681EHR MU$J"KG#LQ3Q_$Z0,-IFM(#;25O- Y,RVG"\"TKOQ?/[N\;:?+UJPMPE]^>J! MW>RZPGX[!:'4:NKW94$J7M99SG6!*)7U+*W*%WG]]5&_KLNR+6-=;;:0FJZ- M*!-"Q(D'/:^.:\QB2-(HA$C%YL1IP#CB\Z9DY)<5+E=Z6SI.=#690(<:NYM# M[_,EE@;@Q6Z*\@P0_I O54R%)&YY/34\[7X:V91AK M\[)@Y QL[ZS"T:N>DI7FLQ6:.+H?";O=')YJ.VR[2)=A'_26= M"AOF1[S-*_SP4*IZ1%+29]'Z*W42UO: (<,L]>4; 08!3R!*>093%G&8H9@P M+\G"5!@=\FA)G=K::U]IE=G0JFU&\WJ(Z]&V=1Q=[ZR>@[!-] 1.SG*,4++* MD'J21V4\(S .&,+YPU#TLO@HAYYL\9N ,./X] M:[[ED]YC.2,?ZIXU]/C\]ORE0ZLY2OJ0 _%RC[__AN6LDNNI:NY[$1.^[\%4 M>AT0^9F A,E?.0M]G[,4)9Y1.J4,ZW2> I%O6E^-3:.)_I& M/[D"DPAM5)R!NFJPS>*+/4!8KK9X2M+(Y15[C#VNI]AW\;")_Q=>/)3X^3&G MMTIC%0RB'(K[O/I;M\<>9QSQR(.J9*M\X\NU1Y:&&'HI0C[/PL"+C8K87)0X M-4+8*@SV- 9*93."N(RV'EE8Q= Q44;A$..T;_1 M1O9A%RX[)XQ% 8Y]&*=!!%&<9)!$07W<09.0491@HV7%:3%38Y9MT'B=E"06 MQ?>JB;#<5H:I,Y4,_9 S(.MQR_70.2:4HU#[NTN'[U>F)1YBX# O<2/J%1,3 M#\WMSTP\NGI@>;TVO9FSV^))90C5M'-3EJJ.J1+PYF5[22OSYCLNV7YSX)OU MZK$H\__B;!XGJO@>99!S+X-(\HAM-14Z([F62D?0 M*@D:+<%/K9[GWVGF_N4E+.RZF&>EC>ME7C+ZR-&\>,,P3K@KBV]Y)6GI?5&^ M+=9D)=:+KC/)W$\D 62(RD5HG*J:S:I8?JR8^WW%_RDCFO+ M"B\LO.RW7[#$C"YOCX(1B$TDB04!5"R5 B1%]85NA(8!*I8'_:Y MT,NU<*_JU+CMR_KI"9PDQ@_ MURO9G8+U>WGHG9W;M/ZZRXI4>G7/F%3>Q74_+!2?7B9U'H&'GH#&,RQU:-N6X@Y)M\M M6&]KL"Q'>^B@8#<0M$_@N/&?&J8?A7WJW#,P$J0HV/=\L;@O%@OI$ZL]N;E@ MD@YBX4.$ KDB%ERZFW$4RG\R02GC7IH:584](6-JY-"I"/Y02H)62\-HSU-8 M:D9V7(>0ZU@.0W#,@S?.FV\W7..$G'$#-,X;>A22T7/I@$3^K;\BUT%=4NR+ M7 ZS-5U)=E\_'ZQ$ A3S4*XZ58M< 5&DXD%]GD*? MSBTC6PO +5[QAZ(\WW'5PH#T,XESF$=<[2F(-X46MB#7!IBLWBR ;E!JP"7X M(U4@V!V$I1R$"1A:NQ_F.VB=+PF$:A& M4<\QO H;QY1M!LMU*4"[IKM+ *JEO%[ZSZZ1OQ<./ V50_E)#F[]74P) MH32./)BD:2H7?(D*]B<8A@S'2#J"6<",,GYV'SZUR:QT TJY0?-X#S;-4\R! M8#B>O=HXF!])GC#8[A'DKH!QCQQ/F'9TQ'CJFH'U[HOEPU=>/JG]GSGBW ^# ME,!$^!E$67"2OP=U%N1BP(; M-BW< ]#C:4AX$,& $0E@A'U($LXAQFF*(QR&:299KECAA6, -R+< ?A5R9" M[6YY7P&='M,-!634O6R+!?A/F&NWMOZN@''+YI\P[:@B_JEKKBRFUE1?^2@7 M-0N_38WS0^*+P ]ABA)5$BV)55XRA7$:>ZDO&"4Q-Z&]'EE38\%:M__^CW[L M_9,_L)35"4#UYK(EF!Q/[=VR4HVB,U"K"GP'.88:F+BI[W1"WNM4:3IO^-E: M2SVW#.PMSU>JK5 =R<4X>_/R>\79AZ5*DZ[4 NF&KO)O=3FX&U+55>[G2Z_]FP+;WY MN.A1D5NT'3.4VLNNP>[45YNI/RD+).8_@XT18&N%7)"U=ECDKN$@6J6T 6J, MRG3#83HDP"N>-.!XK[<]T=?B#5=]J&Z$I)9MFRX?4T)%Y,$,1=*S"I '4T)2 MZ6B%"8YX1 -?OX+W 6FQHGR*YO6D80J 8%CI:O!T=*0$= XTG.,J^NEET:? MM*\%>-/U2:L-T>F69@=_@],]Q^,PT@&?L_$P._>[ LS>H[\ASQWO].\*J_<. M *]YSG5!8A^>GJ5;K[ZG*J]EGC(1!4PDT,=Q!I%' ICY7@#E9['(XE UV!P2 M)[8O9FJOB4TT5+Y1L[P]1@YIOQ.0;D@WZA8IT'9#Q<[C8&3B+$# M4:\2-';:W'-Q8V>N'EHH4.5A?L4_WN85712J>/)F$8=BFH2")S".DP"B+(E@ M*F($$P]1C]"02CHP*Q=X5M;4J*!-%9:Z@JVR.LLW8Y#UR,$2=(X98C!J XH* M7L3#7+=23#GD'!?H#2-/!2%NIW?3CQ_:B31J AJ'4&GI'[CMU,(]K.!!5P< M,X 9)$9]WWH,']SW[=0S1^O[UF/0;M^WOLL&["=U=5GN\$J5^5*I:^6*L_=% M><_Y#_R4+]LU,R5!%OL<N9R$%3#""#R!6= %"4H=U6O+VJL,]C:T!T,C>TD!Q"[WD!OT/TL0*LSZ)16 MB2A@3VT'F!IL$3G =J1MH9UO<(LQ[C ^^@K;BOTV1*MWWT?W6>/M]1A:M[>_ M8WKOL"6=*L5U+R6T40$!\Q/.XQ0*CTC/C&8!Q!'C,(HX0T@N[[S,Z(AT__%3 MHVRE'5#JF:W0#C#36Y0-1\(QLVY XI#ISU< 8 MJ7R9KWA=2."#?"$L'W*RX$U)@8^;%O!1A"E3X:&A0$PZ81F'61@$,(T(HR*+ MLTQH+:U,A$YM;C;25 49VPZYT M!(\;?V4 Q5$@ELF] \/4MQTX;Y;LBRH5_%@LY/W5N[^OY:IT[HF O\/T&AN&*-]"7@] M-K()IV,F.L3P FKF,=V:4-B-\[XD=-S8;TT(CN+!=>^[HJ3O#:7EFK,=4;?K MLI2KI#E+8H(B$L* ^Q0B7SD]B1#0PX'\.!)):)8=TR]N:C[/T,*^Y_'48PY[ M*#GFC:;$;ZOI+A//0*NLY3*_%T&Q7^OWO,CQ"_Y>-/]DU=_+=PWCCMMB61]D MJ6:_76FV3<1,]XWG''E^2A)(?"^53DH4P325"RC5[8I$W ](9G2.K2-T:CQR M)Q_TJ+8%GLN<"FB,/9JP,##+[CTO:VJDTP6EMJ&H.^JVQ7X,]VGZ8-9<$-D!S_5: M:#ANYNNBRXC871+UR!MW-739\*.%D,8M;C9:-N%B*4.4)Z$'J?P60>3%*4RC MV(<1)01+)@DC872:HRMXRZ ?94M&"?Q>Z;HC+HK M\SJ1?::0F.[27!GSUXEYA\MEOGRH[GA9MW;:5M3+HH1PBCD,>2(D-04$9CQ2 M>\&(!")"61H9+;/.2IH:%W6* JEITUG-C'G.0ZI'-5: 9IREB)?*];XDJ"I44,;+;^C+%#:7MQ)-$.WGR5L8N;:AQ@(UX T@WXL MKLPW.//PD1,/^DT\SD"X<+WUV+>;)U46];_JB-B6B%36\WOY=9IGB<>\$">0 M>ED"48HP3)-4P(1XOB_4?FMHU.UFF!I3HQ/Y94NL!;[UP:_G=[@'U3'?] ;' MS6I/A:I(^EUK9DU-!67)* %S&DB.%4+7I\I4@NHTX#((L]-YVC!>;#M72A^L MZ>&JMG3>E651WA:2=FF=BK19!O @HZG/&*0Q91"%JJ$/C3WH(XQ31H*$!T9+ M*Q/A4^/ K>Z@5;[9RE3J@QW]!^=R&XV,'E&ZPMLQ/=J$VI@2AV!FE0B-%!B5 M_H9 H2D_7?/M>G;-6['[RD><79 MG$BN2Q+?@P%EONIBYL.4)@'$L9<1&H8T(T9\9ZS!U$BO4TSE^=4'8:!H-#;L M?FL\$GK\YA1?QR17ZP<:Y4&C/6C4GW7E:9M+6AO Q@B+K6>'XF>WHZRQ%N,V MBAT*TE'_U\$/,N._JES-?Y.^Y=/ZJC)4^.K5CD]=CK&J9]UKK+>,9NT>EE,RSQK;=_- VTJ.>XKH".*CPT=7<@862%7MT>_*0N2K>4Q%&,4^@3B5_R"1 M>A"+,(#"$U[ )-?'JAZB?K+KSK.->'F$O-9:-=4:5.IF6 -U!S"%R(" FM<]UK 1NC=JP5P/1>-P-AT\%V/L'.2^Z.OP"ODPQ@"=SI$Q?\S0O)DE_RQN2\[DVS-( M8E\$A,! Q*JA7"99*V481E&8X3#Q4.H95:W???C4*.E-49;%]SJBNMBVU#3- M>-D!3Y.!!D+BFEXVC2"5@FH=VJAH,V'EV'#+22D[ D9./#DV[3BYY,0U Q-( MA.!T]5F\^T'KHT551^WS4G544O]3N2K?\$*1Q#VO5F6N(FS4'^3R;_^#G2OG MF'DT9IZ 28Q5CBWA4,YU!@4F61P(D7@<&Z6>V-=Q:@32F*BF"F^-!*6J&$C; MH_QB":CJ;J8V>>H?^-86P_06!P.NQU:O/(R.26\[@IU]3=QH.>XF4#N@#[*(7(H:D!A\TU?TM^D MR[DNZPU!5?+A]V5!*EY^4UG:3Z[ E YIO9$H?UN7ZISW#:[RZJ P!'WY M"\Z7JL_*>PGUO7SHYMES'R>Q"&@ J1_$$'EI!'%("4Q#@3R2,I:IKN.:%=+' MUGYJKZ-.8? @-6XZEY:[^AH4 !_]B]#_,IK\\#I^3>UV3IKU!*NLZ=Q?3J+-H7FFM#Z>INK24?J"G0/*:-UY:#JK;W'&RK' M_LL(HV0>$6P%7+OAP=>I-&ZLL!7XC@*'[3SUZ@)BFU?,-AIF3DF8)GXD($Z" M!"(>$(@92:$DX%00$011:A2ZTB]N:M$L397V;6C:CO:#:X2=0EGW#,46=JY7 M;AO %*U]*I;B%((SL/7)=R+]G-0*Z\'+586P4R)?JRY8C_D]U<#Z[AI&-F^Y MX-+O9,T7A-\6U:KZQ%=SE 383[( (E_(?T*404(8@UX6"!1%*0NQ/U_R!Q7M M^U7?ZSLC3FNF9,U,.1+J-M3ASV M+ZF3@Z47P#A9@;RJUDI[0)7Z9K1S#F\] MOKD&OG&(YJT"Z$,'4*W@#$@5[7'(!0RLDL.*N;!]; MYTW5A<:JF_7JL2C5O)A' 8D]DD0P0#23=$$2F%%!8,(#RACU&8F)R>JP7]S4 M5G\;;9N4S1FH:H4!WF@,?LJ7[:<_FQ'&!>#U>,,>G([I8XODEP;)1E>P5=8> MD>B!8I5/+H@RBU;MF=V5!VJVQ0K319FW6($,T)&D: M01;$2'HHF*CH, 9I1OPD\CP5\JI]7*>5L\/17+G7?(YVWDZSPC(1(>#F"""%([7!0251(.AQA[7'[% M_!B9U9#L$SX:2BDWC,DG5G4&Z>=2W7!HS]X,XBC*<0B$7HA!YB6JT M'(40IQE"B?P+U4M?C(%-%OXC$Y7+C^ZK.TMLKMIJ!?F(68A"F"OH@357I,P"R,$B@X MY5X6,1\AH_H>YT5-C1I:]<#"PMG9(:K&YV978.68$$XU('7=0><,&JY.Q [% MO=9IV!FS>T["SMTQL#0$7_(2+VZ6[(8]Y,]A0WK(UR 68\\+(+GF$%V M<=O7M>N-8;&Z@AXJ=BLN7) Y;A4&/0".*C-HWC;PV*S-DOY:W-"_K_.2OUE7 M^5+E5:LSN<^BSJ)I_L+FJ9_XD204B'T5V8,B#C-&?8@3@52S=,*3;,"9NXD. M$SV(K[/9GG'.@) ..5;*5OF LJA&PZ%YM&8;W9$.VEJU5:F&5CVPU;P^LJ]S MKQ7PG?H6C]X&@&;W(,Y$@7&/Y09 SU9O<+-:E3E9K^I<(LEW M=[BT>\ T#$';->QU1(]=O=X CA-UZTWN'I@40ZA'[ ME(_J&MUF=H_E+AIN-UWF=0[C+AIYE-1BZ#Q,>1Y[1/MFQB*FY=(UNX#VF=9S$\*I=1J[:=;@XWS??K=OEP,TZ M;[VS,EZOX3Z=-[.OI)<5MVB;7B(?6SRIG; V=;GVQ^J8\II.WN"*L\URF1-C1AKW?[[/_JQ]T^A8?O;'D#UB,X23(Y);+=H3J/H#-2J@M"!IZ6!B=V6 MM#WRQNT[>]GPH^:R&K<,2(OYM%9/^"SN)"M) OK]^9$OV.=OO+PK\Z*\*5?W M*B&'2ZNJ.?$H]KQ(0!YS#%&$,<095R5;0NI1$478UXIU-!4\-1II5&]R8FKE MP;K6'A12??"L] >X7(%R8X%!4H?)@/0SCTN8'=-0B_!GE:[1(-PH#I3FH%9= M^E8K<.\:88.\&4=(CY0X8Q%QL\29 ;#U9LZ8/&^\U)D!5N[ES@RY?YCK^&'Y M34HHRI=33 C#5/Z#,([DPMN+50\[AE#,4HYC$]^Q3]C46+_3U3B< MM1=1/>?1%DZ.:7NCIOL^;CJ(6/4=>P6.ZCSJF'[H/6K=,SA$HVT ?E-^IJA/; M;0JP'GO8@)+U>90JXR$]4*,&8TC5/BD]BHHUB_N*D1ASH_ MS1D'JL)KKKVNT816FRXL >:>,I2B8%=3H%3=Y--8I0T-4&Q31Y_(L>E#P_P3 M%*)SU\".W*<;A\T#$3&?$PJ)%\<0Q32!6809Y"3R0NEYA)E'3 I8GI%C1!RC M5:Y<*!V'9]Z=PU2/."P@Y9@QSC<5M-AANA\%NXVBS\@:M]]SO\%';9LO7&Z> MH/^VW2*KXSCSYI3MN2A7,1B@D@<^UIM_OJ$ M3,V!Z/0$6T5!HZE^1OY90/MYP!9,CDE@ $)&*?B7(!B(:"H,X? ME;]&R)_Y2=A=K,K02N>Z_6/L[5WK)WO7[C06!7@E?7!2KG'YTARU!^D,J'WZ M^M[?\ L(_?J#8 ;DO<^"A5TJJDNDUE_X_YDG]8\:=J'O",,"\- M8.+%$419DJDF< +Z$8\3/\EBQ(SV-2X)G!IO[>N[TR,#_*%T!K72AENC%T'7 M8P6;4+IV7JY#<4A\H18TM@,(^X6.'2&H!<&)$$"]^X81SJ=B671+J0]U*-BC.P M[*D.;PBL'IM8@SJ"!HEP4^MFN?3QHS9XR(45FGCO+11^>*BT8=$E6CWCQND.J6.^O9 <,@,;HT%M]:SN;2(_78$7O@); M0V>@,;6N5+-CK,4&[*\R1G9[LX]KPKAMVU]E>(XZNK^.%L/>@U_+NO+X2[W6 M;Y;];>I&1GSYLI).4;!M;/XZ5\ MCSZINAE-^8+VBYR(,!$IHY )Y$,4<@9)@F(HA/ %(@)CA(WZ39V6,S56V%&S MV=D':\G ID7PSF"J1PX6D'),#;L@M47_[=/"!1CL%JL[(VO@DI@0R3,$Q1D(D@ M,3UF/"-K:K2PHVI]AD=WE04_21>. Q\95AOJPUK_+,\"@B,GW8.] M"V!8/^,[)V_TX[X+AI\Z^;MTR\":1:H()M^/<-HIB<$#YC.4$9C@"*GEAEII M)"E,2.;'02C2U#4=B#R3%7-(K.P$&88N4HATH/ M%[M%C_I%CEL 2G==7>[VLSK%4KLE)7_DRRK_QINC@8]%U539_8I_ MS.-$U8RD$F9*.41!&*G8IPP&:98PCZ,H38S6*8;RI\8PNQ5;FU- NFO M35P MM89$CY(< NV8HW8QKE4'>[IO#A.5^C]O"GU+&YS4P34!SU5!7"T=7JLRK@E M/25RC1XSM,7:NR=>/DA._4M9?%\]*FEX^3)/0ZRZ\7J09VDJ%UX!AUE,$(P" M$1&?16D<:A5]O"!G:ES6]@OK= 6-LJ#5UK2[VFEH^[G*(F"..6D@5@,:J_4B M<65?M=//'KFM6J^!QUW5^B\?Z 0M%L5WM;/SOBC?%FNR$NM%FXQ:W7/*\V^J MTGJ7TQ@BST]%@B%")) N4$8A9@F2+I"/ H(H$;%9CKF)]*F11J:S@#N M+#)-)C4:!TV_QQ6Z[KV>!MC['6 WQM2'\6T]6O5&=)%_.@0XNQZ/D0;C^CM# MP#GR=@8]Q-X^T283KBL&><^?<+YDJNS/^[RB>/&?')?SB'K(3P2!-%115C&. M89KX$?1$F&$2^%G$S&I@#U9E:N2W45(M.%3"R?5;39IC,GP;RC[2K[-%M9-) M.U,]4 @'=SAG,[ W*(U%0)GD=A?+#%;G.UR:ZKSZ[I<9;#H[8X9/',:F7?LI MZ7Z2?%F'%ITJM>7%.,D089 &H0]1HKIT9XF*RF.81AX/ U480)\Y]<1.C25O M!G>WTX19CPSM@^>8^#J%P8[&[LN3\+-YR MLE+YF\JGK.M]SUF*DI!XJI81DFM5XA-(?";!9RSV!6%)%"57=. \(5)K HW? MH).T3ILW&)8@08<3AIGGI+W*GTR>PP_UQ:S[Y8!%;HWH=8J]O%.?H,> MI5]U)[\.;5R='Z\6O=>P:0ZT?I\RQJBN[85+#(YY'J*1?&$$5,P#1B*>0H M\&(:10AAK4[")Y\^-?JL]3.8ZD=H:1#C-1@XW\N2JC4>TQ#B.T+#@.FN064D M:C-"QXS2SEG?RV%'-XU'6N?TW6.ILQ<-H*7:@5Q6J[(>Z-OB&Y?+I)57I02B# N(!>;0QR3P2.B'H:^U MOS58@ZG16ZLH6+6E,1M5@=J>+ SF^:#!T&!&UQ [9L]FW;G17^7(-1: VH09 MZ.!OJG)T9H#[,> WH&+7PS 27;L9#C->OP;*7NX?].#QW@_7V+WW#KGJ0>9A M=TI N>W6X/L1BCU/OCJ0@"CQ0X@)PI!%..%I&H4L8;J!=GM/GMI[X;;ITR4! M_$4_CFX?JWYZOPH!Q[3=&&^SL\)9:P?'P^T_;;0(N)-&[,:\G;Y@V#E!6PVL M>B]5>/=#?NV7TGM<5ZOB2_YW]=YJ3I3!+/.)GJC ,T?*OW*HY-8)YBU_DZUQI#IZ[ M0[#FU^^/.7T$SR6'N-4=Y"I!0=G$FSIVSPT(\D.%@L'>D+MO@<;^W23&UOEJ ML;$1*",WCML,U':J;L&-<3/0VMK^WA4IK,W=GHHJ@\'&8GD/AYW-DQAT@UW# M20S^2%N+K_\E,-N&=#XVO7N5[J2/MZ'I',&]74_WTH:M&[[(B5679[U=X*KZ M+.KX@YL?>35GE 91[!,H. XA2C(,<1@@R&C$PDCZ")AZ)NN'LY*F]IJO]5-1 MATV\RQ]*1\-UQ'E4]=835K!R_=HT@LEX77$1 JOKB_/21EUG7#3Z<+UQ^08' MR7N_+UE>U4F#G+W[0>6E-T_JM[D7X#0D@L,@20*(&!60H S!)/%B@D(U*B?R0:HKGVX8\SUL./2XQCG(CGE()UMOUPS0V $: M0T;*T;N$XWCI>6G=J MBO5*Y9EMBF^NU(];RPP6T&9#I+$3X@QXQ_2X1WU;Q<&>YCM)?LXP-MAX<(;U M2)L)UC WVQ,8!%OO.M_LB>.MW0=9NK<>'_:$@>F2)7_&.6L;'MTLFTICS?E? M5UI&)"Q)LR2%OJ_2)J- P P)#R*/AT*^+3+?TXK)-Y YN;=#HW+7U:PY.:]+ M'!HF2&K K><:6P;1,=-W^+7JUO UU0L;C1U4[#$ R&X*I8;<<5,I]8$X2JDT MN'5PQ=5RS5GG$N=\,PV(7)EC3&*(0U5W4*@>$$1@B&*2(A)1DH1:X9 7)4V- M:UI%P6*KJ7')U#.88I)Y:<9\&,1$\C=*!"0TB"#VY<]A&F/L>2:=*>U@.EIG M2NP.63W2MH*78ZKNOGX[2KJHIW8)"=O58L](&[LN;+_1)RK 7KCAJN!7%0=V MZO#GW0^Z6*MF\HKIY?\S55B9T0PET@.'"<<4(IXDD*14.H5>G&&?>ZEO5NMZ M@ Y38VI57+G""U,6&8*^'K\XQM0Q\W2=M.MHU99]V\;3=:/BSK%D9J.?U5E9:<$\(#+XN(](E\ M'TH?$T'B">F )E@Q7!Q@JL5P?4*F1F&=GF!'4?!'K:KFN7(OI/VT90LHQ[PT M"".C])U+( S.Y#G[X-&2>BZ9MIO?<_':8=[.>YR7_XX7:_[F9?/C_\IY*1_T M^*)R^19U^$,0>30D20H#QA!$22R)(* )%!ZE898AGR!NXN#HB9T:(2A50:TK MV"A;;]=\NOGW0?$FFNCK.3CV,77,'=? :>R[F*%CU5W1%#VJAV(&QZ%38GCW M,&IZ]_=UOGK9I+7Z481$$#/("8DA$HS -/(CF'AA1(F((LZ,BNGO/WYJ5--H MIY,+JX.='H$,1\0Q4>B#8=Y1_J3-=CN^[XL8MR/[2?...J:?OFKX\N'?UKB4 MLV3Q#J-K[[*Q[PM5.'T.>)^R/T4P8S33,YRE9C&$@Q)3./8PRE'OE$; MXO.BIC;9=S0%M:I Z0K^:+0U?'?W(*SW'K>#FV,"& J9\1O^,AI6W_8]XD9] M\U\V^] +T+AC>.OR8EF'N+?5".,HH@%."$Q8QB#R2 QC@7,\7IW*B8^CF*5BIZ&JK8C3V%*108CE/J$X0QYPB@8 MY5# U.9RIY\J3\<';?L=0:@WI:\!QO&,-L+$>$*?,]SJ?#X2,NIT/F?BX6P^ M>]VPR5S'K'TJED67A-&TSNV"VKK](\P0S3C!,/$%E^]KZ=FGQ,O4FB0V]5XTXN[5?IG)[M[9D!9 MI1--T:.2C!D/= 0J+Y&RZ*DM]SJE)C*1;\ M6MSA.L0P2ZCT->1:(@A%"I&/&4R93V&:9/+GU!,I-R,;AUH >W[QZJGO-SBIC' M(A)!',I%)(IBZ9XA24.,LD1D:1#X66*26W-"AA'/C)!5LRUKH3PN0R_K!(2: M+M1UP+CVCXY6?TK!GRUZ/>?-M^O2G) SKK]RWM C9Z3GTBMG^'[%CB[=*Q%( M^"$6ZO WAB@1%&(21I#YF1 H\8($FZW%>L5-S;]HU0+;G8Z%4GMX7MT%M UY MX6H,1Z.(XVI UA/M]%!QPQRG1;X.B?2:?Y9/^N\:&(Z>+_,5K^NL?UBNY! E..Y:\!PPP' M H=Q9A2=/D2+J1&1_ )&AM'H@\#7(R#GD#KFI4;_MA?$UH*F1,.LKMU 5=68 M76-F0-D!I"$6P]BOP=%N5/L@3<8--HP.OY9U3,Y+?7K?'N0_ M8OF]GD[ ?\,?\N52>6=O\$)UD)^!S7@X&($4498%U(,,1425 MX?-AQK$B(R]*!4F$'(C]$7BW9*^%?R?:'?I2PFC0Z[W5K;"&XS?W!J4O#6$T M:LY HZB]-_-%+*R^?<]+&_4->]'HP[?HY1N&O2D_+*EZ,G_+F_]^:"+>'HN% M?$;5)+C<%XO%^Z+\CDLV)R)& 4<)#,((R24#KDL>$YB).!8,I1E#1D%KAO*G M]E;MU <_=0;\#/(V0K.UX7^ +@U+V0%:0PPCWTR'28^&'(+OF)P.GHAWQK!3B7CG+AT8[Z'21YATH]2>0U.@.<)Q)%=&,8PY MHQ"E5%7JB#F4RRCD,YQX+# +\3@I9FK3O$DE(4K-.MZMT],PEN,TI'I.R/5 M.9[JM8*PP>@.O]2S_J8LY25USM=,Q>=27#UVA6@M!F[T0F,W5N.TJ''#,WK- M/8K(Z+_Z^B2=-GL2B&/H\E,801@9BI=@:,"#\((I\)K1S\\R*F1@H' M22F#DG%/ *E'!]?!XY@*#)&Y*F''8:[M"3&OEK33GUO;<^70*J75JES3U5JU ME;M9LGN^4%N1-W25?ZN##$[%(6+,.8L"#,,P9=(W0 G$29K!@&<)%HB0!!F6 M*3578FHD<4/EPJO*F_.Z/8-V"K'7+8'K &[3:J8#1DF/7UQC[YB!CI%N#0!; M"]Q'E%X#HN6*I@,4&;FDZ7"HCFN:7O&L@;7T/]]^.!5TWP7D[VXZ!J%'!(OE M.*F8$L3#6"ZA"(<\8R+!24P28K2$,I ].7:4JI_)5=G-9[EJ3]AD:/2XT1'@ MCBG1,M;F9>?-4;-;B-Y _KBEZB>.RC([Q1[RB==/ LDVX M>I3.F?J/.ISZAA>2L*J;U2TNRQ?IN-557^<\#6D0$0;#!$>J 5$$<10AJ+() MLTCX7IH8.4M:4J?&+$K;>A%3[Y_RK=Z&M9ZT$- M@4[KIERTQ5)1)BC9+1^E)7G6 X+*>/RV)1/+S4^^6'8;CM M"]A/.?8)19#$'I/+-QY DJ89]'G"!&$B1LPH&T!+ZM08::LTK+4^BEDWI"8] MZ/6HR3J@CJGI,I8.?"$CD.R&%FI)'C?,T 2,HY!#HYNOJ*-UNUMH99MM*9=W M=RH_H%B>6@'Z"[H> MI#$K>^V9L9_WG*R6SZ;(C^+XU35G8B17*N*#*8)HW+84)HE01 )LQ8BI\5,S1546D*E M)E!ZSJXI37X&5SW"NQXMQUPV#"ACBNK'P2K[G!$U*K'TFWO(&1>N-J,#.;C% M_-_^XS?.WN(G7!9?UL^J^LTMEORT:EMV[X0!M&N9D#&?QSB"-%7I M?PGQ8)8(!N,(TY22C%.]GB77*#$U*OFW_P"M'3,@+0&-*:"U!73&-*LBL&.. M'LU<-5[])#36*#BFJ,$#<'F%:F\D6!OOW$3/OO:([&DSP9&Y_L5B \GFM:.> MI-XEH1<$:?TFN>K9H[QG;%C?O86L/,M%4:4O\NM;1VE_%N_S)5[2'"_NBD;\ MNQ\KY5U+]_EC7JWF*,@BWU.!*V&"(?)##E,<"/K7G@W5*^+,KZ76&S#KEEY$EJLX&=\^Z@!:6)1P)?0,9C3RY.DE@N3D*DVC-GPHLS MD81:Z>O]8J9&V:VB8+6CJ8$_>QY.C;6#%9 \>B.YR.DUBK?6!_+@ K$L2P 9RWL\]6/^:R#&_BD.GZWWY M[N&YHD;6E&Q),>[6B&ZD'3WZ'399$CZCG3>71T_:XX)FF3GU?? M%_4B?JDM95DYZYJS[RA0$DP)12 UV*^J<0(XD=IFS#(M2 M2U[JL+-Y?^'C.XK?1)NNW,GM4ZOW'7ARFM>Q>WJC>QC[!$R('Q,E!GD@[ZU5 MVH';J@V^;$&N-;^K47YW%>5@D@H'+"EA!8@?E+S"83DFLH@1;G"//NZ*C&_J M@PO,,)>XA!AQ ;$I!:36PX1%22K",Y+G. OVBT[EC-,A:O?Q;BB^?@'5 (?H M-JP&\83V5.RCRGHW"ND]GS.RAG=Y+AM\UM?IN#RV LCLN5XUUPNQZ3^?FTZS M7!,F285@3HE='!5%#BG/2Z@TKY2IL%(H* 'LO)BQL<%62W#_9/T6+IM4@ZW. MD5U\SR+L1PVWX]8S,]P*643-D"Y$$M<-.2MJX-HA7>:>U@_IO#HRP6LQ=TLK MRS7VI]54M><>O[^XP)OZ6594250R#@FA&<0YL6Q!)76I% 93(C118JP&5V^()QD M>ZY#(O()-"0\QR"3FQRRUM<)6C M7%"E*A_:.AEY;*34*N?'.:M7@F3/R]:V_6FVYOVWG+[M^,W M_'340=[?B\9LWL[+%Z1/PGR_6.KIP[S96Y$OWY=\ON*RSC^:J_IOL]K#N5?_ M];Q:N_W8IH/W=_YK4J+,^ABFA"53 F+-!132*%CE>4$(L;]$81&5_>@Y-EYH M36DW8>4+6._43Y>,>P=$ M;:]+ ATFR3/!C R6 'J+KJ-)#DT >$CB: IQ<9^775%*ZTKNE>INJU>^6:S6 MJ[J8=UUB?7/P=R]6EO?D>B)+@@M!"V@R(2$FVD#*J("ZE)DL-:8Z#_J*W*;. MV#X6>Z5>W0ILSYYM8=C:HK9OUV$9^Q7XQ\:NP*VX&^?4[P,RW$SU_)VXTD' M9Q:"N3X->$DI_4:5!F7N-/ =$W2B46/W#K='I1.4$XHE)9 7'$%L,N8S^Q9K/?/<&MV,',>160G\OWW9Y83[J5T[K06MO#;'PD6/S?%I]04^S_6MJ/N]]_U@ MV;=KTBKMO,J-"A=IH'OF$(3C1K9B\#U,]@&-3S'8P^-M*KE8L/$3M$SH_0HO'HF9_\H0AO&'#.Y+0- @XD#-L0X)QQ)PT MSEX4][I^TFM7OOO+7/NEQN6^!@_K#KS[3= *689(9;Y%"I)<2Z MXI 27D%32$25ID2@H*:2X2J,[<6OR]>;V>*O%7!3NBD:XYJ<;77_]S RB)@7 M/\;H%^V>:<5U1*K!WJCO0DE_#2-%;CAKZR_I"P5A_N"NC=WZY6BK)<]4B9C!T)"J@CA'E25&3"'),TE* M4W(J15#0:K@.8V/&6N==@2:P6=T'[F-'3(;G?G>_$/>]+UYK?P>Z*F)MC.AU M-^P&&-/NN4?H,>S>?#Q0)WOX-PP5QXE_6!'/R_K8]\/\Z7F]7:M@6@FJ.8<9 MY=8CI+*"O% 82F'7?R5A%34HA/@N"1H;N^WI"6I%XQ=_%['UX[$4B/5,5G%@ M!5/1-222\LU%88.2RC63CYGCZO611X%K2S$_%C-[Q\I5.%B_3 0N*\4P@Q)) M;HFA4E 00R!57"-"*HR1##FJ/Q4QSA/[?3W_Y7]0E%?_"S3Z!I[SG4*:,TXR M61F7%%5"+(L*"H$R]Y,RE%1E2>SN_< M_H,,="3/X%D(PXVD%%:5*Y@A"8%<5@+F)N<9,0P+^X@^;3)%AD-S(ZP_+*V$ ME$!Z'C3?!$W?!\I[ROT_[0O;>_>:RXBD/3$^%3/LR?!%,T].@"]?&9OS_OBX MF-?#U@%JJP^KU;-6$TEP7F!1-4<2N*HR2 WA=OE.),MH3LLBJ#7,!3EC\UH; M-<'*Z7D'5K6F8%JK"GZ;SMO?!.:37L+8CQ42(-J=!I^FJ'=?'NFXNJ'J/H'[<:U[02HXD MTCJH D_O&H^-L^IZ-#_K;?Y&01?S)?>(#%AI>OE3@]^BZ*O_1\#3/1K3Q/;M M;>UE%APD?^RG%XB7<\D?H+;9;7S65ML?=G;?;3+U-Z:#WS;&)ZSP.MA$I74" M>]=Z6)]RJ$DX<5$'$QQ9[=8^-'JYU.K4(=-:%[G2J*T-J2M7&])^BDK.*1,* MDY+RD$_195%C^X9L-4WL^G: [4?Z:2#LF:UWZ!WXP,E=X.M@I*U">UG."Q$<.;>IO'*@><=GXO_PE8W:_Z+1#TO;+UL][[1;YDZIG7=J7E MOSXL?OZ;O:5^8_^)W8^P^;%^34\&&^2EO&3"YA6\^.]Q7^OCC_^'^;V4B^?Y M>F5=![?M>#]7I\D0DPJ;3-$*0RT+#7&9E5 0F<&,5ZXZ29F7'(=\R>/4&-O+ MO-$9/#5*WP'>I@:YBA5-Q_CHA,K(F?)S _K'OV1*6J]&44$SPJQCX[7A'R1U; 3I&IO.ZD4JGVT._ZPSK[4+RS"+Y6- ML:8P^+MIL#=0>V:]1F5@=3ZLJ=^H'1)V=P.T 3W:^H!XH)9MZ: .:^<6"EEG M=S?OP89K]A9JWT'OM^";XYSDOR\6ZJ_I;&8%'2>U[2J3;',A%$>BX!6%BF-D MEZY(02H1@4J5NI1%55%C0GSC(.EC8_R-\K7C=9PLN@)[99AB2RJ%38Z?.]P; MY#U_#Y*B'>SZ1J&6U.,-TV!01S<*G&/_-FZ0\*VX=_.UVV)0RCZ<*[?;\'GY M??'7?"(8IF5N.)2"VV6_K"1DN2Q@J:2I*I-AE7LYL1TRQD9@C9J@U?,.U%M6 MBR5PNOIOUUT"]/K.70*8>B:=*(2"MO2N8!"]NW=IW,$V^JX8MK_G=^W2B+7K M5_U3SY_U%[VLEUY6V\]B-GVH'>GVX/"[7CY.1,Y$)7$%,UUPB#'1D M6023+ MO*Q4I8R?0Q,B=&PTL#G\M[(\*X\'0>RQ/.T!N)Z)H=6X#HK8Z QV2M]M(RJ^ M]P-JP,*T!W '6I>F 3EL31J(5N>2U'>LX5:D@=8=+$A#[XU@;=*7.I55K;,S?Z@V6&\4W37"> MG-9M9V)GB6N'/EV&[F"FFTZ/;\BK3%+?9\BM3< 9!396W8':+O#9@$;C.["9 MR*UQH+4../- ;9]U6MOK7V4* [Y8KS*5 WW3AI[2L*]?OUH!Z7Z][-5>!ZGG#,#7V86];O;UC,!$57X.BLT^/S[7 ME>R[.I$<';N6DE*7O /S"EGO74D#:88U-*)2V$CKP>LPCKE-G]$1T6&!YHU! MX&KOH1NJ84?,HB>E#3[+0,5U$['M_^RFQ'Z/1ZM;?C >PLR'W#L#&! M779:LIK\Z\,VU^G62JH3:;[8)[IM)EGE')-<9%#E56D=O4Q EB,-5<5DP1DF M5>85!^LO:'NL=.1',N>>=$#QNM]/V/Q M#(G@2HWK0%L*MSRF@0%;(0AU1VMYC31@J%:(98=Q6D%W1E?:./XB?%JL]URM MHB@$59EQ(0L9Q)EKE8PK#)$@!!5(E$1F@24W.@6.C:G]W*W@TAO=H/OYMRFA M['V[^;*+ZG2V?FH?'JHO0JG+='0+';I>AQ<$9PIW^-T7V07Z?!7,3]:HNF?H M>L(RG!52*YA3@R!FA$"ARP(:KC!ADC)L@E;J5R6.C7FL9K!5#2RV]6)G=;Y. M=#[4==S]N"QW9W""1L?^V*3MH7Q5:G#-B/V!>&DK;#WC9%=I/AT M^1]\]JSWBFJ^7^I_/KM&Q6\7[O1C0@HB5*$SBW6AK-/#$*2295!7%3.X9+D( MXQX/F6-C'Z<"J" MG8YWP&D)&C43]N^^ D3:SMR7A W;<_N*R2?=M*]='UM*PKY>>K5N>[M-D#9% MA;6$)_UCT%FJ,(,+22M:BDK+9RU.7$)A4,9 ]=&.&O@:=&# M\Y?%O<5?]=HZ!5J]XTL7.[7:VS5\J\U43M>3K$*L+(H"&BSLFL(@#+DH*,Q9 ME4F>_+38]",:6SW!"O.I%=0L9&*3L]79=!';@GT0EG-Y.D JEG[@C& MQYLL? #HH@=[_QXUV+\=TT*G@$&(P,?$S:OO=6VL;V$7'5/7'+P^"_YS/EVO MOG[[LXU"D,I(0A&!E&5Q)75;!R6/A>HR-R#;*G71?>9[;.0'OOGWY$E]'/W:N M?-FM]QGHG>\V%G#;ZPU=CCFP'7& MSAIT6F/L_&5Q/M#OSZOI7*]6]])Z5JNIVU'Z:'_QP3I?JTDE7;L IF!EF.O0 MG&-(,V4@H_:=5AAEN0ER=+J$C>V%WN@*]I0%_W#J@EK?P+58)\Y^3DHJ]'I^ M[>.!"_8T?!!)ZDYT"AS49_ Q_=@Q\+HGCD8^Z753Y?3O>O&PY$\_IM+U/VEW M-@NJN59%#GG%),2\**&@%F"#7!VK4N8:!VT<=TH;&Y%89=OROG=@IV_=5">, M0KHQ]N.09,CU3"(=H/6P=^R%2E(BZ98X*)-X&7],)7XWQ7&)"X>MC[:^:_EC M/OWGLW:EDUW\FU9O^.K'^]GBK_:ASW!1E86J("VU=5"X=548*2JH6584>45- MGHL08O$7/3:6V>D)I%44&*MI&+T$P.['-?V V3/Q;)4&6ZWOP!ZX3G'@-.^! MAL(!2\I) >('):AP6([9*F*$Z&9MBT>]W;O>GK%4F!)*:6ZAM__!@EH'J,(8 MYMP4VO7X)D50QXD+XL)O8DZQ*N?D24 *V>62<&J)C&9UTPI.YL M=E;6T*W+N@P^TYNL\_+8?=&O^F'JAIJO/]E'8$(5YT8A^_(CYH)S+0UPS3,H MM12FI!H)XU74]Y* L9% NPVX4Q(X+4.W1H] ]-T;C8=FF,U17U0B=D?/FW[C M]NC1H /OCYXWZ72#],)UL=_TGY8-%LN7,\V*F/VJ8U+E4"HM(2;VN\Y$GD$D MLURB'%%9Z;#O^D598WNMMZJF:!'5A;'O-SX)K_H\_ZI=E8'I_.%WOIJN_IPOQ$HO?[KZ>!_F M3\]K^\_69'M7NW+9%.PAC$FL%(.(N[*BF%+("JI@;LE(,F94GN51!0,2*CDV MLMI5&-@O,+ "?ZY^V4B M]BS MP/W5=M)NZNG/[8^R8;G[N7KSP[Y(>K7MMEU?,[5:/,WT:D'F,F'#MRC3"=3]?V0_)3GW2,_?WE#_Y?B^6;&5^M[G]-5Q-5:E0( M.ZF*JPUOU,(V7Q FK]06V 76); M$T*KAP5,C*=_W@_B)G+&15WO?/ M0R]?'D<%K2^U!V'5!;6\R09PP4Q!I=R\E,OQ6+H"=D7 MVN]:O]$R<#7?B:H?2Z=":IC5]PI\W7MJN;$O#+C?/+3 ./=PJ=5T#5P=_COP M)G4=;!^TDA)ZI\!!6=W']&-J][HG/-[EWJZ<55VRO'(XV6-3*62/VPU7.7Q#G6'U9+J36:O7>JN#VINO>]N;C8O[@"AZ[DK(3 MALM,*&BG9-2^=#? ?BR3#+:>"288L?B*35U(]%.I MZ:S$UZG0U&7\Q>_/BA+GG7XJ8L'^_1<9]@:8WAF*LMM6)9VI89SZR<5!G)=Y5H* MPG/N5<'_JJ2Q$5F;%^..?@[5!8V^H7E#EP"^OMN2#+:^?:18Q")RBJZ@<6-R MT:71!\XRNF+D:;K1M1MN3![8I26LMDDQ)),YJRH%TCPR^W&'#_.[-HNE.^%O*D3:?UBZ1JAO=?/G]BU C!0RSS0L&:\@ M-IQ!CB2"3 B)>*&J*@NJ Y= I[&14K,.D ?K@&F[#IBY=< =$+5E+NKGWP,; M*2>80C\B&WAB>N:[JVNS[9PXYZD/&DR(9]H&S@GT&K;%_FXUP9(B;8@E75%RB$6)(&4E@YFL9%E8;X\)K\.Z3BEC MH]&-HJ#1M"UA#6I=_9=^ET&]ONQ+ E7/Q!:%4M!R[RH*T4N]RR,/MLR[:MS^ M$N_ZQ9%;W76<]28FS&B<:5%)R+4L(";NIXS8]1Q"598IJ904D_5BS6>>>]G[ MHP>]Y%L9_3V^WYT,(!OE *]5#=R+/@#/<[,Y%I*^=Y/;,I?I8^+.&9QV(_A MPK [O>>,.]G*/7M1Y+FVGME_?;B?JS_X\K^U2P9KXZ+;HH@J(SDOF(!57MCO M=<$)Y#)#4/(RIY5Q]=Z"MF2N"1S;I_L;G^E5'93\N-$W\&#[&L*>9]L)<>OY MU6]5K4';*KM->4A?8-(7FK3GW=>$#GOD[0G!R:FW[WUQ[/)16ZK2GY_TDKNA M/[K5Q::XP,L7_E*GI+Y]UA-EM,*69R"MTZ:()1A:& D+KG)3*400SD(;D#ZP40&GSA4Y6. MAD*A2DI'WL('I:502([I*?C^.)IZXZR9KY?U*=?7Z>J_]YH8:U$(A>SJ1;#, M'5DSRTP5=?Y/CA6N>%GRH!JW';+&YOH."1E&.ZY U**QZ&'S.)SRUQY/%VNN(/#TO=]*W^;+[JGWK^K)N ,9E5 MI3!VS41D7=6.:[MZ0ASRC+(29RQC*JCT4)>PL=''H:XN?+[5-BY0KQ-G/P)) MA5[?^Z#1P 53B \B23FD4^"@).)C^C&+>-US8SW>3WH]T=P8J5D%R](=DF18 M0I81#7,C2>FZ#?$J*)]@?_"QT<1&MVEH-O(!8J7&2%A4H#34E1^G&%):,%C2 MW"!D=1!5'K* C$9L@$5B&L3\*#,6AYXI,_YHQD%$&$*@%Q902DS*ZV":LT+W#!,AJT0^+ M6ZW!1NWH*'*O"? \P$P,:]^'F+I<[KMPT: MQL"KY=I5>U'/PFN13P],Q;$\ M9_FS^4T\??JRUNO]IV>-!-VG'G\VW']P^ M)?59RZXWB+9^$Z.%VQAT!ZQY5D)>*@UY)0ID.$%NW4AXF&O4]'DN'?N>E+[7DJW^;B8V M%H -\(T-[I_:*>BS<]=-2*9=_,@P/;J]NV,; M8+\UP%J=[6/4&JW?#?RF+:H8 E;BPII?H@8MKAL!Q6F SZ.XXOCHJ MO=<&A^8\*YGA'!KDVD,964*&<0Z5Q(86@F%+7B'T=%;*V-CHN$1D9-#M>43] MB.9FG'KFE7"(@BFD$X*DC'%>TJ $T6GL,1]T7QQ[VF>II>D_^?;9G24V:4OM(->"8^B S78^!SR6B@3H\IXX=*G>P](9DN5$4(E"AC$%=E MZ7HDVS6@)"(K2YXC%5;!_**HL=%ECPG>-Z=VCXFSNI*ZA\CE[H=O+HL;2?[V M1?:X?D>_.=N?]*_U][_T[*?^8S%?_UA-+%,PQ$P&C209Q%HBR*EB,$=^#_:+X$G^<)B>I6$%\E M^_M$F5%F@U^"+#8[_.)X801IG[_%WC;^<6_AHY,M564<%ZB"A; 8;;(G'- MRGQPA _$#X/T=(=T4\#M7V__8D3ATWP>W*V.\XL,(5HS?MA@@]![E'T;+H^[ M^<9L@H_;E"*LBUQG604)-B[1UKCJ9JY1 GAEZL/C/RV;M1W]V7)7TY*^.+;AP3J1E M5K'2OLV&"@UQP1ADG)208H5%I:61824RPE48&P$D//=+DR%)D6JQWK7:V^;FLJHQ2A$&, MI/6#%">6*E4)BS-CHT&FYUQ J.@7Z JA^#'8[5#VS5 1* MX47&.D%(6U[LO*AA"XMUFGM24JS[ZMAB8IM6+ZXA>I.3]VP)J-TK7\S;%C#- M==_Y+[UZ]\L*MC*F<[Y\J1=C+E7/WFE-MY(>/LSM2VN=A4E9%EB9,H?*587' M9<58<VBM>:_[&_FVDPO9\H. M/L5^W#:2B>N9( ^['KNW'>Q,!3M;-_/:7E^;V^1![\P#&_M2%BSK?1(2US_K M3]^!RZGU#OQI=;;^1=Y8[.W#_.EYO?JH?^H9:MM;E)J+PG )=<6,7:A3!@5B M"@JTUNU?_D=.LO^%(@NGG0'4CYT3P=0SN^X7-6L4 MO0.UJ@#UT"C$ Y-^2HV=D?=\OEY-K%>IN,P9Y-K5O^4,0RI(":W?B5%>$LR$5RB9O\BQ4<L,S(%PB.:X#Q4HD MP3891Z*LRA*'I0J<%S0V2F[U!%M%XZLJ7H+6\U@D 6!]'W[$ M8!61+- -1.)4@0O"!DX4Z#;Y-$W@RO61"[[I?+K6'Z<_M3H*V?ISI'*;6BZ,4BE)KJ JCLKS49BH7WVL]#;,A;L"^\OY?A MW6H]?:QK'3S76H*95?-LM"%8U+W=US_X'#PL%NJOZ6P6N'#TF1C/%61BL/M> M2M;JPEK?DXC9.]#H#)S2"1>4 1"E75GZ"!YVB1D Q.,+Z[%ZLP[ZK MC)65S% &RUQ7$.?*M:G.*A=!0B6M1$9DD!]S*F)L'DRM81B?G,'-CSUN0Z-G MKJB5Z[$C[67CD[+ &3&#OO.7S3Q^PSNNC,Q27,P?ONOEX\<%GZ^^\)>FVUHA MC%)E!JO,=9%5J(0"V[_F):IRG1NC\J!H[G-"QO9..QVA%?0(E!:!9XAG0?1[ MO6^%IN]](*<6:/7JIQQQ%P)ID_O."1HV<:_#U).DO*YKX][UKRY&\5FNZQBJ M-XO5^GZN[._T\J?^N$U ,)+DBE09))PQB(7,H2CL=YU6)2:$E#(307WJ?82. MC0L.= 9.Z3K&LU7[AH0/KQGP(X[4N/9,)"D@#::6$(R24HV7X$&I)P2*8RH* MNC?B+,N%;GV8.QF/=;WS9M_5D=_J#_YK^OC\6+=S=T=GKM#G5[0,:(LCY4<,IXSJ%U"<5$5J))> MP9J]:3@VTFL- 74 %YBUIH Z(@*LML:X<@"/K3F []D3< S4RX1[G,*]]C3V MS+%U#.K.OKOM$1*H3;P#FRFNK00;,T%MYQW866HO !M;P?V(YCC@9/"UYWJ@ M@\17G/.PX\<^YZ/SM+(7P<,=;O:)V\%9:*^";FUEL.F0LC_X[R][?VO;Q".# MB)((&DJ%_>A3!85FR#X5LN1(9+02(JZ+@9\"8_NF[Y=DV'8AVC?A#HB7_5_$ MM90/GB?/\]D>T>_[W#8Y\#>T* A#KZ?N!)Y*O%)C@C"(+O-U]#3$C->(%S%&& M(=;,0)I+"I$RAN$"V';06_-? M$:= -\QP/W ,F,?VS0TP],Q3.P2N'X)?AR)@E^,& M2 ;:H/!X.,(V$BZ8W+D'<'S/<,OW"]H>K+PO71-&0TI/)]]<]_CI^B5'XOMT M;1=:I6"Y("*'6*D*8J,9%!DK869$1DHFQ+/H=7/2K9CTS$FA<'B_A5UVGW%I5EK^Z\/BY[_9VVIOYI_8_0B;'^M7 M].R @[RB7:9L7M'.:^(6<$U-QHG)09)27C"B&C0E9 MAS7#CFTYU6P\\X"RM4T2ULC2",EY4#12!$P# ML%=(7=\C@/Q6A>%F]TQ05RP.7I4=&IAT<=4./>@:Z="$AZ?AD#T AO('G6Z+2-(@]%#-L0\JQY)XT?SU\5]^*^63P^+N9U M7;2F/-[]\_K'8CG]OUI-=$FQ=DU#RJK,FYQO)JB&0J,,5UE9R0-;97 MNE%UTW>V:;4&^%;=^ 9L77C[O?B)4.R9!5H V_ZR;>7%G:;I*,$#CJ3\T"5O M4++P,/R8.7QN":_SW"8T_ETO'I;\Z<=4\MFF3ZS,M'1)AEP2Z0K-4"@*C"&Q M8Y32+E6RW,L-Z)0R-NK8US#0(>A&LYL>DF'4,S&$P1-4 ?JJ^3<7@KXL8;!Z MT%>-W"\+??WB\)W!M^UN[W=[ZX3DBC*>V<4T11IBEA,H&"'0:,(-+ZBH2.F[ M*[@_\-A>ZHUNP"GGOP]X@-7U/_JK]'JBB5(92N\@FIG(O8 49-H5]]XH, M:YP;Y)=?TREE;"]BJVB=\M%J&O&1O0SJ]8]L$JCZ7H/'H!3TK;V*PLW?VLL2 M!OO67C5R_UM[_>+H7#MM;_IAQWWK2KXMGARK;/K99L2^\D@(:*@L[ >855 @ M2P>B8)DD2AJ1!<6I=DH;&QELE*V?<[53-SB5K@-@OT5Y,MAZ)H8#Q/8T3=\V MV N1U*ER'1*'SI&[;OR9Y#B/FV+[$#PMM9S6$1IV_/M'%[OT?YNP$*,9*32I M8%E4N*FZ07.%H,Q%;ET(K"OAY<-[R!H;@>RK6K\2?$_9T*8$EQ'VXY!$N/6] M&-C3\LY2R--,;]';5[E.\7]JOHE=8$;T+K@*4^(&!I?E#=S%X*KAIZT,KM\2 M1RB;\/0WBT=I^KRUP]URL]\-55M">QM_]])B3%7M.)02&D7+$25D%:" M06D]%49+@C,4U/4D0H>Q$=!.7R#W%09FL=S/B07VRS 'B^?0<_V8::)9B;3! M&N:9G2L[30I2E6>P9"B7>565& 46B>MYHH:I&7=IJN[ K%5ZJ@>8';]O2<^( M]_R-V>8Y[:E_!_8FX,WA!&QM2/>5N0' I%^?&#T&_2K= -3QU^J6H2+30L_V M_-KK_O;[R^Z2MCG<_5]\J3YN:ZP4"BLD7""L) 1BE3,HJ&*0&,61_:F@.JSK MXT;M]]@;]^F_2Y[+H?Q;",^9]DM?9%OGV _PAUVVGKFWX%F+#P1-1G( M:5-3;U=KV&359#">I*^F&SEVL_3G8O;3%1IL-(5>0JQ[QICX:Q1I R MFL,<$8%$D;&PUOE3UN%1"Z6]J%L.]N:2+<>M\MO0!9#P5*O3!) MO%_:)7'@_5(/XT_W2WUNNK%]UN]V/.[Z0#JJ>K^L2Y3(E[H7.Z^D8F6&(2(E MAC@K+:]H;-T_4BEE.,FD"MHW]9 Y-D[9TQ-L%0WJP51[<7XVIM2GM/O&Q%5I2S>W@2[=D#/6,[WN]UF]87[B M7<%46/;C,-ZLW>NXE:E O>A\)A,0&T>T7]JS>8=551DA<0EQE1'+SY)":C2! M"AZ MB$KB.*%3.0/'!UTT]#0NZ/*ED=U_+ =I5]&_'NR[_K7^W>KVWQ.94<)0SJ&1 MKN1&GB'(!*XLB)D6E2MI5E1!#8#.RQD=03P_/R:'6\*[IYM$P '!J@EK/A&1P!8FT78(NR!JV45"WP2>] M@JY<'D<.[_AR;KV0U1>]W!S_3>6VQ6Z)L3"=AN3"PI-3D3 M. MPD[E.J6-C2A<04E@%]]--8$P4NB&U8\:DH'5,T%L] 16T2;NX [4NO;2QM@+ ME:1DT2UQ4,KP,OZ8./QNBB@NL.9K?9S#7)\&Y93*/.,&&IQ5$+-,VV4'0K#, M65%I2K567G51.Z6,C2X.L^<#SMFZL>SFBF0(]"$%1:X9OSMA04N2ABN ML, U(P\*"UR].,Y3^$\]??BQUNJ^:0WRZ=F=Y7\V3;62S\_KU9K/5;NA(2>Y MREC.E(($,4MKZ M18N=_O$%C,)F".>8.$*&JB"N=*PN(&=&0XUQH;DR.M=!A>!ZFY\AR+N9G=\& M@-W/]^L-S)YY?J,W:!4'C>9N8ZDM-+6G?.LFIO,-HU!+ZBN&:3"H[Q@%SK$O M&3=(FJ7IV^GLV8J>(*:HHJYJE2C$"+E+8O25L[8*.IP M.7H'5*,F^.W/;V]WOP_DKDL8QZU0(Y![A;5IJV5_2](C&'I=C&YDO>HR],C@ M:PO0X\L3^J/MT"=\=*_^ZWFU=E[Q)#=8FI(RB#7%ECZJ##)<9U,*GE4TPSD) M.A.+U&-L]/+.&"WK+CLUL;@F/*NF(/K4?K43>D8>4W2#CY06^%?REEHCSKA, M8&='SVZ3/Y#].U >NKR^*^4/F)=3%3!<9$CK8O[GJLT-,;JH$#$2>:<=J9?_L M(5'FC+EI8S_WQA\VN//4L)/HS3.71+08>S^=3]?ZH_W\*ONDVE]-Q:R)+'+5 MAJ1CB;U*(??&/LS_1_/E>_MP3*JB4*+" NJ*VH41D]B^SP)#5&%IWV&J[=OL MW8[L!D7&]LK;IXG6X7NN2PAJ\)4"VLQG<+>,/US@N 0H' M3>92C'=K%_>OV@6OR?5S&^SZ5<_XVF6=K]9M9#FG!2\R%X;*[&<>,\8A-9A# M(0A!M%*"BJ 5>(#LL7V:]B,O#Y2OOU>M^G7L563(:LB\^/FT/:'=\P:]%T!*Q[J8?QEA?8 M?H25&L*>F>K8,5LU[<]_V^H,-DI?WHT-9J@0C))2DY?@03DI!(IC,@JZ-[HK MV''G\TW7\TDA%:D(T9#G+O6<20ZYRBA41BM-2I%+KD-2SSMD!7'.8 U(Y;[" M8+98-=3C/OIK_BNX'=A%H/V()Q%\/?/-@9:@41/\YDZ;_]8PCP7/:FP7@NOU MUW4*P'H!OO!ETF,(#[A2MPN[*&_H=F'7##_3+NSJ+;'\,J\#@_]SNO[Q MYGFUMB,O=R5.52E*R3""N28*8IP;R#%64.94&>/J!OM%]GI)&YM?LU$VOJIL M-[B^K)((LMYYI47K+ZLHV&C:2T58+T@27Q('9P\/X4_[PN2EIK9SWTSF? MR\,:+:(41"%AH*DDA1BI' I485B57.050;)0.$&MG#.BQ^:_;&OE/.V5=#$; MO5/7RSDW%YXGFKT@W/>!9W>]G*WR0];+Z4!LB'HYY\2/H5Y.!RR>]7*Z1H@C MM._+NHK#2]V=M2[U,%&(L+R0I64JPR&V9&6)"V&H,VK*BN&B5'0RUP]N \J/ MNDZ%>+U K'F!]D7UN,AJ==PT7RZJ["[+LFT3YC5XK\7RF2]?_N5_Y"3[7XC> M 7_M&JV M@R:&">O4J,HNGS(#L308,EYQR*DN#"N,(KE7O:P0H6-;16W5K%G!.$7;;>* M\W]?P+N9H2\8>^:*6B&PI_(=V(%JM0:UVNWN<0^@!@10] #N0,$2:4 ."XH( M1*LS ,)WK.&"'0*M.PAL"+WWQL*(;Z$0F9)!C)'U M^41)(,OSDA-B5Z\FJ)U(I[2QL?:N)EYD/<*SD/HY;LF ZIF7]XH\[FD*_M%+ MN1PO4/HI 'A6XNL4]>LR_F*AOLZ;XICC7LK%\WR]^L)?W/'(F^>E.QN9:*YD M154!N>09Q 0I*-SYG"F0*7*.2*:\(G*[Q8R-*S9:@J=&S3#&N "E'U7<#E#? MOML&FU;#.]#JF(X9NC%(2@D71 W*!=WF'I/ E:NCS\RD=AOJSC7Y.EW]]^\O MW^U(=?T639$A(L,0:^FRE;,*TMPPB$2I$6&R8BBH%46'K+'QP(&JP.D*G*I1 M32BZ(/8^-TL!7/^G9C&8Q1R974,C]8'917E#'Y==,_S,8=G56R(7'!?CM5?[ M@=IMHW$7JOW=SHJ>8*QT2?(":DTHQ)00R TB4 DJB2 XRW58?YLX/<9&./;9 M(X'+D\@)\%RX] ]KWTN:J)21.EFD-B7A>N[ M-:TDM,SZKJ[Z;KO!,*,JC!"4AC"7>((@I4Q#C5#%#:^,R55@WM^?*YS?CZ[3.\S,;)M\08L M,4:<&*CS4D/,I8&HW^KFSP_;P!,7,9]30:AVYM!XX#WE0K.[NW#UX\G;L1HJG[O1#_RVT?1OKA>R#W81 M:=P>F"3.W^Z2.'#BMH?QIQG;/C=%+TB7SUI]7;SPF5L%;T(9B,QEA7,)E2I< M5 AQRT]#H91YP0V5.L=!E?19%[]7CK=CT'Q'B- 1;%?L) M">E"(?5Z\*RLH5=_70:?6>MU7IXNE;IV7S[I]02CO*2,"T@EI"EN!^-EO\ MQ>U+ T&]Z]3%G+UL>D^N=4G]_1:96]["E8I MR4M.,EAPA2'.:0F%Y @6TG)/+C@N:% UJD#Y8^.=*X7?>JFL%WTBF1SAGMG* MKZI>WP>)0:B]1I&]USX,# (HLMA>H@.]-XO'Q\6\SM \*8,_H9DBG$D"1559 M:L.NC4=!*LAR6KEJHD@S&N8_718V-AYK=-UD8:=L(=<)N:]SE0;(WIVK&L,V MW;K1]&Z_U4;2PE97$4E=V>JRP*%+6UTU_4QMJ^OWQ#+*:OW9N$I\+D#AFU[^ MG$J]^K:8J4F)C.6-,H.DJIBKZ%!8*F'5OQ MF>OTHUW!POKTW_YNNE?*.2"][.K.+-M]2XT-T(3!C56%<2ZP% HE4$A M6%DH66:$!T7J>TL>&\M<7A[L=/=I&'_C?/CQ32\HO]KZ*PS@8#H*!BLI._E+ M'Y2L@D$YYJ[P <*H3.GIY&U;2N.+7DX7ZMUT$4)8Z.FC9*@T1)8-8'3TX^#+@/9S35)X.F94X*1\2:/J]:? M(8F5EO_ZL/CY;_;>FA_^B=V/L/FQ)H7+HP[R\E\U:O.27[\PLO1FVX_YJWYR MSOK\X<_Y=+V:,*9)03($"XP*B#.60RH)ACS/!"D10RRK@MK[G14SMM=ZUWI\ MN=$3/#M% TMHGL?4SY&X':F>W_ =2%L5P9^=((47P.S$(&VQR_.BABULV6GN M21'+[JO#O^GOYNOI^N5-G:\\^S!7^M?_UB\3E]C >"ZAYHX!W&D0*Q&"J*IR M7@E"%/8*$+XH86PO?Z,D:+4$M9K ZNG_33\/Y/5O^LWP]/S&!R,3]$WOM#[Z MFWY^U,&^Z9U&[7_3NR],55Q$S^6/1[[\[[<+%_$ZP-R]O 3%! M^9'SR/1<@^1(Z"L7(CD/P?5J)!?NBPYY7SSJ;VN[&'&KDX]N*JV@]KE72N4% MUM:/*#-F5Q**0*:*PBXL2LRXSJC, MN;=4@;&]&TO7&VVH*-NI$LTPVU'\4D M [!G?KD!NY@H^.N8I(Z"[Y X=!3\=>//1,%[W!1'*&^U6'^8N\U,-_1WO7R< M(%V0K$"N>CZ7$.=&P_J,1"(MN2&*$QW41>A4Q-BHPVD(IEL5@97Y"'Y[T7P9 M&J%Q!DX_IK@-I+XW&AT^.^WN@-,O'2-^X\KX6/?I M_,$.9G]:3>V--8.X.FF;94JIJ6!V74(XS>Q+SPO(2$Y@H0M,\YP35@9U?;XJ M<6P+OSY9.^R/+GMOM6Z.3,]T MJ5?MY&!+A&S0KI#!HE%,0( M9U"@K(*EQVK;LWP-Y[=99]:2] >>J;U9T\^!LN0.M->##P:R^E]"05/BF M9=9;E1J6>!-!>,++J<:-I.TV,:H.:['?@]6/Z=.JK0NE25;IO+0\G.6NN((L M(2MR#BU-8UP4A=(DZ+BZ0];8R':C*ECNZQK(G1W0>M)B&L#Z9KP-5@=J]E!? MRP..M 35(6]8[KEN^ FM>-P2QQ@NIW7K3$K+21^G<_UAK1]7DQ(CP2374#+A M"NV[MFJLY) JB133>5%J&4(8ET6-C2^MH)&6-#G&#DL9ULX\YP^...,KXLEP\Z>7ZY8M] -;6L7GWS^?I MDUO)N%(!E3!,\:J !9,YQ%A:OI 9AA3)RA!MG9"P_:@N86.CC8VN=^#):5NO M#_1&WSLPUY=KCX0#[<<=J>#KF3UVR'W9(O=NA]RG#N2""<0'DJ04TBEP4!+Q M,?V81KSNB2.2ST_UMM7\H:TUMYK0LM)9QBOK8^36Y4"Y7:-(*2#FA6*9-=E" M'-*Y_D1"$&4,T*#^NY,!%ALU@6[U#".*4R#]V.$F>'JFA*UNX-TU3((IX*+= M2=_[4RF#ONP7C3Q^PR]?&/9:URU%#X_ WBQ^ZCEOCL)6?TSGT\?GQ[JQZ)L? M?/F@W3\O^8/^ZA8U$U[A+,-J,>8_,J M6G7;GLZR5AC(5F-0[_L'=".^87ZZ.65 U(<^-=_841^?K^[ 9D::7L6-,6!C M#?@ZW(P$M(P>9F8&ZB+=ZPR%-9>^'=?.?M,W##]<"^K;,3CH2IU@N$A_U!6D MW^NOX3;QV[*8!=$TSXB K"+6,8$&U;HH-X6ET6-[?-3:PIF MB_D#K,.K9CNE YW4R^AZ>JM),.O;;:WAVM.R.3A,77KT.A9I7=G+XH;U::^: M?>+<7K_CUJ*!AWRU5YNN($:6Q )J5[7$Q4!02QI(08P+CDI2,&J"BFE=%SDV M\MCOF/5E.9W+Z9-=[GX6L^E#/O*!AJH$ M> VOGHK_713[2O7^KL%PN<3?U3MOHZ.%Z>CO\/YY[6(-3KL\'+7Y*UF6(U25 MD%&10ZSM?P3!%105S@TR68E+KY5X'\J-F>(:$PZZKFQVK^*(+LELAE'BT',T M('EV=LVQCEK'] W"KBFA[X6'DRCX*HR=$MI+W)Y41HJLH.V![T1(GI5YSF'& M2 %Q42 H,I5!*I527!5,ZZ!HW MRQL;-1S[2#4$\AQ13/R_-ZW \[;7T?@"2VZCH78;?/I:S&H>42 M+^#L1Q(WP394,<2-BJ=KT925#[N!2%SH\(*P@>L:=IM\6L;PRO7A%8Z^+[DK M!?WMY5$L9I,*4VH1$["HF&J:\#'%):2J))521W M95P\VP_2%_[B5K3W<]6V?]L[?-GE.^UVIS K,EHP8K\T50XQ+Y7]TN0%I%AJ M@7!12AI49RM2C[%]ES;]"S_&'K?&SH@VE+< =J9-Y4W#Q:[*?^KYLWYOK3O7VJ[-+,1(2J'+ A94 M$W!S'5VZYH]V3L$EZKJ3 5:$U M%*@T$%?24E-F_3AB).&WT[/#V_W5L% M[\ 6I%K'._#W9=(.V-U0)"XE>E;4P#5$N\P]+1[:>77D)HV+1;B7_WR>KJ8N M!N&P>-B2SU=&+Y=:3;"@>5:A JK,]8%%E82TT Q6A<%428:4R8)V93P%CXTF M[A\>EO51)'BR0_[@*_O#R>!D)QLEH3>?V-J^$=MW[G-1LS++GI_6U7YLVD+:_'9ET6C MT[M?:VVU$C-[XVH]4;H4E1($HL)55^>T@H)H"D4F=<$S*BD+JHN<4+>QT=TN MZ7KF;+O;9OM89V"^M>\.K+8%QQ=F4YB0S\#38O-RZZV9=HA58"!%RLGW8]17 MFM*>27[/Y;7\VM^:!C7W@'SL+P;OY\V/[MB=<]/6 ?S^I M_ GT>YTB .F O5@^(*&(R,)$;4S,]T7]@5KJ;:V2S_-:N8G0%:F8EI"SPKB2 M9A7DHBR@)$(05!3V%SPBXNVJ8"]2&#[T[5ZI>A968+UP-8MDPP)UW:*??/;< MN&81W?VNSX0?+Z-Z99:;=UX[DV5$N[D&;,K:MSDD-:"0$1R:HJRY0I95!YM/-BQN96 MGJS^(NOR7P U;M4\N@K\$2C=O"+NL=3^!5&ONMKM+JI_Y>K( JN[((+W?+K\ M#_M9U6F:T MJ@/#?[>K(/5F\>C2E/"$$R;7IQFL00K9X?%Q!H"-LF%?+FT=]<;+*&1W'ZSXKD* M2HYUWWRSAV6[: ?W.RSOKA;8"%\C!4&4=LWD)WK8-500'"=KJK"[P_,6WS7- MX9NMYJ_ZR158F#^X/>?GU83K'!-=,D@JK%S= P$YY01J52)"$!8%5;YIC%V" MQL9-C:Z@519LM06-NOYICIWH=C-.2LQZYIA8N(*R(GVPB$Z2[!Q\L)Q)'Q/W M4RB]KH^MA-+$(30]F+_S7WIU/U<=-2@-RTMC*@%5:>S"1[ER5X4EZ9RS@F29 M$0P%=D\.4V!L%++1?^/7K)T%H453 N? SX7I$]F>B68+:MNXO5:^/F\;J&YH M+':)2[,$*C%PS98XB$Z+N42._M2KB>:5X$A@*#.162^H M1)!QHV&I&158,EJAH$R-RZ+&1F);3<'N.'O9ZAH9\WT*KQ]KI0&M9W[:X;75 M$GR]AE=\W/=%*/J)_3X5]SKQWQ?-OA@#?OF.Z$@9MUVTVN2Z\MEJ>S)""HQ8 M)C0T.M<04U9!5B$*"=++Z4+9A>!R M[4J;KKN-ZI"_@:"/TPG;LR+NX8IM$IO!5\_"26 M0F9<88I 8QJ+-"E;S,6::S=A+?S=4HIW"CURM-H+:_?Y6I\_OR M##89/7^;G&9WH)Z)/07OP$YWL)VFX]_MW9"PZW4*8-/VQ;Y)HV$[9Z< [Z2W M=I)!PSZE=<&9Y0II7%.95A3*[:I?4M;R\[F[O MAAR;5_VG*XJMFBP3SU7W'C[=?!5G=<^D\^>G#]_?O07?OM]_?_?M=NHXM;'C MF*"]N'G]V[_4;W[]SN\--ZKZYNT[\R^1WNCB\7$Q_[9>R/_^PI>?E_5C MINJ@J4V%NXF1J"P-R:% A%B?DY:0Y::$6BE5509ELO!ZQP)DCNTE;%0&*Z?S M'7CBRWI'3(/?IG/PO%+.$6G"%OX6Z(QXP._I?^X!;XQCI#\U=H*:+3ODP?WI>N]A- MQW9?K:"V!)#]LILLKS)(,LHASDL#15$Q6$C$%56"(Q0497E=Y-CX:*.A:V ; M6$W! U\_QDF+6L^$LZS+=V*0/JGL1-+P.667C#V;4G;QXLC4C5T^ M?1-;<#^O8RJ7^H?+I?^IV]]NGF/K6!BNM'4Q%+>K'V$T9,K204%<@Q>L2QV6 MU;J&)BV'Z(I.4IZX*'928?"$X9B+O^R(S^%TYD%WHCB:&07_6 MYK29\H2>;[^:N2>PQ?M2OL83^1^_UXO]2A&/E$(4))57!(9=T5 M4V>0,29AAAAFN'3A2UXY8S?J,38BV/L"UELL@.^WR8Z)8XF=H)L]C52PO[(# MLC7CL&/YE^ZI2.F8^ YE+_2J27 #W3X M_POPWI^:>.R:CXR[WWTYB@PA6G\W(D8Z5LF.NOBQ6 M:S[[?Z=/;Q:J_B)0B86 ):H8Q$A2R'G.(!&*"(TY5MK+2>X6,S;V;\NKM*K> M@4998+4%3MW0:C1GD>TF]G1X]4SBL5!%5*+I0N+&.C1GAQZX"DV7>:;[M);RI=C-A1'"-RPR:0DF7!UE"JI& ,BM+@HG].PGJL-4M M;FR4\%4+_VP03T3]%K;I<.J9"K8]>!M-]YNWO$E=%L8/E+0QY=TBAPTG]S+_ M))+<[ZY>VH-_6MK0.Y)W ^_+BH/Y1[YB:?UN'_:-0'3G]0&S!<[_ +R W91/Q8 MA3%U$[\ 3V!;\4NCQ$:UVC$^K%;/6KU]7D[G#\TY1IV0LZK_\?-3W:OHW2^] ME-.55I,*4^9J#D/*,(:8J1SRK""053DR1B"[V@JK51ZLPMB(;Z.8"[BL4_W MHM:X3O.KT_M6@?E]$=/BQWW]@MTS_^T7)=XO9[M?F1B(%W"V>/%??*GN0&N= MJU_SUYVBK1?]S]-L@X/M]OGJ$M.=OUT9ST*H.&MV=R]"H M#?;T=DFFM47I/DF1R"7]'H7J,.C'*!*@XR]1[#"1#;L[CMX_Z?5G\YW_FA"% M7$DI[ENZ!.W!Y"Q_;!:2)2Y$%$RFSA]OKGNDZ4 M6O-?@>VR?:#W8[74@/9,95>C>^[ IP;4[QV@AG>K#D I;1MJ'\'#]I<.@.*D M<73(O9$QX)O^:7N9^*NOVE74,B0U1$0[/\>B*W+#849TF6FMC:F\ M,NY/AQX;;UCE@-,N(([L$*IN'P('[?5PW_;3CA\<]D6GLB_F#?0,?7>#K=SO$_:_I:D*L;Z*U7?L@ M4D>+N&3V I70L-)4N2%Y+H):N9X3,C:*<#I"IV0=J'T'G)[@'T[3T.3V\=V"0-O']G*!AT]\[3#U)@N^Z-K89XG[D^^]\-5U]>UIJ MKC[/_X,OIZY/B(M]SREWF!4 4U M>*1U9CKD#>O37#?\Q+7QN.7FFJBN0\O[V>*O7=4I+JA0B)40:>9: M.^<<47KT\CV167M+K:;K]US6N3SUBCY#@AFF&&1E M*1Q]&$@YR:$BR 6NR!S)H(:HIR+&1AJ-AF"C8M3FR!D@_>CA-GAZ)H5 9,(3 M\2X:GS;Y[E3,L EW%\T\2;*[?&7RLH!_\/]:+-_,^&KUR3X";Q>NN-8$TUQC M4@A8"4WM$B.S;[^0!E94J3++B2X+G:@P"[RAZO^=U6$L=?^Z JH]]V-]@?@E 6?Y[%U M2@Z [>:I9'#US$;12,67*3F'1)HJ)0+G5&GU^\N?*T;M!,R#GZ/3 M#[H]LXH#MMYGV:CM,FA_^[-!^6]@JSRXOPYSL'<3CEA2QR9 _* ^33@LQ^Y, MQ C1(7%UY;:WNOGSP_SSDUYR)^,-?YI:8MCN4^:&XTP:#LM*2FA_K*! I8 B M8QFC"DG,@J)>_$6/S>=Y\\.EJ]>IYXN-RFT+/<#G"LS:JC9V>OX].)S.=SK\ M.*T?D'OFM _;ZJ8;M?_FL-YJ#EK5>]E5#DK_BAX_("83D3I1NFE;%]8']83;[8IV]2R*PHL6*0X,H%]1$.N;;S0W-MUV^Y MH:(*2O&/TF)L3+?1;>6.<^1>-W3P/+<3 MY]^_(E26F4*Y/C>T;6,^2]'YXY M9!L#0&-!6]OD;I,UM3&CZ:$.-H8 9TGO!5#\@!RB!LH53<90!L4/+,]**)Z# M)5W0;MEYYVQNG0_"I509J^S"MLPA1I4E2UJ5UB'4#!6"E;D,"GD,5V%L3%FO MP4Q]UEW7=]MS#+>Z!SJ#$?-RTT(W$=JON^#=.8D[*WKQ$^-!'&(-W*7&&-;" M'C!YKHE]1HKCQ;_KN1UZ=C]7]^IQ.I^Z0:T(_>Z7*UVF-XGPQE29)JZSH2P@ MIH6!O+1_E2AGIC R4RHH$=Y+ZMC8KU6Z7OWR [7#*,\/"AJ)2D[(29>$5HGE^^+%Q3'M^5JL(6AU#3Q,^?TN/#L5;$I&-M=X$VQ?2Y,5:"RA)4VQOH* M]JVE2C*H*JPU,R5%515R'G@J8FSG?M^=#" ;Y?8WQD,S,$ZP]',";D.HYS=X M3[D>VA-<-CUQ:L6)F($S*BZ9>9I(+Y9Z^C!O5KKRY?N2SU>SFC__;MUB5RYZ8EG*$I=RA0YU M ;$VR-*7P)#F4E7,2*44#SJZ\A8]-@9K-6XWJN0+6.]T!ES]U_-J71>_#3S- M\I\*SR.M7@#N^URK5?H.;%#>Z WV% =.\[8 ?<+CK6# TIYQ^8L?]J K&):3 MTZ[P$2(6X.<:Z'UU#3H^FZ]Z_;R!ZA5>XRA&#!E5N'5Z4 M4.146]^LJ*3*N:3*OXATL/BQT=I./R!K!<%O? 7:0FR>5=@B)\)C,=XKO'UO M[6W:=_[G?OO..U#K#SX;T%C@RMQOIZ QHE?4 Q;IO:(_T%J]AUD(6[Y'@]BY MB@\?=;C%?+3%!VOZ^%%BR_BN5DZF'<]^IJ9Z]=T5VIL87F(NB@QR1##$6%7V M0T$11*C,D% X0SPHYO^\F+%]%9R6X$!-\(]:T>!*OF=!]5RDWPQ5W\OQ<)0B MBOEV@9"XG.]940,7].TR][2D;^?5D;E!^L%]E[[JI\72C?QA;A;+Q_HSY=;H M'];Z<34I,4.<9@@2K!3$RM7W1EK:=3'5948*A5#0(:Z/T+&11*LSV"H-]K0& M_Z@WJVK%0TOA^4R 'X6DAK5G0DF :'@B3P!$:?-V? 0/FZ83 ,5)5D[(O>&A MG6TTROOI2O+9_]%\^6ZNWO*U]4]PGC.!),PYY1 CQ:"@+(=$BJI$)2L8]]J@ MZQ(R-N)I]02-HL!I"JRJX&U796M_2+NI)150?:\^8S *"@&]!D)T(.C%@0<+ M![UFVGY0Z-5K(S:U0LX"[J6TXUJ:>:^Y71;IB2R05B++8%%A"2T]Y) ;R:'( MLUQ8IL J\V*$FS49&VU\/#B#!'RC+C"-O@';+C=-D,>^UU"P#W%>^3GHO/(. M;.T![X>=EX"=L:'F9Z!-LI[G*6S#[/]K[OIZV\:1^/M^"CX=6B $](>2J#M@ M@:3-'@KTVB!M=W'H@T&1PT981^Y)0C^$2X^ON 4-@F*B>;:O M0"V700_G*@'J9K5\T^8@%FDL)/<2BC/IZ15N2G :I2K>IC).DM1/>3RHJ9 % M7N;FT:ZK.EYM.BTX M=G"](&AG]I^6!>T+@UII4"=.&\5?H(U$TRG'P,=-IZ2)O)QK99FY.3OP'G5T M9Y*8SM79P6+/V5FZY9E34]IT1TIY['N9Q)23"!./^?K$C\"TG>\Q*F7T"+N!^[RC$7&]HSL8C/&S3=QEA!Z1>)GY)4^-;;+ MT4^][ETW":6;2GRY%GK?H-T%;UO1+6@BJ0P]#R>9"# ))<=I" GVXDA( M&:=1,*SKB#6.YF>$6M%>%P)V(ND:P!;M6RE MND"]7%W[A4V_S:D59E*W.;'BIBKEG$B!AO6=%L$^7O)I@]"$5: 6<=DO#+5Y MXW&!0M]F%]4NQ]:6Z M#77//(*VNUJEG.VRV2NO5ZC2..!, X&ZL_&L+'7/_A'QB;O'85@@,PLEN]Y( MV='8S49CEUN-7:!>/M0(>(&T0.JO-7J >L\A7-[KI;2]2,@Y_%9#)G?<3AI; M.0?]<1#FGJ"9+ZK*>G&K'_]F!&P2I\ HZ%9208H)2P2F$8EPF(@P"#@/0 [R M&WMWG9N-;Q@S&IJ[#])Q:SI:] FVD/.JSG49WW^ 5>MRLZ%L:43NLW(?,SGJ M@AUSH_[WV-3LWW$2L_"L$-TK_/R'UL?'.H2!4(]W?6>!)B&H8)-FMC:S7JPY9) M]K!T_,:?&DJKN)UD_.P.*E--F]4DYS)<=D=\@UFRNU>=UYYC(1BC(O4EEL(# M3'@2808BQEDD@,0J-HP8']-\8VY^O>-K7.N,19AZD% N,2A ,"%QAK,XHS@4 M*2- @ ,1B^]-W*]\:5F[ ^LQ$7>07<&WO"BTF%<(U<1\)A#5 AS@=MF+L9 X-CQW+R11O= M/<6)G^AO_B*=3P[9_B>?C[/R_5"2]WK2W>9D^Y>J]2)]6<-'J5R->E1SMKQ9 M5;F.(:__JE4XJ1W.>Q46+,(L)6$$(8:4>9A( ICY7.CS8"2*PX0(04R-A!<(>AG14@EI M9C]L:7R8^7D!/3JV7EL5OF]5>-NI4(G5+HXOT*==%?:RH4XX]'4K'KHNUO?- M+5C\AY)B*B&/&&5,KVRB 8?VB#U*8FXEN-NS56UMI%@V;PS]!;YB1/ L3U_4* M&S@:[AS,=3HHN]W&\$^H3-L7_I"03]K"'_SBB"*J/@NMV\NW$SJ;;@"*Y8_9 M,O_6N)S?69GKHM4W*V5$Q,8/M;FI!4^(E*'(,&0^Z!D1#&>3Z\&Q;=J( MH@MN-L*@'6G05AP]E;@5".U)="H)ZT!#!@544VIJHN(IYQHSJYJRA?#1BJFS MB4Q7+64+C[U**6LW'5-'?*<3;N^*WUA>-J.I/\J^4U>]1^MC 0LF/<8B$#@& MJMMII12GS(^Q\#+@-,IDXLOA!<,FI.?FW%KF45X@J=AODVA-TXKS?9R92@8X M-&= NUY9MQB_*Y#F'#6L-^T/MACOFS[%OC.<3>IZ7>$]50&O(>ZV*G3'P':\ M%-?HCA/6W(Z1=+^X=M0=1IZ2Y7<@UDM%HMM2WY[@DFD":GPE&,@#]LCL02=8YO> M<:E]98]@>^;6S?FW ;#8/8M[A-ZT!W-/"_[DE.Z 2\;9D,OMX(W/J^YT/WR MNCWVKQO$?EZ]8=7=3;GZH6R7N'KX4NFBC7[7]U)W"6@F?EYF5=-Q>N%%)/!" M?9B7@H\)"(E3R@3VA?2(6IP&$!OMO+I@@G_:6;@G#P!PRSC2^O5L4E]I-)>0%U_UK50::>Q MZ(^UG*@3%&4/Z-675LFOT39QMY47?>TDMFB372K$JC%WPNBD7L EU(_=AU-: M8]-UA6YUT"Z%;_/JSZN'*RCXW3TK_VQJS2'SA>!$X$S2 !.9$%V6X6%*/<8Y M34.@1G,#3A&,GR;]0=#X4 MEL/!^N [C,@/?;Z#M[!D/UD)>G&V*C9U.TD0QD'",\RB5*^;1(P9#P+,O#1F M"3#I9]G@3- !(G,S5HI-U/&)6D8-T@V'D!R0P+& CV,+\PPT8X;8'\+((/EB M :N)TBPFCY-9)N4$!D=S)H>NG2X[^.CAJ?S+3K6Y>H8+;4%:AO MH?WWMU79??^2_V^=E]H*7ZVKO ]]>H^RXO-8YMZ,?$B@2/&(FTR&:912G$2 M9DD@0B9"&1J&FO:YG)O-O12B*>)MMK9X-R1RN1$S-R] =:'9P2'MR^K+?1S< M:N?GP;Y/G93H52?GZR9]UE_:R:HWG3MIT8ZX5@-I=]JP'7T[X'3JD-T=V,_$ M^0Z)C9U:6GS[#.7]6\CJ;6(WHY1*&H8X2:,8$P@83C/E&W@8;W;' (DDAXF82AQ M1H6/29)"E&0@4VHTG?0$O;E9@G\SG5HN#M9,-DN#=S>W_V#WW__U%OU1ZHVK ME91F-N.4$H99#XO0.K8C':>[TS,VS*)7&W9?V[,H X&Q:EM.T9S4R@P$X+&] M&7K9(&ULW+W9DEM)CB9\WT^1?\WM MCTK?E[;N'M-:)AME2B.INGKFAN8+7&(7@U23#*743S]PDK&3%)?C<4Y46E5( M$6*<@^5S. !W /_R/[]?3'[YAO/%>#;]US_Q/[,__8+3-,OCZ>=__=-?/[T& M]Z?_^6__]$__\O\!_,?S#V]_>3E+EQ/B[[^4 M^>SBE[_-YG\??PL _[;ZI1>SKS_FX\]?EK\()N3]?YW_,R:F2G89HC,(*F<% MT40&7HC &5/,NOS_?_YG&X-*WGM0,@E040GP/ M@]*LR%I4Y_4Y]Z&0\_?L_ MUR\Q+/ 78FZZ6'W[KW_ZLEQ^_>=??_WCCS_^_#W.)W^>S3__*AB3OUY]^D^; MCW]_\/D_Y.K3G CX=?6OUQ]=C+=]D![+?_V/W]Y^3%_P(L!XNEB&::HO6(S_ M>;'ZX=M9"LN5S']*UR\[/U&_@ZN/0?T1< &2__G[(O_IW_[IEU_6XIC/)O@! MRR_US[]^>'/GE6'Z>3S+/Z;A8IP6?TZSBU_KIWY],2-,O ^?*\VK9RQ_?,5_ M_=-B?/%UL(,JG*9$*Z^^7_<_/*O-T1\G>."<+-B^BW]8/., M^K8S",+O2YQF7'-[]:K)+-WYT*3*>C:_^LU)B#A9_724<3Q:/?E97"SG(2U' M5@8?T#A@!ATHBPH<\QIRX:@DLL)DOLM_I7U!Q*]4L\#TY\^S;[_2@TE%@O^7 MJG^%]5]7PGGPRK603J/]:C6^F9;9_&(EVT\A3G#D11&F! X^\D2+QEOZF]40 MI/-<6U*5U6>SL>OM=SFZK?AG\_3+;)YQ3J;FZO5AGAZ X"[,-Y_X]6N8TX,@ M?1E/KG50;4X7NES..I;J6GU$^I]^(0D4G,\QOUUK;R>C*RZ79(QQ]3%)"P6[\K'Y2S]_=GW\6*D/1=%>0%:YDB2*<2(4B0>AUY+ MEV3Q=@\\2EC$%=6;-ZTP\BM.EHNKGZR@ HQOC-'_^"E)_6&F&VW/6HA^ !BZ M3?_+V4483T=2GP( MF)E=7,RF*P9^PXN(\Q'CRF 0"I+G%LB3(PN"[#@*&&#@P6LBU1YCLV)XI?, W9'D7(Y^]94'2GDQ_ M 654@&@I"BHR6&^J@Y=2"S?WFH)^4-.YV]*IH'L&S#-B(E=&7D_"YY'RJ*(G MPHM6F0AG"0(3"7)$D7QF2B$[&R%W7CDH3_9$#_E!T'!/#AKGB'@@*%D[TU>[8.1% MZ"PLR&0I0)^=5Q^$$/_D$'*Z> >"#]H/IXMQ%

]N6[GW]L.R8^S)P>0L*0\BKGT]GN#O MEZOC@1*-Y=9HR#YP4)Z\:)*" R91(E?,JZ3.1LC]MQZ&C*>3.#U+JH- Q ?\ M/*Y7::;+W\,%CKCCT2GIH' DV^>-I;V1 O.@6)%H+>?\?'=TVYL/0\;329N> M+=U!H./--,WF9.I60EE=A7@QNYPNYS]>S#)ME,PDCIP#,TJ1NUV0]LB5%E_/]D ,(.0P[3R>1VK7L!P&E3^'[FTR2&I?Q^E;LQF(*F7+,1#Z7B@)W M%2EF-UI!<#)PX[(4LJO4Z@X2#H//4\NQ=B'O00#G6/E(Q>*$4 M \5+S?9XHI_B>_+8E>#"HQ:NJVUJR^L/ \S32;=V(^4%_?7=_-/LC^DH M%AM2)*=3E=[S\,* \G<1K%S(>$DQ6N^J[^?OY M[-MXFG!D-&VKTA<(15 \YXP#GYD&EYAQ+*%(!;O%RCT*#@/,T\G.=B;M(:'F M_6RQ#)/_._ZZ2L4PV9L:E]EJ??\GD]AL/P\332=.> M+,V>4?!V5N_!?)E-K[)#AFN73+&08I:@!-8;FR0%YU7UJ&@;-><7GMU_ZV'W MT9Y.-O8LJ?:,B(^8+N>$9B[BI_%R@B..TA5M+=BZ$:I2ZEF4#& UTR:EQ&2. M9R/B_EL/0\33R<*>)=6>$7'G)L/()D%!5@I 9(IZ-&G(.5(6BA4F."^%2.?# MX#HIU;.E.X@ 9',O;GWZ6%%.*KE6H9U ZD/0C4O)G2TT):CK_AR[ ,&[9& M@AM;&.V/26(D1SH@>,T3\.A"E"BTYETEQK93KIL!P&- M5Q($9X52TB0MK4LF2EP17**RBP!/3/TX?PJ MO#T$' :5IY8[/5_6@X#,QR\XF5Q1;YA+UM6[ER'D>HL?(81D 64V+GF%2IU? MG??PO857[N'CL-P\W32J1U+?A XJE?PYB_"$C_/YC]&H43!,LM0 M1 PU_V,A:NW NY"Y*2Y@/#_/NN7%AQ5T/IU4Z[FR[0P:__+K XD2=W\_L_W= M=#&;C'/M<'C=Y6(N&X?VQ?OI4[MLF'<<"V=VTKMJ9%)OIEW@ M]0NO>[&Q+)G&I" D+T Q+L&1[0"%KG9^E-F[?=FJTSL [2#HW!Y''_ ;3B_Q M-2TTDO3JD7\;DQ-VN5C2Z^:OOJ?)9367SQ8+\N,Q?PK?1RFB*45I,,@HSC.) M51D($#7$D\64S/<%2J?+X 1B^^V3U 6*[C=+:JVQ033>6BS?E;_,9GGQ;)H_ MXOS;..'BXVR2:=>X8VUV^9TD]=,CHR5PNI'^ &S,!](%$?"%3.5+VILGLZ]51ANN M1@[)1A91C^ASO3S**"XI9#59R4DQ&0)];>0L[2&K7[>H(]4_<(RZTL, 0/41 M)Y/JQ$WS;V'^=[PEK)$SM-I8H=W7U47G;0'':H55SES2_NM+WIW5VQ$S6SR*R&4BQ%!SY(\,50 ML"!L3 DSLWG?*>D9CM%^POIUEMJ@JDM=# !:SR[JO8'_7BGE77E#ZIE^'L<) MUN!SN1@AB3%^'\?S?P^02WY6:Z2")D71K/G"<-[F_=U,<)6M7%>G@;"+../TME(S@ M&<]">NU+N>=@[>BM?-1K^^E&U@9"C87>-YR>I?^Z'%_UM" Q7:;EY7R]L[]; M?L'YZOS@=UR.G):)B=K@8M5?B_BHQ3J!1!EB,DZ@NS\S90>2#GUC/SW+&H*H MB:@'L,T]$-6(*>:DY@@H52(1Q01>)P;:J$+_0^GVWBSK,$/03[.SMIO9>?(> M4FIIG3EY.UO0%FRM-U9XH$@30:'6U5P:B-PHX[U%T>CH: LQ_6Y?3=-))TI\ M"*"I)O+WV71VEY7-&KB64G!%19,L,"](2L810YH4KWCA-ONBN6XSA.0P^OK= MU)I JWN]#&!/6UWBI4WZ.O)D6J$-'%*BW9@L[&J=1$B&F3IR(3#=9AS2/4)Z M3DTVT/6L.\$?CQN_QLT4/]<;%(]@IT;&.U1)2;#.!%"VIC#J7?#B'8G&:EIL M;?*3^^GJ.4?9'E<=JF4 YFDW(]PZ5@(J4*LC:%,[<9@8@'-O2E1HDMMWM?9T M?)T'K7:)RO;0ZD89 W"Q;IS#J_LSX^DE,75SF^PYEMDH0#+F0&E1"%OTP4(6D87)%EWO:^M M\;E7PYHPU6]PV<*9&PH"!K,8B,7-8GZ.4ZS7.!*FX+CAM<$GL9%$!E?/2W64 M0GHA,]O;PO]<(#\@J)^>W>U!>)[DA[!'X_)6M*T4^;$I19#"U*-1DR%B)G^C M" Q>E13V]F,^8U^^348_[;M;@N5T*0_ QKP*\RF9R,5[G*]*,)Z'Q3A=B\6$ M;#&X"$IK"GV\)&8D(\=4L=K_IG#M]\T]/!TR>\GJJ;=W2PQUIX8!F)VMS(QD M1H^U9IUB7O)JLW3DB9+MS$5:=.BYSVUN!F\EI]\L1H?J/@1(1\E^@ !Z.9Y< M+C&/O/)**,Z@)/I"WARQD74&$VB!,9):UFT#P0G2+_OD^5_X9U M$#'F9]\H;OB\Z=/UKCRH,UQ+;9HW/%[+3T1=*YD=\2KKA!91.T/6>8&1LRQ5GHQ3HB3.VB)U(\&']=E.\&3JW-TB3:GKGH%C M.8(3KM21F:9<)03>%,R%-2B M5OHGN[>;Z!G5#\<1VFUN+06C&*ZZ.GJ_[F[@D160QL:,3BCC;!.NC\^M-7,5 M6R)E?\[M&.D/8J]='0END4WE9GV\\2E\7T\$I'^88UC@2US_>2V^XBU:\B/ M^GKCKO8C=[5]I(B%@GTFA6V43^F ^'X#Y\<$ZF-K>@ ASSZ67Q/#X\_3=4?" M]&,US; V*B3%3_/JN\D:!OD_+Q?+JJ-K(8T8CSP[Q^MQG0:5@X0H@J[W5T/0 M)@8;&]W/;,/0 "Y2/28PCU@8CX62@2^6&S74TB%B=[FX!@RCR SESJIH@*VN;AS!M$#N'(V4'1WJ>WA7+?=P2S% M*>_*3U:R-BX*+XA#CP94T )<$@9T<$8Z'2FX:=/WYDS">Z[2'3#$N];Z .SW M%DZON!S%(KQD'*'4R%M)E2%(26+TP1N>(R;6JN?73J+ZM;^/&6%VI9G.0-8Z MJ?L\3,(TX<EJ<+O0!A-YKZC?#,6[*,+1@@2D/*2;R M"8PQX*47M$T'F8MGB;&6R+E'3K\ .D>_6Z%RCK '@)@785&[E]4_7OW7Y?A; MF-23N&?+%V$^_S&>?E[UY1@9%853VH&6&D$59NHXV0#96VE#,=[(-AF9@\@; M J+.@L%]]Z=SG0P :,]2FET2&Q\P(;%$<0.Y=%=C?)BA1>B< )YLH(.G'+D8DV)ZS[J.HWF]<]K#K3P #0]&;ZC:B>S7_4SBZ>2=@.[(:"25 M0*^"!LT3JU,*'41)/J/+L@2GF BN34N+ XCK-PW5/9:ZUL< (':7^!"Y2#EQ M<,)K4*Q$"))4GXK,TNG",FMC@8Z'3;,..PTVK)-E/(#LXOMY+5]?_G@_"22. M::Z>W*H[<+6G)D6F1% @K":I^"3 >9]!NNAYL$DPWLKX[*9J"/Y.)X%99Z(? M@)VYWU636+@>MU&G)?PQGDQ&);O HU. V5(H8'V!J$* B$P&8:4SME4;@)]3 M-P3'J!-8=:Z* <#KFNYHBI.L!.!9KD:3>?!!1:);&"6M\S*W:<5T%$P:^SR= MP.0DD0X "K=\LMIKXLHM"RK7XB=(KHJ#%?+( CH0&0T)PSN23;N3W/OD#,'# MZ00DYPM[ (C9]'G6RC'FDX3\7*,J\%-=?#EE]F$A+ZH;M?RQ\W-!)Y1E8"UO8@C 3:0,.FGL(M<);Z6C! M*U\=_A"4LYF'1D>FNVGJ]ZRB#09V ^TEIQEY[!0.HL;>\XK#A#],, T/R2WOI 1B,3 MF?0<(V1O:($E;LB2)TGK+?@L_=C#J0 $#0-+SR\5XBHO% MB]E%)/>@JF7'K(PK7G]<<>JXXU8I!5ER20ZE3^ MYX#,9F:UD [;0.UTFOO- M&37"XB.I< !@746W6]8<8\D*Z1F8D!2L.@.'0@LO*R\3D\$7;../[2"HWYQ3 M(YAU(?P!8&@+!UGE8D0=PV%E'53F:/-7*""[5")]QURCH7$G(J=9(JH1!\R D"G("9)O\U#9J M!N-E-8S_SE7" *S/R\UK;[5DOKJV<$N&MU.W6:#6.@ 7(M.Z,PC!\@S2EJ#0 MTNHI;;);QU(Z&->J'0";*F\ X#S!D;S%K&8BKGHAR3H A*)F"3$H#[;0WV,I M).K!A -'PO8Q7+5VL'T\M0X PWM6([>2Z1P4>"V0.&$D0Y0:"DICBL5B6,.F M&*<;S<=P]]JAKR.%# !:MY@8*1:$B5P0K4R#LEF08TS193*;-M89; M1/1[0/G8*?^C1#Z D(&L[<5XU7!EL:IHW1C<5%EA6HF4BX+(%;&B72&_P!9@ M@65N;>2YTC\@)0\>@X?: M>L&SY)WD;>KTMA#3=Z%P-WI^6,EPEM '@)MJ76?36_3'*- &KT&:>K'>YP0! M)44.+OHD43,N&A5WWJ.D[PLX31!SEK@' )=G.:_N((7)^S#.;Z8OPM7$YJIY&76,9IO!Q954XAI2WB9#+[HXK\]6S^LB@5)!T=I$"_1<%1G%+3XTJM4XALR^ZFA,D" MO)NO!)I7\<[5O-%1U"YB<@@\TDZA)'((RGDHII3$ XE1MSGN.8R^OG.OC1'8 M0$F#@]YZ -ZSR^67V7S\WYA'1?@H8\TO%T$.0^8&8CVGP))5+,;&@FW&&>ZG MJ^^<[*-"[2RE#!1B;Q:+2^*$:1E3#9M9S1*%1E#:--\>3=- M?6=B>X#6"##!!J%306/:(.T XOI.T39& M6]?J&1;B'NS\7+CL,!0RT75R1:I71)QC8$W@/"\BYED.90J*AL(6BX,QT\E&(W*8[Z3ZJ^CT+>'QYQ)*-&WN!.^CZER[5,==T#/?SV??QB2_YS_^NJA%PN^^KLHJIY^? MI>7XV_HH]KKAGM:9!6D@Y3KX($L)4=+Z)I?G919Q;_]^K;D<080@ZI M3C*RM+IMH5"*O&J=K9:6V1)RF\G4>XCJ>7Y=[XAYT+ZE&_7UB,0:3XQ^GTVK MV-[6^=R;T4>CDD4*BB'X9&A+D9&#JS.ZL\G%HS&)'*2?A2:['M[S_):AP*@3 MV0_ BJW"].=$_VK,-G&P7@$82101'20TY$LK'L!['0"C,+7O@L/8Z+[W5GIZ MGNXR%-!UJ+2^S=:++_0'OIF^#N/YZBR.(KKM;8C>37'$B@TZU6RW4F20D2GP MCAP6I2VB8MD[=9A!.^JU/0^+&0KJ&NMK $;P02NWC3%_CE,LX^6(UPM412!( M'>O84E6E9AE$K;T2)>O8*%K^"6$]#ZH9"D!;J'$ J%R);4'*W'*?N?*24QV= MJUVB=<55@IA"@<*-=B;E('B;0N5]5/4\)&=H>.Q,@0, XYN+KV3YUZG7VGKU M[?@;YO4LH4^SY_ARO/@Z(V&^*Z."3* B8=E8KYY&IL'G+(&$I2Q6+UBUN2IP M,(G]7D<9'$S;J'8 F%W5YM8.@R3,M7"O@C1E0@@)"44V>U %$9RP%*0)4R(W M7NO8IA9Q)TG]7F@9'":[4=T@*ON)_'HZCB]Q_>X*)$+/3D(((/@@OHXUM3.?!-/9[069P.&VDW $8SX>KUQZ MKTA>'.M!/V/$CC3TQ3A;9"BAB#9%CGO)ZC>K5,+& MZ[AJ[+\9GFJD-,@D@[0:GDJ.!P09&,@H3'+UKDFC65>GT=MO]KPW9':NRH%" M]MX0PWJ8^6 >W0B-U$D6BM5J+RR5';G-TCL(2JAB'(^&M[EM?1J]_:;>>]^[ M.U/E !S)PZ^FC#BSC.N8@96Z?SC.P1D7P)145%%3\)T23M&[>CUM7YDY P/49E$ MJYDI4,7+VNPF@N!1Y!2,%+;-(,S#:1SD#>#.T'+_/*B-Z@;AEC[@[9J7=]/5 M_:@1Y[%H4_<6B[5WA"7FO'7D:2>3F8G2%_LX:+Q/VB"O[CX:",]2U+G8^]3. M+EX-.L-U']8JX\V_Y%%*B3,9,DE,:MIBD-5&.5C;@ 4GLK2RM+G0<0R5_8;M M?<.R*_4-!Z&'2W24"NI5$T[R>UR=;A7!L5Q (L5VSN5,[GG/CF2_$?HCH[.1 MZH8;Y6S*A+<*DL>,)=L UHE:*)PSQ7%> "?.,X5VDODVO6R.IW4P3> >)'TJ2PQ'J8/K@4QU1*L Y MGZ&(8 +WY#4WFO&^BZ)!1BZM@-:)6H;C#KZ_9J8R<;5R7LP6]7*HC28&\FAI M;Q"@>!53)(ZX%87$I]"E1CU5=Q,UR'"DF5'K2#G]PVU5O7%EH]]=+B?AQ^+& M3*^[M-S4$VWX?C:?UW*/^M=I3)\<:1*FY-* CQA! M>>T@AA A9&.S5"[Y^P.T=]3D-"!ND,%)UU@=A&8'L%T?+NX1BU*89 (()8FS MP!,$2X%@':O_:\[U6YC@ZIH>R7&D9@-7+'2VASGM. F<'TT.XV,N];[0,PQV#%FLU/=%NM:U"-M M3)!8& 17Z^V+]."54."*"D8E#*C:7$%^7#X'TQ*\V_4R8+ ,8!,YSVY85:V& M(S?.UG)7[R+XY!TP(XHH+B>?VP21[3>&Q^A&/B"@'Z7*DW'[=;6<2 +SY0#0 MRVP.])\%5\=ETB*MY]'* V=*6EUT<+I-<[#VZ'V,3N=#0N\QJCP3O:^FW5QG MN1+?=0GBU4'?-&\)3EZ.%VDR6US.\::[6K(.E>60?2WO-I&DK4/M@$&[CM.I MB-BHN_69E ^FLWKW"'XTA0[ "]_P^6[^GLSYYIO5_8EUUV<*O.F'%[,IDKG_ ML:Z%N+I><7M8Z&)Q>8&9CS0FEB(G3TFYFO,DGRG6O@5&YJ0"6B*@365JMWST M>S#WN!B\GVKI#Q!/LJ_WECG!=]@YK\'WKBG$33M]_XRE[EM^[QEG;+@U:!"! M&P*TBH0B+P4#@C!!/ ;K?//>W[O).W^$^N8EGU8%N-F6K%BRP'2@G4M:#S$6 M!9;59B_D'679IM_$73H&T[R[(UP\G*)^LM0'L&5?4[^62&WM1^:85NZS[^/% M"(4KP9=(QCZ1P45T9/L=DL[I*],J.='F[L%>L@:"J!/TO0LZ9PM_ $BZQ\/+ MV4483T>K^_X)P-FR'P" M;LT)^@TO(LY'P7*NLS*@O3>@LN(0!(7TD1O,2EB!M@UX'I#2+W Z4._NF4PG MR'H 8'F6\RJ$")/W89S?3#Y:Y,( MV4M6OQ?GN@=1=SH8 * ^4 PZGF)^%>93"HD7&RZ*X[DPJ<&66J;L:EU2M!%8 M$2H89"GP-A=^M]/3[WVX[B'4@=0'@)UG*5U>7$YJZ+MJ\U$E-,E$^J3F Q$!TW2?*B-+:Y37$PB?W>D6A@I)KH9@"@VS+^ M;L,(#]*%$AEHGF@K5[) M)4;BS:YVJR0MXG:=I+4[T6"[D'5C>P' *)G?X1Y M_D0?7H4@6LN Q43 G(EX)A4$C!30EI!$*2E8W^;P_@X9 ^D2<7YX?[IP!X", M[>,>;MWD73S_\?"B;^7XANUIKDT&?@\7N%ESLCA%1I:#CS7(,-:1=349$LDX MD#238VT UH*;GF<;G0ZN@P9[/**F!X#VFWL$*Y/^U^EXN?CP\:\;HYX3DT(8 M#KD@A3*)I.LP2\B!JY"LC:A:!0%[R.HYF=4[:AZ$$EVI< !X?(_S,IM?U*J* M=4W%A@VGI*F5$$!^*FU'MA9(T.H&9E)@J$VTC:87[B"HY[UZ:!CL0FT#0-^U M#_268O,W]-?%R(=2,] D!LE3':Z3(#"22G:9&*@^,S::S?6 EH'4UW=X_'.: MF < E(?7H!\>LGZ832:O9_.ZX$996N6B)&G).NY=) 3/N8 0M922@FW)'ZO7 M_%Y"!W).="(N?MKQLSLE#0"#:T/[[G*Y6(9IO8(_$BG)5&> E>1J<9@GVKG. M$ 6)4.F0=:..B ](&5HW^ X5ORV(.%D+@[D^_E! (Z\5$TH),*Z.E:O-FAWZ M"#DR,OTA([D(C7:^[=>UAM/MO2&N;K1R;IN%]QUC[4Y#YI'TR@2! K2E-4/K M@X-+40)J7T2=/9A9FVG@=\@86DOU=I@Z7?I#\*&J6&H;!\PO+^>T>V^PN6[G M4/]QW:YA<=.O 3%K'HDY[PV"BKF -S6ADNM1OPH^V#8EL,?3VN_ITZ-OF^WT M.%RDKJ8#;V?0<: M'"Y8UZMQ.X+2\43O6XVGMM[9T %#M2H_# M1>IZ,;ZZ^#J9_<#U!O+^ V4XU.ES@KI;F3BY'K"09%6TA:74CD:.&D'($G;2/A7/' M&Q7/G$1NSU.J!H#:#M4Y ,S>&?NUXZ[_:IW&^]O*!UR7>.-'G'\;)UQ+ITX. M^SQ=/64EJ)%'KWS1%K#.TE8: P2I"A0TD8GDI EM"E1;Q*T]*Y,04<)Y"[6Y?P%M;('C/!3'JN6ISK?6\PW#^#W%HU(U:NCD-OPNU MUJV7-@VPR$.];EATEYWC^RUM>V2;)DL_);ZCSDJ;\> UR*57I]M=V%GT6FIO M"'6U'U6] M*UOD?],][1,)_SD]]^^C*%DI7B?0-;FJ6/%DL2.GY<2 M+461P"6;(;%BL[6.)PR/)8W!F;"&R+IOUAJH:]#&Z@-^P^DE5IF3%5_);_'' M>/GEQ>5B.;L@ DZQ8#]_:'=F[4@&.K)UF[>^OO76O]UZZ0:E/<)HLL>3*T8 MI&BHQ-SFVL.A%/9KX5K@Z6&9;P-=#=JXU9;-4P)PG=-U@AF[_>O=&:R=1'5D MFJZ>_V-+1VHA>>"R3HESM7-+2:ZV5T%PQ#/7V0C>J+'M'J+.KZ1\\.@;*&=; M&*(KD 5]4=R3F8Z(Y,T-7[GCU\WQ;0%O"4+O-:^TGLR*:] M#S]JVXI%33S4-X;)31XU(2_6T3XI2]T[B?':/@H!5=9<&)=+:5-_L(>H#CIS MUK3Q8O.*JS?<$?0VZ!LDSHTQ4 HG61A1P(4<@7G/T 8G9&YSS'TBP?U:L*Y0 MM:5W9W/M#=IPO9U-/W_"^46=!W^*R;KS^]T9J]UD=62FZH.W['TH/(O6,,A% M(] .5""03D$8J^J$\*AXFWMSV^DYUSC=%N,->*45,97:Y85)3DP2>'WDM4VI M9LD*$TLCT[.5G'X-2PP72?:[D.?OOMCIV+6_NT5 9KHPKOI*35JB7XDLC11YE< MB=8:W>:"P9F$]^Q&/1Y6[YO(QU3XH*WHU823]SA?\7N*_7SPC.XLYW[R.K*9 M]U]R<]C-==9\^V3W[R2,[]-..(;ZK"<'K=W[ K[/Y:@#V=03@6:E# MR< S7P?!D(\>/7WA)GI-H;^7OE%SB!T4G5VV=>^YVZ(31(:LL S.U*K&NKO[ MG!!,R#&($#07;:X4'$!;VDM6O4>D,(_<-2W>J&+1)>5N+ M($_*:&]^L\/#KRVD=&1)UH^^N>IAE-4V)P@%!2B6 \3,*0QGUBH*@ D9;1R3 MNW25)8<=$G[K73)-^H" MLY^N?NW%&4AX<.#5G?@';2)JY?)XW8F&XHIZ-YRXQ6DZ\;;/OL=U6=![(-$= M69A;[WMV[WU;SD8H6/8R" 2.M()635 B)X\WY8 Y1B,I?&ZR-(\B\WS[]#E, M?@O+"M+[;[M9)X1E58H08$76M:.WA=7I#H:80J2=-#62Q4'D]6NMVJ'JH3'K M6E>#MFFWZ@)7X^TNTW+5;HYLQ:IWT6HXT.]XTMV@@Y_=I'CW"'8Z*W:[]4;" MSN8$XEE:CK^M;I+=7%DSQ:"W!!]I"* Y]&V_$2)(0;E&3"O:54)1V%*,1Y,,+Y$QA.J-G'=*=3V70C7 FM;)UZVU.+ M;>-/![N?>,O[IX_M]-KW<4QT=1*WZB!TD]JLW7QD+N *JQMF4>"D")!$+#KZ M4!RVJ=.X2\>Y9FV+]'Z?+6^!7P:3O?,%E M\^Y2+[[4J;W5JW\UG\_($I*VTZK/RTW=N,PQ!.'!.F9!)5NQDS0PE05W(M11 M<"VK,@ZB\OPQ7G_LTD"->-;O?S.]_9DQQ3^$JUL14%!2R^ 39&R1%?T/8$ZOFG^U,ZO7;WAL\[J=M3[, M;'+9649X-M%33,(\0I3<@-0:F30BQ4;S) !>GKH,A&%T^/H_,)F %MY[-H8U9_?Y\]8H MA<)!2:&*DAQK+[D H6V,TDFTC1)6QU+:[P#C1X-G4P4.?!?_21^S3ZM"X=.V M[\,>_8A-V;8Q\\BMV8HRMO#HP+$D0!FDJ!U%;>97LM=DY2BJ[F-?ZK!@)'S^ M/*\]HE=M6#>O74G^9OUH6URV.8,MM5>B%07H48I$D7/1288BVQC @\CK.Q?= M/9*V5'ETK*4!;,-;I;7JUCF];D#PXQZ+JFC!-,N@8ZTF1%UJ'_8$VEB15%'6 M-G*=3R"VW\WX,6#96H.#WHIO=>@[?=-]^) F+00;;J3[&L49ES5+9(&R5*J6 MZ#((6!)(&WPH/-F8VYQH-FPD^#%]P7PYP7?E^B4O+N=U1=X#>I0VRQ01_*JJ MSS.RQH)YT*BD9MPIWZKLX4 *^ZX9[P8W#RH!6NAGT(9H3]^^TPW3SQ_Z*(T' M&QJNX]K"2:L2EP(AU:Z4RJL$WL=0>[5Q=+Z(Z-HX'H_2?K#J_\[*V:*%6U=: MLPRY& E.)ENW< ZQD/,0T$N6I$M*YI_AZZ@W/J7^@<< Y(EOQ]_P@2!?7RZK$"]J]=9Z6LBK[[66_7Z(PZ54VB4/-AZ R" M1"J"8<;'-L?L>X@Z")/-)D<^/B;/U4J;-JP- M+=*.)IQ1*6.S-$ HJI/N6 1?? %K&;(06&2A3?*L33/6&XS7Y[^9UJOU]WI1 M84@Z1:'!DHJ)8Y?!IT#;)-ZS$(V6UR.E''H$W-@VY% M)YN;'4]JUR:LH=G9V1A*6*N9U J"\.0&.Q8(5I+<8%?'J ?--7]:S<)NL/XW M''_^4DMXON$\?,;?+R\BSM^5]3CF>SMMHIC2%RS K<3:CL9!*+$ *PX]IMK6 MM$TCL9/('6B3L6.PM-M$M5+;H*W63WIXG6[$#GOPHS4C:VCB=K>:"AEM0@03/1 &#'!:B>X:13I=-R2[%[F^'=<;L[]G_]X/Y_ER[3\RWQV^?5^ M$*$EBZ8.;) 4.BB' J(A&12I@G 8I'+E9R@ZZ?U.T3TP QZH[YN$7;ZEGS_$0U:\S7< M9O"RR50."WK:4.]B4(AM^.! R<76<;('9=M M1-0I&P-N '@,!G=;P,=6]0#V_VN6#^#TK]-97.#\6V7XS?3K)>U$:39-]%MK M-_^FI%+SQ') $";X.F&QS@)"#3::(KG//(LV<_!:<-/OGM\,];TK_HF!_Y9; MXWR*LO*G5QD/GB'JQ$ J9KDTM,X;S4,ZB=Q^C_T' =_35#=HCW33@_+T4[7; MO]]U9]>&CNB]KIXI6":B2A!R-*"4B.!*(!A9F4RF\(+)5BT%N^CONLHP;/,U MUAU'[U]GYAICDAI25)J8I>42#,'8V^--U;@P,W=M(G+,)Z=R(Z,U?/+Q7A*,25A((ZG:UQ/UX?RMTBX*;7G2JA4!"@;Z L:#S%$"4YP MK),BK QMYA0>1V=WQN[JO;?U\?S'K>]6JV04I=8N6@:B,$=RL08B*@7"9ZVB M2<:8-O7>QU+:KSEKB+;=YJZ!"@>0)=E3(_O\QV_A/V?S%Y- 3'\?+T;>2D;F M.X%7+ %)U 'YR)F\8D."C(&[Z-L<,AU.9,]W_9JBY?YQ4R/5#1N5-XS]'B[P MY>PBC*=\2*!5W7F$(A^;!:0H7R*+W">?VR2I M#B)OL$ \'R"SUMH: 0?N#IUR9IL7217OLX;JAU:.(>0ZH!827\83U+B;;J4 M;*.FYUO)C[D/GZV, 0)JL_"RC\((3<&Z][0L."L098D@H\H2L\K6M/'XMM/3 MH;.ZR/"__^,WS/6N_=NW+UZ$BS"??;S\6DL!7H3E%UQ> M->:\X7%C;YDEHVI#!(>UF8H0#@)]A6B38>@%K;=[C?=WW!LYD8!A(>D4Q<\> M60L#,%);;/E;^L'J;'+$,3"1B'CT@99?< :\#QJ<=4G;$D6R;8[U]U'5[]G^ MH^Z"G2EG $"[OUQ>D+C&>757AD0U#]/%FJQ1RK63ORR0N*(52SXJ1!,3!$$+ MUEO/@FLS/^10"H>1ISL?$S_9.3M1T " MZVU]?6UK%'FF)Q7' 1:DI@C844* MAL#F&(/B"35O,_YK+UG]>OK-(-:=*H:.JTVCXI'VOG!+0:].&2G*U@[H!Q%T M*2X5:70V;5I/'$)=OSMI/R@[13%]!P2;@MT/6#W:.B<'YZN>"].$[^)DO!XE M\>]A/JX.QQVS_>RBCM8996.%Y5R03XIDL;5AM+*R!G)%ML]758MK.U.C)3V.40K#8E M2AO)#3ZLL?2!+SP(6/II :N%K >P;ZX3U9-MB>H5LT01'VEM(M-1@0O!D- \ M!\]=(A:YC@R94[+EX=-^Z@X"FWDR8&NFF,& ;>NIR+7!OMVQFHSW>$9L"JD= M41S!!E$OJ]I(X8TR8(VW!3UZ$1[]6'X?P0=!TCY12+95WZ OQ/UTL-[=>6*S MJ^8N9UR>._>5CSA5\!CF'WO:H!1U\Z7HM5 (JTH1%%^4 ")+GD+63NA_V&F# MHUQ$"48HB"Q+4$8S\ H#Q?3".862L_+X0P;[KI/H'C?'S!8\2B<];MR+^7*T MZ;KV;OX1Y]_&"5>'@M%B9L5FH "]SH]7'H+CM9V 3SIJ[DLXZ"2>7G +3_3= M?2SMHJ#GQL&=Z7;6H:"' 91:]+WA8'%UNZ44##$IX+S61VHK('(3P&F>+%,V M'-B9YABT/"2C'\ATH]F',#E3S'VG+G[#7.\M;8YIC%A*[,YC>U?XN3J:=2*P :CZ)589;&C'DKU(@4(0QA34_IP4OM;I MNO0S"@6B+5P?JNS;#^[GF*:=ND\66L_[P$<2^FIH_)U.E=7D%6TR$UI2R,FP MYL8DQ$!?LM 1M9,Y87?[P$XR^CW.:^(Z="/ROG&S;K1ZFX7-*G+!ZZ)L[5!)Y&&YVD='?=M*1>F==R[I'P*1Z6#/_,?KKQQ%+ MEG:\6(>*(2='2C"2@>.@,0BAHN=%[*L;7F#Z\^?9MU\W3UP#9//-"A\K9-R\ MKT<8=*.TV5D2'$ :^??9]*]7U]J+E[3!8B2WN>1Z34%"*,:#5(HS%)G\H#8W M1FX1T9_CT2TBSI7O *"Q8W>]R7][1%]H=X4Z/J/.]A$0DBS I??T(VN-:G.4 M\#/*^KW^T;E7TD0A P#83S*'K[ZGR66NYR"+16U EC^%[Z-4>T.1EPZU 0 M M)![JD3 'ZZQ)%H.7>S>H9MGG;<0.,J]V(EIFCZNZIWUT]7N8UWLPWYH>5CUX MR2,>3^UG\)$/I+)$9E5$"&'E<=&.ZD0F' L9BW-.<-^FR% SD8/R M>O'>06>8(69^>*= @XV(0IV2>&Z+!V MEZ-PAZL,/A8/QF0IDRCD*1SDUA^.A+Z/&$Y4V7VEGR"_GM7^VW@ZOKB\V!"> MG!>.QP28O*NQB0(O:X9(Z-%%(W\?5&^*W%HZ\#S]J MOK4.KQ]A+HS^%R%R&^JBD;61>*Z]'@VK&[ M]XK)]I?Q_.R%@W0[3U3QEHJ= M3N7=-X:VQ7 ?ZJSE*KCEY7RZN3&P^69U3_I9H9>_OYRG+V&!+\,2/V"]YE]K MF.;X[.O7^>Q;F(Q21,Z90L!<>W#0$H501.UN*H4Q0D=;#KL\T8S$0=JX#G Z M#)T.'MFU)?@L_9U8?/$ES#_C2(LDM;+U=INN*51=:&,QY*SDXJ27G+@[K!'* MT:\>Y)'*8R#Q+!T,'F&;T.6FQ'.][MZ."[ZG13?_-%M_;I0*&D3M@8*8U6D5 MN;6E*$!!').#HX-/W2#O4)+ZK;CM$9%-=#: 4&1O=?N;::KSF?$EKO]\/9M? M??ZJA._-=$NGWU$QJ*3TEISO1,O5< TADFON2])2"QN";M-TI0D[_58#-P'] M<-3?N[7><+U5 M?%^&GV>3K^[\KOYHQUT_AA[26-O(XY!YZ ')XZ/ZE.4A=9 M0](E%BVBX\4?9J@[H*;?>N*&-OJQ-?6TS\.O?OH\3&I,>J_4L>$9^4$O?L1S M\^,%\*5W:],5[I+/T9VEU57-!BQ/' MJVG0O^/RJG-.T2$I62A8%&A B1PA2&D!,7BGK!4Q-FJ)NX>JIW&6?@QN'K1G MZTHG)QO);SB/LX9>[*JNGY@:!::2S\R##DX2-R5#],H"*]RF7*N0>)LVW_NH MZC?)]!@(ZTPG0X^21LPJN_(IA/?D4R1,M8.A@B+1>?K.1-EF5,[Y3?^:)8_Z M0MAI6AFTIW?5J&F,BZMVL;-RZX=G^'*'/KH[;^TD9CKRQZX[7E&,DB:SQ>4< M;\9)!HDFH((LG*K3!2@NX-Y#SL8&I'>7^Q%<1VMX#U'G6JWK1W\(?_P6"*KC M,%F,0DF"J\)!6T;K@BD#P:@(*=.ZLY:B,Q1M.;U-3K^>5E>(N&^9SI?\ #:] M:R;^-IO__4T]':+@:3%BO%[*RAY0,5%O<.K:ZE( +ZFDR+5AI8W#OIV>?AVI MY@ Z7?9#0E!MO+4@:_^7V2PO1M$1^:X$8$(S4%E(J*TI07.KHG3,'W0;+0+8W3,X[LS3BD MT7 A6,Q$;RV.,+2SNSJFP%H9>(P4G:HV]S(.I[%?@]<.7[NG5G>JM2&4M*V* MNFSM%I^U!<X)W)BCI3437<4%$ZZ03% M!Y[V2A<17*[]G'@R.A$+'KM;]P,L=#Q9_2=+<0#INSW;X-OK"X$L)I.*8D!> MDZ6ML#9O*\F"T4)&ZSAW*C=Q2@^A;BA#LILX%,W4- #H_7Y9%TR]?UJG[(ZG MG_]*/"Y&3LG:;E:M!QLIKPSX9 3$Q%(AWYV5V";%LYV>?OW5[O5^OQ'?^4H8 M$)3>?5U-6IM^WG0M7(R*LDK60;P!LR#+C@ZBJJVL97#>:H8 *:N$@UO+KZ&\;RR\':V6(Q"4IH++,"]]W6ZD8:PNAV%"8.+)K+4 M9B_<3D^_1Z/-T=2!$@8 I=UB^NL"R^6DUJB-HA0N6H[ 6:E3_:0"^E$&QTT6 M/BHE&IWD'$)=OV>JS6'6N8(&<>?Z]J"T=^6^Y$;1:ZMM"1!]CG6/KZQ(A*0H M?*$P-;/[5=-=W>O?2U>_M7S-H=:A4I[JX=J++S7J'D^O/M+FC&W76Q[EJ.T@ M%GLY<6' 'W;3/D?;0X+*9FA ,M\PR M!C8D6D72*7">_$GGA/-&":]=F_AQ"S%]%U&>I=Y]8#E!UGUW.;@[?"TF95B2 MG"BOK?(R)B 6' B;-;F8+'%K?^8;#65:76<:VCVK[AAQ#4#1=\:NZ>@322%! MQWEVJ%K(YU,RA;5- 5D@%HK)&<38$BN=I'+.9@7,@EW'=J^[!% MSC@B8QZR-2I"]J"-? M9 9'7A3PF)432@;AVUYQ&%I13KVXPI',+L_UYA[7"$X; Y+6FY2^]HUM,P'V M'[,HYQA\G5&4"@VQAKR\#HN M50/FX)T,6F?99GL]@LBAG$=TBY/#[^6>I;1AX_&&L=_#!6ZR>WQ542<=E(BT MJC$7\*XH$(X"\%!+D,-CWU_:2NA@+_2>!YC#@7FV]OK.H&\ZN]?\_W0VF7T> MX]4H<<6#3H$;L-P3%SYSB/4 R4K4(7%GN3UL8,[.5PP6/>=K==:YB =@Q:Y' M!> ZLEY\&7^]8L41'\P: 2777DW5(XF%Y*216Y8YX-9#LBA66+$<7/40N R@E#?A,K!07R#_(5LB( M3>"TAZC!W@CO'%E=:68 (#OH=G/6:%-T#DP*Q).U')P)$33WQ).++J@V:/N' MJO9L%%6>IJ9A0^\O\]51AY44U!@+').G:"=X""S6B_ R"B&MH 7[V+!;4398 ME_]$+!P.MN,5,XBZESTRIPFAEX-:FZ6.63#PDCQ+BCX4A%1DG>)G%&$^YT9S MB2*HJ"4N^>[*@@\PE<^9;I39/(G<8MPJ'AMQ3=/DT 4L(Q!'+1J9: MG"(2A0/*)0-!.4Z1 */_-(N\T?6X$PGN-U,_:- >K<\G"=O7L\OY2)J2;90% MC(\%E/$.8HP!6,@8="A*ER'X"E?T]ML%9LB@/5J;?5_7VJPC.%0U+:@JJ>?:AL%YZ%5]D9=3]NVW&AYPPB^IW6WAZ*CZJD81O0FN@3 M/EEIT(/2M7^S\QQO14P:'95_MT4=A .X-.PSY+:7Y)]&RF MX9XW)7;WP[I+F1Y(<$>)T/?A1SU&7Q#@5B\.D\5-_0"+3%D,% ZG! I3(:!9 M#QD=9YP D%.;VU5[B#K7*+TB-<]^(*YNP]V1\M7(=RQ2BA 3K2*&H(+4$)B5 MH#7'[!G/R-J<"OV4M'X3E%TAY;XAZE8C ]CW-@OXP^Q'F-QF(U@IA*6PW=72 M9N6YA.BTJ&>HW@>1K)6Q";!V$-1O>K 5G+J0_G! ]'X^*[A8D$["Y#7><*.S MLE(Y#=%CK"/=:X]G%J"HK)3VUNI&12#[Z>HW;]<84EWHHN\8\6IUD&*(B"\D MJ9?X#2>SK_7"Y15#PC$I(IE:CDF"DDG1HJD-"&6M)[31L_N]W'<$@X>\K=^L M6=>0:2/D =BCCV$MI5??TWB!G\+WC>2NV$DF\^SJ#!Y68U.GR=!JF< 80<&( MI\@TM[E5^!/"^LUOM;)(76IC ."Z*5$IE]-K#_#'%3<^%[1%%TC*TU)QQ8"/ MEF)=*S%&KF+R;897[J>KWWQ5*VAUJ(L!(.O=\@O.'T;45]Q8:QV&R, Y68UP M8;2)U_&]R1<3O=!"MFE3O)^N?G-0K9#5H2X&@*S=C&27C PY [?*@+*Q]K$* M&0(/7C!I?$'9TC<_$4_NJ>&I&PT,.GGY=C;]7,N@7F)<=C$J>^_SNDMA'DYV M1UG,^J)MG=2YT<)H)&"1+Z306W!9(DAIC7;9&V_;'#%LI^=MRI^2-BFF9"&G6(>EF ^Q0@HLXC5F*7ZBWUDUO-!&%FE$@CIG !0987!(GIPVQDGFDA:'32 ]&C3;J.D? M-6>I^'X1Z[GR'B!F-K6]*AM;,G)0JTK+;!PXKB2P)*S*WB?+V]S'VDY/O[@Y M7\\_ T(O'RZO2;1YCMBA!*E?'L9)X?*A%W#%J%#IKSMLT M=7M(R[ @F\Z4]>#0LEE 0A#?K-1^7:E&>Z7V[A49ZAQ4"BWH MGTRC]. 6:OHU,>=J>"]@3A#W "#S ;_-)M_&T\]WF=E82_2*?H5IL,YKLI:T M63L;) @EN&=1Y\);C97:0]:00'2*UA^,#.I*!0/ TT=,%%[F:INOIJ1X%QW+ MM-EJ)\CK\W4H#C<@O%9*&,&R;)/O>T!*O]M5Y[@Y3]0]8F4Q7XX^U,&4*PML M7% FY (V);YID"6D@1(X^6I*ZW)8'0L]]18VZ+O[N+CSVGZO8G3ENIPNR2&H M?X/:()5BF2E:PXBQ&>5#MW>$ Z',;.4-E]Y5^@OQZ5OMO MX^GXXO+BJKVBS,YEHCEPE I'W2\>)#B[[RZ9]6?HKA9 M%U+L6_WA^RW"K4_>^^(@QK/T[K#[TX>I__:K^W$$.E/_ MR5(<@'_X[V$^KMO=A[!<6T G3-"].NZV3&_ROORYK;.I8TW^>_Y'3MR\M$4+)T1Q&VI9#DN=%/B%JR1/2E %T ME*WY]9T%@(NX8CF%4W3;#EHDJ'-R^2HK,RLK\R@Y=X:3K:_L6?)*" ^&DR04 M2P(\^;@0K7%:>RZ0M>F3?)^6<2/0XW3[!% .$'0'4-G&0>^_XV(V_7*^>CN= MA5FB>+JR]&E>%M>?O)ME_.O3G^%;_>1J^^3%"$$1&$75-7"29=.?UTA+_QHF MBVIS;',4V?T \!#,/!S(GD"!':#U55CB+>HE>6QO0Y6;,QJ\_4S'N*F1@?%TA(@[ ,C/GL"OUTT%N<249*J9:O(956)U*KEEH#DW MUC"A2J,2\D<(&K=T?&A_:0BI=P">VR>>UXGD3;SP:KY8S/^L:>;PC3Y9_9@X MC%QAS3M$2U\L+8RH*8CPVC/#>"I)-ZISV8/*GNI?#H3%$Z?2@^JH _S]+"_B MKG:NO)RM)C%9$QP:T+H&NX)[""Z1BUJ,1>]5B:'-[<['*.KI['H87 TB^PXP M]&$Q3XAY^9:D]FZYO"1?D-;+[:+9B:D3?IQ00-Y=G4=;FSJX+* 8I7(Q&46C MN:[/T];3P<(PN!I8'V/?\=S'_)ZE1!HCW;W%4-OP3B1SH1CR0Y'7I<1= >>K M=58^J!S(E;Q[(/[(W<]CJ.@I4W4IZ4GE[[%GKBWO+M##(6VT^4GHB7D][/;83.?6.\+ MDOT%C,:!JG/*(MED8,$X*Y,)OIPB/GRC8N5Y69B=,E(_&X&1NO7&;@)"+DZ"/M<8;65]AI"WSF1>/>\AQ\EQM2K'U! M9'VS"$NXO%C=YNC=+-%26.*$8W84;S (7I#!E;D>4 =?>Z658M<'E.D P#SS MVG$O=3:&SY B[V"/>\@#?#W_^G6Z6J\5Q ^X2%5]7W"B2DB<,PG%>F(-#8(S MR8&,3EEOA:?E<[*DU2-$[H0]_Q*PUUI#8UNRA_CZ_;(>&]!/Y]]Q%F:KY83Y MX)5G9)81"[F,6D-4&,"CB,9[E.KN'-4]HKY[K]LMX\E> GP:R7ALU/PLHBL> M-@,Y-X'KY_7M=_R."UH1'ZOR)JX8-*4.K+,N@Q(N0DA>@U,LN.P*.8+Y@&UP MM[?OAJD7D48_C09>(L0^7<8E_ONR!KKSW\@=H CDXBS]^W*ZG*XG6T^PV$"" M=6"Q'I7;.C2]1 \F6^NE$-FRW>;2MZ!N-XB^B(Q\'QKL&<*;"M:WT[\POSX/ MBR]8/[Y9JB%ANYUG.5A3N M3N?YS2Q/DA*%HZHG3K)VT- Q%V=DM&UZY.U!Y&[P>E&I]U8JZ@!] M/XOK(V;\^JWJZL-BFF[G6434*N-NGG0=KL/?S0-KWV=F"@;<,]*X*)M;L: MVB!H&TP"@A (&K.*HDCF=)MB[],UW..<&:\E65A;6RN71*M+)%G/LE*TDI:< M/<4I=+\-]_;!P"X-]_81> >;V\.-P81%'TL QPQMT"YX\)898!FC\Y)IS1OY M4"^BX=Y>*MZIX=X>\NX0,]LK(MP;5"P'6%]]4Y*X(.H9L.2=E5(D$4_3IK&' M.X''ZWFWAGO["+T'Z-SO (?&R&11@12&@=**5E-V&DIPSD21R0BWZ6ETGY:^ M('.(AI]ON+>/N#L S ,MPH2WSDF5@2/)0G%I*'R,#K2.6GA>Y_[]SVVX=\S> M=*2LNT/+=@$QA2%9SR&P8BH/2*&FK#5=/FH=4BR-,HHOHN'>7AK>I>'>/N+N M #)/=WL34DLK,0#/-9,N8J:]FTOP(OC$LRU6M/&$7UK#O;VTOE?#O7U4T &> M[G>!\R+SG$,!(8H"I7+M&,@%>!F39K)8#&W\XI?0<.\8W!PGZ@ZP\EA*-*.W M7D5=%1OJQ6D)P0A?NPEQARX&6]I8G6.NEI^T.=\Q;LX04N\./*_#8O.CV MBFDV&M$'!.35:%KE(-#W@"EQKF(QZ-O,0GZ*JIXR.0>J_4DH':&#+O"T>>VF MVPN^GB\WH]65S1%#*5 T19TJA0!>U_8NV0@5/2(OK8ZU'B2HIYAK*!0=+_G] M >0W )KAESK'^G.;:HZLD]>LMD!DSM=2)0>Q5.,IPQY?/D3C0>>7U:QXXL$+CA;:)(!,4?2D* M:5LQ :S3S,GHZTVC)DOJ":*.JDM]4PJF.G+M^@6U8.0CIOFLA@IK5;W",E]@ M??$"<;5>0-OC_0E+$NM5%A#$/$400H%+08*T7 MO$C)EG\/, '2,Z]P,!9B? M2E1/J)BNBRX^G9,.:A.S_'K^]1O.ENO''F&BGG[@<-9J#\*'*K2XAE^]2W3S MSH]X4;V,M6NSIBI6JCZ$'W5/O)FOZ94NL;@*E%A;+)4,/C@&40>CG!#D S4: M#W@4W4?GC+:%,._+PQH[6RQJG^+U.U_]N/F=+1UG?X9%WL3%6M+Z+N0MBB@T M*!4#.$T>)'D4PE $(DRCH6>#L3!RD'@Z_-[+9HT"@@X"SP\78?9[^+HY(N>B M2A Y&%LHYF&YSL+5&3++F1>-SH@V <-M*L;%X$A N-MEZE"M=(2H;8Z9 BV= M;T ;2F$CD%FX-%FXUA0&=O4P/U,Q[BH.ER?CP#C .&.?0/NC/3$/JWF MZ5]GLTQ.+8F-O-OU@JE<;0\1R.E%'\E5CJ$:<68\V6_E0) C;521G.UX,7BG MU_6!BD.4.6\JV;&Q\H8<^?D/Q#53'RX7Z9QL["U>!%?:EA"!60JHE,((@='. MKUE 9*B21;<32IYYT;CISJ'P,:0T.]A@GMV8']N7;])_LO!@ULW1"ZLG6-P MQG1@!+QGS[]=7S+YBK8 M57>D7W#;)2EXAS)9 X:Q.EK1,'!!!,A"9LE8-*T*^YJS-G) <6*L#K54F@#G M):^DJRX]ZT^79Y>K\_EB^O\Q3\B <6?'2U$XJTD/P)8.4GJ%$A\RT.>X? MG)61]Y87NE(& 48'*^/L8OT[F!^6Q)N_ZA]Q8G2,+!D):!.K!Z81G(L>BL_! M)B\CQ1)-X+X;?>.>-X^,X08J[ "8U_$++KY/$S[,V^_SV7=<$NMK<2[7[81N M?UZSQ[_/5_^)JWJ&]F6V7J&.)VY2S,"P#I2H@;$K-@*W/'JN5"JQ3:U?,Y;& M;8<^,OS[ ,K?><5L?,"W\\7V1_7W^,36,O$2!+A'?,AJ))C MFWDFI^5SW([P?]>U=3RDNJY?>!,6,PJ>:F'&6F9'5"X\]JCA:A9V(G:@:H6[ M[[H^QU5!&,':?]@J"O Y!-^J=L$+=%_X/S+(GP[GZ9WLS)??-V$$C?ILO5G5KO@(QV3^6I N@7>UZ)C4GP^@EV.2Q)!-4Y&T\ M_,U'(]:;?Q:\ M,P62*N23*,9VO-Y/;[F%.?KN+MZ>)*.;(N^="R[B"@_7T^^V.Y M+;%400JI@P/Z8D I17ZKLPF*U3&[(DMD;:K@;Q$Q(DB&4>E\&/F."(U40XC% MC\D?GR8)4ZT"X=\X>;'AE7^@!#LP!Z_GZ\K\Q>9*VW3YKU<_7N$LG7\-BW^M#69- MD13%+4A66Y;49LA1: T^BQ*)'_2B4:N\9RCKIN2XJ;/21$]=XNZ*F^TR#,GP MA,R"<_4^DM)U1&56D)GE3*'&8MNT2'N.LI$[[0V*@V=!=H12.@#91_R.LTO< M)-%FZ_#TG]/5^>O+Y6K^%1?;73IYX4P]Q2?/L.;.K 07@P(C=9;6B&A#FVL7 M.Y'7&]R.0<3])H\#JZ<#S/V.J[/E$E?+&]?B;(%ARPR/$5&Y&GG4OCYU.*"W M-?S0F)/"6&@3:.-Q/T76R$T@6V)L.'5T@*T'C/]U(_GHBC..8@U$77NBN@(N M!P\4:6C+78[(VV0NGR!JY*KG\5VT@[33(]!N-9_W2H8W!"4] M6!F<4EUK;)3C.GN$Z ))3"H)L=XV M<8&%J(0)R%LUWGZ>NI%O29QXNQQ<7QU@\*KFZ/TWK,MI]F7+)(7ETG(K/ 4P MFMQ7%;ROXP9%;6X0I U.ZMCF?MJC)/5U?'R\]N\Z_H.HH@-,;<*7B?>UBH@, M,?D1G&11$KAJZ[7(7 K.N M:]J^Z^$3?0O1,P7%&.V+L5ZS-JF&IZ@:.2)L#:/!%'(PN+[C(L['KM+[=/GU M:UC\F)???K*[O0'&T+OCCDFO/ M:..307M0R GH4FK0)B;AO BA4<354\&?MS(QQPLP9(4\@E0O'Y8,MAC)$^,^ ML>;=45]XP=\^.!JBX&\?E8USO.5@N4W]R&RX,!*A"/(H M%&V/X)(OP$V(EL)N\E)VJM;>!T3WR1BO>.MXS=Z'R9%B'KL]Y6]U9$LZOVJ? M:((,)14(F9,L4O84RA0$R\FOS38+;L1SKM;]QXZN\&-U-!]$8!VH^A>L,KCJ MHIIYB"5RL*Z&%DXH\,(IR%E11"O0F+!;?]H[#QZO/J^-N@\6VMB5WH_6,PL6 ME2\N 2>X.-!5+=ZA'L4PFA@;3H\6OQI31#:" M@I69 RTT%FU 9I)1# Y-[/Q\K:MRE$.L5#-]=8#!9RH&-[>F:VYBN43Z+W\. M?TV$E-Z&$* H56=N>@/!FPS&.I*EXHSGIZXT-"OO?(C8OC(\QR-FOX+/H]77 M 4+_L9@OE^2\ENEJ$BTKQDH&+&9&X:A10 ZG@L*D5T*YK.^&8$.5M-P0\0+. M[8Y!U*'B'CN 6]/]6UA\FMNT@C-:';49HY:/1 MH C#H#B/X&CK LVY=8:D[76C=NS-#]NVN_JR;NMO2(R+6;BXVM)K_J9.)OYU M^AWSILABX]F:Y#C]4V=88ZF5%A$\=Y:$(GCF+@I3VEP]/H[NOART@]#U^!%< M+Y.W+%C ==&/)\\TDC\*.4?N9#)9E)T2(G^_A-I>ZMTIH;:/K/MH MM^"=URXB ^+>U5D<"3R+ F3A/KFH05-VBVX5!HR*@IV,"LREL9 "LD:]-9FV6:N[;[=5T[<@.,01!PKWPZ@L>>N M>Q,T2V7)]3-UO[7D_&5BT<=$0G-"2^9RLKD-C@ZEN)?3PI/Y.2=5<3]0WBO/ M:XK,M7$@Q&3K48=-X++G('R,RH28X]T1N_]3T_2G0=$ J?M]5-IU^NUMF"[^ M7[@@]J_^,"\;X082]S3$Z<6Z:^]O&):71/A\%C[65KZ+;5_^Y1'YM\'>/5P" MKHTX!LK 7=/TRW29+N:5@.5UGD2GI#22HZA#[242? ;O4JA_XBGJI$MJTR3A M*:J.M;;7S][HX.Q!';R?7:N ?H'^N]1U'Q1UX$M>,O_IQ_#"@ FXP*.4UZM)X73])7R>H/"UX'H/P<)KL"9];.:YO M&-_G[ZIT%9E2UDC@6)E#26&#)SL04D$R#HJ5U.;&U5YD=H+6 7'R&!0'5UI/ MB'PW^W9)WG^5&+]J=Z43!:B9U9*(1$+SM9S,>9!>*I649(8WQM]]HCI!V_!0 M> QT1^JE4XB)JY;'R(S@+$$6Q$ MBX6HC88H+5?)VA0:-5AY@JAQ\TWC0NP0 MO70*,;EE17MKG)65=E<[G-91YI[X\8D[EZ1A =OD.Y\@:MS:JG$A=HA>>H+8 MJQ^WQ/9V@?^^Q%GZL?8R>)+%R6#!>%=[CW*DF$T:(!%I(;A D]JTAMV!N$ZL M6B]!Q2 Z[ F6#S&T7<&8LXO18&VV%:N_(,%+F\$YXZ)63A3;IJ1]!^(Z\>>& M L0.H<,QVND4<,OK=;NU[2[(2 9< !-9@4HUJ5^8 ,VC+Q1L91L:[[E/4-<) MY(:"Q"[1ZC'ZZ0ES1^P>-^=:QH>0,VHHAA=R: 3Y''Z38Q7,1--_00M8<2+:,U[U'X-J9X M-_HZ,<:G!]"\N38[P.BKRR5)9[E\/?\:I[.U6FLY (F.E$-_6DXS+K;GRAO^ M?TP<8L:$ 3RK]YS%NDLQ,R CUR&Y;+!1UO$ 8L=%;PO,S$^KP XP^K04)U%Q MK:TN8/*Z8M21J^0C RZ4LYB,3[;-KE[CX7EVG34YMT%JAPU[=LE1H &&T4K;V@>[J@C^>S1']KLVF$BW1YL>ES M.[^X>#M?_!D6F<2F0DBQ3I]WY#&E34\E =8$*XH(OC3J4MV'C)4M=+UOFWZF?OEQSM!Q-9[6C]KHC/7Z)0&;SFIR) DHK()M \R MI)(U3VW:_S=AIY.UT =D=TC7G18_!R^B;[B@/?S3*BQ6QW>X>'U._R-.K^7Q MOCP2:$Q,S"X*XDN2:.L59K)?%&^0)ZBT+JEH@>XYUV?/=W9R>-85@ENJ;>Q^ M*X>NRD<6Y6OZ84WO_R-,9[_.E^NK&!_IH=?/GOAL-05*%KBUH49*#D+V"IRU MQOI2,D_/NO.C4-Y)&KJ_E=$UA/ZVCE-0+D@TI"2F!2C:!"%:[R!%RV1TKEXB M^ILY3LTF?/6YN/K!SY&.TYM9/E5J:=OCZ-/Y_$_B>W6.US)X,,\R+_0KSZ5Y MA\@[M:2K05+J9&(\1<8J<:?1EP3*)4UK+_I-^SL;! HC592EL:7L^FY;Y"EE MYP*@#R2C9"T9 AG!*&5%;>Z>6.,K0G_CNVW[8*_=W;9]5-R!PW3+M*SWM>N9 MP:46!"&+@!9K-Z_B(:(S8'W6ENDHHF_3*^XQBCI!WFD!,F^@K4Y1MZU2HWA= MY:SLNBP-5/$&G%<:+'-91)Z346WJJ!ZG:5SD#:/S'8!T@ (ZA%+=&6IGIH]A M=35C(PHODV(26%D/7$VJ9C %(,M0U#P#+B.5,G8:;N[ M['Q8S./6SYZ7#^%'_>#Z#IT.+K, -FD%9- EN2 4[1FII3#1A!!VZYV\^SO' M32(/C*"6\N[ 5CT2MKWZ<6W3H[$N9:[!*R]!A>@@A!(AEL2C$3IXM]/HD[U- MU;.D=7)8,:K[-:S^^@7DK55LN(PVZP#&B'HKN&AP*4A XR4*YE W&DWZ+&GC M;IT#0V$WH!VHE[$WT&W;+EJ$F'^VWRX51J1;4#;7Q&B]$!QD@D1^@$K,EIS2 M3OOEHZ_H$B6'ZG$^N% [L$$[]MI0G.6(N9!X:K\B+P,$27%/L"[2EA\X=VTJ M9@?LKO,"+LXL5V&HD[ MS!W%%]U=9R^<'-5=9Q^E]83(!_H?.)V#+(R,/X]VVY)(.@E%,14LN1S)-BX9 M/K O12?==?:"PAY]*?;12T\0>^(*NS)126DU;152UD,7K%W/'?C"E"N6B]1^ M1SZJ+T7[&H=>MN-!=-@3+)^XYFZE*T$*A,)"G78B] '-"78A_M= JX>WT/I+ >92#WA!%C2B8!'CVCD"XBET[%D$[H\[VX MOA1[0>*0OA3[Z*<#S%5^-FD"3.>S*)ZV#Z'T/:S #I ]'U":'OFB_EU6)Z_O9C_N37&C#A@2FHP+$10C-@F+_G'GBX_'L S1;K(MI@G"] 4"?;';'4 ML30*E)&6%\FL-SL5.>X.FS$MS!$JNZOT ^0WLMI_F\ZF7R^_;@G/P06*#J/]@*7;@I [;ELTE-(@Z0HFI@.(J M0.0!03N=@O/"6M=F=OCI^SW:OZ<',SXN.E@4A[1BLY9LA8PD8D;^@DI:0*SW M+8OP4=;>A(RU.6-\<;WT1H36 "WW]M'SP5#^CHLX'P_,=XN-)Z9D*^M="BTT M![(>Q#0SGC8ULB(Q&E_<3I[A*+K^O%#7+A^\L$-;DSOSL@IKCQGZY4.1D%PA>)H0XN;XAX)23DCA2LLQ<9S M$ :\\KPN+?UCEF^2@P^OFUL],WW@,B(CKXM+K,E("]XF"2X5\LFDS"FQYZ"T M_VL[V=>/!<1/);WMY-ZU@?J53"\N/UU^(YM3[6^X>!4NPBSAIW/$U3"V:N]W M#&>VCF-O( NV(>(:HDK%K.IP-Y4]?;'60Z0? 5,:N:PM=44;)^=G.H[U]]Y_ M6R^+V9?U8S].OYROWI<_EAL'9.*=])L^E/7NA4I8(#!:AYPA6JZE,J9-?=J3 M9(W:73#52:+_V;^LC[,&WYD4J M6JG 98W/G4@4G]L )M?)(N2:!GM2@[DW!^.6'9W,[6NDTGZA?..;[,&ZB0B!Q^ 5@:[X4P#W>4IW0J=[<>@< M6$6]0_!V$[(/N$@U C1,EY"*!AF<)8G2WN&=0N#,2\4P._*'3@_!!RC="8+^ MI4/P6!6]@%..F_/FL+I^D1C/U;:G&.XA"X&3( N M$3I,4!!9+*"]8M)&S0)O<_8Z[#G&KTBA&S[B/&R;^RPW!II6>G4=EBE<_">& MQ43&HH4IY!M84V]K9 G.!%?'RL?,??YK/5^7(B@DRLBM?)6B+,:<,@P1HHDAN&R9@4VR2Z M#Z6XJR.5YN \5F4O")IUV7W^U!VV*KUC=[AZU16 E MM:NCG)-A<&\EC=U?\TGN/L]?X8%WG;#GY/,&RD4Z&3(RL>8( K#B+] MODD4K)CP7.!QZ,N[.HDY!%8GD?H+LFV3B!:53QY*2FESGRQ(15]T1,5X\E*W MZ8"S*X5='9FR;OQ+]ZMG7^MW$..&\$N0<>%]K8.L8 M !Z%4=7:$B1#2! M0!*J"3?2B#8YIV/J;4YU/'$,JH80> >6[)E:1D-F.0JGR1#7;J"B5ET4YX%G M;B.SP6C>9J[6 *6DISIA:("B0\3?KQ&Z5<7(LTR!>5W'7A-#1=7;)H:3P)0U M+*= 7D#'I:23.&AGRH&K"3WY4=9>=Z\.J_QA EK=O_ER7 M?\S+%E/SV;+5#:==7];RJM-!##+UVORU_H6JD-H6+"L;F/ ,S#L S4?2!!%P?C;+O]0) M+/-O54)O_OJ&L^5-_SNM2\@2I*D];G.V$&7MV>P,II"4X[9-#F\'XL:M0&D' MK*'UT@'4/N'%Q::1T6]A\2^L&8*?^\LVSJM'?I/20* M8D"Y7-.;W( U)3M?!$?;QL':B;QQJTC:86UXW70 N(>#G5^OV[*%(IS*#(%" M:1(8UNI )RF,]A0\:TS>^Y;%2X\2-G;=9IL0<4AM= "NG_/HVW4R,5S)C$*! M]'7.(TH+COQ*L((%I@+)+[3)6CU(3H^YA@,5_N0IQB'2?P$G%[>3SU>#+5HE MV)]X?LN<^JYLM4FC,QNE=YJ,F"+'7*'3X$/0P)1Q)B8G#6MS9ZYEZ["KPBER M#VGC%P[!U(Y5Q%*FI47K@D#@T3@A6&J37WB8GK&-T<&:?]KV'"3N#O:O.[TV MWD=:=3/,[V9O_DKGM;W^V_GBL2J68'EA6070+E=6HZ? @WP!R9-QF+4(;J<) M-?NG' XG>FRG:C#XG4IQ76^0K^=?OTY7ZX479C<-1M,4ET=LBSL\=;C-<%\6 M!MH";[WV[.YKKQNR7@,U:1],4 R,3JR.D#80$2/XE 0K*0O!V_BS>Y%Y=* X MK_VU;[UB$^T4%E#40AB]KJ^2HH K,4/6:$N.4=M&"?J'Z1EW VV'FWN!XO': M&'E SZ_3U?3+6C/DWVXG*Q8?K+8)M*&(1S&CP7E9P"J54QW3SM1.6-II2L_] M]X_L? V@T?E@XNT*')_I;VSS=\9ZGBTR"%42*HH,+D<)0A=E2$(ZQ9UZ_!X MD1LJQAOI=:Q6'P7(@2(>^R;I%_2"@$/5-A]8AF/CX/7B55B0>Y^VM'-EF<[.0BGK M=@M*0]39 K,^1>T=N[>3/*+_.P\>;YK;\'H_1F8=Q.;W]LN;I*ES)A3E%-1$ M/"B.=90+BY!#*2ZK+(5I=&;Q*$TC1];#^18#BW]LP_'[9<7^^_(AK-9>^W*) MBQ7FM_/%1\2_*!K=3!.:)"NR-#Y!5JD.3[5B,T8U:Q.,I*]W8;VXVJ=7%S@%\P7/][-2IV:AGDC M@HF(T:#+GGBJ,^&U8^ MRU"X8E(+'H-K,^UD/SI';FLS+ 1/H*JN,\IGZ=^7 MTTWSVH^X7"TN4[U>-?L29OG]ZAP7:\G^CJLCTLO[OF*X7/-1S V4>/[IQ6>S M_)$"L]HOD^*R[^NQBM?)PV*CRUR[.J2PMFHMM$UZLG Z,V:3DT[%1L=+NY)X M=+'E]L[>^_+(*VOE\M:3I35+X8GV8%S"VJ=45$^64^A*9G:%,3M0>2X M+ET;9-TKQVRDLPZVYZY4[:.5?@&V3?-$#!0/(0>?.#'#.*W/B FL]5Y[PZQ+YI00Z_U.U5[* MW^M.U3Z:&#M _16_A(OU4MLF^5C1/"5R1:UPDM9:S! 5"4@G[HU S0I+S[EH M#SZY2R0_X>(+/8G[14C6#SITU,,XH0#I3397!6Q7HLH M0F@34?B=I\ M7ANJ?%C@MTU1YY8M&5.V]?1(,"3+:*4'AXS5WF^!JZASSG8GO.S^SI[O&1T, MGD8B[\"_72=1?KXKE3#(G!4#89VFM6") X,!;,A,EX))ND;5U_=H&;='[?!@ M&DCJ'>#FIP"R.F/K('*)B^]XD\U-U@IEHH <#/'D:,_U/D6(CK9CF9(0C::B M[4+=N'[0J4+QP?4T]N[W6$+X[$Y">))#-(+D UP46I^%28A9%N Z9F-+8M;N MUEM[US=VE$H<1-'SUE+OP(Q=W8%Y.U_03OY].K]YJN<4U7,Z0U4$KG!W?I\NOEVMJO%]'K^5=Z_GD= M/_D=-\['46=V.S]]R..ZPU@:Z*3N#:%D]>.FEI\<[I1K>_\45!VB4ZL."GUA MQF7ZE\O49LK,SW0<:Z1V$&H]^]XX"UX'R2PGMS2NVU:%3#Q+!99'0:LP*]>H M<]P^5(Z[51Z!DKNFJIEJ.M@;KP.?C;PJ:_/9NJ2BIO(3RUY&7EW13%)3HM3P MQP"+1L8Z%%(UNDGY)%GC JL=&NZ>Z ZFF@YP=H>'J_"Z3FA1S$/)3-4F5+50 MQS/(-JMH@F=>M&D4^R Y(Y_;#J?N^="R[P! MY;=YT68+2\VBLG_=;E\K$ MWP1")D?IO E LJ1 J!2$H&($6=#[8&/(&,?TQSK)AYULZVRJP!X ^O[UN[/5 M:C&-EZLJK,_S#VL%_(ZK]^5S^.OC_.*" NL_PR)/O"E1\%( 592@!%J(A3S? MXK3SMG@5L$U\M >1+\*C.Q M=Z'92'4=H/+3:I[^=3Z_(&TM-UO-1&F9E381 MN'4"5+ %0LD.M$0Z&08/J%V.YBL]\ V8FD]>LGJ M(063;.$FF-#&M!ZXE39>3L>T']4L,2_P__^N_ 5!+ M 0(4 Q0 ( MT?U8]*B_T2@< &